"text","relation"
"This study therefore characterized the binding of <e1>DF</e1> to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at <e2>sigma-1 receptors</e2> (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked <e1>PCP</e1> sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at <e2>sigma-1 receptors</e2> (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of <e1>DF</e1> to the <e2>sigma receptors</e2> and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of <e1>DF</e1> to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at <e2>sigma-2 receptors</e2> (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of <e1>DF</e1> to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at <e2>sigma-1 receptors</e2> (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of <e1>DM</e1> and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at <e2>sigma-2 receptors</e2> (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of <e1>DM</e1> and DR. We found that DF, DM, and DR were relative high-affinity ligands at <e2>sigma-1 receptors</e2> (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and <e1>DR</e1>. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at <e2>sigma-2 receptors</e2> (Ki=4-11 microM).","Regulator"
"This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and <e1>DR</e1>. We found that DF, DM, and DR were relative high-affinity ligands at <e2>sigma-1 receptors</e2> (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).","Regulator"
"Binding of <e1>dimemorfan</e1> to <e2>sigma-1 receptor</e2> and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan.","Regulator"
"At 4 hours, losartan blocked 43% of the <e2>Ang II</e2>-induced systolic blood pressure increase; <e1>valsartan</e1>, 51%; and irbesartan, 88% (P<0.01 between drugs).","Downregulator"
"At 4 hours, losartan blocked 43% of the <e2>Ang II</e2>-induced systolic blood pressure increase; valsartan, 51%; and <e1>irbesartan</e1>, 88% (P<0.01 between drugs).","Downregulator"
"This study thus demonstrates that the first administration of the recommended starting dose of <e1>irbesartan</e1> induces a greater and longer lasting <e2>Ang II receptor</e2> blockade than that of valsartan and losartan in normotensive subjects.","Downregulator"
"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting <e2>Ang II receptor</e2> blockade than that of <e1>valsartan</e1> and losartan in normotensive subjects.","Downregulator"
"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting <e2>Ang II receptor</e2> blockade than that of valsartan and <e1>losartan</e1> in normotensive subjects.","Downregulator"
"Eletriptan, like sumatriptan, zolmitriptan, <e1>naratriptan</e1> and rizatriptan had highest affinity for the <e2>human 5-HT1B</e2>, 5-HT1D and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like sumatriptan, zolmitriptan, <e1>naratriptan</e1> and rizatriptan had highest affinity for the human 5-HT1B, <e2>5-HT1D</e2> and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like sumatriptan, zolmitriptan, <e1>naratriptan</e1> and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative <e2>5-ht1f</e2> receptor.","Regulator"
"Eletriptan, like sumatriptan, zolmitriptan, naratriptan and <e1>rizatriptan</e1> had highest affinity for the <e2>human 5-HT1B</e2>, 5-HT1D and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like sumatriptan, zolmitriptan, naratriptan and <e1>rizatriptan</e1> had highest affinity for the human 5-HT1B, <e2>5-HT1D</e2> and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like sumatriptan, zolmitriptan, naratriptan and <e1>rizatriptan</e1> had highest affinity for the human 5-HT1B, 5-HT1D and putative <e2>5-ht1f</e2> receptor.","Regulator"
"Kinetic studies comparing the binding of <e1>[3H]eletriptan</e1> and [3H]sumatriptan to the <e2>human recombinant 5-HT1B</e2> and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.","Regulator"
"Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of <e1>[3H]eletriptan</e1> binding at human 5-HT1B and <e2>5-HT1D</e2> receptors.","Regulator"
"Kinetic studies comparing the binding of [3H]eletriptan and <e1>[3H]sumatriptan</e1> to the <e2>human recombinant 5-HT1B</e2> and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.","Regulator"
"Kinetic studies comparing the binding of [3H]eletriptan and <e1>[3H]sumatriptan</e1> to the human recombinant 5-HT1B and <e2>5-HT1D</e2> receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.","Regulator"
"Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of <e1>[3H]eletriptan</e1> binding at human 5-HT1B and <e2>5-HT1D</e2> receptors.","Regulator"
"Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of <e1>[3H]eletriptan</e1> binding at human <e2>5-HT1B</e2> and 5-HT1D receptors.","Regulator"
"Kinetic studies comparing the binding of [3H]eletriptan and <e1>[3H]sumatriptan</e1> to the human recombinant 5-HT1B and <e2>5-HT1D</e2> receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.","Regulator"
"Kinetic studies comparing the binding of [3H]eletriptan and <e1>[3H]sumatriptan</e1> to the human recombinant <e2>5-HT1B</e2> and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.","Regulator"
"Kinetic studies comparing the binding of [3H]eletriptan and <e1>[3H]sumatriptan</e1> to the human recombinant <e2>5-HT1B</e2> and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.","Regulator"
"Characterisation of the <e2>5-HT receptor</e2> binding profile of <e1>eletriptan</e1> and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.","Regulator"
"Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of <e1>[3H]eletriptan</e1> binding at <e2>human 5-HT1B</e2> and 5-HT1D receptors.","Regulator"
"Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of <e1>[3H]eletriptan</e1> binding at human 5-HT1B and <e2>5-HT1D</e2> receptors.","Regulator"
"The affinity of <e1>eletriptan</e1> ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of <e2>5-HT receptors</e2> was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.","Regulator"
"<e1>Eletriptan</e1>, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the <e2>human 5-HT1B</e2>, 5-HT1D and putative 5-ht1f receptor.","Regulator"
"<e1>Eletriptan</e1>, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, <e2>5-HT1D</e2> and putative 5-ht1f receptor.","Regulator"
"<e1>Eletriptan</e1>, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative <e2>5-ht1f</e2> receptor.","Regulator"
"Eletriptan, like <e1>sumatriptan</e1>, zolmitriptan, naratriptan and rizatriptan had highest affinity for the <e2>human 5-HT1B</e2>, 5-HT1D and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like <e1>sumatriptan</e1>, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, <e2>5-HT1D</e2> and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like <e1>sumatriptan</e1>, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative <e2>5-ht1f</e2> receptor.","Regulator"
"The affinity of eletriptan (<e1>(R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole</e1>) for a range of <e2>5-HT receptors</e2> was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.","Regulator"
"Eletriptan, like sumatriptan, <e1>zolmitriptan</e1>, naratriptan and rizatriptan had highest affinity for the <e2>human 5-HT1B</e2>, 5-HT1D and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like sumatriptan, <e1>zolmitriptan</e1>, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, <e2>5-HT1D</e2> and putative 5-ht1f receptor.","Regulator"
"Eletriptan, like sumatriptan, <e1>zolmitriptan</e1>, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative <e2>5-ht1f</e2> receptor.","Regulator"
"Among neuroleptics, the four most potent compounds at the <e2>human serotonin transporter</e2> were <e1>triflupromazine</e1>, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"Among neuroleptics, the four most potent compounds at the <e2>human serotonin transporter</e2> were triflupromazine, <e1>fluperlapine</e1>, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"Among neuroleptics, the four most potent compounds at the <e2>human serotonin transporter</e2> were triflupromazine, fluperlapine, <e1>chlorpromazine</e1>, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"Among neuroleptics, the four most potent compounds at the <e2>human serotonin transporter</e2> were triflupromazine, fluperlapine, chlorpromazine, and <e1>ziprasidone</e1> (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, <e1>chlorpromazine</e1>, and ziprasidone (K(D) 24-39 nM); and at the <e2>norepinephrine transporter</e2>, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the <e2>norepinephrine transporter</e2>, chlorpromazine, <e1>zotepine</e1>, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the <e2>norepinephrine transporter</e2>, chlorpromazine, zotepine, <e1>chlorprothixene</e1>, and promazine (K(D) 19-25 nM).","Regulator"
"Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflu<e1>promazine</e1>, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the <e2>norepinephrine transporter</e2>, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"At the <e2>human dopamine transporter</e2>, only <e1>pimozide</e1> (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.","Regulator"
"At the <e2>human dopamine transporter</e2>, only pimozide (K(D) = 69+/-3) <e1>ziprasidone</e1> (K(D) = 76+/-5) had notable potency.","Regulator"
"Among <e1>neuroleptics</e1>, the four most potent compounds at the <e2>human serotonin transporter</e2> were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).","Regulator"
"Pharmacological profile of <e1>neuroleptics</e1> at <e2>human monoamine transporters</e2>.","Regulator"
"<e1>Disodium cromoglycate</e1> does not prevent terbutaline-induced desensitization of <e2>beta 2-adrenoceptor</e2>-mediated cardiovascular in vivo functions in human volunteers.","Not"
"<e1>Disodium cromoglycate</e1> affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in <e2>beta 1-adrenoceptor</e2>-mediated exercise tachycardia after 2 weeks' administration of terbutaline.","Not"
"Disodium cromoglycate does not prevent <e1>terbutaline</e1>-induced desensitization of <e2>beta 2-adrenoceptor</e2>-mediated cardiovascular in vivo functions in human volunteers.","Agonist"
"beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective <e2>beta-adrenoceptor</e2> agonist <e1>isoprenaline</e1>; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.","Agonist"
"A multicenter, randomized study of <e1>argatroban</e1> versus heparin as adjunct to tissue plasminogen activator (<e2>TPA</e2>) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.","Regulator"
"A multicenter, randomized study of <e1>argatroban</e1> versus heparin as adjunct to <e2>tissue plasminogen activator</e2> (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.","Regulator"
"CONCLUSIONS: <e1>Argatroban</e1>, as compared with heparin, appears to enhance reperfusion with <e2>TPA</e2> in patients with AMI, particularly in those patients with delayed presentation.","Regulator"
"A multicenter, randomized study of <e1>argatroban</e1> versus heparin as adjunct to tissue plasminogen activator (<e2>TPA</e2>) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.","Regulator"
"OBJECTIVES: This study examined the effect of a small-molecule, direct <e2>thrombin</e2> inhibitor, <e1>argatroban</e1>, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).","Downregulator"
"OBJECTIVES: This study examined the effect of a small-molecule, direct <e2>thrombin</e2> inhibitor, <e1>argatroban</e1>, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).","Downregulator"
"<e1>Losartan</e1>, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to <e2>Ang II</e2>.","Not"
"Losartan, <e1>EXP</e1>, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to <e2>Ang II</e2>.","Not"
"Losartan, EXP, and <e1>irbesartan</e1> caused a rightward parallel shift without any major effects on the maximal response to <e2>Ang II</e2>.","Not"
"In both vascular preparations, <e1>candesartan</e1> caused a marked decrease in the maximal contractile response of the angiotensin II (<e2>Ang II</e2>) concentration-response curve.","Downregulator"
"The functional inhibitory characteristics of the <e2>angiotensin II</e2> type 1 receptor blockers (ARB) <e1>candesartan</e1>; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.","Downregulator"
"In both vascular preparations, <e1>candesartan</e1> caused a marked decrease in the maximal contractile response of the angiotensin II (<e2>Ang II</e2>) concentration-response curve.","Downregulator"
"In both vascular preparations, <e1>candesartan</e1> caused a marked decrease in the maximal contractile response of the angiotensin II (<e2>Ang II</e2>) concentration-response curve.","Downregulator"
"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor</e2> blockers (ARB) candesartan; <e1>irbesartan</e1>; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.","Downregulator"
"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor</e2> blockers (ARB) <e1>candesartan</e1>; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.","Downregulator"
"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor</e2> blockers (ARB) candesartan; irbesartan; and <e1>losartan</e1> and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.","Downregulator"
"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor</e2> blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite <e1>EXP 3174</e1> (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.","Downregulator"
"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor</e2> blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite <e1>EXP</e1> 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.","Downregulator"
"Dose-dependent inhibition of platelet <e2>cyclooxygenase-1</e2> and monocyte cyclooxygenase-2 by <e1>meloxicam</e1> in healthy subjects.","Downregulator"
"Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte <e2>cyclooxygenase-2</e2> by <e1>meloxicam</e1> in healthy subjects.","Downregulator"
"Concentration-response curves for the inhibition of monocyte <e2>COX-2</e2> and platelet COX-1 were obtained in vitro after the incubation of <e1>meloxicam</e1> with whole blood samples.","Downregulator"
"Concentration-response curves for the inhibition of monocyte COX-2 and platelet <e2>COX-1</e2> were obtained in vitro after the incubation of <e1>meloxicam</e1> with whole blood samples.","Downregulator"
"Concentration-response curves for the inhibition of monocyte COX-2 and platelet <e2>COX-1</e2> were obtained in vitro after the incubation of <e1>meloxicam</e1> with whole blood samples.","Downregulator"
"Concentration-response curves for the inhibition of monocyte <e2>COX-2</e2> and platelet COX-1 were obtained in vitro after the incubation of <e1>meloxicam</e1> with whole blood samples.","Downregulator"
"Concentration-response curves for the inhibition of monocyte <e2>COX-2</e2> and platelet COX-1 were obtained in vitro after the incubation of <e1>meloxicam</e1> with whole blood samples.","Downregulator"
"Concentration-response curves for the inhibition of monocyte COX-2 and platelet <e2>COX-1</e2> were obtained in vitro after the incubation of <e1>meloxicam</e1> with whole blood samples.","Downregulator"
"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and <e1>prostaglandin E2</e1> was measured in plasma as an index of monocyte <e2>COX-2</e2> activity.","Substrate"
"The production of <e1>thromboxane B2</e1> in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet <e2>COX-1</e2> activity.","Substrate"
"Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by <e1>(-)-pindolol</e1> alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, <e2>5-HT1A</e2>, and 5-HT1B receptors.","Regulator"
"Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by <e1>(-)-pindolol</e1> alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and <e2>5-HT1B</e2> receptors.","Regulator"
"<e1>(-)-Pindolol</e1>, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors <e2>(AR)s</e2>, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.","Regulator"
"<e1>(-)-Pindolol</e1>, which possesses significant affinity for <e2>5-HT1A</e2>, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.","Regulator"
"<e1>(-)-Pindolol</e1>, which possesses significant affinity for 5-HT1A, <e2>5-HT1B</e2>, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.","Regulator"
"In distinction, the preferential <e2>beta 1-AR</e2> antagonist, <e1>betaxolol</e1>, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.","Antagonist"
"In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential <e2>beta 2-AR</e2> antagonist, <e1>ICI118,551</e1>, did not increase basal levels of DA, NAD, or 5-HT.","Antagonist"
"The selective <e2>5-HT1A</e2> receptor antagonist, <e1>WAY100,635</e1>, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.","Antagonist"
"The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective <e2>5-HT1B</e2> antagonist, <e1>SB224,289</e1>, was ineffective.","Antagonist"
"UNLABELLED: <e1>Entacapone</e1> is a potent and specific peripheral <e2>catechol-O-methyltransferase</e2> (COMT) inhibitor.","Downregulator"
"UNLABELLED: <e1>Entacapone</e1> is a potent and specific peripheral catechol-O-methyltransferase (<e2>COMT</e2>) inhibitor.","Downregulator"
"The goal of this project was to address the possibility that 5-hydroxytryptamine (<e1>5-HT</e1>) stimulates <e2>eNOS</e2> activity in bovine aortic endothelial cell (BAEC) cultures.","Upregulator"
"<e1>5-hydroxytryptamine</e1> evokes <e2>endothelial nitric oxide synthase</e2> activation in bovine aortic endothelial cell cultures.","Upregulator"
"The goal of this project was to address the possibility that 5-hydroxytryptamine (<e1>5-HT</e1>) stimulates <e2>eNOS</e2> activity in bovine aortic endothelial cell (BAEC) cultures.","Upregulator"
"The high affinity <e2>5-HT1B</e2> receptor agonist, <e1>5-nonyloxytryptamine</e1> (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.","Agonist"
"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS</e2> selective antagonists (0.01-10 microM): <e1>L-Nomega -monomethyl-L-arginine</e1> (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).","Antagonist"
"These responses were effectively blocked by the <e2>5-HT1B</e2> receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, <e1>methiothepin</e1>, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).","Antagonist"
"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/<e2>5-HT2 receptor</e2> antagonist, <e1>methiothepin</e1>, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).","Antagonist"
"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS</e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (<e1>L-NMMA</e1>) and L-N omega-iminoethyl-L-ornithine (L-NIO).","Antagonist"
"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS</e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and <e1>L-N omega-iminoethyl-L-ornithine</e1> (L-NIO).","Antagonist"
"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS</e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (<e1>L-NIO</e1>).","Antagonist"
"Here, we tested the hypothesis that 5-HT receptors mediate <e2>eNOS</e2> activation by measuring agonist-stimulated <e1>[3H]L-citrulline</e1> ([3H]L-Cit) formation in BAEC cultures.","Substrate"
"Here, we tested the hypothesis that 5-HT receptors mediate <e2>eNOS</e2> activation by measuring agonist-stimulated [3H]L-citrulline (<e1>[3H]L-Cit</e1>) formation in BAEC cultures.","Substrate"
"Here, we tested the hypothesis that 5-HT receptors mediate <e2>eNOS</e2> activation by measuring agonist-stimulated [3H]L-citrulline (<e1>[3H]L-Cit</e1>) formation in BAEC cultures.","Substrate"
"5-hydroxytryptamine evokes endothelial <e1>nitric oxide</e1> synthase activation in bovine aortic endothelial cell cultures.","Substrate"
"Activation of endothelial <e1>nitric oxide</e1> synthase (<e2>eNOS</e2>) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.","Substrate"
"Activation of <e2>endothelial nitric oxide synthase</e2> (e<e1>NO</e1>S) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.","Substrate"
"Activation of endothelial nitric oxide synthase (e<e1>NO</e1>S) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.","Substrate"
"We found that 5-HT stimulated the conversion of <e1>[3H]L-arginine</e1> ([3H]L-Arg) to [3H]L-Cit, indicating <e2>eNOS</e2> activation.","Substrate"
"We found that 5-HT stimulated the conversion of [3H]L-arginine (<e1>[3H]L-Arg</e1>) to [3H]L-Cit, indicating <e2>eNOS</e2> activation.","Substrate"
"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by <e1>caffeine</e1> in vivo and that <e2>ATM</e2> kinase activity is directly inhibited by caffeine in vitro.","Downregulator"
"We report that the radiation-induced activation of the <e2>kinase</e2> Cds1 [4] (also known as Chk2 [5]) is inhibited by <e1>caffeine</e1> in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.","Downregulator"
"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by <e1>caffeine</e1> in vivo and that <e2>ATM</e2> kinase activity is directly inhibited by caffeine in vitro.","Downregulator"
"We report that the radiation-induced activation of the <e2>kinase</e2> Cds1 [4] (also known as Chk2 [5]) is inhibited by <e1>caffeine</e1> in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.","Downregulator"
"We report that the radiation-induced activation of the kinase <e2>Cds1</e2> [4] (also known as Chk2 [5]) is inhibited by <e1>caffeine</e1> in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.","Downregulator"
"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as <e2>Chk2</e2> [5]) is inhibited by <e1>caffeine</e1> in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.","Downregulator"
"<e1>Caffeine</e1> inhibits the checkpoint <e2>kinase</e2> ATM.","Downregulator"
"<e1>Caffeine</e1> inhibits the checkpoint kinase <e2>ATM</e2>.","Downregulator"
"<e1>Citalopram</e1> protected against the RTI-76-induced inhibition of <e2>SERT</e2> binding.","Regulator"
"The turnover of <e2>SERT</e2> was determined from the rate of recovery of binding after administration of <e1>RTI-76</e1>, an irreversible inhibitor of ligand binding.","Regulator"
"The turnover of <e2>SERT</e2> was determined from the rate of recovery of binding after administration of <e1>RTI-76</e1>, an irreversible inhibitor of ligand binding.","Downregulator"
"The turnover of <e2>SERT</e2> was determined from the rate of recovery of binding after administration of <e1>RTI-76</e1>, an irreversible inhibitor of ligand binding.","Downregulator"
"The turnover of <e2>SERT</e2> was determined from the rate of recovery of binding after administration of <e1>RTI-76</e1>, an irreversible inhibitor of ligand binding.","Downregulator"
"The decrease and recovery of <e1>[3H]-5-HT</e1> uptake correlated highly (r = 0.93) with the recovery of <e2>SERT</e2> binding.","Substrate"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of <e1>losartan</e1>) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Regulator"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, <e1>tasosartan</e1> 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Regulator"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: <e1>candesartan</e1> 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Regulator"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, <e1>telmisartan</e1> 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Regulator"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, <e1>E3174</e1> (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Regulator"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of <e1>losartan</e1>) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Regulator"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, <e1>eprosartan</e1> 100 and the prodrug candesartan cilexetil 280.","Regulator"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug <e1>candesartan cilexetil</e1> 280.","Regulator"
"The mode of (functional) <e2>AT1</e2> receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, <e1>saprisartan</e1>, zolasartan, irbesartan, valsartan, telmisartan, E3174).","Antagonist"
"The mode of (functional) <e2>AT1</e2> receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, <e1>zolasartan</e1>, irbesartan, valsartan, telmisartan, E3174).","Antagonist"
"The mode of (functional) <e2>AT1</e2> receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, <e1>irbesartan</e1>, valsartan, telmisartan, E3174).","Antagonist"
"The mode of (functional) <e2>AT1</e2> receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, <e1>valsartan</e1>, telmisartan, E3174).","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, <e1>telmisartan</e1> 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, <e1>E3174</e1> (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of <e1>losartan</e1>) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"<e1>Losartan</e1> was the first, but by no means remained the only, <e2>AT1</e2> receptor antagonist.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, <e1>tasosartan</e1> 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: <e1>candesartan</e1> 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, <e1>telmisartan</e1> 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, <e1>E3174</e1> (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of <e1>losartan</e1>) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, <e1>eprosartan</e1> 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug <e1>candesartan cilexetil</e1> 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of <e1>losartan</e1>) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, <e1>tasosartan</e1> 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, <e1>eprosartan</e1> 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"Among the current <e2>AT1</e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: <e1>candesartan</e1> 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Antagonist"
"The <e2>mNQO</e2> activity was insensitive to <e1>dicoumarol</e1>, a potent inhibitor of cytosolic NQO1.","Not"
"The mNQO activity was insensitive to <e1>dicoumarol</e1>, a potent inhibitor of cytosolic <e2>NQO1</e2>.","Downregulator"
"A role of cytosolic <e2>NQO1</e2> in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of <e1>quinones</e1> was established.","Substrate"
"The <e2>mNQO</e2> activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of <e1>2,6-dichlorophenolindophenol</e1> and menadione.","Substrate"
"The <e2>mNQO</e2> activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and <e1>menadione</e1>.","Substrate"
"<e2>Quinone oxidoreductases</e2> are flavoproteins that catalyze two-electron reduction and detoxification of <e1>quinones</e1>.","Substrate"
"In addition, the stereospecificity required at <e2>opioid receptors</e2> appears to be retained at the nociceptin receptor, since <e1>(+)-quadazocine</e1> is inactive at both receptors.","Not"
"In addition, the stereospecificity required at opioid receptors appears to be retained at the <e2>nociceptin receptor</e2>, since <e1>(+)-quadazocine</e1> is inactive at both receptors.","Not"
"The affinity and functional profile of opioids possessing activity at the <e2>nociceptin receptor</e2> was determined using [3H]nociceptin and nociceptin-stimulated <e1>[35S]GTPgammaS</e1> binding.","Regulator"
"Lofentanil exhibited full agonism for enhancement of <e1>[35S]GTPgammaS</e1> binding to human recombinant <e2>ORL1</e2> receptors (EC(50) 50 nM).","Regulator"
"<e1>Lofentanil</e1> exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant <e2>ORL1</e2> receptors (EC(50) 50 nM).","Agonist"
"The related piperidines ohmefentanyl and <e1>sufentanil</e1> and the nonselective opioid receptor agonist etorphine were less potent <e2>nociceptin receptor</e2> agonists.","Agonist"
"The related piperidines ohmefentanyl and sufentanil and the nonselective <e2>opioid receptor</e2> agonist <e1>etorphine</e1> were less potent nociceptin receptor agonists.","Agonist"
"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist <e1>etorphine</e1> were less potent <e2>nociceptin receptor</e2> agonists.","Agonist"
"The nonselective <e2>opioid receptor</e2> partial agonist <e1>buprenorphine</e1> and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.","Agonist"
"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist <e1>(-)-quadazocine</e1> exhibited pure antagonism at rat brain receptors, but displayed partial agonism at <e2>human ORL1</e2> receptors.","Agonist"
"The <e2>mu-opioid receptor</e2>-selective agonist <e1>lofentanil</e1> potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).","Agonist"
"The related <e1>piperidines</e1> ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent <e2>nociceptin receptor</e2> agonists.","Agonist"
"The related piperidines <e1>ohmefentanyl</e1> and sufentanil and the nonselective opioid receptor agonist etorphine were less potent <e2>nociceptin receptor</e2> agonists.","Agonist"
"The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist <e1>naloxone benzoylhydrazone</e1> was a pure antagonist at both rat brain and human <e2>ORL1</e2> receptors.","Antagonist"
"The kappa(1)+kappa(3)-opioid receptor agonist/<e2>mu-opioid receptor</e2> antagonist <e1>naloxone benzoylhydrazone</e1> was a pure antagonist at both rat brain and human ORL1 receptors.","Antagonist"
"The nonselective <e2>opioid receptor</e2> partial agonist buprenorphine and the nonselective opioid receptor antagonist <e1>(-)-quadazocine</e1> exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.","Antagonist"
"Thirty-week administration of <e1>UFT</e1> with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of <e2>thymidylate synthase</e2> inhibition and the decrease of thymidine kinase activity in the tumor cells.","Downregulator"
"Thirty-week administration of <e1>UFT</e1> with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of <e2>thymidine kinase</e2> activity in the tumor cells.","Downregulator"
"Thirty-week administration of UFT with or without <e1>leucovorin</e1> markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of <e2>thymidylate synthase</e2> inhibition and the decrease of thymidine kinase activity in the tumor cells.","Downregulator"
"Thirty-week administration of UFT with or without <e1>leucovorin</e1> markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of <e2>thymidine kinase</e2> activity in the tumor cells.","Downregulator"
"<e2>Thymidylate synthase</e2> is inhibited by <e1>5-fluorodeoxyuridine monophosphate</e1>, forming an inactive ternary complex with intracellular folate.","Downregulator"
"<e2>Thymidylate synthase</e2> and thymidine kinase are key enzymes involved in the de novo and salvage pathways for <e1>pyrimidine nucleotide</e1> synthesis, respectively.","Substrate"
"Thymidylate synthase and <e2>thymidine kinase</e2> are key enzymes involved in the de novo and salvage pathways for <e1>pyrimidine nucleotide</e1> synthesis, respectively.","Substrate"
"Ornithine decarboxylase (<e2>ODC</e2>) catalyses the first step in the synthesis of the polyamines putrescine, <e1>spermidine</e1> and spermine.","Substrate"
"<e2>Ornithine decarboxylase</e2> (ODC) catalyses the first step in the synthesis of the polyamines putrescine, <e1>spermidine</e1> and spermine.","Substrate"
"Ornithine decarboxylase (<e2>ODC</e2>) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and <e1>spermine</e1>.","Substrate"
"<e2>Ornithine decarboxylase</e2> (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and <e1>spermine</e1>.","Substrate"
"Ornithine decarboxylase (<e2>ODC</e2>) catalyses the first step in the synthesis of the polyamines <e1>putrescine</e1>, spermidine and spermine.","Substrate"
"<e2>Ornithine decarboxylase</e2> (ODC) catalyses the first step in the synthesis of the polyamines <e1>putrescine</e1>, spermidine and spermine.","Substrate"
"The selective <e2>alpha(2)-adrenoceptor</e2> ligand <e1>rauwolscine</e1> antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43.","Regulator"
"The selective <e2>alpha(1)-adrenoceptor</e2> ligands <e1>prazosin</e1> and doxazosin (each 3 microM) had no effect on noradrenaline responses.","Regulator"
"The selective <e2>alpha(1)-adrenoceptor</e2> ligands prazosin and <e1>doxazosin</e1> (each 3 microM) had no effect on noradrenaline responses.","Regulator"
"The selective <e2>alpha(2)-adrenoceptor</e2> ligand rauwolscine antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against <e1>noradrenaline</e1> was 8.43.","Regulator"
"In <e2>alpha(2A)-adrenoceptor</e2> transfected cells the rank order of agonist potency was <e1>A-54741</e1> (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).","Agonist"
"In <e2>alpha(2A)-adrenoceptor</e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)><e1>dexmedetomidine</e1> (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).","Agonist"
"In <e2>alpha(2A)-adrenoceptor</e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)><e1>UK-14304</e1> (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).","Agonist"
"In <e2>alpha(2A)-adrenoceptor</e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)><e1>B-HT 920</e1> (7.05)>noradrenaline (6.92).","Agonist"
"In <e2>alpha(2A)-adrenoceptor</e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)><e1>noradrenaline</e1> (6.92).","Agonist"
"<e2>Glucocorticoid receptors</e2> were activated by <e1>dexamethasone</e1> as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.","Upregulator"
"The <e2>glucocorticoid receptor</e2> antagonist <e1>RU-486</e1> (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.","Antagonist"
"The <e2>glucocorticoid receptor</e2> antagonist RU-486 (<e1>mifepristone</e1>) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.","Antagonist"
"A positron emission tomography study of <e1>quetiapine</e1> in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine <e2>D2</e2> receptor occupancy.","Regulator"
"CONCLUSIONS: <e1>Quetiapine</e1> shows a transiently high <e2>D2</e2> occupancy, which decreases to very low levels by the end of the dosing interval.","Regulator"
"A positron emission tomography study of <e1>quetiapine</e1> in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high <e2>dopamine D2 receptor</e2> occupancy.","Regulator"
"RESULTS: <e1>Quetiapine</e1> was an effective antipsychotic and improved the extrapyramidal symptoms and <e2>prolactin</e2> level elevation noted at baseline.","Upregulator"
"The attachment of a <e1>fatty acid</e1> chain to LysB29 provided <e2>insulin</e2> detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies.","Part_of"
"Finally, <e1>cysteine</e1> 53 in the <e2>M1P1 external loop</e2> is required for functional expression of TWIK-2 but is not critical for subunit self-assembly.","Part_of"
"Finally, <e1>cysteine</e1> 53 in the M1P1 external loop is required for functional expression of <e2>TWIK-2</e2> but is not critical for subunit self-assembly.","Part_of"
"In a physiological K(+) gradient, <e2>TWIK-2</e2> is half inhibited by 0.1 mm <e1>Ba(2+)</e1>, quinine, and quinidine.","Downregulator"
"In a physiological K(+) gradient, <e2>TWIK-2</e2> is half inhibited by 0.1 mm Ba(2+), <e1>quinine</e1>, and quinidine.","Downregulator"
"In a physiological K(+) gradient, <e2>TWIK-2</e2> is half inhibited by 0.1 mm Ba(2+), quinine, and <e1>quinidine</e1>.","Downregulator"
"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of <e1>eicosapentaenoic acid</e1> (EPA) blocked <e2>Delta-5-desaturase</e2> activity, the terminal enzymatic step in AA synthesis.","Downregulator"
"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (<e1>EPA</e1>) blocked <e2>Delta-5-desaturase</e2> activity, the terminal enzymatic step in AA synthesis.","Downregulator"
"<e1>Nicorandil</e1> 20 micromol/L reversed only 50% of the effect of <e2>ATX-II</e2> and failed to completely suppress TdP in the LQT3 model (5/6 to 3/6).","Regulator"
"BACKGROUND: This study examines the effects of <e1>nicorandil</e1>, a <e2>K(+) channel</e2> opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).","Upregulator"
"Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, <e1>d-sotalol</e1> (100 micromol/L) to block <e2>I(Kr)</e2> (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).","Downregulator"
"Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, <e1>d-sotalol</e1> (100 micromol/L) to block I(Kr) (LQT2 model), and <e2>ATX-II</e2> (20 nmol/L) to augment late I(Na) (LQT3 model).","Downregulator"
"<e1>Isoproterenol</e1> (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block <e2>I(Kr)</e2> (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).","Downregulator"
"<e1>Isoproterenol</e1> (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and <e2>ATX-II</e2> (20 nmol/L) to augment late I(Na) (LQT3 model).","Downregulator"
"We have studied the effects of two fibrates, <e1>bezafibrate</e1> and Wy-14,643, on <e2>UCP-3</e2> and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.","Regulator"
"We have studied the effects of two fibrates, <e1>bezafibrate</e1> and Wy-14,643, on UCP-3 and <e2>UCP-2</e2> mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.","Regulator"
"<e2>Peroxisome proliferator-activated receptor alpha</e2> (PPARalpha) activators, <e1>bezafibrate</e1> and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","Upregulator"
"Peroxisome proliferator-activated receptor alpha (<e2>PPARalpha</e2>) activators, <e1>bezafibrate</e1> and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","Upregulator"
"<e2>Peroxisome proliferator-activated receptor alpha</e2> (PPARalpha) activators, bezafibrate and <e1>Wy-14,643</e1>, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","Upregulator"
"Peroxisome proliferator-activated receptor alpha (<e2>PPARalpha</e2>) activators, bezafibrate and <e1>Wy-14,643</e1>, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","Upregulator"
"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, <e1>bezafibrate</e1> and Wy-14,643, increase <e2>uncoupling protein-3</e2> mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","Upregulator"
"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and <e1>Wy-14,643</e1>, increase <e2>uncoupling protein-3</e2> mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","Upregulator"
"We have studied the effects of two fibrates, <e1>bezafibrate</e1> and Wy-14,643, on <e2>UCP-3</e2> and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.","Upregulator"
"We have studied the effects of two fibrates, bezafibrate and <e1>Wy-14,643</e1>, on <e2>UCP-3</e2> and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.","Upregulator"
"We have studied the effects of two fibrates, <e1>bezafibrate</e1> and Wy-14,643, on <e2>UCP-3</e2> and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.","Upregulator"
"Since it has been proposed that <e2>UCP-3</e2> could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and <e1>Wy-14, 643</e1> treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.","Upregulator"
"We have studied the effects of two fibrates, <e1>bezafibrate</e1> and Wy-14,643, on <e2>UCP-3</e2> and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.","Upregulator"
"<e2>Uncoupling proteins</e2> (UCPs) are inner mitochondrial membrane transporters which act as pores for <e1>H(+)</e1> ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.","Substrate"
"Uncoupling proteins (<e2>UCPs</e2>) are inner mitochondrial membrane transporters which act as pores for <e1>H(+)</e1> ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.","Substrate"
"In order to define the biochemical mechanism involved in the hepatoprotection afforded by <e1>Sch B</e1> pretreatment, we examined the activity of DT-diaphorase (<e2>DTD</e2>) in hepatocytes isolated from Sch B pretreated rats.","Upregulator"
"<e1>Schisandrin B</e1> protects against menadione-induced hepatotoxicity by enhancing <e2>DT-diaphorase</e2> activity.","Upregulator"
"In order to define the biochemical mechanism involved in the hepatoprotection afforded by <e1>Sch B</e1> pretreatment, we examined the activity of DT-diaphorase (<e2>DTD</e2>) in hepatocytes isolated from Sch B pretreated rats.","Upregulator"
"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against <e1>menadione</e1>-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma <e2>alanine aminotransferase</e2> activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.","Downregulator"
"<e2>Creatine phosphokinase</e2> activity in plasma increased slightly (compared to control, <e1>pyridostigmine</e1> or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.","Upregulator"
"<e2>Creatine phosphokinase</e2> activity in plasma increased slightly (compared to control, <e1>pyridostigmine</e1> or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.","Upregulator"
"The group treated with <e1>pyridostigmine</e1> alone showed decreased plasma <e2>butyrylcholinesterase</e2> (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.","Downregulator"
"The group treated with <e1>pyridostigmine</e1> alone showed decreased plasma butyrylcholinesterase (<e2>BChE</e2>) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.","Downregulator"
"The group treated with <e1>pyridostigmine</e1> alone showed decreased plasma butyrylcholinesterase (<e2>BChE</e2>) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.","Downregulator"
"However, <e2>AChE</e2> activity in triceps muscle decreased significantly (78% of control) in the group treated with <e1>pyridostigmine</e1> plus exercise.","Downregulator"
"RESULT(S): <e1>Buserelin acetate</e1>, a GnRH agonist (0.1-10 ng/mL), had no significant effect on <e2>MCP-1</e2> expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.","Not"
"OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as <e1>danazol</e1> and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (<e2>MCP-1</e2>) expression by endometrial epithelial cells.","Downregulator"
"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on <e2>MCP-1</e2> expression, whereas danazol (10(-7)-10(-5) M), a <e1>testosterone</e1> analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.","Downregulator"
"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on <e2>MCP-1</e2> expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and <e1>dexamethasone</e1>, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.","Downregulator"
"RESULT(S): <e1>Buserelin acetate</e1>, a <e2>GnRH</e2> agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.","Agonist"
"<e1>Clenbuterol</e1> caused significant increases in both <e2>NGF</e2> mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.","Not"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>clenbuterol</e1>, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (<e1>CB1093</e1>) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (<e1>CB1093</e1>) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (<e1>CB1093</e1>) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>clenbuterol</e1>, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>clenbuterol</e1>, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (<e1>CB1093</e1>) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>clenbuterol</e1>, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Upregulator"
"<e1>Clenbuterol</e1> caused significant increases in both <e2>NGF</e2> mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.","Upregulator"
"The present studies were undertaken to compare two compounds, a <e1>vitamin D(3)</e1> analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF</e2> synthesis in vivo.","Downregulator"
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>clenbuterol</e1>, a long-acting <e2>beta(2)-adrenoceptor</e2> agonist, both of which induce NGF synthesis in vivo.","Agonist"
"Protective effect of <e1>halothane</e1> anesthesia on retinal light damage: inhibition of metabolic <e2>rhodopsin</e2> regeneration.","Regulator"
"Consequently, <e2>photoreceptors</e2> of mice and rats anesthetized with <e1>halothane</e1> were completely protected against degeneration induced by white light.","Regulator"
"Protective effect of <e1>halothane</e1> anesthesia on retinal light damage: inhibition of metabolic <e2>rhodopsin</e2> regeneration.","Downregulator"
"RESULTS: <e1>Halothane</e1> anesthesia reversibly inhibited metabolic <e2>rhodopsin</e2> regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.","Downregulator"
"RESULTS: <e1>Halothane</e1> anesthesia reversibly inhibited metabolic <e2>rhodopsin</e2> regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.","Downregulator"
"Protective effect of <e1>halothane</e1> anesthesia on retinal light damage: inhibition of metabolic <e2>rhodopsin</e2> regeneration.","Downregulator"
"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with <e2>5-HT1A</e2> and 5-HT1B receptor agonists [<e1>buspirone</e1> (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.","Agonist"
"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and <e2>5-HT1B</e2> receptor agonists [buspirone (partial 5-HT1A agonist), <e1>anpirtoline</e1> (5-HT1B agonist)] in the mouse forced swimming test.","Agonist"
"<e1>Pemetrexed disodium</e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>dihydrofolate reductase</e2>, and glycinamide ribonucleotide formyl transferase.","Downregulator"
"<e1>Pemetrexed disodium</e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyl transferase</e2>.","Downregulator"
"<e1>Pemetrexed disodium</e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits <e2>thymidylate synthase</e2>, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.","Downregulator"
"Pemetrexed disodium (<e1>Alimta</e1>, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>dihydrofolate reductase</e2>, and glycinamide ribonucleotide formyl transferase.","Downregulator"
"Pemetrexed disodium (<e1>Alimta</e1>, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyl transferase</e2>.","Downregulator"
"Pemetrexed disodium (<e1>Alimta</e1>, LY231514) is a novel, multitargeted antifolate that inhibits <e2>thymidylate synthase</e2>, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.","Downregulator"
"Pemetrexed disodium (Alimta, <e1>LY231514</e1>) is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>dihydrofolate reductase</e2>, and glycinamide ribonucleotide formyl transferase.","Downregulator"
"Pemetrexed disodium (Alimta, <e1>LY231514</e1>) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyl transferase</e2>.","Downregulator"
"Pemetrexed disodium (Alimta, <e1>LY231514</e1>) is a novel, multitargeted antifolate that inhibits <e2>thymidylate synthase</e2>, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.","Downregulator"
"To mechanistically evaluate this regional selectivity, we assessed <e2>cyclo-oxygenase-2</e2> (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and <e1>AOM</e1>-treated rats.","Upregulator"
"To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (<e2>COX-2</e2>) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and <e1>AOM</e1>-treated rats.","Upregulator"
"We took advantage of the previous observations that <e1>phosphatidylserine</e1> inhibits <e2>DGK-delta</e2> (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol.","Downregulator"
"<e2>Diacylglycerol kinase</e2> (DGK) catalyzes the conversion of diacylglycerol to <e1>phosphatidic acid</e1>, making it an attractive candidate for a signal transduction component.","Substrate"
"Diacylglycerol kinase (<e2>DGK</e2>) catalyzes the conversion of diacylglycerol to <e1>phosphatidic acid</e1>, making it an attractive candidate for a signal transduction component.","Substrate"
"<e2>Diacylglycerol kinase</e2> (DGK) catalyzes the conversion of <e1>diacylglycerol</e1> to phosphatidic acid, making it an attractive candidate for a signal transduction component.","Substrate"
"Diacylglycerol kinase (<e2>DGK</e2>) catalyzes the conversion of <e1>diacylglycerol</e1> to phosphatidic acid, making it an attractive candidate for a signal transduction component.","Substrate"
"<e1>Nordihydroguaiaretic acid</e1> (NDGA) has been shown to inhibit both 5-lipoxygenase and <e2>ornithine decarboxylase</e2> and is active against several cancer cell lines and at least one mouse tumor model.","Downregulator"
"<e1>Nordihydroguaiaretic acid</e1> (NDGA) has been shown to inhibit both <e2>5-lipoxygenase</e2> and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.","Downregulator"
"Nordihydroguaiaretic acid (<e1>NDGA</e1>) has been shown to inhibit both 5-lipoxygenase and <e2>ornithine decarboxylase</e2> and is active against several cancer cell lines and at least one mouse tumor model.","Downregulator"
"Nordihydroguaiaretic acid (<e1>NDGA</e1>) has been shown to inhibit both <e2>5-lipoxygenase</e2> and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.","Downregulator"
"<e2>Carbonic anhydrase</e2> (CA) is a zinc enzyme that catalyses the reversible hydration reaction of <e1>CO2</e1> and plays a major role in the acid-base balance.","Substrate"
"Carbonic anhydrase (<e2>CA</e2>) is a zinc enzyme that catalyses the reversible hydration reaction of <e1>CO2</e1> and plays a major role in the acid-base balance.","Substrate"
"The temporal profile of butyrylcholinesterase (<e2>BuChE</e2>) and in vitro <e1>pralidoxime</e1>-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.","Upregulator"
"The temporal profile of butyrylcholinesterase (<e2>BuChE</e2>) and in vitro pralid<e1>oxime</e1>-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.","Upregulator"
"The temporal profile of butyrylcholinesterase (<e2>BuChE</e2>) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 <e1>organophosphate</e1>-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.","Downregulator"
"The temporal profile of butyrylcholinesterase (<e2>BuChE</e2>) and in vitro pralid<e1>oxime</e1>-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.","Downregulator"
"Potent <e2>alpha(2A)-adrenoceptor</e2>-mediated vasoconstriction by <e1>brimonidine</e1> in porcine ciliary arteries.","Regulator"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists <e1>brimonidine</e1>, apraclonidine, and oxymetazoline.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists brimonidine, <e1>apraclonidine</e1>, and oxymetazoline.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists brimonidine, apraclonidine, and <e1>oxymetazoline</e1>.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists <e1>brimonidine</e1>, apraclonidine, and oxymetazoline.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists brimonidine, <e1>apraclonidine</e1>, and oxymetazoline.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists brimonidine, apraclonidine, and <e1>oxymetazoline</e1>.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists <e1>brimonidine</e1>, apraclonidine, and oxymetazoline.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists brimonidine, apraclonidine, and <e1>oxymetazoline</e1>.","Agonist"
"The segments were contracted with the <e2>alpha(2)-adrenoceptor</e2> agonists brimonidine, <e1>apraclonidine</e1>, and oxymetazoline.","Agonist"
"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for <e1>BRL44408</e1> (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional <e2>alpha(2A)-adrenoceptors</e2>.","Antagonist"
"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), <e1>ARC 239</e1> (5.8) and for prazosin (6.0) suggesting the presence of functional <e2>alpha(2A)-adrenoceptors</e2>.","Antagonist"
"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for <e1>prazosin</e1> (6.0) suggesting the presence of functional <e2>alpha(2A)-adrenoceptors</e2>.","Antagonist"
"The following alpha(2)-adrenoceptor antagonists were applied: <e1>BRL44408</e1> (<e2>alpha(2A)</e2>-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).","Antagonist"
"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), <e1>ARC239</e1> (<e2>alpha(2B)</e2>- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).","Antagonist"
"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), <e1>ARC239</e1> (alpha(2B)- and <e2>alpha(2C)</e2>-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).","Antagonist"
"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (<e2>alpha(2B)</e2>- and alpha(2C)-selective), and <e1>prazosin</e1> (alpha(2B)- and alpha(2C)-selective).","Antagonist"
"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and <e2>alpha(2C)</e2>-selective), and <e1>prazosin</e1> (alpha(2B)- and alpha(2C)-selective).","Antagonist"
"<e1>Pemetrexed disodium</e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, <e2>thymidylate synthase</e2>, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.","Downregulator"
"<e1>Pemetrexed disodium</e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, <e2>dihydrofolate reductase</e2>, and glycinamide ribonucleotide formyltransferase.","Downregulator"
"<e1>Pemetrexed disodium</e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyltransferase</e2>.","Downregulator"
"Pemetrexed disodium (<e1>ALIMTA</e1>) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, <e2>thymidylate synthase</e2>, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.","Downregulator"
"Pemetrexed disodium (<e1>ALIMTA</e1>) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, <e2>dihydrofolate reductase</e2>, and glycinamide ribonucleotide formyltransferase.","Downregulator"
"Pemetrexed disodium (<e1>ALIMTA</e1>) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyltransferase</e2>.","Downregulator"
"In organisms that synthesize tetrahydrofolate de novo, <e1>dihydrofolate</e1> synthetase (<e2>DHFS</e2>) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.","Substrate"
"UNLABELLED: <e1>Rabeprazole</e1> is an inhibitor of the gastric <e2>proton pump</e2>.","Downregulator"
"UNLABELLED: <e1>Rabeprazole</e1> is an inhibitor of the <e2>gastric proton pump</e2>.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor <e1>Aliskiren</e1> (SPP100): comparison with enalapril.","Upregulator"
"There was a dose-dependent decrease in plasma renin activity, Ang I, and <e2>Ang II</e2> following single doses of <e1>Aliskiren</e1> starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.","Downregulator"
"There was a dose-dependent decrease in plasma renin activity, <e2>Ang I</e2>, and Ang II following single doses of <e1>Aliskiren</e1> starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.","Downregulator"
"There was a dose-dependent decrease in plasma renin activity, Ang I, and <e2>Ang II</e2> following single doses of <e1>Aliskiren</e1> starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.","Downregulator"
"<e2>Angiotensin II</e2> suppression in humans by the orally active renin inhibitor <e1>Aliskiren</e1> (SPP100): comparison with enalapril.","Downregulator"
"<e2>Angiotensin II</e2> suppression in humans by the orally active renin inhibitor Aliskiren (<e1>SPP100</e1>): comparison with enalapril.","Downregulator"
"There was a dose-dependent decrease in plasma renin activity, Ang I, and <e2>Ang II</e2> following single doses of <e1>Aliskiren</e1> starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor <e1>Aliskiren</e1> (SPP100): comparison with enalapril.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor <e1>Aliskiren</e1> (SPP100): comparison with enalapril.","Downregulator"
"<e1>Aliskiren</e1> has the potential to become the first orally active renin inhibitor that provides a true alternative to <e2>ACE</e2>-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor Aliskiren (<e1>SPP100</e1>): comparison with enalapril.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor <e1>Aliskiren</e1> (SPP100): comparison with enalapril.","Downregulator"
"We tested the new orally active nonpeptidic <e2>renin</e2> inhibitor SPP100 (Aliskiren, an <e1>octanamide</e1> with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor <e1>Aliskiren</e1> (SPP100): comparison with enalapril.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor <e1>Aliskiren</e1> (SPP100): comparison with enalapril.","Downregulator"
"Angiotensin II suppression in humans by the orally active <e2>renin</e2> inhibitor Aliskiren (<e1>SPP100</e1>): comparison with enalapril.","Downregulator"
"<e1>Aliskiren</e1> has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and <e2>Ang II receptor</e2> antagonists in therapy for hypertension and other cardiovascular and renal diseases.","Antagonist"
"Almost all patients with <e2>SUR1</e2> (38/41) or KIR6.2 (5/7) mutations were resistant to <e1>diazoxide</e1>.","Not"
"Almost all patients with SUR1 (38/41) or <e2>KIR6.2</e2> (5/7) mutations were resistant to <e1>diazoxide</e1>.","Not"
"The earliest known <e2>AChE</e2> inhibitors, namely, <e1>physostigmine</e1> and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).","Downregulator"
"The earliest known <e2>AChE</e2> inhibitors, namely, physostigmine and <e1>tacrine</e1>, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).","Downregulator"
"<e1>Donepezil hydrochloride</e1> inaugurates a new class of <e2>AChE</e2> inhibitors with longer and more selective action and with manageable adverse effects.","Downregulator"
"Experimentation using isoforms of <e2>alefacept</e2> engineered to have <e1>amino acid</e1> substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B.","Part_of"
"Experimentation using isoforms of alefacept engineered to have <e1>amino acid</e1> substitutions in the <e2>IgG1 C(H)2 domain</e2> that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B.","Part_of"
"<e1>Thalidomide</e1>--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of <e2>TNF alpha</e2>.","Downregulator"
"As a prodrug <e1>leflunomide</e1> is completely converted to its active metabolite A 77 1726 (M1) which blocks the <e2>dihydroorotate dehydrogenase</e2>, a key enzyme of the pyrimidine de novo synthesis.","Downregulator"
"As a prodrug leflunomide is completely converted to its active metabolite <e1>A 77 1726</e1> (M1) which blocks the <e2>dihydroorotate dehydrogenase</e2>, a key enzyme of the pyrimidine de novo synthesis.","Downregulator"
"<e1>Fulvestrant</e1>, the first agent in this new class, not only induces the degradation of the <e2>estrogen receptor</e2> but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.","Downregulator"
"A recent study showed that <e1>anastrozole</e1>, an <e2>aromatase</e2> inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.","Downregulator"
"Because <e2>rhoA</e2> requires <e1>GGPP</e1> for its function, this links the microarray and biochemical data and identifies rhoA as a potential mediator of the anticancer properties of lovastatin.","Regulator"
"Because <e2>rhoA</e2> requires GGPP for its function, this links the microarray and biochemical data and identifies rhoA as a potential mediator of the anticancer properties of <e1>lovastatin</e1>.","Regulator"
"<e1>Lovastatin</e1>, a specific inhibitor of <e2>HMG-CoA reductase</e2>, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.","Downregulator"
"Regulation of <e2>norepinephrine transporter</e2> abundance by <e1>catecholamines</e1> and desipramine in vivo.","Regulator"
"Regulation of <e2>norepinephrine transporter</e2> abundance by catecholamines and <e1>desipramine</e1> in vivo.","Regulator"
"Chronic treatment with the <e2>NET</e2> inhibitor, <e1>desipramine</e1> (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.","Downregulator"
"Chronic treatment with the <e2>NET</e2> inhibitor, <e1>desipramine</e1> (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.","Downregulator"
"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific <e2>alpha(4)beta(2*) nAChR</e2> agonist <e1>metanicotine</e1>, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.","Agonist"
"Probes were perfused with artificial cerebrospinal fluid containing <e1>nicotine</e1>, the specific <e2>alpha(4)beta(2*) nAChR</e2> agonist metanicotine, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.","Agonist"
"<e1>Cilostazol</e1> decreases levels of serum triglycerides and causes some increase in <e2>HDL</e2>-cholesterol levels.","Upregulator"
"<e1>Cilostazol</e1> undergoes intensive and finally complete hepatic metabolism via the <e2>cytochrome P450</e2> systems.","Substrate"
"Mutants <e2>Y751A</e2>, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>cilostazol</e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Not"
"Mutants Y751A, <e2>D950A</e2>, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>cilostazol</e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Not"
"Mutants Y751A, D950A, and <e2>F1004A</e2> had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>cilostazol</e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Not"
"To identify <e1>amino acid</e1> residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of <e2>PDE3A</e2> using a model created on basis of homology to the PDE4B crystal structure.","Part_of"
"To identify <e1>amino acid</e1> residues involved in <e2>PDE3</e2>-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the PDE4B crystal structure.","Part_of"
"We changed the residues to <e1>alanine</e1> using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of <e2>PDE3</e2>.","Part_of"
"Identification of interaction sites of cyclic nucleotide <e2>phosphodiesterase type 3A</e2> with milrinone and <e1>cilostazol</e1> using molecular modeling and site-directed mutagenesis.","Regulator"
"Identification of interaction sites of cyclic nucleotide <e2>phosphodiesterase type 3A</e2> with <e1>milrinone</e1> and cilostazol using molecular modeling and site-directed mutagenesis.","Regulator"
"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant <e2>PDE3A</e2> to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>cilostazol</e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"In contrast, the mutants <e2>T844A</e2>, F972A and Q975A showed increased K(i) for <e1>cilostazol</e1> but no difference for milrinone from the recombinant PDE3A.","Downregulator"
"In contrast, the mutants T844A, <e2>F972A</e2> and Q975A showed increased K(i) for <e1>cilostazol</e1> but no difference for milrinone from the recombinant PDE3A.","Downregulator"
"In contrast, the mutants T844A, F972A and <e2>Q975A</e2> showed increased K(i) for <e1>cilostazol</e1> but no difference for milrinone from the recombinant PDE3A.","Downregulator"
"Mutants Y751A, D950A, and F1004A had reduced sensitivity to <e1>milrinone</e1> (K(i) changed from 0.66 microM for the recombinant <e2>PDE3A</e2> to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"In contrast, the mutants <e2>T844A</e2>, F972A and Q975A showed increased K(i) for cilostazol but no difference for <e1>milrinone</e1> from the recombinant PDE3A.","Downregulator"
"In contrast, the mutants T844A, <e2>F972A</e2> and Q975A showed increased K(i) for cilostazol but no difference for <e1>milrinone</e1> from the recombinant PDE3A.","Downregulator"
"In contrast, the mutants T844A, F972A and <e2>Q975A</e2> showed increased K(i) for cilostazol but no difference for <e1>milrinone</e1> from the recombinant PDE3A.","Downregulator"
"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and <e1>cilostazol</e1>, specific inhibitors of <e2>PDE3</e2>.","Downregulator"
"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by <e1>milrinone</e1> and cilostazol, specific inhibitors of <e2>PDE3</e2>.","Downregulator"
"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and <e1>cilostazol</e1>, specific inhibitors of <e2>PDE</e2>3.","Downregulator"
"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant <e2>PDE3A</e2> to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>cilostazol</e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by <e1>milrinone</e1> and cilostazol, specific inhibitors of <e2>PDE3</e2>.","Downregulator"
"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and <e1>cilostazol</e1>, specific inhibitors of <e2>PDE3</e2>.","Downregulator"
"Mutants <e2>Y751A</e2>, D950A, and F1004A had reduced sensitivity to <e1>milrinone</e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"Mutants Y751A, <e2>D950A</e2>, and F1004A had reduced sensitivity to <e1>milrinone</e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"Mutants Y751A, D950A, and <e2>F1004A</e2> had reduced sensitivity to <e1>milrinone</e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"Mutants Y751A, D950A, and F1004A had reduced sensitivity to <e1>milrinone</e1> (K(i) changed from 0.66 microM for the recombinant <e2>PDE3A</e2> to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant <e2>PDE3A</e2> to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>cilostazol</e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Downregulator"
"The comparison between <e2>MalP</e2> structures shows that His377, through a hydrogen bond with the <e1>6-hydroxyl</e1> group of Glc1P substrate, triggers a conformational change of the 380s loop.","Regulator"
"The bacterial enzyme maltodextrin phosphorylase (<e2>MalP</e2>) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>Glc1P</e1>).","Regulator"
"The bacterial enzyme maltodextrin phosphorylase (<e2>MalP</e2>) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>Glc1P</e1>).","Regulator"
"The 2.0A crystal structure of the <e2>MalP</e2>/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential <e1>pyridoxal phosphate</e1> (PLP) cofactor.","Cofactor"
"The 2.0A crystal structure of the <e2>MalP</e2>/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (<e1>PLP</e1>) cofactor.","Cofactor"
"The bacterial enzyme <e2>maltodextrin phosphorylase</e2> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as <e1>glucose-1-phosphate</e1> (Glc1P).","Substrate"
"The bacterial enzyme maltodextrin phosphorylase (<e2>MalP</e2>) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as <e1>glucose-1-phosphate</e1> (Glc1P).","Substrate"
"The bacterial enzyme <e2>maltodextrin phosphorylase</e2> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>Glc1P</e1>).","Substrate"
"The bacterial enzyme maltodextrin phosphorylase (<e2>MalP</e2>) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>Glc1P</e1>).","Substrate"
"OBJECTIVE: <e1>Fondaparinux sodium</e1> is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to <e2>antithrombin III</e2>.","Regulator"
"OBJECTIVE: <e1>Fondaparinux sodium</e1> is the first in a new class of synthetic <e2>factor Xa</e2> inhibitors that binds reversibly with high affinity to antithrombin III.","Downregulator"
"It is caused by a deficiency of <e1>propionyl-CoA</e1> carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA.","Substrate"
"It is caused by a deficiency of <e1>propionyl-CoA</e1> carboxylase (<e2>PCC</e2>, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA.","Substrate"
"It is caused by a deficiency of <e1>propionyl-CoA</e1> carboxylase (PCC, <e2>EC 6.4.1.3</e2>), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA.","Substrate"
"It is caused by a deficiency of <e2>propionyl-CoA carboxylase</e2> (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>D-methylmalonyl-CoA</e1>.","Substrate"
"It is caused by a deficiency of propionyl-CoA carboxylase (<e2>PCC</e2>, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>D-methylmalonyl-CoA</e1>.","Substrate"
"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, <e2>EC 6.4.1.3</e2>), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>D-methylmalonyl-CoA</e1>.","Substrate"
"The present study determined whether <e1>quetiapine</e1>, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to <e2>5-HT(1A)</e2> agonism.","Regulator"
"The present study determined whether quetiapine, <e1>iloperidone</e1> and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to <e2>5-HT(1A)</e2> agonism.","Regulator"
"The present study determined whether quetiapine, iloperidone and <e1>melperone</e1>, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to <e2>5-HT(1A)</e2> agonism.","Regulator"
"Although only <e1>clozapine</e1> and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>5-HT(2A)</e2> and D(2) blockade.","Downregulator"
"Although only <e1>clozapine</e1> and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>D(2)</e2> blockade.","Downregulator"
"Although only clozapine and <e1>ziprasidone</e1> are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>5-HT(2A)</e2> and D(2) blockade.","Downregulator"
"Although only clozapine and <e1>ziprasidone</e1> are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>D(2)</e2> blockade.","Downregulator"
"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, <e1>WAY100635</e1>, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>5-HT(2A)</e2> and D(2) blockade.","Downregulator"
"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, <e1>WAY100635</e1>, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>D(2)</e2> blockade.","Downregulator"
"The present study determined whether <e1>quetiapine</e1>, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to <e2>5-HT(1A)</e2> agonism.","Agonist"
"Although only <e1>clozapine</e1> and ziprasidone are directly acting <e2>5-HT(1A)</e2> agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.","Agonist"
"Although only clozapine and <e1>ziprasidone</e1> are directly acting <e2>5-HT(1A)</e2> agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.","Agonist"
"Although only clozapine and ziprasidone are directly acting <e2>5-HT(1A)</e2> agonists, <e1>WAY100635</e1>, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.","Antagonist"
"BACKGROUND: The novel antiepileptic drug <e1>retigabine</e1> is the first selective M-current potassium channel opener for <e2>KCNQ2/3</e2> and KCNQ3/5 channels.","Upregulator"
"BACKGROUND: The novel antiepileptic drug <e1>retigabine</e1> is the first selective M-current potassium channel opener for KCNQ2/3 and <e2>KCNQ3/5</e2> channels.","Upregulator"
"BACKGROUND: The novel antiepileptic drug <e1>retigabine</e1> is the first selective <e2>M-current potassium channel</e2> opener for KCNQ2/3 and KCNQ3/5 channels.","Upregulator"
"OBJECTIVE: Because of these physiological effects and the widespread use of the selective <e2>COX-2</e2> inhibitor, <e1>celecoxib</e1>, we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing.","Downregulator"
"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of <e2>COX</e2>-2 in the wound healing process by comparing the effects of a nonselective COX inhibitor, <e1>diclofenac</e1>, with a selective COX-2 inhibitor, SC-791.","Downregulator"
"In vitro autoradiography studies (rat brain slices) with <e1>(S,S)-[(11)C]-MeNER</e1> produced a regional distribution pattern that was consistent with the reported distribution of <e2>NET</e2>.","Regulator"
"In vitro autoradiography studies (rat brain slices) with <e1>(S,S)-[(11)C]-MeNER</e1> produced a regional distribution pattern that was consistent with the reported distribution of <e2>NET</e2>.","Regulator"
"These radiotracers are close analogues of <e1>reboxetine</e1>, a potent and selective ligand for the <e2>norepinephrine transporter</e2> (NET).","Regulator"
"These radiotracers are close analogues of <e1>reboxetine</e1>, a potent and selective ligand for the norepinephrine transporter (<e2>NET</e2>).","Regulator"
"The effects of histamine H1-receptor antagonists, <e1>promethazine</e1> and homochlorcyclizine, both of which are inhibitors of <e2>CYP2D6</e2>, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Downregulator"
"The effects of histamine H1-receptor antagonists, promethazine and <e1>homochlorcyclizine</e1>, both of which are inhibitors of <e2>CYP2D6</e2>, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Downregulator"
"The effects of histamine H1-receptor antagonists, <e1>promethazine</e1> and homochlorcyclizine, both of which are inhibitors of <e2>CYP2D6</e2>, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Downregulator"
"The effects of histamine H1-receptor antagonists, promethazine and <e1>homochlorcyclizine</e1>, both of which are inhibitors of <e2>CYP2D6</e2>, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Downregulator"
"The effects of <e2>histamine H1-receptor</e2> antagonists, <e1>promethazine</e1> and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Antagonist"
"The effects of <e2>histamine H1-receptor</e2> antagonists, promethazine and <e1>homochlorcyclizine</e1>, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Antagonist"
"<e2>Histamine H1-receptor</e2> antagonists, <e1>promethazine</e1> and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.","Antagonist"
"<e2>Histamine H1-receptor</e2> antagonists, promethazine and <e1>homochlorcyclizine</e1>, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.","Antagonist"
"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of <e2>CYP2D6</e2>, on the steady-state plasma concentrations (Css) of <e1>haloperidol</e1> and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Substrate"
"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of <e2>CYP2D6</e2>, on the steady-state plasma concentrations (Css) of <e1>haloperidol</e1> and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.","Substrate"
"Yeast epi<e2>arginase</e2> regulation, an enzyme-enzyme activity control: identification of residues of <e1>ornithine</e1> carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities.","Not"
"In <e2>OTCase</e2>, mutations of putative ornithine binding residues, Asp-182, <e1>Asn</e1>-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.","Part_of"
"In <e2>OTCase</e2>, mutations of putative ornithine binding residues, Asp-182, <e1>Asn</e1>-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.","Part_of"
"In <e2>OTCase</e2>, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, <e1>Cys</e1>-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.","Part_of"
"In <e2>OTCase</e2>, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and <e1>Glu</e1>-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.","Part_of"
"The four <e1>lysine</e1> residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of <e2>OTCase</e2> to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.","Part_of"
"The four lysine residues located in the SMG loop, <e1>Lys</e1>-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of <e2>OTCase</e2> to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.","Part_of"
"The four lysine residues located in the SMG loop, <e1>Lys</e1>-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of <e2>OTCase</e2> to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.","Part_of"
"The four lysine residues located in the SMG loop, <e1>Lys</e1>-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of <e2>OTCase</e2> to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.","Part_of"
"The four lysine residues located in the SMG loop, <e1>Lys</e1>-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of <e2>OTCase</e2> to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.","Part_of"
"In <e2>arginase</e2>, two <e1>cysteines</e1> at the C terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.","Part_of"
"In the presence of ornithine and arginine, ornithine carbamoyltransferase (OT<e1>C</e1>ase) and <e2>arginase</e2> form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.","Part_of"
"In <e2>OTCase</e2>, mutations of putative ornithine binding residues, <e1>Asp</e1>-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.","Part_of"
"In the presence of <e1>ornithine</e1> and arginine, ornithine carbamoyltransferase (<e2>OTCase</e2>) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.","Regulator"
"In the presence of <e1>ornithine</e1> and arginine, ornithine carbamoyltransferase (<e2>OTCase</e2>) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.","Regulator"
"In the presence of <e1>ornithine</e1> and arginine, ornithine carbamoyltransferase (<e2>OTCase</e2>) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.","Downregulator"
"On the other hand, <e1>pranlukast</e1> did not modify the eosinophil spontaneous adhesion to the resting or <e2>IL-4</e2> plus TNF-alpha-stimulated pulmonary endothelial cells.","Not"
"On the other hand, <e1>pranlukast</e1> did not modify the eosinophil spontaneous adhesion to the resting or IL-4 plus <e2>TNF-alpha</e2>-stimulated pulmonary endothelial cells.","Not"
"Similarly, <e1>pranlukast</e1> did not modulate <e2>IL-5</e2>- or FMLP-activated eosinophil adhesion to the resting endothelial cells.","Not"
"<e1>5TFI</e1> was incorporated into a model target protein, <e2>murine dihydrofolate reductase</e2> (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.","Regulator"
"<e1>5TFI</e1> was incorporated into a model target protein, murine dihydrofolate reductase (<e2>mDHFR</e2>), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.","Regulator"
"This binding was not significantly inhibited by the <e1>lysine</e1> analogue epsilon-amino caproic acid (EACA), indicating that <e2>plasminogen</e2> binding was not just through lysine binding sites as suggested for other plasminogen binding sites.","Not"
"This binding was not significantly inhibited by the lysine analogue <e1>epsilon-amino caproic acid</e1> (EACA), indicating that <e2>plasminogen</e2> binding was not just through lysine binding sites as suggested for other plasminogen binding sites.","Not"
"This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (<e1>EACA</e1>), indicating that <e2>plasminogen</e2> binding was not just through lysine binding sites as suggested for other plasminogen binding sites.","Not"
"This binding was not significantly inhibited by the <e1>lysine</e1> analogue epsilon-amino caproic acid (EACA), indicating that <e2>plasminogen</e2> binding was not just through lysine binding sites as suggested for other plasminogen binding sites.","Not"
"Inhibition of binding of both plasminogen and plasmin to <e2>gp330</e2> by <e1>benzamidine</e1> was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.","Regulator"
"Inhibition of binding of both plasminogen and plasmin to <e2>gp330</e2> by benzamidine was similar, although <e1>EACA</e1> inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.","Regulator"
"Inhibition of binding of both plasminogen and plasmin to <e2>gp330</e2> by benzamidine was similar, although <e1>EACA</e1> inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.","Regulator"
"Inhibition of binding of both <e2>plasminogen</e2> and plasmin to gp330 by <e1>benzamidine</e1> was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.","Downregulator"
"Inhibition of binding of both <e2>plasmin</e2>ogen and plasmin to gp330 by <e1>benzamidine</e1> was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.","Downregulator"
"This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (<e1>EACA</e1>), indicating that <e2>plasmin</e2>ogen binding was not just through lysine binding sites as suggested for other plasminogen binding sites.","Downregulator"
"This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (<e1>EACA</e1>), indicating that <e2>plasminogen</e2> binding was not just through lysine binding sites as suggested for other plasminogen binding sites.","Downregulator"
"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective <e2>alpha-adrenoceptor</e2> antagonists, <e1>phentolamine</e1> (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).","Antagonist"
"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective <e2>alpha-adrenoceptor</e2> antagonists, phentolamine (0.3-3 mg/kg) and <e1>phenoxybenzamine</e1> (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).","Antagonist"
"Involvement of <e2>alpha(1)-adrenoceptor</e2>s was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, <e1>prazosin</e1> (0.3 mg/kg).","Antagonist"
"The <e2>alpha(2)-adrenoceptor</e2> antagonist, <e1>rauwolscine</e1> (0.5 mg/kg), was without antagonistic effects.","Antagonist"
"<e2>alpha(1A)-Adrenoceptor</e2> selective antagonists, <e1>2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane</e1> (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","Antagonist"
"<e2>alpha(1A)-Adrenoceptor</e2> selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (<e1>WB-4101</e1>; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","Antagonist"
"<e2>alpha(1A)-Adrenoceptor</e2> selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and <e1>5-methylurapidil</e1> (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","Antagonist"
"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the <e2>alpha(1B)-adrenoceptor</e2> selective antagonist, <e1>4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline</e1> (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","Antagonist"
"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the <e2>alpha(1B)-adrenoceptor</e2> selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (<e1>L-765314</e1>; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","Antagonist"
"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the <e2>alpha(1D)-adrenoceptor</e2> selective antagonist, <e1>8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione</e1> (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","Antagonist"
"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the <e2>alpha(1D)-adrenoceptor</e2> selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (<e1>BMY-7378</e1>; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","Antagonist"
"To further investigate this positive correlation and its possible therapeutic implications, a selective <e2>COX-2</e2> inhibitor, <e1>etodolac</e1>, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.","Downregulator"
"On the other hand, ligands for the renal <e2>Na(+)-transporter</e2> (<e1>amiloride</e1> and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.","Regulator"
"On the other hand, ligands for the renal <e2>Na(+)-transporter</e2> (amiloride and <e1>triamterene</e1>) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.","Regulator"
"However, other <e2>alpha(1)-adrenoceptor</e2> antagonists (<e1>tamsulosin</e1>, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.","Antagonist"
"However, other <e2>alpha(1)-adrenoceptor</e2> antagonists (tamsulosin, <e1>WB4101</e1> and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.","Antagonist"
"However, other <e2>alpha(1)-adrenoceptor</e2> antagonists (tamsulosin, WB4101 and <e1>corynanthine</e1>) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.","Antagonist"
"Of 18 mutations where <e2>hNET</e2> <e1>amino acid</e1> residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).","Part_of"
"A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant <e2>hNET</e2>s reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for <e1>tricyclic</e1> antidepressants and cocaine.","Regulator"
"A comparison of the results with previous data for desipramine and <e1>cocaine</e1> inhibition of norepinephrine uptake by the mutant <e2>hNET</e2>s reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.","Regulator"
"A comparison of the results with previous data for desipramine and cocaine inhibition of <e1>norepinephrine</e1> uptake by the mutant <e2>hNETs</e2> reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.","Substrate"
"The potency of MrIA was greater for inhibition of uptake by <e2>hNET</e2> of <e1>[3H]norepinephrine</e1> (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).","Substrate"
"The potency of MrIA was greater for inhibition of uptake by <e2>hNET</e2> of [3H]norepinephrine (Ki 1.89 microM) than <e1>[3H]dopamine</e1> (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).","Substrate"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, <e2>ACY-1</e2>) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except <e1>L-aspartic acid</e1>, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Not"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [<e2>EC 3.5.1.14</e2>], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except <e1>L-aspartic acid</e1>, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Not"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric <e2>metalloprotein</e2> having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except <e1>L-aspartic acid</e1>, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Not"
"A cDNA encoding the complete amino acid sequence of <e2>aminoacylase 1</e2> (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except <e1>L-aspartic acid</e1>, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Not"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (<e2>N-acylamino acid aminohydrolase</e2>, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except <e1>L-aspartic acid</e1>, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Not"
"From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that <e2>porcine kidney ACY-1</e2> consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with <e1>acetylalanine</e1> at the N-terminus.","Part_of"
"From sequence analysis of the cD<e1>N</e1>A and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that <e2>porcine kidney ACY-1</e2> consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.","Part_of"
"From sequence analysis of the cDNA and the N- and C-terminal <e1>amino acid</e1> analyses of the purified protein, it is deduced that <e2>porcine kidney ACY-1</e2> consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.","Part_of"
"The amino acid sequence deduced from the <e1>nucleotide</e1> sequence of the cDNA from porcine liver was identical to that deduced for <e2>porcine kidney ACY-1</e2>.","Part_of"
"Comparison of the <e1>amino acid</e1> sequence of porcine ACY-1 with those of other <e2>Zn2+-binding metalloenzymes</e2> showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.","Part_of"
"Comparison of the <e1>amino acid</e1> sequence of <e2>porcine ACY-1</e2> with those of other Zn2+-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.","Part_of"
"A cDNA encoding the complete <e1>amino acid</e1> sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, <e2>ACY-1</e2>) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Part_of"
"A cDNA encoding the complete <e1>amino acid</e1> sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [<e2>EC 3.5.1.14</e2>], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Part_of"
"A cDNA encoding the complete <e1>amino acid</e1> sequence of <e2>aminoacylase 1</e2> (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Part_of"
"A cDNA encoding the complete <e1>amino acid</e1> sequence of aminoacylase 1 (<e2>N-acylamino acid aminohydrolase</e2>, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Part_of"
"From sequence analysis of the cD<e1>N</e1>A and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that <e2>porcine kidney ACY-1</e2> consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.","Part_of"
"From sequence analysis of the cDNA and the N- and <e1>C</e1>-terminal amino acid analyses of the purified protein, it is deduced that <e2>porcine kidney ACY-1</e2> consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.","Part_of"
"From sequence analysis of the cDNA and the N- and C-terminal <e1>amino acid</e1> analyses of the purified protein, it is deduced that <e2>porcine kidney ACY-1</e2> consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.","Part_of"
"From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that <e2>porcine kidney ACY-1</e2> consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 <e1>amino acids</e1> with acetylalanine at the N-terminus.","Part_of"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, <e2>ACY-1</e2>) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids</e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Substrate"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [<e2>EC 3.5.1.14</e2>], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids</e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Substrate"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric <e2>metalloprotein</e2> having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids</e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Substrate"
"A cDNA encoding the complete amino acid sequence of <e2>aminoacylase 1</e2> (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids</e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Substrate"
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (<e2>N-acylamino acid aminohydrolase</e2>, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids</e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","Substrate"
"We tested the hypothesis that 2 common polymorphisms in the gene for <e2>beta(1)-adrenergic receptor</e2> are associated with antihypertensive response to <e1>metoprolol</e1> in patients with uncomplicated hypertension.","Regulator"
"We tested the hypothesis that 2 common polymorphisms in the gene for <e2>beta(1)-adrenergic receptor</e2> are associated with antihypertensive response to <e1>metoprolol</e1> in patients with uncomplicated hypertension.","Regulator"
"<e2>Beta 1-adrenergic receptor</e2> polymorphisms and antihypertensive response to <e1>metoprolol</e1>.","Regulator"
"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2</e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, <e1>salsalate</e1>, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.","Downregulator"
"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2</e2>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, <e1>salsalate</e1>, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.","Downregulator"
"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2</e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or <e1>acetaminophen</e1>) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.","Downregulator"
"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2</e2>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or <e1>acetaminophen</e1>) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.","Downregulator"
"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2</e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received <e1>celecoxib</e1> 200 mg/day or rofecoxib 25 mg/day for three weeks.","Downregulator"
"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2</e2>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received <e1>celecoxib</e1> 200 mg/day or rofecoxib 25 mg/day for three weeks.","Downregulator"
"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2</e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or <e1>rofecoxib</e1> 25 mg/day for three weeks.","Downregulator"
"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2</e2>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or <e1>rofecoxib</e1> 25 mg/day for three weeks.","Downregulator"
"RESULTS: <e1>Eprosartan</e1> tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating <e2>Ang-II</e2> levels (p<0.01).","Upregulator"
"We sought to assess the effects of the <e2>angiotensin type 1 (AT1) receptor</e2> blocker <e1>eprosartan</e1> on HRV and BRG.","Downregulator"
"<e2>AT1</e2> antagonism by <e1>eprosartan</e1> lowers heart rate variability and baroreflex gain.","Antagonist"
"<e2>AT1</e2> antagonism by <e1>eprosartan</e1> lowers heart rate variability and baroreflex gain.","Antagonist"
"The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or <e1>N-ethylmaleimide</e1>, agents known to impair the function of <e2>Gi</e2>/Go transducer proteins.","Regulator"
"The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or <e1>N-ethylmaleimide</e1>, agents known to impair the function of Gi/<e2>Go</e2> transducer proteins.","Regulator"
"These results confirm and strengthen the idea of alpha <e1>N-acetyl</e1> beta-endorphin-(1-31) acting as a non-competitive regulator of <e2>mu opioid</e2>- and alpha 2-adrenoceptor-mediated supraspinal antinociception.","Regulator"
"The antinociceptive activity of the <e2>alpha 2-adrenoceptor</e2> agonist clonidine was also increased in mice treated with alpha <e1>N-acetyl</e1> beta-endorphin-(1-31).","Regulator"
"The antinociceptive activity of the <e2>alpha 2-adrenoceptor</e2> agonist <e1>clonidine</e1> was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).","Agonist"
"<e1>Loperamide</e1>, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress <e2>ACTH</e2> and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.","Not"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Not"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Not"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Not"
"After the combined pituitary stimulation test (100 micrograms human <e2>CRH</e2>, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide</e1> from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","Not"
"After the combined pituitary stimulation test (100 micrograms human <e2>CRH</e2>, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide</e1> from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","Not"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Not"
"<e1>Loperamide</e1> has no significant effect on <e2>insulin</e2>-hypoglycemia-induced ACTH and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.","Not"
"<e1>Loperamide</e1>, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress <e2>ACTH</e2> and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.","Not"
"After the combined pituitary stimulation test (100 micrograms <e2>human CRH</e2>, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide</e1> from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","Downregulator"
"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms <e2>GnRH</e2>, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide</e1> from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","Downregulator"
"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms <e2>GH-releasing hormone</e2>, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide</e1> from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","Downregulator"
"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms <e2>TRH</e2>), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide</e1> from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","Downregulator"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Downregulator"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Downregulator"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Downregulator"
"<e1>Loperamide</e1>, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress <e2>ACTH</e2> and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.","Downregulator"
"After the combined pituitary stimulation test (100 micrograms human <e2>CRH</e2>, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide</e1> from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).","Downregulator"
"In seven normal subjects, basal <e2>ACTH</e2> plasma levels were significantly suppressed 3 h after <e1>loperamide</e1> administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).","Downregulator"
"We also examined the effects of <e1>WEB 2086</e1>, a <e2>platelet-activating factor (PAF) receptor</e2> antagonist, in parallel.","Antagonist"
"The compounds identified as <e2>5-LO</e2> inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where <e1>hydroxamic acids</e1> are potent and more selective inhibitors of 5-LO.","Downregulator"
"The <e1>benzothiophene hydroxyurea</e1>, zileuton, is the first selective <e2>5-LO</e2> inhibitor evaluated for the treatment of patients with IBD.","Downregulator"
"The benzothiophene hydroxyurea, <e1>zileuton</e1>, is the first selective <e2>5-LO</e2> inhibitor evaluated for the treatment of patients with IBD.","Downregulator"
"The unique role of the enzyme <e2>5-lipoxygenase</e2> (5-LO) in the production of <e1>leukotrienes</e1> (LTs) makes it a likely target for biochemical manipulation.","Substrate"
"The unique role of the enzyme 5-lipoxygenase (<e2>5-LO</e2>) in the production of <e1>leukotrienes</e1> (LTs) makes it a likely target for biochemical manipulation.","Substrate"
"The unique role of the enzyme <e2>5-lipoxygenase</e2> (5-LO) in the production of leukotrienes (<e1>LTs</e1>) makes it a likely target for biochemical manipulation.","Substrate"
"The unique role of the enzyme 5-lipoxygenase (<e2>5-LO</e2>) in the production of leukotrienes (<e1>LTs</e1>) makes it a likely target for biochemical manipulation.","Substrate"
"In this study, we investigated the expression and function of <e2>p53</e2>R2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated <e1>COOH</e1>-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.","Part_of"
"In PC3 cells, <e1>hydroxyurea</e1> inhibited <e2>hRRM2</e2> and resulted in increased sensitivity to UV irradiation.","Downregulator"
"Ribonucleotide reductase (<e2>RR</e2>) is responsible for the de novo conversion of the ribonucleoside diphosphates to <e1>deoxyribonucleoside diphosphates</e1>, which are essential for DNA synthesis and repair.","Substrate"
"<e2>Ribonucleotide reductase</e2> (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to <e1>deoxyribonucleoside diphosphates</e1>, which are essential for DNA synthesis and repair.","Substrate"
"Ribonucleotide reductase (<e2>RR</e2>) is responsible for the de novo conversion of the <e1>ribonucleoside diphosphates</e1> to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.","Substrate"
"<e2>Ribonucleotide reductase</e2> (RR) is responsible for the de novo conversion of the <e1>ribonucleoside diphosphates</e1> to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.","Substrate"
"These data suggest that, after SCI, <e1>minocycline</e1> treatment modulated expression of <e2>cytokines</e2>, attenuated cell death and the size of lesions, and improved functional recovery in the injured rat.","Regulator"
"Furthermore, RT-PCR analyses revealed that <e1>minocycline</e1> treatment increased expression of <e2>interleukin-10</e2> mRNA but decreased tumor necrosis factor-alpha expression.","Upregulator"
"Furthermore, RT-PCR analyses revealed that <e1>minocycline</e1> treatment increased expression of interleukin-10 mRNA but decreased <e2>tumor necrosis factor-alpha</e2> expression.","Downregulator"
"In addition, <e1>minocycline</e1> treatment significantly reduced the specific <e2>caspase-3</e2> activity after SCI as compared to that of vehicle control.","Downregulator"
"CONCLUSION: <e1>Nandrolone phenylpropionate</e1> up-regulated the density of <e2>AR</e2> in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.","Not"
"OBJECTIVE: To assess the effects of nandrolone phenylpropionate (<e1>NP</e1>) on androgen receptor (<e2>AR</e2>) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.","Not"
"CONCLUSION: <e1>Nandrolone phenylpropionate</e1> up-regulated the density of <e2>AR</e2> in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.","Upregulator"
"OBJECTIVE: To assess the effects of nandrolone phenylpropionate (<e1>NP</e1>) on androgen receptor (<e2>AR</e2>) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.","Upregulator"
"or were chronically pretreated with the selective <e2>beta(2)-adrenoceptor</e2> agonist <e1>salbutamol</e1> (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.","Regulator"
"The pretreatment with <e1>salbutamol</e1> induced a 59% down-regulation of left ventricular <e2>beta(2)-adrenoceptors</e2> compared to control.","Downregulator"
"or were chronically pretreated with the selective <e2>beta(2)-adrenoceptor</e2> agonist <e1>salbutamol</e1> (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.","Agonist"
"Rats received a concomitant treatment with the selective <e2>beta(1)-adrenoceptor</e2> antagonist, <e1>bisoprolol</e1> (50 mg/kg/day p.o.)","Antagonist"
"Characterization of the mouse cold-<e1>menthol</e1> receptor <e2>TRPM8</e2> and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay.","Upregulator"
"The Ca(2+) response of <e2>hVR1</e2>-transfected HEK293 cells to the endogenous VR1 agonist <e1>N-arachidonoyl-dopamine</e1> was potentiated by low pH.","Upregulator"
"Characterization of the mouse cold-<e1>menthol</e1> receptor <e2>TRPM8</e2> and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay.","Upregulator"
"<e2>TRPM8</e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and <e1>icilin</e1>.","Upregulator"
"TRPM8 (<e2>CMR1</e2>) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, <e1>eucalyptol</e1> and icilin.","Upregulator"
"TRPM8 (CMR1) is a <e2>Ca(2+)-permeable channel</e2>, which can be activated by low temperatures, menthol, <e1>eucalyptol</e1> and icilin.","Upregulator"
"<e2>TRPM8</e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, <e1>eucalyptol</e1> and icilin.","Upregulator"
"TRPM8 (<e2>CMR1</e2>) is a Ca(2+)-permeable channel, which can be activated by low temperatures, <e1>menthol</e1>, eucalyptol and icilin.","Upregulator"
"TRPM8 (CMR1) is a <e2>Ca(2+)-permeable channel</e2>, which can be activated by low temperatures, <e1>menthol</e1>, eucalyptol and icilin.","Upregulator"
"Characterization of the mouse cold-<e1>menthol</e1> receptor <e2>TRPM8</e2> and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay.","Upregulator"
"TRPM8 (<e2>CMR1</e2>) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and <e1>icilin</e1>.","Upregulator"
"TRPM8 (CMR1) is a <e2>Ca(2+)-permeable channel</e2>, which can be activated by low temperatures, menthol, eucalyptol and <e1>icilin</e1>.","Upregulator"
"<e2>TRPM8</e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and <e1>icilin</e1>.","Upregulator"
"Known VR1 antagonists (<e1>BCTC</e1>, thio-BCTC and capsazepine) were also able to block the response of <e2>TRPM8</e2> to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Downregulator"
"Known VR1 antagonists (BCTC, <e1>thio-BCTC</e1> and capsazepine) were also able to block the response of <e2>TRPM8</e2> to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Downregulator"
"Known VR1 antagonists (BCTC, thio-BCTC and <e1>capsazepine</e1>) were also able to block the response of <e2>TRPM8</e2> to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Downregulator"
"The Ca(2+) response of h<e2>VR1</e2>-transfected HEK293 cells to the endogenous VR1 agonist <e1>N-arachidonoyl-dopamine</e1> was potentiated by low pH.","Agonist"
"Known <e2>VR1</e2> antagonists (<e1>BCTC</e1>, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Antagonist"
"Known <e2>VR1</e2> antagonists (BCTC, <e1>thio-BCTC</e1> and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Antagonist"
"Known <e2>VR1</e2> antagonists (BCTC, thio-BCTC and <e1>capsazepine</e1>) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Antagonist"
"Inhibitory effects of the monoamine oxidase inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes <e2>CYP2C19</e2>, CYP2C9, and CYP2D6.","Regulator"
"Inhibitory effects of the monoamine oxidase inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes CYP2C19, <e2>CYP2C9</e2>, and CYP2D6.","Regulator"
"Inhibitory effects of the monoamine oxidase inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes CYP2C19, CYP2C9, and <e2>CYP2D6</e2>.","Regulator"
"Inhibitory effects of the monoamine oxidase inhibitor <e1>tranylcypromine</e1> on the <e2>cytochrome P450</e2> enzymes CYP2C19, CYP2C9, and CYP2D6.","Regulator"
"Inhibitory effects of the <e2>monoamine oxidase</e2> inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.","Downregulator"
"The inhibitory effects of <e1>tranylcypromine</e1>, a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO</e2>), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.","Downregulator"
"Inhibitory effects of the monoamine oxidase inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes <e2>CYP2C19</e2>, CYP2C9, and CYP2D6.","Downregulator"
"Inhibitory effects of the monoamine oxidase inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes CYP2C19, CYP2C9, and <e2>CYP2D6</e2>.","Downregulator"
"Inhibitory effects of the monoamine oxidase inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes CYP2C19, <e2>CYP2C9</e2>, and CYP2D6.","Downregulator"
"Inhibitory effects of the <e2>monoamine oxidase</e2> inhibitor <e1>tranylcypromine</e1> on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.","Downregulator"
"Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than <e1>atorvastatin</e1>, a compound that blocks <e2>HMG-CoA reductase</e2>.","Downregulator"
"Although highly homologous to other class III RTKs, <e2>Flt3</e2> is resistant to the <e1>phenylaminopyrimidine</e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Not"
"Although highly homologous to other class III RTKs, <e2>Flt3</e2> is resistant to the phenylaminopyrimidine <e1>STI571</e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Not"
"Although highly homologous to other class III RTKs, <e2>Flt3</e2> is resistant to the phenylaminopyrimidine STI571 (<e1>Gleevec</e1>, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Not"
"Although highly homologous to other class III RTKs, <e2>Flt3</e2> is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>Imatinib</e1>), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Not"
"Although highly homologous to other class III RTKs, <e2>Flt3</e2> is resistant to the phenylaminopyrimidine <e1>STI571</e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Regulator"
"Compounds of several other structural families, including the <e1>quinoxaline</e1> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the <e1>quinoxaline</e1> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline <e1>AG1296</e1>, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline <e1>AG1296</e1>, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the <e1>bis(1H-2-indolyl)-1-methanone</e1> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the <e1>bis(1H-2-indolyl)-1-methanone</e1> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone <e1>D-65476</e1>, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone <e1>D-65476</e1>, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the <e1>indolinones</e1> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the <e1>indolinones</e1> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones <e1>SU5416</e1> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones <e1>SU5416</e1> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and <e1>SU11248</e1>, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and <e1>SU11248</e1>, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the <e1>indolocarbazoles</e1> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the <e1>indolocarbazoles</e1> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles <e1>PKC412</e1> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles <e1>PKC412</e1> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and <e1>CEP-701</e1>, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and <e1>CEP-701</e1>, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Although highly homologous to other class III <e2>RTKs</e2>, Flt3 is resistant to the <e1>phenylaminopyrimidine</e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the <e1>phenylaminopyrimidine</e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor</e2> or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the <e1>phenylaminopyrimidine</e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the <e1>piperazonyl quinazoline</e1> CT53518, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the <e1>piperazonyl quinazoline</e1> CT53518, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline <e1>CT53518</e1>, are potent inhibitors of <e2>Flt3</e2> kinase.","Downregulator"
"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline <e1>CT53518</e1>, are potent inhibitors of Flt3 <e2>kinase</e2>.","Downregulator"
"Although highly homologous to other class III <e2>RTKs</e2>, Flt3 is resistant to the phenylaminopyrimidine <e1>STI571</e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine <e1>STI571</e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor</e2> or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine <e1>STI571</e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit</e2>.","Downregulator"
"Although highly homologous to other class III <e2>RTKs</e2>, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>Gleevec</e1>, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>Gleevec</e1>, Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor</e2> or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>Gleevec</e1>, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit</e2>.","Downregulator"
"Although highly homologous to other class III <e2>RTKs</e2>, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>Imatinib</e1>), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>Imatinib</e1>), a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor</e2> or c-Kit.","Downregulator"
"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>Imatinib</e1>), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit</e2>.","Downregulator"
"Although highly homologous to other class III RTKs, <e2>Flt3</e2> is resistant to the phenylaminopyrimidine <e1>STI571</e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.","Downregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of <e2>HIF</e2>-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Regulator"
"In vivo, <e1>hydralazine</e1> induced <e2>HIF</e2>-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels.","Regulator"
"<e2>Collagen prolyl hydroxylase</e2> is a known target of <e1>hydralazine</e1>.","Regulator"
"In vivo, <e1>hydralazine</e1> induced <e2>HIF</e2>-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (<e2>endothelin-1</e2>, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, <e2>adrenomedullin</e2>, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, <e2>haem oxygenase 1</e2>, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and <e2>vascular endothelial growth factor</e2> [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [<e2>VEGF</e2>]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"In vivo, <e1>hydralazine</e1> induced HIF-1alpha and <e2>VEGF</e2> protein in tissue extracts and elevated plasma VEGF levels.","Upregulator"
"In vivo, <e1>hydralazine</e1> induced HIF-1alpha and <e2>VEGF</e2> protein in tissue extracts and elevated plasma VEGF levels.","Upregulator"
"Novel mechanism of action for <e1>hydralazine</e1>: induction of hypoxia-inducible factor-1alpha, <e2>vascular endothelial growth factor</e2>, and angiogenesis by inhibition of prolyl hydroxylases.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of <e2>HIF-1alpha</e2> and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of <e2>HIF</e2>-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"<e1>Hydralazine</e1> induced rapid and transient expression of <e2>HIF-1alpha</e2> and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","Upregulator"
"In vivo, <e1>hydralazine</e1> induced <e2>HIF-1alpha</e2> and VEGF protein in tissue extracts and elevated plasma VEGF levels.","Upregulator"
"Novel mechanism of action for <e1>hydralazine</e1>: induction of <e2>hypoxia-inducible factor-1alpha</e2>, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.","Upregulator"
"<e1>Hydralazine</e1> dose-dependently inhibited <e2>PHD</e2> activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.","Downregulator"
"<e1>Hydralazine</e1> dose-dependently inhibited <e2>PHD</e2> activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.","Downregulator"
"Novel mechanism of action for <e1>hydralazine</e1>: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of <e2>prolyl hydroxylases</e2>.","Downregulator"
"Thus, <e1>hydralazine</e1> activates the HIF pathway through inhibition of <e2>PHD</e2> activity and initiates a pro-angiogenic phenotype.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, <e1>ketoprofen</e1>, meclofenamic acid, and piroxicam had little selectivity toward <e2>COX</e2> isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.","Regulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, <e1>meclofenamic acid</e1>, and piroxicam had little selectivity toward <e2>COX</e2> isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.","Regulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and <e1>piroxicam</e1> had little selectivity toward <e2>COX</e2> isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.","Regulator"
"RESULTS: <e1>Aspirin</e1>, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward <e2>COX</e2> isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.","Regulator"
"RESULTS: Aspirin, <e1>diclofenac</e1>, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward <e2>COX</e2> isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.","Regulator"
"RESULTS: Aspirin, diclofenac, <e1>indomethacin</e1>, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward <e2>COX</e2> isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.","Regulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas <e1>NS398</e1>, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2</e2> than COX-1.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas <e1>NS398</e1>, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1</e2>.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, <e1>carprofen</e1>, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2</e2> than COX-1.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, <e1>carprofen</e1>, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1</e2>.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, <e1>tolfenamic acid</e1>, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2</e2> than COX-1.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, <e1>tolfenamic acid</e1>, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1</e2>.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, <e1>nimesulide</e1>, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2</e2> than COX-1.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, <e1>nimesulide</e1>, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1</e2>.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and <e1>etodolac</e1> had more than 5 times greater preference for inhibiting <e2>COX-2</e2> than COX-1.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and <e1>etodolac</e1> had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1</e2>.","Downregulator"
"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>Canine COX-2</e2> was selectively inhibited by <e1>etodolac</e1>, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.","Downregulator"
"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>Canine COX-2</e2> was selectively inhibited by etodolac, <e1>nimesulide</e1>, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.","Downregulator"
"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>Canine COX-2</e2> was selectively inhibited by etodolac, nimesulide, and <e1>NS398</e1>; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, <e1>tolfenamic acid</e1>, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2</e2> than COX-1.","Downregulator"
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, <e1>carprofen</e1>, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2</e2> than COX-1.","Downregulator"
"CONCLUSIONS: The most interesting findings were the high mRNA expression of <e2>P2Y12</e2> receptors in lymphocytes potentially explaining the anti-inflammatory effects of <e1>clopidogrel</e1>, P2Y13 receptors in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes.","Regulator"
"<e1>Acarbose</e1> served as inhibitor of an interfering <e2>acid alpha-glucosidase</e2> present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.","Downregulator"
"The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-<e1>amino acid</e1> span in the substrate access channel in <e2>retinaldehyde dehydrogenase II</e2> is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.","Part_of"
"After 12 months of treatment, <e1>carvedilol</e1> significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (<e2>plasma BNP</e2> concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).","Downregulator"
"Effects of <e1>carvedilol</e1> on plasma <e2>B-type natriuretic peptide</e2> concentration and symptoms in patients with heart failure and preserved ejection fraction.","Downregulator"
"After 12 months of treatment, <e1>carvedilol</e1> significantly improved all end points (plasma concentration of B-type natriuretic peptide [<e2>BNP</e2>] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).","Downregulator"
"<e1>Levetiracetam</e1> binds selectively and with high affinity to a <e2>synaptic vesicle protein</e2> known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.","Regulator"
"<e1>Levetiracetam</e1> binds selectively and with high affinity to a synaptic vesicle protein known as <e2>SV2A</e2>, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.","Regulator"
"Psychopharmacology of anticonvulsants: <e1>levetiracetam</e1> as a <e2>synaptic vesicle protein</e2> modulator.","Regulator"
"<e1>Terbinafine</e1>: mode of action and properties of the <e2>squalene epoxidase</e2> inhibition.","Downregulator"
"<e1>Terbinafine</e1>: mode of action and properties of the <e2>squalene epoxidase</e2> inhibition.","Downregulator"
"<e1>Terbinafine</e1>: mode of action and properties of the <e2>squalene epoxidase</e2> inhibition.","Downregulator"
"In contrast, inhibition of rat liver <e1>squalene</e1> epoxidase only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with squalene.","Downregulator"
"Terbinafine (<e1>Lamisil</e1>) has primarily fungicidal action against many fungi as a result of its specific mechanism of <e2>squalene epoxidase</e2> inhibition.","Downregulator"
"Although <e1>celecoxib</e1> inhibits PG biosynthesis, most do not affect the <e2>peroxidase</e2> activity of COX, which can generate proximate carcinogens.","Not"
"Although <e1>celecoxib</e1> inhibits PG biosynthesis, most do not affect the peroxidase activity of <e2>COX</e2>, which can generate proximate carcinogens.","Not"
"Because <e1>thalidomide</e1> does not completely inhibit <e2>COX-2</e2> expression or PG biosynthesis, a therapeutic strategy combining celecoxib with thalidomide might be more effective than using either agent alone.","Not"
"<e1>Thalidomide</e1> decreased the stability of <e2>TNF</e2>-mRNA and COX-2 mRNA.","Regulator"
"<e1>Thalidomide</e1> decreased the stability of TNF-mRNA and <e2>COX-2</e2> mRNA.","Regulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction <e1>pitavastatin</e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).","Regulator"
"Effect of <e1>pitavastatin</e1> on <e2>apolipoprotein A-I</e2> production in HepG2 cell.","Regulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)><e1>simvastatin</e1> (10 microM)>atorvastatin (30 microM).","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)><e1>atorvastatin</e1> (30 microM).","Upregulator"
"Further study revealed that <e1>pitavastatin</e1> increased <e2>ABCA1</e2> mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.","Upregulator"
"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and <e1>Y27632</e1>) increased <e2>apoA-I</e2> production in the HepG2 cells.","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction <e1>pitavastatin</e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction <e1>pitavastatin</e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).","Upregulator"
"Further study revealed that <e1>pitavastatin</e1> increased <e2>ABCA1</e2> mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction <e1>pitavastatin</e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction <e1>pitavastatin</e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)><e1>simvastatin</e1> (10 microM)>atorvastatin (30 microM).","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)><e1>atorvastatin</e1> (30 microM).","Upregulator"
"Each statin induced <e2>apoA-I</e2> expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction <e1>pitavastatin</e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).","Upregulator"
"The induction of <e2>apoA-I</e2> by statins disappeared with addition of <e1>mevalonate</e1>, which indicates that the effect is HMG-CoA reductase inhibition-dependent.","Downregulator"
"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that <e2>Rho</e2> and Rho kinase inhibitor (C3T and <e1>Y27632</e1>) increased apoA-I production in the HepG2 cells.","Downregulator"
"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and <e2>Rho kinase</e2> inhibitor (C3T and <e1>Y27632</e1>) increased apoA-I production in the HepG2 cells.","Downregulator"
"Based on <e2>HMG-CoA reductase</e2> inhibition, <e1>pitavastatin</e1>-induced apoA-I more efficiently than simvastatin and atorvastatin.","Downregulator"
"Further study revealed that <e1>pitavastatin</e1> increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that <e2>Rho</e2> and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.","Downregulator"
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two <e2>receptor tyrosine kinase</e2> inhibitors, <e1>imatinib</e1> and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.","Downregulator"
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, <e1>imatinib</e1> and SU11248, were used to disrupt <e2>PDGFR</e2>-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.","Downregulator"
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, <e1>imatinib</e1> and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or <e2>VEGFR</e2> inhibition.","Downregulator"
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two <e2>receptor tyrosine kinase</e2> inhibitors, imatinib and <e1>SU11248</e1>, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.","Downregulator"
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and <e1>SU11248</e1>, were used to disrupt <e2>PDGFR</e2>-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.","Downregulator"
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and <e1>SU11248</e1>, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or <e2>VEGFR</e2> inhibition.","Downregulator"
"RESULTS: <e1>Imatinib</e1>, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or <e2>VEGFR</e2> inhibition.","Downregulator"
"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable <e2>COX-1</e2> prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not <e1>etodolac</e1>.","Not"
"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable <e2>COX-1</e2> prostanoid TXB2 was significantly reduced by <e1>phenylbutazone</e1> (P<0.05), but not etodolac.","Downregulator"
"The objective of the present study was to compare the anti-inflammatory effects of the preferential <e2>COX</e2>-2 inhibitor etodolac with the non-selective COX inhibitor <e1>phenylbutazone</e1> in horses with lipopolysaccharide (LPS)-induced synovitis.","Downregulator"
"However, MS A2756G was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR <e2>A66G</e2> (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"However, <e2>MS</e2> A2756G was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"However, MS <e2>A2756G</e2> was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"However, MS A2756G was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was <e2>MTRR</e2> A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"However, MS A2756G was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR <e2>A66G</e2> (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"However, <e2>MS</e2> A2756G was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"However, MS <e2>A2756G</e2> was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [<e2>methylenetetrahydrofolate reductase</e2> (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (<e2>MTHFR</e2>) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) <e2>C677T</e2> and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and <e2>A1298C</e2>; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; <e2>methionine synthase</e2> (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (<e2>MS</e2>) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) <e2>A2756G</e2>; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; <e2>methionine synthase reductase</e2> (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (<e2>MTRR</e2>) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"We studied several single nucleotide polymorphisms (SNP) in <e1>Hcy</e1>-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) <e2>A66G</e2>] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.","Regulator"
"However, MS A2756G was significantly associated with <e1>cobalamin</e1> levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was <e2>MTRR</e2> A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).","Regulator"
"<e1>Bosentan</e1> partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in <e2>insulin</e2> level in normoglycemic stressed rats.","Not"
"<e1>Bosentan</e1> partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in <e2>insulin</e2> level in normoglycemic stressed rats.","Regulator"
"<e1>Bosentan</e1> partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in <e2>insulin</e2> level in normoglycemic stressed rats.","Regulator"
"To test this, we studied the possible effect of the endothelin receptor antagonist, <e1>bosentan</e1> (50 and 100 mg kg(-1)) on serum glucose and <e2>insulin</e2> levels as well as on liver glycogen contents in normoglycemic stressed animals.","Regulator"
"Effect of <e1>bosentan</e1> (<e2>ETA</e2>/ETB receptor antagonist) on metabolic changes during stress and diabetes.","Antagonist"
"Effect of <e1>bosentan</e1> (ETA/<e2>ETB</e2> receptor antagonist) on metabolic changes during stress and diabetes.","Antagonist"
"To test this, we studied the possible effect of the <e2>endothelin receptor</e2> antagonist, <e1>bosentan</e1> (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.","Antagonist"
"Levels of superoxide anion (O2-), reduced or oxidized glutathione (<e1>GSH</e1> or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (<e2>complex I</e2>/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.","Upregulator"
"Pre-irradiation administration of RP-1 enhanced levels of <e1>GSH</e1> induced increase in complex I (upto 16 h), <e2>complex I/III</e2> (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).","Upregulator"
"Levels of superoxide anion (O2-), reduced or oxidized glutathione (<e1>GSH</e1> or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (<e2>complex II/III</e2>) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.","Upregulator"
"Jo2-induced activation of <e2>caspase</e2>-3 or -9 in liver tissues was inhibited by <e1>minocycline</e1> pretreatment, and yet the direct addition of minocycline to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.","Not"
"In contrast, <e2>caspase-8</e2> activation and Bid truncation triggered by Jo2 were not diminished by <e1>minocycline</e1> pretreatment in mouse livers.","Not"
"In contrast, caspase-8 activation and <e2>Bid</e2> truncation triggered by Jo2 were not diminished by <e1>minocycline</e1> pretreatment in mouse livers.","Not"
"Effects of <e1>minocycline</e1> on <e2>Fas</e2>-mediated fulminant hepatitis in mice.","Regulator"
"Effects of <e1>minocycline</e1> on <e2>Fas</e2>-mediated fulminant hepatitis in mice.","Regulator"
"Moreover, <e1>minocycline</e1> efficiently suppressed the release of <e2>cytochrome c</e2> from mitochondria of the liver tissues from Jo2-challenged mice.","Downregulator"
"Moreover, <e1>minocycline</e1> efficiently suppressed the release of <e2>cytochrome c</e2> from mitochondria of the liver tissues from Jo2-challenged mice.","Downregulator"
"Jo2-induced activation of <e2>caspase</e2>-3 or -9 in liver tissues was inhibited by <e1>minocycline</e1> pretreatment, and yet the direct addition of minocycline to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.","Downregulator"
"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (<e1>PAG</e1>), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyper<e2>amylase</e2>mia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.","Regulator"
"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic <e2>myeloperoxidase oxidase</e2> (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; <e1>PAG</e1>, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f.","Upregulator"
"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (<e2>MPO</e2>) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; <e1>PAG</e1>, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f.","Upregulator"
"Also, prophylactic, as well as therapeutic, treatment with the <e2>CSE</e2> inhibitor, <e1>DL-propargylglycine</e1> (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.","Downregulator"
"Also, prophylactic, as well as therapeutic, treatment with the <e2>CSE</e2> inhibitor, DL-propargylglycine (<e1>PAG</e1>), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.","Downregulator"
"Cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form <e1>H2S</e1>.","Substrate"
"Cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase</e2> (CBS) utilize L-cysteine as substrate to form <e1>H2S</e1>.","Substrate"
"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS</e2>) utilize L-cysteine as substrate to form <e1>H2S</e1>.","Substrate"
"<e2>Cystathionine-gamma-lyase</e2> (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form <e1>H2S</e1>.","Substrate"
"Of these two enzymes, <e2>cystathionine-gamma-lyase</e2> (CSE) is believed to be the key enzyme that forms <e1>H2S</e1> in the cardiovascular system.","Substrate"
"Cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form <e1>H2S</e1>.","Substrate"
"Cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS) utilize <e1>L-cysteine</e1> as substrate to form H2S.","Substrate"
"Cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase</e2> (CBS) utilize <e1>L-cysteine</e1> as substrate to form H2S.","Substrate"
"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS</e2>) utilize <e1>L-cysteine</e1> as substrate to form H2S.","Substrate"
"<e2>Cystathionine-gamma-lyase</e2> (CSE) and cystathionine-beta-synthase (CBS) utilize <e1>L-cysteine</e1> as substrate to form H2S.","Substrate"
"Recent insights in the role of ATP-binding cassette (ABC) transporters <e2>ABCG5</e2> and ABCG8, the discovery of ezetimibe, the first approved direct <e1>cholesterol</e1> absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.","Regulator"
"Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and <e2>ABCG8</e2>, the discovery of ezetimibe, the first approved direct <e1>cholesterol</e1> absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.","Regulator"
"ABCG5 and ABCG8 themselves are regulated by <e1>cholesterol</e1> via <e2>liver X receptors</e2> (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.","Regulator"
"ABCG5 and ABCG8 themselves are regulated by <e1>cholesterol</e1> via liver X receptors (<e2>LXRs</e2>), which are also activated by oxysterols and some derivatives of plant sterols.","Regulator"
"<e2>Sterol transporters</e2>: targets of natural <e1>sterols</e1> and new lipid lowering drugs.","Regulator"
"Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of <e1>ezetimibe</e1>, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (<e2>NPC1L1</e2>) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.","Regulator"
"ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (<e2>LXRs</e2>), which are also activated by oxy<e1>sterols</e1> and some derivatives of plant sterols.","Upregulator"
"Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct <e1>cholesterol</e1> absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (<e2>NPC1L1</e2>) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.","Substrate"
"Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct <e1>cholesterol</e1> absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as <e2>sterol transporter</e2> in the gut, focused attention on sterol transport processes in the small intestine and the liver.","Substrate"
"<e2>NPC1L1</e2> could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant <e1>sterols</e1>.","Substrate"
"NPC1L1 could recently be identified as a major <e2>sterol transporter</e2> for the intestinal uptake of cholesterol as well as plant <e1>sterols</e1>.","Substrate"
"[Change of dopamine transporter activity (<e2>DAT</e2>) during the action of <e1>bupropion</e1> (in depression)].","Regulator"
"[Change of dopamine transporter activity (<e2>DAT</e2>) during the action of <e1>bupropion</e1> (in depression)].","Regulator"
"[Change of dopamine transporter activity (<e2>DAT</e2>) during the action of <e1>bupropion</e1> (in depression)].","Regulator"
"[Change of <e2>dopamine transporter</e2> activity (DAT) during the action of <e1>bupropion</e1> (in depression)].","Regulator"
"[Change of dopamine transporter activity (<e2>DAT</e2>) during the action of <e1>bupropion</e1> (in depression)].","Regulator"
"<e1>Bupropion</e1> has an antidepressant effect through blocking the <e2>dopamine transporter</e2>.","Downregulator"
"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>bexarotene</e1>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the <e2>IL-2R</e2> and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.","Regulator"
"In vitro studies demonstrated that the <e2>retinoid X receptor</e2> (RXR) retinoid, <e1>bexarotene</e1>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.","Regulator"
"In vitro studies demonstrated that the retinoid X receptor (<e2>RXR</e2>) retinoid, <e1>bexarotene</e1>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.","Regulator"
"Our results demonstrate that the combination of denileukin diftitox and <e1>bexarotene</e1> is well tolerated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of <e2>CD25</e2> expression on circulating leukemia cells.","Upregulator"
"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>bexarotene</e1>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the <e2>p55</e2> and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.","Upregulator"
"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>bexarotene</e1>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and <e2>p75</e2> subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.","Upregulator"
"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>bexarotene</e1>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the <e2>IL-2R</e2> and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.","Upregulator"
"Unlike <e2>transferrin receptor</e2>, the protease domain of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding <e1>arginine</e1> patch.","Part_of"
"Unlike transferrin receptor, the <e2>protease domain</e2> of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding <e1>arginine</e1> patch.","Part_of"
"Unlike transferrin receptor, the protease domain of <e2>PSMA</e2> contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding <e1>arginine</e1> patch.","Part_of"
"<e2>PSMA</e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including <e1>folate</e1>, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.","Substrate"
"PSMA acts as a <e2>glutamate carboxypeptidase</e2> (GCPII) on small molecule substrates, including <e1>folate</e1>, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.","Substrate"
"PSMA acts as a glutamate carboxypeptidase (<e2>GCPII</e2>) on small molecule substrates, including <e1>folate</e1>, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.","Substrate"
"<e2>PSMA</e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug <e1>methotrexate</e1>, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.","Substrate"
"PSMA acts as a <e2>glutamate carboxypeptidase</e2> (GCPII) on small molecule substrates, including folate, the anticancer drug <e1>methotrexate</e1>, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.","Substrate"
"PSMA acts as a glutamate carboxypeptidase (<e2>GCPII</e2>) on small molecule substrates, including folate, the anticancer drug <e1>methotrexate</e1>, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.","Substrate"
"<e2>PSMA</e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide <e1>N-acetyl-l-aspartyl-l-glutamate</e1>.","Substrate"
"PSMA acts as a <e2>glutamate carboxypeptidase</e2> (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide <e1>N-acetyl-l-aspartyl-l-glutamate</e1>.","Substrate"
"<e2>PSMA</e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide <e1>N-acetyl-l-aspartyl-l-glutamate</e1>.","Substrate"
"The two active sites of dimeric <e2>5-aminolevulinate synthase</e2> (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential <e1>amino acids</e1> from each subunit.","Part_of"
"The two active sites of dimeric 5-aminolevulinate synthase (<e2>ALAS</e2>), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential <e1>amino acids</e1> from each subunit.","Part_of"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including <e1>ondansetron</e1>, granisetron, tropisetron renzapride and zacopride.","Not"
"Some 5-HT3 antagonists have <e2>5-HT4</e2> agonist activity (for example, renzapride, zacopride) and others do not (for example, <e1>ondansetron</e1>, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.","Not"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including ondansetron, <e1>granisetron</e1>, tropisetron renzapride and zacopride.","Not"
"Some 5-HT3 antagonists have <e2>5-HT4</e2> agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, <e1>granisetron</e1>), while tropisetron in high concentrations is a 5-HT4 antagonist.","Not"
"While the substituted <e1>benzamide</e1> prokinetics (for example, metoclopramide, cisapride) also block <e2>5-HT3</e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.","Downregulator"
"While the substituted benzamide prokinetics (for example, <e1>metoclopramide</e1>, cisapride) also block <e2>5-HT3</e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.","Downregulator"
"While the substituted benzamide prokinetics (for example, metoclopramide, <e1>cisapride</e1>) also block <e2>5-HT3</e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.","Downregulator"
"While the substituted <e1>benzamide</e1> prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>5-HT4</e2> receptor.","Agonist"
"While the substituted benzamide prokinetics (for example, <e1>metoclopramide</e1>, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>5-HT4</e2> receptor.","Agonist"
"While the substituted benzamide prokinetics (for example, metoclopramide, <e1>cisapride</e1>) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>5-HT4</e2> receptor.","Agonist"
"Some 5-HT3 antagonists have <e2>5-HT4</e2> agonist activity (for example, <e1>renzapride</e1>, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.","Agonist"
"Some 5-HT3 antagonists have <e2>5-HT4</e2> agonist activity (for example, renzapride, <e1>zacopride</e1>) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.","Agonist"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and <e1>zacopride</e1>.","Antagonist"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including ondansetron, granisetron, tropisetron <e1>renzapride</e1> and zacopride.","Antagonist"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and <e1>zacopride</e1>.","Antagonist"
"Some 5-HT3 antagonists have <e2>5-HT4</e2> agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while <e1>tropisetron</e1> in high concentrations is a 5-HT4 antagonist.","Antagonist"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including <e1>ondansetron</e1>, granisetron, tropisetron renzapride and zacopride.","Antagonist"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including ondansetron, <e1>granisetron</e1>, tropisetron renzapride and zacopride.","Antagonist"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including ondansetron, granisetron, <e1>tropisetron</e1> renzapride and zacopride.","Antagonist"
"A number of selective <e2>5-HT3</e2> antagonists have been developed including ondansetron, granisetron, tropisetron <e1>renzapride</e1> and zacopride.","Antagonist"
"We present our studies to demonstrate that <e2>HM74</e2>A, but not HM74, binds <e1>niacin</e1> at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","Not"
"We present our studies to demonstrate that <e2>HM74</e2>A, but not HM74, binds <e1>niacin</e1> at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","Not"
"We present our studies to demonstrate that <e2>HM74</e2>A, but not HM74, binds <e1>niacin</e1> at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","Not"
"We present our studies to demonstrate that <e2>HM74A</e2>, but not HM74, binds <e1>niacin</e1> at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","Regulator"
"A <e2>G-protein coupled receptor</e2> to <e1>niacin</e1> (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.","Regulator"
"A <e2>G-protein coupled receptor</e2> to niacin (<e1>nicotinic acid</e1>) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.","Regulator"
"We present our studies to demonstrate that <e2>HM74A</e2>, but not HM74, binds <e1>niacin</e1> at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","Regulator"
"We present our studies to demonstrate that <e2>HM74A</e2>, but not HM74, binds <e1>niacin</e1> at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","Regulator"
"<e1>Niacin</e1> mediates lipolysis in adipose tissue through its <e2>G-protein coupled receptor HM74A</e2>.","Regulator"
"We present our studies to demonstrate that HM74A, but not HM74, binds <e1>niacin</e1> at high affinities and effectively mediates <e2>Gi</e2> signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.","Upregulator"
"On the other hand, the <e2>FUM1</e2> (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form <e1>malate</e1> at all.","Not"
"On the other hand, the FUM1 (<e2>fumarase</e2>) gene disrupted mutant produced significantly higher levels of fumarate but did not form <e1>malate</e1> at all.","Not"
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the <e2>KGD1</e2> (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of <e1>succinate</e1> than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.","Substrate"
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (<e2>alpha-ketoglutarate dehydrogenase</e2>) gene disrupted mutant produced a lower level of <e1>succinate</e1> than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.","Substrate"
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of <e1>succinate</e1> than the wild-type strain, while the <e2>SDH1</e2> (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.","Substrate"
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of <e1>succinate</e1> than the wild-type strain, while the SDH1 (<e2>succinate dehydrogenase</e2>) gene-disrupted mutant produced an increased level of succinate.","Substrate"
"On the other hand, the <e2>FUM1</e2> (fumarase) gene disrupted mutant produced significantly higher levels of <e1>fumarate</e1> but did not form malate at all.","Substrate"
"On the other hand, the FUM1 (<e2>fumarase</e2>) gene disrupted mutant produced significantly higher levels of <e1>fumarate</e1> but did not form malate at all.","Substrate"
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of <e1>succinate</e1> than the wild-type strain, while the <e2>SDH1</e2> (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.","Substrate"
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the <e2>KGD1</e2> (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of <e1>succinate</e1> than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.","Substrate"
"A double mutant of the two <e2>fumarate reductase</e2> isozyme genes (OSM1 and FRDS) showed a <e1>succinate</e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.","Substrate"
"A double mutant of the two fumarate reductase isozyme genes (<e2>OSM1</e2> and FRDS) showed a <e1>succinate</e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.","Substrate"
"A double mutant of the two fumarate reductase isozyme genes (OSM1 and <e2>FRDS</e2>) showed a <e1>succinate</e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.","Substrate"
"As examples, <e1>ketorolac</e1>, flurbiprofen, ketoprofen and indomethacin have increased <e2>COX-1</e2> selectivity when compared with naproxen and ibuprofen.","Regulator"
"As examples, ketorolac, <e1>flurbiprofen</e1>, ketoprofen and indomethacin have increased <e2>COX-1</e2> selectivity when compared with naproxen and ibuprofen.","Regulator"
"As examples, ketorolac, flurbiprofen, <e1>ketoprofen</e1> and indomethacin have increased <e2>COX-1</e2> selectivity when compared with naproxen and ibuprofen.","Regulator"
"As examples, ketorolac, flurbiprofen, ketoprofen and <e1>indomethacin</e1> have increased <e2>COX-1</e2> selectivity when compared with naproxen and ibuprofen.","Regulator"
"As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased <e2>COX-1</e2> selectivity when compared with <e1>naproxen</e1> and ibuprofen.","Regulator"
"As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased <e2>COX-1</e2> selectivity when compared with naproxen and <e1>ibuprofen</e1>.","Regulator"
"<e1>Vitamin E</e1> supplementation alters <e2>HDL</e2>-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol.","Regulator"
"<e1>Vitamin E</e1> supplementation alters HDL-cholesterol concentration and <e2>paraoxonase</e2> activity in rabbits fed high-cholesterol diet: comparison with probucol.","Regulator"
"<e1>Vitamin E</e1> supplementation alters <e2>HDL</e2>-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol.","Regulator"
"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma <e2>paraoxonase</e2> activity were only significantly higher in <e1>vitamin E</e1> group after 8 weeks.","Upregulator"
"Hepatic ACAT activity was significantly lower in both vitamin E and <e1>probucol</e1> groups than in HC-control group, while <e2>HMG-CoA reductase</e2> activity was the highest only in the probucol group.","Upregulator"
"However, plasma <e2>high-density lipoprotein</e2>-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>vitamin E</e1> group after 8 weeks.","Upregulator"
"However, plasma high-density lipoprotein-cholesterol (<e2>HDL</e2>-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>vitamin E</e1> group after 8 weeks.","Upregulator"
"However, plasma high-density lipoprotein-cholesterol (<e2>HDL</e2>-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>vitamin E</e1> group after 8 weeks.","Upregulator"
"<e1>Vitamin E</e1> and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and <e2>low-density lipoprotein</e2> cholesterol compared to HC-control group.","Downregulator"
"Vitamin E and <e1>probucol</e1> significantly suppressed an increase in plasma total-cholesterol (total-C) and <e2>low-density lipoprotein</e2> cholesterol compared to HC-control group.","Downregulator"
"Hepatic mRNA expressions of <e2>apo B-100</e2> and apo C-III were significantly lower in <e1>probucol</e1> group than in other groups.","Downregulator"
"Hepatic mRNA expressions of apo B-100 and <e2>apo C-III</e2> were significantly lower in <e1>probucol</e1> group than in other groups.","Downregulator"
"Vitamin E supplementation alters <e2>HDL</e2>-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with <e1>probucol</e1>.","Downregulator"
"Hepatic <e2>ACAT</e2> activity was significantly lower in both <e1>vitamin E</e1> and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.","Downregulator"
"Hepatic <e2>ACAT</e2> activity was significantly lower in both vitamin E and <e1>probucol</e1> groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.","Downregulator"
"To do this we cloned and expressed <e2>CCR5</e2> from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and <e1>[3H]-maraviroc</e1> with human recombinant CCR5.","Regulator"
"<e1>[3H]-maraviroc</e1> bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from <e2>macaque CCR5</e2>.","Regulator"
"To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [<e1>125I</e1>]-MIP-1beta and [3H]-maraviroc with <e2>human recombinant CCR5</e2>.","Regulator"
"To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and <e1>[3H]-maraviroc</e1> with <e2>human recombinant CCR5</e2>.","Regulator"
"To do this we cloned and expressed <e2>CCR5</e2> from rhesus macaque and compared the binding properties of [<e1>125I</e1>]-MIP-1beta and [3H]-maraviroc with human recombinant CCR5.","Regulator"
"<e1>Maraviroc</e1> inhibited binding of [125I]-MIP-1beta to <e2>CCR5</e2> from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).","Regulator"
"To do this we cloned and expressed <e2>CCR5</e2> from rhesus macaque and compared the binding properties of [<e1>125I</e1>]-MIP-1beta and [3H]-maraviroc with human recombinant CCR5.","Regulator"
"[3H]-<e1>maraviroc</e1> bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from <e2>macaque CCR5</e2>.","Antagonist"
"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel <e2>CCR5</e2> antagonists, such as <e1>maraviroc</e1> (UK-427,857).","Antagonist"
"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel <e2>CCR5</e2> antagonists, such as <e1>maraviroc</e1> (UK-427,857).","Antagonist"
"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel <e2>CCR5</e2> antagonists, such as maraviroc (<e1>UK-427,857</e1>).","Antagonist"
"<e1>Maraviroc</e1> inhibited binding of [125I]-MIP-1beta to <e2>CCR5</e2> from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).","Antagonist"
"As <e2>CRABPI</e2> was elevated far more than any other genes, we observed that the <e1>retinoids</e1>, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.","Regulator"
"As <e2>CRABPI</e2> was elevated far more than any other genes, we observed that the retinoids, <e1>all-trans retinoic acid</e1> and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.","Regulator"
"As <e2>CRABPI</e2> was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and <e1>9-cis retinoic acid</e1>, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.","Regulator"
"As CRABPI was elevated far more than any other genes, we observed that the <e1>retinoids</e1>, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in <e2>p75NTR</e2> PC-3 cells, but not in neo control PC-3 cells.","Regulator"
"As CRABPI was elevated far more than any other genes, we observed that the retinoids, <e1>all-trans retinoic acid</e1> and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in <e2>p75NTR</e2> PC-3 cells, but not in neo control PC-3 cells.","Regulator"
"As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and <e1>9-cis retinoic acid</e1>, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in <e2>p75NTR</e2> PC-3 cells, but not in neo control PC-3 cells.","Regulator"
"As <e2>CRABPI</e2> was elevated far more than any other genes, we observed that the <e1>retinoids</e1>, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.","Upregulator"
"GPR109A (<e2>PUMA-G</e2>/HM74A) mediates <e1>nicotinic acid</e1>-induced flushing.","Regulator"
"<e2>GPR109A</e2> (PUMA-G/HM74A) mediates <e1>nicotinic acid</e1>-induced flushing.","Regulator"
"Recently, a <e2>G-protein-coupled receptor</e2>, termed GPR109A (HM74A in humans, PUMA-G in mice), was described and shown to mediate the <e1>nicotinic acid</e1>-induced antilipolytic effects in adipocytes.","Regulator"
"<e2>GPR109A</e2> (PUMA-G/HM74A) mediates <e1>nicotinic acid</e1>-induced flushing.","Regulator"
"GPR109A (PUMA-G/<e2>HM74A</e2>) mediates <e1>nicotinic acid</e1>-induced flushing.","Regulator"
"GPR109A (<e2>PUMA-G</e2>/HM74A) mediates <e1>nicotinic acid</e1>-induced flushing.","Regulator"
"Its special profile of actions, especially the rise in <e2>HDL</e2>-cholesterol levels induced by <e1>nicotinic acid</e1>, is unique among the currently available pharmacological tools to treat lipid disorders.","Upregulator"
"<e1>Bisoprolol</e1> markedly suppressed the dobutamine-induced PRA increase in Arg389- but only marginally in Gly389-<e2>beta1AR</e2> subjects.","Regulator"
"OBJECTIVES: The purpose of this research was to find out whether, in humans, <e1>dobutamine</e1>-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (<e2>beta1AR</e2>) genotype-dependent.","Regulator"
"OBJECTIVES: The purpose of this research was to find out whether, in humans, <e1>dobutamine</e1>-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (<e2>beta1AR</e2>) genotype-dependent.","Regulator"
"OBJECTIVES: The purpose of this research was to find out whether, in humans, <e1>dobutamine</e1>-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (<e2>beta1AR</e2>) genotype-dependent.","Regulator"
"<e1>Bisoprolol</e1> markedly suppressed the dobutamine-induced PRA increase in Arg389- but only marginally in Gly389-<e2>beta1AR</e2> subjects.","Regulator"
"OBJECTIVES: The purpose of this research was to find out whether, in humans, <e1>dobutamine</e1>-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (<e2>beta1AR</e2>) genotype-dependent.","Regulator"
"OBJECTIVES: The purpose of this research was to find out whether, in humans, <e1>dobutamine</e1>-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (<e2>beta1AR</e2>) genotype-dependent.","Regulator"
"The Arg389Gly beta1-adrenoceptor polymorphism and <e1>catecholamine</e1> effects on plasma-<e2>renin</e2> activity.","Regulator"
"Although chronic <e1>valproic acid</e1> produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter <e2>phospholipase A(2)</e2> activity, suggesting that it targets a different enzyme in the turnover pathway.","Not"
"Furthermore, <e2>brain microsomal Acsl</e2> did not produce <e1>valproyl-CoA</e1>.","Not"
"RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of <e1>arachidonic acid</e1>, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective <e2>phospholipase A(2)</e2>.","Regulator"
"RATIONALE: Several drugs used to treat bipolar disorder (<e1>lithium</e1> and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective <e2>phospholipase A(2)</e2>.","Downregulator"
"MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (<e2>Acsl</e2>), we show in vitro that <e1>valproic acid</e1> is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.","Downregulator"
"RATIONALE: Several drugs used to treat bipolar disorder (lithium and <e1>carbamazepine</e1>), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective <e2>phospholipase A(2)</e2>.","Downregulator"
"<e1>Valproic acid</e1> selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by <e2>brain microsomal long-chain fatty acyl-CoA synthetases</e2>: relevance to bipolar disorder.","Downregulator"
"CONCLUSIONS: This study shows that <e1>valproic acid</e1> acts as a non-competitive inhibitor of <e2>brain microsomal Acsl</e2>, and that inhibition is substrate-selective.","Downregulator"
"Valproic acid selectively inhibits conversion of arachidonic acid to <e1>arachidonoyl-CoA</e1> by <e2>brain microsomal long-chain fatty acyl-CoA synthetases</e2>: relevance to bipolar disorder.","Substrate"
"Valproic acid selectively inhibits conversion of <e1>arachidonic acid</e1> to arachidonoyl-CoA by <e2>brain microsomal long-chain fatty acyl-CoA synthetases</e2>: relevance to bipolar disorder.","Substrate"
"On the other hand, holocarboxylase synthetase (<e2>HCS</e2>) mRNA levels were markedly low in the deficient animals, and increased upon <e1>biotin</e1> injection.","Regulator"
"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for <e1>biotin</e1> effects on specific genes and proteins, such as HCS and <e2>hexokinases</e2>, and on their proteomes.","Regulator"
"On the other hand, holocarboxylase synthetase (<e2>HCS</e2>) mRNA levels were markedly low in the deficient animals, and increased upon <e1>biotin</e1> injection.","Upregulator"
"On the other hand, <e2>holocarboxylase synthetase</e2> (HCS) mRNA levels were markedly low in the deficient animals, and increased upon <e1>biotin</e1> injection.","Upregulator"
"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by <e1>indomethacin</e1>, a preferential <e2>COX-1</e2> inhibitor, but not by NS-398, a selective COX-2 inhibitor.","Downregulator"
"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by <e1>NS-398</e1>, a selective <e2>COX-2</e2> inhibitor.","Downregulator"
"Involvement of <e2>COX-1</e2> and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced <e1>prostaglandin E2</e1> production by microglia.","Substrate"
"Involvement of COX-1 and up-regulated <e2>prostaglandin E synthases</e2> in phosphatidylserine liposome-induced <e1>prostaglandin E2</e1> production by microglia.","Substrate"
"These observations strongly suggest that the up-regulation of terminal <e2>PGESs</e2> that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced <e1>PGE2</e1> production by microglia.","Substrate"
"Furthermore, PS liposome-induced <e1>PGE2</e1> production was significantly suppressed by indomethacin, a preferential <e2>COX-1</e2> inhibitor, but not by NS-398, a selective COX-2 inhibitor.","Substrate"
"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially <e2>mPGES-2</e2>, plays the pivotal role in PS liposome-induced <e1>PGE2</e1> production by microglia.","Substrate"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>kinase</e2> inhibitors (MKIs) <e1>sorafenib</e1>, sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) <e1>sorafenib</e1>, sunitinib, and AG013736, which target multiple <e2>VEGFRs</e2> as well as PDGFR-beta.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) <e1>sorafenib</e1>, sunitinib, and AG013736, which target multiple VEGFRs as well as <e2>PDGFR-beta</e2>.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>kinase</e2> inhibitors (MKIs) sorafenib, <e1>sunitinib</e1>, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, <e1>sunitinib</e1>, and AG013736, which target multiple <e2>VEGFRs</e2> as well as PDGFR-beta.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, <e1>sunitinib</e1>, and AG013736, which target multiple VEGFRs as well as <e2>PDGFR-beta</e2>.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>kinase</e2> inhibitors (MKIs) sorafenib, sunitinib, and <e1>AG013736</e1>, which target multiple VEGFRs as well as PDGFR-beta.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and <e1>AG013736</e1>, which target multiple <e2>VEGFRs</e2> as well as PDGFR-beta.","Downregulator"
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and <e1>AG013736</e1>, which target multiple VEGFRs as well as <e2>PDGFR-beta</e2>.","Downregulator"
"<e1>Sorafenib</e1> has the added advantage of inhibiting multiple different <e2>Raf</e2> isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.","Downregulator"
"<e1>Sorafenib</e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target <e2>TGF-alpha</e2>/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.","Downregulator"
"<e1>Sorafenib</e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/<e2>EGFR</e2> signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.","Downregulator"
"<e1>Sorafenib</e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of <e2>VEGFR</e2> and PDGFR-beta.","Downregulator"
"<e1>Sorafenib</e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and <e2>PDGFR-beta</e2>.","Downregulator"
"<e2>Thymidylate synthase</e2> expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with <e1>5-fluorouracil</e1>.","Regulator"
"Several variables associated to <e2>thymidylate synthase</e2> (TS), the biological target of 5-fluorouracil (<e1>5FU</e1>) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.","Regulator"
"Several variables associated to thymidylate synthase (<e2>TS</e2>), the biological target of 5-fluorouracil (<e1>5FU</e1>) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.","Regulator"
"Several variables associated to <e2>thymidylate synthase</e2> (TS), the biological target of <e1>5-fluorouracil</e1> (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.","Regulator"
"Several variables associated to thymidylate synthase (<e2>TS</e2>), the biological target of <e1>5-fluorouracil</e1> (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.","Regulator"
"Several variables associated to thymidylate synthase (<e2>TS</e2>), the biological target of 5-fluorouracil (<e1>5FU</e1>) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.","Downregulator"
"When <e2>delta-receptor</e2> binding was determined by using <e1>[3H]DPDPE</e1>, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.","Regulator"
"When <e2>delta-receptor</e2> binding was determined by using [3H]<e1>DPDPE</e1>, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.","Regulator"
"To our surprise, when <e2>mu-receptor</e2> binding was determined by using <e1>[3H]Tyr-D-Ala-Gly-MePhe-Gly-ol</e1> (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.","Regulator"
"To our surprise, when <e2>mu-receptor</e2> binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (<e1>DAMGO</e1>), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.","Regulator"
"To our surprise, when <e2>mu-receptor</e2> binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of <e1>DPDPE</e1> treatment.","Regulator"
"Chronic effect of <e1>[D-Pen2,D-Pen5]enkephalin</e1> on <e2>rat brain opioid receptors</e2>.","Regulator"
"Therefore, in the present studies, animals were rendered tolerant to the <e2>delta-opioid receptor</e2>-selective agonist [D-Pen2,D-Pen5]enkephalin (<e1>DPDPE</e1>), and receptor binding activities were measured.","Downregulator"
"Therefore, in the present studies, animals were rendered tolerant to the <e2>delta-opioid receptor</e2>-selective agonist [D-Pen2,D-Pen5]enkephalin (<e1>DPDPE</e1>), and receptor binding activities were measured.","Agonist"
"Therefore, in the present studies, animals were rendered tolerant to the <e2>delta-opioid receptor</e2>-selective agonist <e1>[D-Pen2,D-Pen5]enkephalin</e1> (DPDPE), and receptor binding activities were measured.","Agonist"
"By contrast, neither amoxapine nor <e1>amitriptyline</e1> can be considered as possible ligands of <e2>5-HT1A</e2> and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).","Not"
"By contrast, neither amoxapine nor <e1>amitriptyline</e1> can be considered as possible ligands of 5-HT1A and <e2>5-HT1B</e2> receptors because their affinities for these sites are in the micromolar range (or even worse).","Not"
"), whereas <e1>amitriptyline</e1> is essentially inactive on <e2>5-HT3</e2> receptors.","Not"
"By contrast, neither <e1>amoxapine</e1> nor amitriptyline can be considered as possible ligands of <e2>5-HT1A</e2> and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).","Not"
"By contrast, neither <e1>amoxapine</e1> nor amitriptyline can be considered as possible ligands of 5-HT1A and <e2>5-HT1B</e2> receptors because their affinities for these sites are in the micromolar range (or even worse).","Not"
"Interestingly, <e1>amoxapine</e1> binds with a good affinity (IC50 = 0.30 microM) to <e2>5-HT3</e2> receptors labelled by [3H]zacopride in cortical membranes.","Regulator"
"Interestingly, amoxapine binds with a good affinity (IC50 = 0.30 microM) to <e2>5-HT3</e2> receptors labelled by <e1>[3H]zacopride</e1> in cortical membranes.","Regulator"
"In vitro binding studies showed that both <e1>amoxapine</e1> and amitriptyline interact in the nanomolar range with <e2>5-HT2</e2> receptors labelled by [3H]ketanserin in cortical membranes.","Regulator"
"In vitro binding studies showed that both amoxapine and <e1>amitriptyline</e1> interact in the nanomolar range with <e2>5-HT2</e2> receptors labelled by [3H]ketanserin in cortical membranes.","Regulator"
"In vitro binding studies showed that both amoxapine and amitriptyline interact in the nanomolar range with <e2>5-HT2</e2> receptors labelled by <e1>[3H]ketanserin</e1> in cortical membranes.","Regulator"
"The second part of this study consisted of looking for possible changes in central <e2>5-HT receptors</e2> 24 h after either a single or a repeated (for 14 days) treatment with <e1>amoxapine</e1> (10 mg/kg i.p.","Regulator"
"Interestingly, <e1>amoxapine</e1> binds with a good affinity (IC50 = 0.30 microM) to <e2>5-HT3</e2> receptors labelled by [3H]zacopride in cortical membranes.","Antagonist"
"<e1>DVS</e1> showed weak binding affinity (62% inhibition at 100 microM) at the <e2>human dopamine (DA) transporter</e2>.","Regulator"
"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (<e2>hSERT</e2>) or norepinephrine (NE) transporter (hNET) with K(i) values for <e1>DVS</e1> of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.","Regulator"
"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (<e2>hNET</e2>) with K(i) values for <e1>DVS</e1> of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.","Regulator"
"Competitive radioligand binding assays were performed using cells expressing either the <e2>human serotonin (5-HT) transporter</e2> (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for <e1>DVS</e1> of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.","Downregulator"
"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (<e2>hSERT</e2>) or norepinephrine (NE) transporter (hNET) with K(i) values for <e1>DVS</e1> of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.","Downregulator"
"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or <e2>norepinephrine (NE) transporter</e2> (hNET) with K(i) values for <e1>DVS</e1> of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.","Downregulator"
"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (<e2>hNET</e2>) with K(i) values for <e1>DVS</e1> of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.","Downregulator"
"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory <e2>5-HT(1A)</e2> autoreceptors, a 5-HT(1A) antagonist, <e1>N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt</e1> (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).","Antagonist"
"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory <e2>5-HT(1A)</e2> autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (<e1>WAY-100635</e1>) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).","Antagonist"
"Inhibition of <e1>[3H]5-HT</e1> or [3H]NE uptake by DVS for the <e2>hSERT</e2> or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.","Substrate"
"Inhibition of [3H]5-HT or <e1>[3H]NE</e1> uptake by DVS for the hSERT or <e2>hNET</e2> produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.","Substrate"
"Further, <e1>cholesterol</e1> metabolites, predominantly the oxysterols, the natural ligands for <e2>liver X receptor</e2> (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.","Regulator"
"Further, <e1>cholesterol</e1> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (<e2>LXR</e2>), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.","Regulator"
"Further, cholesterol metabolites, predominantly the <e1>oxysterols</e1>, the natural ligands for <e2>liver X receptor</e2> (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.","Regulator"
"Further, cholesterol metabolites, predominantly the <e1>oxysterols</e1>, the natural ligands for liver X receptor (<e2>LXR</e2>), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.","Regulator"
"Further, <e1>cholesterol</e1> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of <e2>sterol regulatory element binding protein-1c</e2> (SREBP-1c) that bound to the regulatory regions of these genes.","Upregulator"
"Further, <e1>cholesterol</e1> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (<e2>SREBP-1c</e2>) that bound to the regulatory regions of these genes.","Upregulator"
"Further, cholesterol metabolites, predominantly the <e1>oxysterols</e1>, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of <e2>sterol regulatory element binding protein-1c</e2> (SREBP-1c) that bound to the regulatory regions of these genes.","Upregulator"
"Further, cholesterol metabolites, predominantly the <e1>oxysterols</e1>, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (<e2>SREBP-1c</e2>) that bound to the regulatory regions of these genes.","Upregulator"
"The tissue <e1>RA</e1> level is maintained through a cascade of metabolic reactions where <e2>retinal dehydrogenases</e2> (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.","Substrate"
"The tissue <e1>RA</e1> level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (<e2>RALDHs</e2>) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.","Substrate"
"Regulation of <e1>retinal</e1> dehydrogenases and retinoic acid synthesis by cholesterol metabolites.","Substrate"
"The tissue RA level is maintained through a cascade of metabolic reactions where <e1>retinal</e1> dehydrogenases (<e2>RALDHs</e2>) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.","Substrate"
"Hypermethlyation of <e2>RELN and GAD67 promoters</e2> can be induced by treating mice with <e1>methionine</e1>, and these mice display brain and behavioral abnormalities similar to +/rl.","Upregulator"
"Functional and bioenergetic consequences of <e2>AT1</e2> antagonist <e1>olmesartan medoxomil</e1> in hearts with postinfarction LV remodeling.","Antagonist"
"Functional and bioenergetic consequences of <e2>AT1</e2> antagonist <e1>olmesartan medoxomil</e1> in hearts with postinfarction LV remodeling.","Antagonist"
"Experiments with Schwann cell primary cultures revealed an effect of <e1>retinoic acid</e1> on the expression of the <e2>neuregulin receptor</e2> ErbB3, suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.","Regulator"
"Experiments with Schwann cell primary cultures revealed an effect of <e1>retinoic acid</e1> on the expression of the neuregulin receptor <e2>ErbB3</e2>, suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.","Regulator"
"Regulation of <e1>retinoic acid</e1> receptors alpha, beta and retinoid X receptor alpha after sciatic nerve injury.","Regulator"
"Since the effect of <e1>retinoic acid</e1> is mediated via retinoic acid receptors and <e2>retinoid X receptors</e2>, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.","Regulator"
"RESULTS: <e1>Imatinib</e1> inhibited <e2>RET</e2> Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.","Downregulator"
"RESULTS: <e1>Imatinib</e1> inhibited <e2>RET</e2> Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.","Downregulator"
"RESULTS: <e1>Imatinib</e1> inhibited RET <e2>Y1062</e2> phosphorylation in a dose-dependent manner after 1.5 hours of exposure.","Downregulator"
"RESULTS: <e1>Imatinib</e1> inhibited <e2>RET</e2> Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.","Downregulator"
"Cellular effects of <e1>imatinib</e1> on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated <e2>RET</e2> mutations.","Downregulator"
"We evaluated <e1>imatinib</e1>, a <e2>tyrosine kinase</e2> inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.","Downregulator"
"In eukaryotes, the most prominent Mo-enzymes are (1) <e2>sulfite oxidase</e2>, which catalyzes the final step in the degradation of <e1>sulfur</e1>-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.","Substrate"
"Among them, <e1>tamibarotene</e1> (Am80) is an RARalpha- and RARbeta-specific (but <e2>RARgamma</e2>- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Not"
"Among them, <e1>tamibarotene</e1> (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and <e2>RXRs</e2>-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Not"
"Among them, tamibarotene (<e1>Am80</e1>) is an RARalpha- and RARbeta-specific (but <e2>RARgamma</e2>- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Not"
"Among them, tamibarotene (<e1>Am80</e1>) is an RARalpha- and RARbeta-specific (but RARgamma- and <e2>RXRs</e2>-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Not"
"Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but <e2>RARgamma</e2>- and RXRs-nonbinding) synthetic <e1>retinoid</e1> that is effective in the treatment of psoriasis patients and relapsed APL.","Not"
"Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and <e2>RXRs</e2>-nonbinding) synthetic <e1>retinoid</e1> that is effective in the treatment of psoriasis patients and relapsed APL.","Not"
"<e1>Retinoid</e1> is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of <e2>nuclear hormone receptor</e2> superfamily.","Regulator"
"<e1>Retinoid</e1> is a collective term for compounds which bind to and activate <e2>retinoic acid receptors</e2> (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.","Regulator"
"Among them, <e1>tamibarotene</e1> (Am80) is an <e2>RARalpha</e2>- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Regulator"
"Among them, <e1>tamibarotene</e1> (Am80) is an RARalpha- and <e2>RARbeta</e2>-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Regulator"
"Among them, tamibarotene (<e1>Am80</e1>) is an <e2>RARalpha</e2>- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Regulator"
"Among them, tamibarotene (<e1>Am80</e1>) is an RARalpha- and <e2>RARbeta</e2>-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.","Regulator"
"The most important endogeneous <e1>retinoid</e1> is all-trans-retinoic acid (ATRA) which is an <e2>RARalpha</e2>, beta and gamma ligand.","Regulator"
"Among them, tamibarotene (Am80) is an RARalpha- and <e2>RARbeta</e2>-specific (but RARgamma- and RXRs-nonbinding) synthetic <e1>retinoid</e1> that is effective in the treatment of psoriasis patients and relapsed APL.","Regulator"
"<e1>Retinoid</e1> is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of <e2>nuclear hormone receptor</e2> superfamily.","Upregulator"
"<e1>Retinoid</e1> is a collective term for compounds which bind to and activate <e2>retinoic acid receptors</e2> (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.","Upregulator"
"The cholesterol-lowering drug <e1>simvastatin</e1> inhibits LFA-1 signaling by binding to an allosteric site on <e2>CD11a</e2> (LFA-1 alpha chain), which leads to immunomodulation.","Regulator"
"The cholesterol-lowering drug <e1>simvastatin</e1> inhibits LFA-1 signaling by binding to an allosteric site on CD11a (<e2>LFA-1 alpha chain</e2>), which leads to immunomodulation.","Regulator"
"<e1>Simvastatin</e1> regulates non-neuronal cholinergic activity in T lymphocytes via <e2>CD11a</e2>-mediated pathways.","Regulator"
"<e1>Simvastatin</e1> regulates non-neuronal cholinergic activity in T lymphocytes via <e2>CD11a</e2>-mediated pathways.","Downregulator"
"The cholesterol-lowering drug <e1>simvastatin</e1> inhibits <e2>LFA-1</e2> signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.","Downregulator"
"Similar to <e1>menthol</e1>, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other <e2>thermoTRPs</e2>.","Regulator"
"Similar to menthol, both <e1>camphor</e1> and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other <e2>thermoTRPs</e2>.","Regulator"
"Similar to menthol, both camphor and <e1>cinnamaldehyde</e1> (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other <e2>thermoTRPs</e2>.","Regulator"
"<e1>Menthol</e1>, popularly known for its cooling effect, activates <e2>TRPM8</e2>--a cold-activated thermoTRP ion channel.","Upregulator"
"<e1>Menthol</e1>, popularly known for its cooling effect, activates TRPM8--a cold-activated <e2>thermoTRP ion channel</e2>.","Upregulator"
"However, human physiological studies demonstrate a paradoxical role of <e1>menthol</e1> in modulation of warm sensation, and here, we show that menthol also activates heat-activated <e2>TRPV3</e2>.","Upregulator"
"However, human physiological studies demonstrate a paradoxical role of <e1>menthol</e1> in modulation of warm sensation, and here, we show that menthol also activates heat-activated <e2>TRPV3</e2>.","Upregulator"
"We further show that <e1>menthol</e1> inhibits <e2>TRPA1</e2>, potentially explaining the use of menthol as an analgesic.","Upregulator"
"Similar to menthol, both <e1>camphor</e1> and cinnamaldehyde (initially reported to be specific activators of <e2>TRPV3</e2> and TRPA1, respectively) also modulate other thermoTRPs.","Upregulator"
"Similar to menthol, both <e1>camphor</e1> and cinnamaldehyde (initially reported to be specific activators of TRPV3 and <e2>TRPA1</e2>, respectively) also modulate other thermoTRPs.","Upregulator"
"Similar to menthol, both camphor and <e1>cinnamaldehyde</e1> (initially reported to be specific activators of <e2>TRPV3</e2> and TRPA1, respectively) also modulate other thermoTRPs.","Upregulator"
"Similar to menthol, both camphor and <e1>cinnamaldehyde</e1> (initially reported to be specific activators of TRPV3 and <e2>TRPA1</e2>, respectively) also modulate other thermoTRPs.","Upregulator"
"We further show that <e1>menthol</e1> inhibits <e2>TRPA1</e2>, potentially explaining the use of menthol as an analgesic.","Downregulator"
"These currents were produced by <e2>glutamate-aspartate transporters</e2> (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate</e1>, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.","Downregulator"
"These currents were produced by glutamate-aspartate transporters (<e2>GLAST</e2>) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate</e1>, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.","Downregulator"
"These currents were produced by glutamate-aspartate transporters (GLAST) (<e2>excitatory amino acid transporter 1</e2>) because they were weakly inhibited by <e1>dihydrokainate</e1>, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.","Downregulator"
"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate</e1>, an antagonist of <e2>glutamate transporter-1</e2> (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.","Antagonist"
"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate</e1>, an antagonist of glutamate transporter-1 (<e2>excitatory amino acid transporter 2</e2>) and were absent from IPCs in GLAST-/- cochleas.","Antagonist"
"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated <e2>anion channel</e2> and blocked by the transporter antagonist <e1>D,L-threo-beta-benzyloxyaspartate</e1>.","Antagonist"
"The <e1>glutamate</e1>-aspartate transporter <e2>GLAST</e2> mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea.","Substrate"
"The <e1>glutamate</e1>-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea.","Substrate"
"Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by <e1>L-glutamate</e1>, a prominent feature of <e2>GLAST</e2>, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.","Substrate"
"<e1>Labetalol</e1> and the enantiomers lacked affinity at <e2>alpha 2-adrenoceptors</e2> while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than labetalol.","Not"
"Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at <e2>alpha 1-adrenoceptors</e2> the order of potency was <e1>prazosin</e1> much greater than RR-SR greater than labetalol.","Regulator"
"Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at <e2>alpha 1-adrenoceptors</e2> the order of potency was prazosin much greater than RR-SR greater than <e1>labetalol</e1>.","Regulator"
"At <e2>beta 1-adrenoceptors</e2>, the affinity of the compound RR-SR was about 3 times that of <e1>labetalol</e1>.5.","Regulator"
"<e2>Proline oxidase</e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to <e1>pyrroline- 5-carboxylate</e1> (P5C).","Substrate"
"Proline oxidase (<e2>POX</e2>), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to <e1>pyrroline- 5-carboxylate</e1> (P5C).","Substrate"
"<e2>Proline oxidase</e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (<e1>P5C</e1>).","Substrate"
"Proline oxidase (<e2>POX</e2>), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (<e1>P5C</e1>).","Substrate"
"Overexpression of <e1>proline</e1> oxidase induces proline-dependent and mitochondria-mediated apoptosis.","Substrate"
"Proline oxidase (<e2>POX</e2>), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of <e1>proline</e1> to pyrroline- 5-carboxylate (P5C).","Substrate"
"<e2>Proline oxidase</e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of <e1>proline</e1> to pyrroline- 5-carboxylate (P5C).","Substrate"
"Proline oxidase (<e2>POX</e2>), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of <e1>proline</e1> to pyrroline- 5-carboxylate (P5C).","Substrate"
"To further investigate the molecular basis of <e2>POX</e2>-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an <e1>L-proline</e1>-dependent apoptotic response.","Substrate"
"To further investigate the molecular basis of <e2>POX</e2>-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an <e1>L-proline</e1>-dependent apoptotic response.","Substrate"
"METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, venlafaxine, <e1>bupropion</e1>) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and <e2>norepinephrine transporter</e2> knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.","Downregulator"
"The exception was <e1>bupropion</e1>, a dual norepinephrine transporter/<e2>dopamine transporter</e2> blocker, which tended to increase spontaneous locomotor activity.","Downregulator"
"Coadministration of reboxetine and the <e2>dopamine transporter</e2> blocker <e1>GBR 12909</e1> also increased spontaneous locomotor activity.","Downregulator"
"<e1>Tamoxifen</e1> blocks the action of estrogen by binding to the <e2>ER</e2>, and possesses both ER-agonist and antagonist properties.","Regulator"
"Endocrine therapy that targets the <e1>estrogen</e1> receptor (<e2>ER</e2>) is a standard of care for the treatment of postmenopausal women with ER-positive breast cancer.","Regulator"
"The selective <e2>ER</e2> modulator (SERM) <e1>tamoxifen</e1> has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of ER-positive disease.","Regulator"
"<e1>Fulvestrant</e1> is a novel <e2>ER</e2> antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.","Downregulator"
"<e1>Tamoxifen</e1> blocks the action of estrogen by binding to the <e2>ER</e2>, and possesses both ER-agonist and antagonist properties.","Agonist"
"<e1>Tamoxifen</e1> blocks the action of estrogen by binding to the <e2>ER</e2>, and possesses both ER-agonist and antagonist properties.","Antagonist"
"<e1>Fulvestrant</e1> is a novel <e2>ER</e2> antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.","Antagonist"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four <e1>N</e1>-terminal truncation mutants were generated: PDE5Delta1-321 contained <e2>GAF-B</e2> domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.","Part_of"
"Truncated proteins with a complete <e2>GAF-B</e2> were dimers, but those lacking the N-terminal 46 <e1>amino acids</e1> of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.","Part_of"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four <e1>N</e1>-terminal truncation mutants were generated: <e2>PDE5Delta1-321</e2> contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.","Part_of"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four <e1>N</e1>-terminal truncation mutants were generated: PDE5Delta1-321 contained <e2>GAF-B domain</e2>, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.","Part_of"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four <e1>N</e1>-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; <e2>PDE5Delta1-419</e2> contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.","Part_of"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four <e1>N</e1>-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; <e2>PDE5Delta1-465</e2> contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.","Part_of"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four <e1>N</e1>-terminal truncation mutants were generated: PDE5Delta1-321 contained <e2>GAF-B</e2> domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.","Part_of"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained <e2>GAF-B</e2> domain, <e1>C</e1> domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.","Part_of"
"To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, <e1>C</e1> domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and <e2>PDE5Delta1-534</e2> contained only C domain.","Part_of"
"A 46-<e1>amino acid</e1> segment in <e2>phosphodiesterase-5</e2> GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.","Part_of"
"A 46-<e1>amino acid</e1> segment in phosphodiesterase-5 <e2>GAF-B domain</e2> provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.","Part_of"
"Truncated proteins with a complete <e2>GAF-B</e2> were dimers, but those lacking the N-terminal 46 <e1>amino acids</e1> of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.","Part_of"
"Binding of <e1>cGMP</e1> to <e2>GAF-A</e2> increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.","Regulator"
"Phosphodiesterase-5 (<e2>PDE5</e2>) contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP</e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).","Regulator"
"Binding of <e1>cGMP</e1> to <e2>GAF-A</e2> increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.","Regulator"
"All <e2>PDE5</e2> constructs had similar affinities for <e1>3-isobutyl-1-methylxanthine</e1>, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.","Regulator"
"All PDE5 constructs had similar affinities for <e1>3-isobutyl-1-methylxanthine</e1>, sildenafil, tadalafil, and UK-122764, but mutants containing a complete <e2>GAF-B</e2> had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.","Regulator"
"All <e2>PDE5</e2> constructs had similar affinities for 3-isobutyl-1-methylxanthine, <e1>sildenafil</e1>, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.","Regulator"
"A 46-amino acid segment in phosphodiesterase-5 <e2>GAF-B</e2> domain provides for high vardenafil potency over <e1>sildenafil</e1> and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"All <e2>PDE5</e2> constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, <e1>tadalafil</e1>, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.","Regulator"
"A 46-amino acid segment in phosphodiesterase-5 <e2>GAF-B</e2> domain provides for high vardenafil potency over sildenafil and <e1>tadalafil</e1> and is involved in phosphodiesterase-5 dimerization.","Regulator"
"All <e2>PDE5</e2> constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and <e1>UK-122764</e1>, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.","Regulator"
"All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and <e1>UK-122764</e1>, but mutants containing a complete <e2>GAF-B</e2> had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.","Regulator"
"A 46-amino acid segment in phosphodiesterase-5 <e2>GAF-B</e2> domain provides for high <e1>vardenafil</e1> potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in phosphodiesterase-5 <e2>GAF-B</e2> domain provides for high <e1>vardenafil</e1> potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in <e2>phosphodiesterase-5</e2> GAF-B domain provides for high vardenafil potency over <e1>sildenafil</e1> and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in <e2>phosphodiesterase-5</e2> GAF-B domain provides for high vardenafil potency over <e1>sildenafil</e1> and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in phosphodiesterase-5 <e2>GAF-B domain</e2> provides for high vardenafil potency over <e1>sildenafil</e1> and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in <e2>phosphodiesterase-5</e2> GAF-B domain provides for high vardenafil potency over sildenafil and <e1>tadalafil</e1> and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in <e2>phosphodiesterase-5</e2> GAF-B domain provides for high vardenafil potency over sildenafil and <e1>tadalafil</e1> and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in phosphodiesterase-5 <e2>GAF-B domain</e2> provides for high vardenafil potency over sildenafil and <e1>tadalafil</e1> and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in <e2>phosphodiesterase-5</e2> GAF-B domain provides for high <e1>vardenafil</e1> potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in <e2>phosphodiesterase-5</e2> GAF-B domain provides for high <e1>vardenafil</e1> potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"A 46-amino acid segment in phosphodiesterase-5 <e2>GAF-B domain</e2> provides for high <e1>vardenafil</e1> potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.","Regulator"
"Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP</e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (<e2>cNPK</e2>s).","Upregulator"
"Phosphodiesterase-5 (<e2>PDE5</e2>) contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP</e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).","Upregulator"
"<e2>Phosphodiesterase-5</e2> (PDE5) contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP</e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).","Substrate"
"Phosphodiesterase-5 (<e2>PDE5</e2>) contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP</e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).","Substrate"
"Phosphodiesterase-5 (<e2>PDE5</e2>) contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP</e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).","Substrate"
"However, the expression of <e2>AT1R</e2> was not suppressed by other AT1R antagonists such as <e1>candesartan</e1> or olmesartan.","Not"
"However, the expression of <e2>AT1R</e2> was not suppressed by other AT1R antagonists such as candesartan or <e1>olmesartan</e1>.","Not"
"Since previous studies have demonstrated that PPARgamma activators suppressed <e2>AT1R</e2> expression, we examined whether <e1>telmisartan</e1> affects AT1R expression in vascular smooth muscle cells.","Regulator"
"<e1>Telmisartan</e1> downregulates angiotensin II type 1 receptor through activation of <e2>peroxisome proliferator-activated receptor gamma</e2>.","Upregulator"
"Since previous studies have demonstrated that <e2>PPARgamma</e2> activators suppressed AT1R expression, we examined whether <e1>telmisartan</e1> affects AT1R expression in vascular smooth muscle cells.","Upregulator"
"Since the suppression of <e2>AT1R</e2> expression was prevented by pretreatment with <e1>GW9662</e1>, a PPARgamma antagonist, PPARgamma should have participated in the process.","Upregulator"
"<e1>Telmisartan</e1> downregulates <e2>angiotensin II type 1 receptor</e2> through activation of peroxisome proliferator-activated receptor gamma.","Downregulator"
"Since previous studies have demonstrated that PPARgamma activators suppressed <e2>AT1R</e2> expression, we examined whether <e1>telmisartan</e1> affects AT1R expression in vascular smooth muscle cells.","Downregulator"
"Since previous studies have demonstrated that PPARgamma activators suppressed <e2>AT1R</e2> expression, we examined whether <e1>telmisartan</e1> affects AT1R expression in vascular smooth muscle cells.","Downregulator"
"The deletion and mutation analysis of the AT1R gene promoter indicated that a <e2>GC box</e2> located in the proximal promoter region is responsible for the <e1>telmisartan</e1>-induced downregulation.","Downregulator"
"Since previous studies have demonstrated that PPARgamma activators suppressed <e2>AT1R</e2> expression, we examined whether <e1>telmisartan</e1> affects AT1R expression in vascular smooth muscle cells.","Downregulator"
"OBJECTIVE: <e1>Telmisartan</e1>, an angiotensin II type 1 receptor (<e2>AT1R</e2>) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).","Downregulator"
"<e1>Telmisartan</e1> downregulates angiotensin II type 1 receptor through activation of <e2>peroxisome proliferator-activated receptor gamma</e2>.","Agonist"
"OBJECTIVE: <e1>Telmisartan</e1>, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (<e2>PPARgamma</e2>).","Agonist"
"However, the expression of <e2>AT1R</e2> was not suppressed by other AT1R antagonists such as <e1>candesartan</e1> or olmesartan.","Antagonist"
"However, the expression of <e2>AT1R</e2> was not suppressed by other AT1R antagonists such as candesartan or <e1>olmesartan</e1>.","Antagonist"
"<e1>Telmisartan</e1> downregulates <e2>angiotensin II type 1 receptor</e2> through activation of peroxisome proliferator-activated receptor gamma.","Antagonist"
"OBJECTIVE: <e1>Telmisartan</e1>, an angiotensin II type 1 receptor (<e2>AT1R</e2>) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).","Antagonist"
"Since the suppression of AT1R expression was prevented by pretreatment with <e1>GW9662</e1>, a <e2>PPARgamma</e2> antagonist, PPARgamma should have participated in the process.","Antagonist"
"Upon differentiation, osteoclasts express vesicular <e1>glutamate</e1> transporter 1 (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons.","Substrate"
"Upon differentiation, osteoclasts express vesicular <e1>glutamate</e1> transporter 1 (<e2>VGLUT1</e2>), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons.","Substrate"
"<e2>VGLUT1</e2> is localized in transcytotic vesicles and accumulates <e1>L-glutamate</e1>.","Substrate"
"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble <e1>methotrexate</e1> (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of <e2>mammalian DHFR</e2> activity.","Downregulator"
"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (<e1>MTX</e1>, 1) structure features and fitted with functional groups believed to enhance inhibition of <e2>mammalian DHFR</e2> activity.","Downregulator"
"In order to produce potent new leads for anticancer drugs, a new series of <e1>quinazoline</e1> analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of <e2>mammalian DHFR</e2> activity.","Downregulator"
"Synthesis, <e2>dihydrofolate reductase</e2> inhibition, antitumor testing, and molecular modeling study of some new <e1>4(3H)-quinazolinone</e1> analogs.","Downregulator"
"Administration of <e1>m-chlorophenylpiperazine</e1> and fenfluramine, both of which induce anorexic effects via <e2>5-HT2C</e2> receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.","Regulator"
"Administration of <e1>m-chlorophenylpiperazine</e1> and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or <e2>5-HT1B</e2> receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.","Regulator"
"Administration of m-chlorophenylpiperazine and <e1>fenfluramine</e1>, both of which induce anorexic effects via <e2>5-HT2C</e2> receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.","Regulator"
"Administration of m-chlorophenylpiperazine and <e1>fenfluramine</e1>, both of which induce anorexic effects via 5-HT2C receptors and/or <e2>5-HT1B</e2> receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.","Regulator"
"A significant positive correlation was found between dietary intake of total <e1>SFA</e1>s and total MUFAs and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Regulator"
"A significant positive correlation was found between dietary intake of total <e1>SFA</e1>s and total MUFAs and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Regulator"
"A significant positive correlation was found between dietary intake of total SFAs and total <e1>MUFA</e1>s and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Regulator"
"A significant positive correlation was found between dietary intake of total SFAs and total <e1>MUFA</e1>s and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Regulator"
"A significant positive correlation was found between dietary intake of total <e1>SFAs</e1> and total MUFAs and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Upregulator"
"A significant positive correlation was found between dietary intake of total <e1>SFAs</e1> and total MUFAs and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Upregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total <e1>MUFAs</e1> and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Upregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total <e1>MUFAs</e1> and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Upregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of <e1>linoleic acid</e1> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Downregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of <e1>linoleic acid</e1> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Downregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (<e1>LA</e1>) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Downregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of linoleic acid (<e1>LA</e1>) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.","Downregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and <e1>alpha-linolenic acid</e1> (LNA) and the expression of PBMC D6D and D5D genes.","Downregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and <e1>alpha-linolenic acid</e1> (LNA) and the expression of PBMC D6D and D5D genes.","Downregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC <e2>D6D</e2> and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<e1>LNA</e1>) and the expression of PBMC D6D and D5D genes.","Downregulator"
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and <e2>D5D</e2> genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<e1>LNA</e1>) and the expression of PBMC D6D and D5D genes.","Downregulator"
"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC <e2>D6D</e2> and D5D genes, whilst high <e1>EFAs</e1> intake appears to decrease expression of PBMC D6D and D5D genes.","Downregulator"
"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and <e2>D5D</e2> genes, whilst high <e1>EFAs</e1> intake appears to decrease expression of PBMC D6D and D5D genes.","Downregulator"
"The evolution of <e1>progesterone</e1> receptor ligands.","Regulator"
"Because <e1>progesterone</e1> (1) affects both menstruation and gestation via the progesterone receptor (<e2>PR</e2>), research aimed at modulating its activity is usually surrounded by controversy.","Regulator"
"<e1>Decitabine</e1> inhibits <e2>DNA methyltransferase</e2> and has shown therapeutic effects in patients with hematologic malignancies.","Downregulator"
"Our data suggest that <e1>l-arginine</e1> is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (<e2>SLC3A2</e2>/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.","Substrate"
"Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human <e1>5'-methylthioadenosine</e1> phosphorylase (<e2>MTAP</e2>).","Substrate"
"Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human 5'-methylthioadenosine phosphorylase (<e1>MTA</e1>P).","Substrate"
"Blocking <e1>retinyl ester</e1> formation by a targeted knock down of <e2>Lratb</e2> results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.","Substrate"
"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to <e2>retinal dehydrogenase 2</e2> (raldh2), the key enzyme for <e1>retinoic acid</e1> synthesis.","Substrate"
"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (<e2>raldh2</e2>), the key enzyme for <e1>retinoic acid</e1> synthesis.","Substrate"
"<e2>P2Y12</e2> has been shown to be the target of the <e1>thienopyridine</e1> drugs, ticlopidine and clopidogrel.","Regulator"
"<e2>P2Y12</e2> has been shown to be the target of the thienopyridine drugs, <e1>ticlopidine</e1> and clopidogrel.","Regulator"
"<e2>P2Y12</e2> has been shown to be the target of the thienopyridine drugs, ticlopidine and <e1>clopidogrel</e1>.","Regulator"
"<e1>ADP</e1> initiates platelet aggregation by 'simultaneous activation of two <e2>G protein-coupled receptors</e2>, P2Y1 and P2Y12.","Upregulator"
"<e1>ADP</e1> initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, <e2>P2Y1</e2> and P2Y12.","Upregulator"
"<e1>ADP</e1> initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and <e2>P2Y12</e2>.","Upregulator"
"<e1>ADP</e1> initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and <e2>P2Y12</e2>.","Downregulator"
"Here, the active sites of <e2>P2Y12</e2> for <e1>ATP</e1> as well as ADP are predicted by bioinformatics and molecular modeling.","Downregulator"
"<e1>Cd</e1> decreased ERalpha expression, but not <e2>ERbeta</e2>.","Not"
"<e1>Estradiol</e1> (E2) stimulates BC cells proliferation by binding the <e2>estrogen receptor</e2> (ER).","Regulator"
"<e1>Estradiol</e1> (E2) stimulates BC cells proliferation by binding the estrogen receptor (<e2>ER</e2>).","Regulator"
"Estradiol (<e1>E2</e1>) stimulates BC cells proliferation by binding the <e2>estrogen receptor</e2> (ER).","Regulator"
"Estradiol (<e1>E2</e1>) stimulates BC cells proliferation by binding the estrogen receptor (<e2>ER</e2>).","Regulator"
"<e1>Cadmium</e1> induces mitogenic signaling in breast cancer cell by an <e2>ERalpha</e2>-dependent mechanism.","Regulator"
"<e1>Cd</e1> decreased <e2>ERalpha</e2> expression, but not ERbeta.","Regulator"
"Purpose of our study was to evaluate whether <e1>Cd</e1> regulates MCF-7 cell proliferation by activating ERK1/2, <e2>Akt</e2> and PDGFRalpha kinases.","Upregulator"
"Purpose of our study was to evaluate whether <e1>Cd</e1> regulates MCF-7 cell proliferation by activating ERK1/2, Akt and <e2>PDGFRalpha</e2> kinases.","Upregulator"
"Purpose of our study was to evaluate whether <e1>Cd</e1> regulates MCF-7 cell proliferation by activating ERK1/2, Akt and PDGFRalpha <e2>kinases</e2>.","Upregulator"
"<e1>Cd</e1> rapidly increased c-jun, <e2>c-fos</e2> and PDGFA expression.","Upregulator"
"<e1>Cd</e1> rapidly increased <e2>c-jun</e2>, c-fos and PDGFA expression.","Upregulator"
"<e1>Cd</e1> rapidly increased c-jun, c-fos and <e2>PDGFA</e2> expression.","Upregulator"
"Purpose of our study was to evaluate whether <e1>Cd</e1> regulates MCF-7 cell proliferation by activating ERK1/2, <e2>Akt</e2> and PDGFRalpha kinases.","Upregulator"
"Purpose of our study was to evaluate whether <e1>Cd</e1> regulates MCF-7 cell proliferation by activating ERK1/2, Akt and <e2>PDGFRalpha</e2> kinases.","Upregulator"
"<e1>Cd</e1> rapidly increased <e2>c-jun</e2>, c-fos and PDGFA expression.","Upregulator"
"<e1>Cd</e1> rapidly increased c-jun, <e2>c-fos</e2> and PDGFA expression.","Upregulator"
"<e1>Cd</e1> rapidly increased c-jun, c-fos and <e2>PDGFA</e2> expression.","Upregulator"
"<e1>Cd</e1> decreased <e2>ERalpha</e2> expression, but not ERbeta.","Downregulator"
"Since the <e1>GnRH</e1> receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human <e2>androgen receptor</e2>.","Not"
"Since the <e1>GnRH</e1> receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the <e2>human androgen receptor</e2>.","Regulator"
"This mechanism involves the <e1>calcium</e1>-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/<e2>steroid receptor co-factor</e2>, Hic-5.","Regulator"
"This mechanism involves the <e1>calcium</e1>-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, <e2>Hic-5</e2>.","Regulator"
"This mechanism involves the <e1>calcium</e1>-dependent <e2>tyrosine kinase</e2> Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.","Regulator"
"This mechanism involves the <e1>calcium</e1>-dependent tyrosine kinase <e2>Pyk2</e2>, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.","Regulator"
"This mechanism involves the <e1>calcium</e1>-dependent tyrosine kinase Pyk2, the <e2>non-receptor tyrosine kinase</e2> c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.","Regulator"
"This mechanism involves the <e1>calcium</e1>-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase <e2>c-Src</e2> and the focal adhesion protein/steroid receptor co-factor, Hic-5.","Regulator"
"This mechanism involves the <e1>calcium</e1>-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the <e2>focal adhesion protein</e2>/steroid receptor co-factor, Hic-5.","Regulator"
"<e1>Gonadotropin-releasing hormone</e1> functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving <e2>Hic-5</e2>.","Regulator"
"Since the <e1>GnRH</e1> receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human <e2>androgen receptor</e2>.","Regulator"
"In this setting there is a <e1>GnRH</e1>-induced association and nuclear translocation of the androgen receptor with <e2>Hic-5</e2>.","Regulator"
"Since the <e1>GnRH</e1> receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the <e2>human androgen receptor</e2>.","Regulator"
"In this setting there is a <e1>GnRH</e1>-induced association and nuclear translocation of the androgen receptor with <e2>Hic-5</e2>.","Regulator"
"Since the <e1>GnRH</e1> receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the <e2>human androgen receptor</e2>.","Regulator"
"Since the <e1>GnRH</e1> receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human <e2>androgen receptor</e2>.","Regulator"
"Gonadotropin-releasing hormone functionally antagonizes <e1>testosterone</e1> activation of the <e2>human androgen receptor</e2> in prostate cells through focal adhesion complexes involving Hic-5.","Upregulator"
"<e1>GnRH</e1>-induced <e2>Pyk2</e2> activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.","Upregulator"
"<e1>GnRH</e1>-induced <e2>c-Src</e2> activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.","Upregulator"
"Gonadotropin-releasing hormone functionally antagonizes <e1>testosterone</e1> activation of the human <e2>androgen receptor</e2> in prostate cells through focal adhesion complexes involving Hic-5.","Upregulator"
"In this setting there is a <e1>GnRH</e1>-induced association and nuclear translocation of the androgen receptor with <e2>Hic-5</e2>.","Downregulator"
"Since the <e1>GnRH</e1> receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human <e2>androgen receptor</e2>.","Downregulator"
"<e1>Gonadotropin-releasing hormone</e1> functionally antagonizes testosterone activation of the <e2>human androgen receptor</e2> in prostate cells through focal adhesion complexes involving Hic-5.","Antagonist"
"Recently, it was reported that <e1>METH</e1>, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing <e2>rat trace amine-associated receptor 1</e2> (rTAAR1).","Regulator"
"Recently, it was reported that <e1>METH</e1>, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Regulator"
"Recently, it was reported that METH, <e1>AMPH</e1>, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing <e2>rat trace amine-associated receptor 1</e2> (rTAAR1).","Regulator"
"Recently, it was reported that METH, <e1>AMPH</e1>, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Regulator"
"Recently, it was reported that METH, AMPH, <e1>POHA</e1>, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing <e2>rat trace amine-associated receptor 1</e2> (rTAAR1).","Regulator"
"Recently, it was reported that METH, AMPH, <e1>POHA</e1>, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs <e1>para-tyramine</e1> (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing <e2>rat trace amine-associated receptor 1</e2> (rTAAR1).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs <e1>para-tyramine</e1> (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (<e1>TYR</e1>) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing <e2>rat trace amine-associated receptor 1</e2> (rTAAR1).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (<e1>TYR</e1>) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and <e1>beta-phenylethylamine</e1> (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing <e2>rat trace amine-associated receptor 1</e2> (rTAAR1).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and <e1>beta-phenylethylamine</e1> (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (<e1>PEA</e1>) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing <e2>rat trace amine-associated receptor 1</e2> (rTAAR1).","Regulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (<e1>PEA</e1>) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Regulator"
"Recently, it was reported that <e1>METH</e1>, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (r<e2>TAAR1</e2>).","Regulator"
"Recently, it was reported that METH, <e1>AMPH</e1>, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (r<e2>TAAR1</e2>).","Regulator"
"Recently, it was reported that METH, AMPH, <e1>POHA</e1>, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (r<e2>TAAR1</e2>).","Regulator"
"<e2>Trace amine-associated receptor 1</e2> displays species-dependent stereoselectivity for isomers of meth<e1>amphetamine</e1>, amphetamine, and para-hydroxyamphetamine.","Regulator"
"<e2>Trace amine-associated receptor 1</e2> displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and <e1>para-hydroxyamphetamine</e1>.","Regulator"
"<e2>Trace amine-associated receptor 1</e2> displays species-dependent stereoselectivity for isomers of <e1>methamphetamine</e1>, amphetamine, and para-hydroxyamphetamine.","Regulator"
"EC50 values for <e1>S-(+)-METH</e1> were 0.89, 0.92, and 4.44 microM for <e2>rTAAR1</e2>, mTAAR1, and h-rChTAAR1, respectively.","Upregulator"
"EC50 values for <e1>S-(+)-METH</e1> were 0.89, 0.92, and 4.44 microM for rTAAR1, <e2>mTAAR1</e2>, and h-rChTAAR1, respectively.","Upregulator"
"EC50 values for <e1>S-(+)-METH</e1> were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and <e2>h-rChTAAR1</e2>, respectively.","Upregulator"
"Recently, it was reported that <e1>METH</e1>, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Upregulator"
"Recently, it was reported that METH, <e1>AMPH</e1>, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Upregulator"
"Recently, it was reported that <e1>METH</e1>, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (r<e2>TAAR1</e2>).","Upregulator"
"Recently, it was reported that METH, <e1>AMPH</e1>, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (r<e2>TAAR1</e2>).","Upregulator"
"Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (<e1>PEA</e1>) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (r<e2>TAAR1</e2>).","Agonist"
"PEA was a potent and full agonist at each species of TAAR1, whereas <e1>TYR</e1> was a full agonist for the <e2>rodent TAAR1s</e2> but was a partial agonist at h-rChTAAR1.","Agonist"
"The discovery that <e1>METH</e1> and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (<e2>mTAAR1</e2>) and a human-rat chimera (hrChTAAR1).","Agonist"
"EC50 values for S-(+)-<e1>METH</e1> were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and <e2>h-rChTAAR1</e2>, respectively.","Agonist"
"PEA was a potent and full agonist at each species of TAAR1, whereas <e1>TYR</e1> was a full agonist for the rodent TAAR1s but was a partial agonist at <e2>h-rChTAAR1</e2>.","Agonist"
"Recently, it was reported that <e1>METH</e1>, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (<e2>rTAAR1</e2>).","Agonist"
"Finally, we showed that <e1>chlorate</e1> activated endocrine cell development by inducing <e2>neurogenin 3</e2> (Neurog3) expression in early endocrine progenitor cells.","Upregulator"
"Finally, we showed that <e1>chlorate</e1> activated endocrine cell development by inducing neurogenin 3 (<e2>Neurog3</e2>) expression in early endocrine progenitor cells.","Upregulator"
"Simple <e1>benzenesulfonamides</e1> were rather ineffective <e2>hCA VI</e2> inhibitors, with inhibition constants in the range of 1090-6680 nM.","Not"
"The metallic taste reported as a side effect after the treatment with systemic <e1>sulfonamides</e1> may be due to the inhibition of the <e2>salivary CA VI</e2>.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, <e1>dichlorophenamide</e1>, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as <e1>acetazolamide</e1>, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, <e1>methazolamide</e1>, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, <e1>ethoxzolamide</e1>, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"DNA cloning, characterization, and inhibition studies of the <e2>human secretory isoform VI</e2>, a new target for <e1>sulfonamide</e1> and sulfamate inhibitors.","Downregulator"
"DNA cloning, characterization, and inhibition studies of the <e2>human secretory isoform VI</e2>, a new target for sulfonamide and <e1>sulfamate</e1> inhibitors.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, <e1>dorzolamide</e1>, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, <e1>brinzolamide</e1>, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, <e1>topiramate</e1>, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, <e1>sulpiride</e1>, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and <e1>indisulam</e1>, or the orphan drug benzolamide, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug <e1>benzolamide</e1>, showed effective <e2>hCA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, <e1>brinzolamide</e1>, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective h<e2>CA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, <e1>sulpiride</e1>, and indisulam, or the orphan drug benzolamide, showed effective h<e2>CA VI</e2> inhibitory activity, with inhibition constants of 0.8-79 nM.","Downregulator"
"The kinetic parameters for the <e1>CO2</e1> hydration reaction proved h<e2>CA VI</e2> to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C).","Substrate"
"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel <e2>CA VI</e2>, which leads to the formation of protons and <e1>bicarbonate</e1> and may have a role in cariogenesis.","Substrate"
"The kinetic parameters for the <e1>CO2</e1> hydration reaction proved <e2>hCA VI</e2> to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C).","Substrate"
"Transmembrane isoforms of <e2>adenylate cyclases</e2> (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate <e1>cAMP</e1> production in response to calcium entry.","Substrate"
"Transmembrane isoforms of adenylate cyclases (<e2>AC</e2>) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate <e1>cAMP</e1> production in response to calcium entry.","Substrate"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta</e2>2 protein levels in human glioma cell lines.","Regulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta</e2>2 protein levels in human glioma cell lines.","Regulator"
"Here, we report that the antifibrotic drug <e1>5-methyl-1-phenyl-2-(1H)-pyridone</e1> (pirfenidone, PFD) elicits growth-inhibitory effects and reduces <e2>TGF-beta2</e2> protein levels in human glioma cell lines.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (<e1>pirfenidone</e1>, PFD) elicits growth-inhibitory effects and reduces <e2>TGF-beta2</e2> protein levels in human glioma cell lines.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta2</e2> protein levels in human glioma cell lines.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta2</e2> protein levels in human glioma cell lines.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta</e2>2 protein levels in human glioma cell lines.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta2</e2> protein levels in human glioma cell lines.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta2</e2> protein levels in human glioma cell lines.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta</e2>2 protein levels in human glioma cell lines.","Downregulator"
"<e1>PFD</e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta <e2>pro-protein convertase</e2> furin.","Downregulator"
"<e1>PFD</e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase <e2>furin</e2>.","Downregulator"
"In addition, <e1>PFD</e1> reduces the protein levels of the <e2>matrix metalloproteinase (MMP)-11</e2>, a TGF-beta target gene and furin substrate involved in carcinogenesis.","Downregulator"
"<e1>Pirfenidone</e1> inhibits <e2>TGF-beta</e2> expression in malignant glioma cells.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta</e2>2 protein levels in human glioma cell lines.","Downregulator"
"<e1>PFD</e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta <e2>pro-protein convertase</e2> furin.","Downregulator"
"<e1>PFD</e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase <e2>furin</e2>.","Downregulator"
"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD</e1>) elicits growth-inhibitory effects and reduces <e2>TGF-beta</e2>2 protein levels in human glioma cell lines.","Downregulator"
"We used immunofluorescence microscopy and <e1>digitonin</e1> permeabilization assays to determine the subcellular location of endogenous <e2>BAAT</e2> in primary human and rat hepatocytes.","Regulator"
"UNLABELLED: <e2>Bile acid-coenzyme A:amino acid N-acyltransferase</e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to <e1>taurine</e1> and glycine.","Substrate"
"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>BAAT</e2>) is the sole enzyme responsible for conjugation of primary and secondary bile acids to <e1>taurine</e1> and glycine.","Substrate"
"UNLABELLED: <e2>Bile acid-coenzyme A:amino acid N-acyltransferase</e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and <e1>glycine</e1>.","Substrate"
"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>BAAT</e2>) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and <e1>glycine</e1>.","Substrate"
"UNLABELLED: <e2>Bile acid-coenzyme A:amino acid N-acyltransferase</e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary <e1>bile acids</e1> to taurine and glycine.","Substrate"
"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>BAAT</e2>) is the sole enzyme responsible for conjugation of primary and secondary <e1>bile acids</e1> to taurine and glycine.","Substrate"
"The absence or presence of a cytosolic pool of <e2>BAAT</e2> has important implications for the intracellular transport of unconjugated/deconjugated <e1>bile salts</e1>.","Substrate"
"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the <e2>riboflavin kinase</e2>, enzyme that converts riboflavin to <e1>flavinmononucleotide</e1>) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.","Substrate"
"[Construction of the flavinogenic yeast Candida famata strains with high <e1>riboflavin</e1> kinase activity using gene engineering].","Substrate"
"The pyridoxal 5'-phosphate binding <e1>lysine</e1> in <e2>mouse ODC</e2> was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.","Part_of"
"The pyridoxal 5'-phosphate binding <e1>lysine</e1> in <e2>mouse ODC</e2> was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.","Part_of"
"This <e1>lysine</e1> is contained in the sequence <e2>PFYAVKC</e2>, which is found in all known ODCs from eukaryotes.","Part_of"
"This <e1>lysine</e1> is contained in the sequence PFYAVKC, which is found in all known <e2>ODCs</e2> from eukaryotes.","Part_of"
"This lysine is contained in the sequence <e1>PFYAVKC</e1>, which is found in all known <e2>ODCs</e2> from eukaryotes.","Part_of"
"The pyridoxal 5'-phosphate binding <e1>lysine</e1> in mouse <e2>ODC</e2> was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.","Part_of"
"Using a similar procedure to analyze <e2>ODC</e2> labeled by reaction with [5-14C]DFMO, it was found that lysine 69 and <e1>cysteine</e1> 360 formed covalent adducts with the inhibitor.","Part_of"
"<e1>Cysteine</e1> 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -<e2>WGPTCDGL(I)D</e2>-, which is present in all known eukaryote ODCs.","Part_of"
"<e1>Cysteine</e1> 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -WGPTCDGL(I)D-, which is present in all known <e2>eukaryote ODCs</e2>.","Part_of"
"Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -<e1>WGPTCDGL(I)D</e1>-, which is present in all known <e2>eukaryote ODCs</e2>.","Part_of"
"The <e1>pyridoxal 5'-phosphate</e1> binding lysine in <e2>mouse ODC</e2> was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.","Regulator"
"Using a similar procedure to analyze <e2>ODC</e2> labeled by reaction with <e1>[5-14C]DFMO</e1>, it was found that lysine 69 and cysteine 360 formed covalent adducts with the inhibitor.","Regulator"
"<e2>Mouse ornithine decarboxylase</e2> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for <e1>pyridoxal 5'-phosphate</e1> and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).","Regulator"
"Mouse ornithine decarboxylase (<e2>ODC</e2>) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for <e1>pyridoxal 5'-phosphate</e1> and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).","Regulator"
"<e2>Mouse ornithine decarboxylase</e2> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, <e1>alpha-difluoromethylornithine</e1> (DFMO).","Downregulator"
"Mouse ornithine decarboxylase (<e2>ODC</e2>) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, <e1>alpha-difluoromethylornithine</e1> (DFMO).","Downregulator"
"<e2>Mouse ornithine decarboxylase</e2> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (<e1>DFMO</e1>).","Downregulator"
"Mouse ornithine decarboxylase (<e2>ODC</e2>) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (<e1>DFMO</e1>).","Downregulator"
"Mechanism of the irreversible inactivation of <e2>mouse ornithine decarboxylase</e2> by <e1>alpha-difluoromethylornithine</e1>.","Downregulator"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2</e2>] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Regulator"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1</e2>), SNAT2, and SNAT4].","Regulator"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2</e2>, and SNAT4].","Regulator"
"Pre-steady-state currents in <e2>neutral amino acid transporters</e2> induced by photolysis of a new caged <e1>alanine</e1> derivative.","Regulator"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2</e2>] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1</e2>), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2</e2>, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2</e2>] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1</e2>), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2</e2>, and SNAT4].","Substrate"
"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>4-methoxy-7-nitroindolinyl</e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>ASCT2</e2>, SNAT1, and SNAT2.","Substrate"
"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>4-methoxy-7-nitroindolinyl</e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>SNAT1</e2>, and SNAT2.","Substrate"
"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>4-methoxy-7-nitroindolinyl</e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>SNAT2</e2>.","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the <e2>neutral amino acid transporters</e2> of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the <e2>solute carrier 1</e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>SLC1</e2>, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>alanine serine cysteine transporter 1</e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>ASCT1</e2>), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2</e2>] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and <e2>SLC38</e2> families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>sodium-coupled neutral amino acid transporter 1</e2> (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1</e2>), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2</e2>, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral <e1>amino acids</e1>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>SNAT4</e2>].","Substrate"
"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>MNI</e1>) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>ASCT2</e2>, SNAT1, and SNAT2.","Substrate"
"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>MNI</e1>) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>SNAT1</e2>, and SNAT2.","Substrate"
"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>MNI</e1>) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>SNAT2</e2>.","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the <e2>neutral amino acid transporters</e2> of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the <e2>solute carrier 1</e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>SLC1</e2>, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>alanine serine cysteine transporter 1</e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>ASCT1</e2>), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2</e2>] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and <e2>SLC38</e2> families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>sodium-coupled neutral amino acid transporter 1</e2> (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1</e2>), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2</e2>, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine</e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>SNAT4</e2>].","Substrate"
"Pre-steady-state currents in <e2>neutral amino acid transporters</e2> induced by photolysis of a new caged <e1>alanine</e1> derivative.","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the <e2>solute carrier 1</e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>SLC1</e2>, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>alanine serine cysteine transporter 1</e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>ASCT1</e2>), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2</e2>] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>sodium-coupled neutral amino acid transporter 1</e2> (SNAT1), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1</e2>), SNAT2, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2</e2>, and SNAT4].","Substrate"
"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine</e1>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>SNAT4</e2>].","Substrate"
"Reticulated platelets and uninhibited <e2>COX-1</e2> and COX-2 decrease the antiplatelet effects of <e1>aspirin</e1>.","Regulator"
"Reticulated platelets and uninhibited COX-1 and <e2>COX-2</e2> decrease the antiplatelet effects of <e1>aspirin</e1>.","Regulator"
"Immature (reticulated) platelets may modulate the antiplatelet effects of <e1>aspirin</e1> through uninhibited <e2>cyclooxygenase</e2> (COX)-1 and COX-2.","Regulator"
"Immature (reticulated) platelets may modulate the antiplatelet effects of <e1>aspirin</e1> through uninhibited cyclooxygenase <e2>(COX)-1</e2> and COX-2.","Regulator"
"Reticulated platelets and uninhibited COX-1 and <e2>COX-2</e2> decrease the antiplatelet effects of <e1>aspirin</e1>.","Regulator"
"Stimulated <e2>P-selectin</e2> and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after <e1>aspirin</e1>.","Upregulator"
"Stimulated P-selectin and <e2>integrin alpha(IIb)beta(3)</e2> expression were also higher in the upper tertile both before and after <e1>aspirin</e1>.","Upregulator"
"We also found that <e1>17beta-estradiol</e1> protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and <e2>ER</e2>-dependent manner.","Regulator"
"Neuroprotection by <e1>estrogen</e1> against MPP+-induced dopamine neuron death is mediated by <e2>ERalpha</e2> in primary cultures of mouse mesencephalon.","Regulator"
"Neuroprotection by <e1>estrogen</e1> against MPP+-induced dopamine neuron death is mediated by <e2>ERalpha</e2> in primary cultures of mouse mesencephalon.","Regulator"
"Neuroprotection by <e1>estrogen</e1> against MPP+-induced dopamine neuron death is mediated by <e2>ERalpha</e2> in primary cultures of mouse mesencephalon.","Regulator"
"Neuroprotection by <e1>estrogen</e1> against MPP+-induced dopamine neuron death is mediated by <e2>ERalpha</e2> in primary cultures of mouse mesencephalon.","Regulator"
"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the <e2>ERbeta</e2> agonist, <e1>DPN</e1>, protected against dopamine cell loss.","Agonist"
"At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the <e2>ER</e2> antagonist, <e1>ICI 182,780</e1>.","Antagonist"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB</e2>) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Regulator"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB</e2>) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Regulator"
"Differential activation of <e2>cAMP response element binding protein</e2> in discrete nucleus accumbens subregions during early and late <e1>cocaine</e1> sensitization.","Upregulator"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB</e2>) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Upregulator"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB</e2>) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Upregulator"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the <e2>cyclic adenosine monophosphate (cAMP) response element binding protein</e2> (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Upregulator"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB</e2>) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Upregulator"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB</e2>) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Upregulator"
"The present study examined the differential <e1>cocaine</e1>-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB</e2>) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.","Upregulator"
"The carboxylation of glutamic acid residues to <e1>gamma-carboxyglutamic acid</e1> (Gla) by the <e2>vitamin K-dependent gamma-glutamyl carboxylase</e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.","Substrate"
"The carboxylation of glutamic acid residues to <e1>gamma-carboxyglutamic acid</e1> (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>gamma-carboxylase</e2>) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.","Substrate"
"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (<e1>Gla</e1>) by the <e2>vitamin K-dependent gamma-glutamyl carboxylase</e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.","Substrate"
"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (<e1>Gla</e1>) by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>gamma-carboxylase</e2>) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.","Substrate"
"The carboxylation of <e1>glutamic acid</e1> residues to gamma-carboxyglutamic acid (Gla) by the <e2>vitamin K-dependent gamma-glutamyl carboxylase</e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.","Substrate"
"The carboxylation of <e1>glutamic acid</e1> residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>gamma-carboxylase</e2>) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.","Substrate"
"Furthermore, with respect to <e2>GSTM1</e2> and GSTT1 there were statistically significant differences in <e1>TTCA</e1>-levels between genotypes among exposed workers but not among controls.","Regulator"
"Furthermore, with respect to GSTM1 and <e2>GSTT1</e2> there were statistically significant differences in <e1>TTCA</e1>-levels between genotypes among exposed workers but not among controls.","Regulator"
"<e1>Histamine</e1> regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, <e2>H3R</e2> and H4R).","Regulator"
"<e1>Histamine</e1> regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and <e2>H4R</e2>).","Regulator"
"<e1>Histamine</e1> regulates many functions by binding to four <e2>histamine G-coupled receptor proteins</e2> (H1R, H2R, H3R and H4R).","Regulator"
"<e1>Histamine</e1> regulates many functions by binding to four histamine G-coupled receptor proteins (<e2>H1R</e2>, H2R, H3R and H4R).","Regulator"
"<e1>Histamine</e1> regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, <e2>H2R</e2>, H3R and H4R).","Regulator"
"and (3) Does <e1>RAMH</e1> inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (<e2>PKA</e2>)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?","Downregulator"
"and (3) Does <e1>RAMH</e1> inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (<e2>ERK1/2</e2>)/ets-like gene-1 (Elk-1)?","Downregulator"
"and (3) Does <e1>RAMH</e1> inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (<e2>Elk-1</e2>)?","Downregulator"
"(2) Does in vivo administration of <e1>(R)-(alpha)-(-)-methylhistamine dihydrobromide</e1> (RAMH) (<e2>H3R</e2> agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?","Agonist"
"(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (<e1>RAMH</e1>) (<e2>H3R</e2> agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?","Agonist"
"(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (<e2>H3R</e2> agonist), <e1>thioperamide maleate</e1> (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?","Antagonist"
"The 2.0-A resolution structure of <e2>Thermus thermophilus PRODH</e2> reveals a distorted (betaalpha)(8) barrel catalytic core domain and a hydrophobic alpha-helical domain located above the <e1>carboxyl</e1>-terminal ends of the strands of the barrel.","Part_of"
"<e2>Proline dehydrogenase</e2> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to <e1>glutamate</e1>.","Substrate"
"Proline dehydrogenase (<e2>PRODH</e2>) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to <e1>glutamate</e1>.","Substrate"
"Proline dehydrogenase (PRODH) and <e2>Delta(1)-pyrroline-5-carboxylate dehydrogenase</e2> (P5CDH) catalyze the two-step oxidation of proline to <e1>glutamate</e1>.","Substrate"
"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<e2>P5CDH</e2>) catalyze the two-step oxidation of proline to <e1>glutamate</e1>.","Substrate"
"Finally, we demonstrate that <e2>T. thermophilus PRODH</e2> reacts with O(2) producing <e1>superoxide</e1>.","Substrate"
"This is significant because <e1>superoxide</e1> production underlies the role of <e2>human PRODH</e2> in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.","Substrate"
"<e2>Proline dehydrogenase</e2> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of <e1>proline</e1> to glutamate.","Substrate"
"Proline dehydrogenase (<e2>PRODH</e2>) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of <e1>proline</e1> to glutamate.","Substrate"
"Proline dehydrogenase (PRODH) and <e2>Delta(1)-pyrroline-5-carboxylate dehydrogenase</e2> (P5CDH) catalyze the two-step oxidation of <e1>proline</e1> to glutamate.","Substrate"
"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<e2>P5CDH</e2>) catalyze the two-step oxidation of <e1>proline</e1> to glutamate.","Substrate"
"Finally, we demonstrate that <e2>T. thermophilus PRODH</e2> reacts with <e1>O(2)</e1> producing superoxide.","Substrate"
"Results of early clinical trials with both topically (<e1>cipamfylline</e1>, CP80,633) and systemically (CC-10004) active <e2>PDE4</e2> inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.","Downregulator"
"Results of early clinical trials with both topically (cipamfylline, <e1>CP80,633</e1>) and systemically (CC-10004) active <e2>PDE4</e2> inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.","Downregulator"
"Consequently, <e2>PDE4</e2> inhibitors including <e1>cilomilast</e1> and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.","Downregulator"
"Consequently, <e2>PDE4</e2> inhibitors including cilomilast and <e1>AWD 12-281</e1> have been tested in several models of allergic and irritant skin inflammation.","Downregulator"
"The <e2>phosphodiesterase (PDE) 4</e2> is the predominant <e1>cyclic AMP</e1> degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.","Substrate"
"Mechanism of specific membrane targeting by <e2>C2 domain</e2>s: localized pools of target lipids enhance <e1>Ca2+</e1> affinity.","Regulator"
"<e1>Ca2+</e1> activation targets the <e2>PKCalpha C2 domain</e2> to the plasma membrane and the cPLA2alpha C2 domain to the internal membranes, with no detectable spatial overlap.","Regulator"
"<e1>Ca2+</e1> activation targets the PKCalpha C2 domain to the plasma membrane and the <e2>cPLA2alpha C2 domain</e2> to the internal membranes, with no detectable spatial overlap.","Regulator"
"For the isolated <e2>PKCalpha C2 domai</e2>n in the presence of physiological Ca2+ levels, the target lipids <e1>phosphatidylserine</e1> (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.","Regulator"
"For the isolated <e2>PKCalpha C2 domai</e2>n in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (<e1>PS</e1>) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.","Regulator"
"For the isolated <e2>PKCalpha C2 domai</e2>n in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and <e1>phosphatidylinositol-4,5-bisphosphate</e1> (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.","Regulator"
"For the isolated <e2>PKCalpha C2 domai</e2>n in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (<e1>PIP2</e1>) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.","Regulator"
"For the <e2>cPLA2alpha C2 domain</e2>, the target lipid <e1>phosphatidylcholine</e1> (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.","Regulator"
"Mechanism of specific membrane targeting by <e2>C2 domains</e2>: localized pools of target lipids enhance <e1>Ca2+</e1> affinity.","Upregulator"
"Treatment with <e1>rosiglitazone</e1> or cholestyramine had no effect on <e2>BAT</e2> activity in any subcellular compartment.","Not"
"Treatment with rosiglitazone or <e1>cholestyramine</e1> had no effect on <e2>BAT</e2> activity in any subcellular compartment.","Not"
"After <e1>clofibrate</e1> treatment, male rats displayed an increase in peroxisomal <e2>BAT</e2> specific activity and a decrease in cytosolic BAT specific activity, whereas females showed an opposite response.","Regulator"
"After <e1>clofibrate</e1> treatment, male rats displayed an increase in peroxisomal <e2>BAT</e2> specific activity and a decrease in cytosolic BAT specific activity, whereas females showed an opposite response.","Regulator"
"<e2>Bile acid coenzyme A:amino acid N-acyltransferase</e2> (BAT) is responsible for the amidation of <e1>bile acids</e1> with the amino acids glycine and taurine.","Substrate"
"Bile acid coenzyme A:amino acid N-acyltransferase (<e2>BAT</e2>) is responsible for the amidation of <e1>bile acids</e1> with the amino acids glycine and taurine.","Substrate"
"<e1>Asparagine</e1> secretion by MSCs was directly related to their <e2>ASNS</e2> expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.","Substrate"
"Because of their low <e1>asparagine</e1> synthetase (<e2>ASNS</e2>) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.","Substrate"
"Because of their low <e1>asparagine</e1> synthetase (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.","Substrate"
"However, the heterogeneity of the <e1>NMDA</e1> receptors, frequently composed of <e2>NR1</e2> and NR2A-D subunits, has been less studied.","Regulator"
"However, the heterogeneity of the <e1>NMDA</e1> receptors, frequently composed of NR1 and <e2>NR2A</e2>-D subunits, has been less studied.","Regulator"
"Thus, we determined the contribution of <e1>NMDA</e1> receptor subtypes on <e2>Abeta(1-40)</e2> toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/NR2B subunits.","Regulator"
"Stimulation of <e2>NR1</e2>/NR2A receptors with NMDA/<e1>glycine</e1> revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).","Regulator"
"Stimulation of NR1/<e2>NR2A</e2> receptors with NMDA/<e1>glycine</e1> revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).","Regulator"
"Stimulation of NR1/NR2A receptors with NMDA/<e1>glycine</e1> revealed an increase in intracellular calcium in cells pre-exposed to <e2>Abeta(1-40)</e2>.","Regulator"
"<e1>MK-801</e1> ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive <e2>NMDA receptor</e2> antagonist, partially prevented the decrease in cell viability and the energy impairment.","Antagonist"
"MK-801 (<e1>(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate</e1>), a noncompetitive <e2>NMDA receptor</e2> antagonist, partially prevented the decrease in cell viability and the energy impairment.","Antagonist"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (<e1>ALA</e1>; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Undefined"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>DHA</e1>; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"Competition between 24:5n-3 and ALA for <e2>Delta 6 desaturase</e2> may limit the accumulation of <e1>DHA</e1> in HepG2 cell membranes.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (<e1>ALA</e1>; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>DHA</e1>; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"The use of <e2>Delta 6 desaturase</e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to <e1>docosahexaenoic acid</e1> (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to <e1>docosahexaenoic acid</e1> (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"Competition between 24:5n-3 and ALA for <e2>Delta 6 desaturase</e2> may limit the accumulation of <e1>DHA</e1> in HepG2 cell membranes.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>DHA</e1>; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>DHA</e1>; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"Competition between 24:5n-3 and <e1>ALA</e1> for <e2>Delta 6 desaturase</e2> may limit the accumulation of DHA in HepG2 cell membranes.","Substrate"
"The use of <e2>Delta 6 desaturase</e2> (D6D) twice in the conversion of <e1>alpha-linolenic acid</e1> (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of <e1>alpha-linolenic acid</e1> (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"Competition between 24:5n-3 and <e1>ALA</e1> for <e2>Delta 6 desaturase</e2> may limit the accumulation of DHA in HepG2 cell membranes.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (<e1>ALA</e1>; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"The use of Delta 6 desaturase (<e2>D6D</e2>) twice in the conversion of alpha-linolenic acid (<e1>ALA</e1>; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.","Substrate"
"(-)-Stepholidine (<e1>SPD</e1>), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor <e2>D1</e2> agonist and D2 antagonist.","Regulator"
"(-)-Stepholidine (<e1>SPD</e1>), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and <e2>D2</e2> antagonist.","Regulator"
"(-)-Stepholidine (<e1>SPD</e1>), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor <e2>D1</e2> agonist and D2 antagonist.","Regulator"
"Insights into dynamical behaviors of D1 and D2 receptors and their interaction modes with <e1>SPD</e1> are crucial in understanding the structural and functional characteristics of <e2>dopamine receptors</e2>.","Regulator"
"<e2>Dopamine D1 receptor</e2> agonist and D2 receptor antagonist effects of the natural product <e1>(-)-stepholidine</e1>: molecular modeling and dynamics simulations.","Agonist"
"<e1>(-)-Stepholidine</e1> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a <e2>dopamine receptor D1</e2> agonist and D2 antagonist.","Agonist"
"(-)-Stepholidine (<e1>SPD</e1>), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a <e2>dopamine receptor D1</e2> agonist and D2 antagonist.","Agonist"
"Dopamine D1 receptor agonist and <e2>D2 receptor</e2> antagonist effects of the natural product <e1>(-)-stepholidine</e1>: molecular modeling and dynamics simulations.","Antagonist"
"<e1>(-)-Stepholidine</e1> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and <e2>D2</e2> antagonist.","Antagonist"
"(-)-Stepholidine (<e1>SPD</e1>), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and <e2>D2</e2> antagonist.","Antagonist"
"A novel variant <e2>L263F</e2> in human <e1>inosine 5'-monophosphate</e1> dehydrogenase 2 is associated with diminished enzyme activity.","Not"
"The Ki for mycophenolic acid inhibition of the <e2>L263F</e2> variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and <e1>nicotinamide adenine dinucleotide</e1> did not change significantly.","Not"
"Variants in the <e2>IMPDH2</e2> gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving <e1>mycophenolic acid</e1>.","Regulator"
"The Ki for <e1>mycophenolic acid</e1> inhibition of the <e2>L263F</e2> variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.","Downregulator"
"Reducing GSH levels in female mice CNS by pretreatment with <e1>diethyl maleate</e1> or L-propargyl glycine did not result in inhibition of <e2>complex I</e2> activity, unlike male mice.","Not"
"Reducing GSH levels in female mice CNS by pretreatment with diethyl maleate or <e1>L-propargyl glycine</e1> did not result in inhibition of <e2>complex I</e2> activity, unlike male mice.","Not"
"<e1>L-BOAA</e1> causes loss of GSH and inhibition of mitochondrial <e2>complex I</e2> in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.","Not"
"L-BOAA causes loss of <e1>GSH</e1> and inhibition of mitochondrial <e2>complex I</e2> in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.","Not"
"We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, <e2>glutaredoxin</e2> in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (<e1>L-BOAA</e1>), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.","Regulator"
"We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, <e2>glutaredoxin</e2> in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (<e1>L-BOAA</e1>), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.","Regulator"
"We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, <e2>glutaredoxin</e2> in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (<e1>L-BOAA</e1>), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.","Regulator"
"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to <e1>L-BOAA</e1> toxicity as evidenced by activation of <e2>AP1</e2>, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.","Upregulator"
"<e1>L-BOAA</e1> causes loss of GSH and inhibition of mitochondrial <e2>complex I</e2> in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.","Upregulator"
"<e1>Estrogen</e1> protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of <e2>glutaredoxin</e2> in the CNS.","Upregulator"
"<e1>L-BOAA</e1> causes loss of GSH and inhibition of <e2>mitochondrial complex I</e2> in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.","Downregulator"
"<e1>L-BOAA</e1> causes loss of GSH and inhibition of <e2>mitochondrial complex I</e2> in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.","Downregulator"
"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>GABA</e1>, share the same vesicular inhibitory amino acid transporter (<e2>VIAAT</e2>) and are both present in neurons during postnatal development.","Substrate"
"We have expressed VIAAT and the <e2>plasmalemmal transporters</e2> for glycine and <e1>GABA</e1> in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.","Substrate"
"The transporters GlyT2 and <e2>VIAAT</e2> cooperate to determine the vesicular <e1>glycine</e1>rgic phenotype.","Substrate"
"The transporters GlyT2 and <e2>VIAAT</e2> cooperate to determine the vesicular <e1>glycine</e1>rgic phenotype.","Substrate"
"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>GABA</e1>, share the same vesicular inhibitory amino acid transporter (<e2>VIAAT</e2>) and are both present in neurons during postnatal development.","Substrate"
"The transporters <e2>GlyT2</e2> and VIAAT cooperate to determine the vesicular <e1>glycine</e1>rgic phenotype.","Substrate"
"The transporters GlyT2 and <e2>VIAAT</e2> cooperate to determine the vesicular <e1>glycine</e1>rgic phenotype.","Substrate"
"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, <e1>glycine</e1> and GABA, share the same <e2>vesicular inhibitory amino acid transporter</e2> (VIAAT) and are both present in neurons during postnatal development.","Substrate"
"The transporters GlyT2 and <e2>VIAAT</e2> cooperate to determine the vesicular <e1>glycine</e1>rgic phenotype.","Substrate"
"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>GABA</e1>, share the same <e2>vesicular inhibitory amino acid transporter</e2> (VIAAT) and are both present in neurons during postnatal development.","Substrate"
"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>GABA</e1>, share the same vesicular inhibitory amino acid transporter (<e2>VIAAT</e2>) and are both present in neurons during postnatal development.","Substrate"
"The transporters GlyT2 and <e2>VIAAT</e2> cooperate to determine the vesicular <e1>glycine</e1>rgic phenotype.","Substrate"
"We have expressed VIAAT and the <e2>plasmalemmal transporters</e2> for <e1>glycine</e1> and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.","Substrate"
"Consequently, other cation species may compete with <e1>Na+</e1> to regulate the time <e2>KARs</e2> remain in the open state.","Regulator"
"Consequently, other cation species may compete with <e1>Na+</e1> to regulate the time <e2>KARs</e2> remain in the open state.","Regulator"
"Additionally, Na+ and <e1>Cl-</e1> ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on <e2>KARs</e2>.","Regulator"
"<e1>Na+</e1>/Cl- dipole couples agonist binding to <e2>kainate receptor</e2> activation.","Upregulator"
"Na+/<e1>Cl-</e1> dipole couples agonist binding to <e2>kainate receptor</e2> activation.","Upregulator"
"<e2>Kainate-selective ionotropic glutamate receptors</e2> (GluRs) require external Na+ and Cl- as well as the neurotransmitter <e1>L-glutamate</e1> for activation.","Upregulator"
"Kainate-selective ionotropic glutamate receptors (<e2>GluRs</e2>) require external Na+ and Cl- as well as the neurotransmitter <e1>L-glutamate</e1> for activation.","Upregulator"
"<e2>Kainate-selective ionotropic glutamate receptors</e2> (GluRs) require external <e1>Na+</e1> and Cl- as well as the neurotransmitter L-glutamate for activation.","Upregulator"
"Kainate-selective ionotropic glutamate receptors (<e2>GluRs</e2>) require external <e1>Na+</e1> and Cl- as well as the neurotransmitter L-glutamate for activation.","Upregulator"
"<e2>Kainate-selective ionotropic glutamate receptors</e2> (GluRs) require external Na+ and <e1>Cl-</e1> as well as the neurotransmitter L-glutamate for activation.","Upregulator"
"Kainate-selective ionotropic glutamate receptors (<e2>GluRs</e2>) require external Na+ and <e1>Cl-</e1> as well as the neurotransmitter L-glutamate for activation.","Upregulator"
"Additionally, <e1>Na+</e1> and Cl- ions coactivate <e2>GluR6</e2> receptors by establishing a dipole, accounting for their common effect on KARs.","Upregulator"
"Additionally, Na+ and <e1>Cl-</e1> ions coactivate <e2>GluR6</e2> receptors by establishing a dipole, accounting for their common effect on KARs.","Upregulator"
"This effect probably involves interaction of <e1>phenserine</e1> with a regulatory element in the 5'-untranslated region of the <e2>APP</e2> gene that controls APP expression.","Regulator"
"<e1>Phenserine</e1> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of <e2>beta-amyloid precursor protein</e2> (APP) in neuronal cell culture by reducing APP translation.","Regulator"
"<e1>Phenserine</e1> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (<e2>APP</e2>) in neuronal cell culture by reducing APP translation.","Regulator"
"<e1>Phenserine</e1> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (<e2>APP</e2>) in neuronal cell culture by reducing APP translation.","Downregulator"
"As a consequence, <e1>phenserine</e1> reduces <e2>beta-amyloid</e2> peptide (Abeta) formation in vitro and in vivo.","Downregulator"
"As a consequence, <e1>phenserine</e1> reduces beta-amyloid peptide (<e2>Abeta</e2>) formation in vitro and in vivo.","Downregulator"
"<e1>Phenserine</e1> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (<e2>APP</e2>) in neuronal cell culture by reducing APP translation.","Downregulator"
"<e1>Phenserine</e1>, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (<e2>AChE</e2>) and was shown to improve cognition in various experimental paradigms in rodents and dogs.","Downregulator"
"<e1>Phenserine</e1>, a derivative of physostigmine, was first described as an inhibitor of <e2>acetylcholinesterase</e2> (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.","Downregulator"
"Phenserine is also unique because of differing actions of its enantiomers: <e1>(-)-phenserine</e1> is the active enantiomer for inhibition of <e2>AChE</e2>, whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.","Downregulator"
"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of <e2>AChE</e2>, whereas <e1>(+)-phenserine</e1> ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.","Downregulator"
"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of <e2>AChE</e2>, whereas (+)-phenserine ('<e1>posiphen</e1>') has weak activity as an AChE inhibitor and can be dosed much higher.","Downregulator"
"Phenserine, a derivative of <e1>physostigmine</e1>, was first described as an inhibitor of acetylcholinesterase (<e2>AChE</e2>) and was shown to improve cognition in various experimental paradigms in rodents and dogs.","Downregulator"
"Phenserine, a derivative of <e1>physostigmine</e1>, was first described as an inhibitor of <e2>acetylcholinesterase</e2> (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.","Downregulator"
"<e1>Phenserine</e1>, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (<e2>AChE</e2>) and was shown to improve cognition in various experimental paradigms in rodents and dogs.","Downregulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by <e1>metformin</e1>, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).","Not"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>AICAR</e1>).","Not"
"CONCLUSIONS AND IMPLICATIONS: Activation of <e2>alpha1-AMPK</e2> is associated with inhibition of apical amiloride-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of <e1>metformin</e1>.","Regulator"
"CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical <e2>amiloride-sensitive Na(+) channels</e2> (ENaC), which has important implications for the clinical use of <e1>metformin</e1>.","Regulator"
"CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive Na(+) channels (<e2>ENaC</e2>), which has important implications for the clinical use of <e1>metformin</e1>.","Regulator"
"Additional pharmacological effects evoked by <e1>AICAR</e1> and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, <e2>ENaC</e2> activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.","Regulator"
"Additional pharmacological effects evoked by <e1>AICAR</e1> and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where <e2>Na+K+ATPase</e2> is an important component.","Regulator"
"Additional pharmacological effects evoked by AICAR and <e1>phenformin</e1> on I(ouabain), with potential secondary effects on apical Na+ conductance, <e2>ENaC</e2> activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.","Regulator"
"Additional pharmacological effects evoked by AICAR and <e1>phenformin</e1> on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where <e2>Na+K+ATPase</e2> is an important component.","Regulator"
"Additional pharmacological effects evoked by AICAR and phenformin on I(<e1>ouabain</e1>), with potential secondary effects on apical Na+ conductance, <e2>ENaC</e2> activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.","Regulator"
"Additional pharmacological effects evoked by AICAR and phenformin on I(<e1>ouabain</e1>), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where <e2>Na+K+ATPase</e2> is an important component.","Regulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>AICAR</e1>).","Upregulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by metformin, <e1>phenformin</e1>, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).","Upregulator"
"We have completed an extensive study of the pharmacological effects of these drugs on <e2>AMPK</e2> activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and <e1>ouabain</e1>-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.","Upregulator"
"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase</e2> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>AICAR</e1>).","Upregulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>AICAR</e1>).","Upregulator"
"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase</e2> (AMPK) is activated by <e1>metformin</e1>, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).","Upregulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by <e1>metformin</e1>, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).","Upregulator"
"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase</e2> (AMPK) is activated by metformin, <e1>phenformin</e1>, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).","Upregulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by metformin, <e1>phenformin</e1>, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).","Upregulator"
"KEY RESULTS: <e1>Phenformin</e1>, AICAR and metformin increased <e2>AMPK (alpha1)</e2> activity and decreased I(amiloride).","Upregulator"
"KEY RESULTS: Phenformin, <e1>AICAR</e1> and metformin increased <e2>AMPK (alpha1)</e2> activity and decreased I(amiloride).","Upregulator"
"KEY RESULTS: Phenformin, AICAR and <e1>metformin</e1> increased <e2>AMPK (alpha1)</e2> activity and decreased I(amiloride).","Upregulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by metformin, <e1>phenformin</e1>, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).","Upregulator"
"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase</e2> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, <e1>5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside</e1> (AICAR).","Upregulator"
"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK</e2>) is activated by metformin, phenformin, and the AMP mimetic, <e1>5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside</e1> (AICAR).","Upregulator"
"Compared with normal control group, <e1>PTZ</e1>-kindled mice had significantly higher levels of malondialdehyde, nitrite, <e2>myeloperoxidase</e2> but had lower levels of reduced glutathione in the whole brain homogenate.","Upregulator"
"Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or <e1>rofecoxib</e1> (selective <e2>COX-2</e2> inhibitor) against chemical kindling in mice.","Downregulator"
"Neuroprotective effect of <e1>nimesulide</e1>, a preferential <e2>COX-2</e2> inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.","Downregulator"
"Neuroprotective effect of <e1>nimesulide</e1>, a preferential <e2>COX-2</e2> inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.","Downregulator"
"Neuroprotective effect of <e1>nimesulide</e1>, a preferential <e2>COX-2</e2> inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.","Downregulator"
"Previous studies have explored the protective effect of <e1>naproxen</e1> (non-selective <e2>COX</e2>-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice.","Downregulator"
"Brain cyclooxygenases (<e2>COX</e2>), the rate-limiting enzyme in <e1>prostaglandin</e1> synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.","Substrate"
"Brain <e2>cyclooxygenases</e2> (COX), the rate-limiting enzyme in <e1>prostaglandin</e1> synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.","Substrate"
"<e1>Isothiocyanates</e1>, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by <e2>glutathione S-transferases</e2> (GSTs) before urinary excretion.","Regulator"
"<e1>Isothiocyanates</e1>, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione S-transferases (<e2>GSTs</e2>) before urinary excretion.","Regulator"
"While vitamin C is essential for <e2>PHD</e2> activity in vitro, <e1>N-acetyl-L-cysteine</e1> had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.","Not"
"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and <e1>gallic acid</e1> or n-propyl gallate efficiently inhibited the activity of all three <e2>PHDs</e2>, demonstrating different functions of these antioxidants.","Downregulator"
"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or <e1>n-propyl gallate</e1> efficiently inhibited the activity of all three <e2>PHDs</e2>, demonstrating different functions of these antioxidants.","Downregulator"
"<e1>LTC4</e1> synthase (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.","Substrate"
"<e1>LTC4</e1> synthase (<e2>LTC4S</e2>), the pivotal enzyme for the biosynthesis of LTC4 (ref.","Substrate"
"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>eicosanoid</e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, <e2>microsomal glutathione S-transferases</e2> (MGSTs), and microsomal prostaglandin E synthase 1 (ref.","Substrate"
"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>eicosanoid</e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (<e2>MGSTs</e2>), and microsomal prostaglandin E synthase 1 (ref.","Substrate"
"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>eicosanoid</e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and <e2>microsomal prostaglandin E synthase 1</e2> (ref.","Substrate"
"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>glutathione</e1> metabolism that includes 5-lipoxygenase-activating protein, <e2>microsomal glutathione S-transferases</e2> (MGSTs), and microsomal prostaglandin E synthase 1 (ref.","Substrate"
"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>glutathione</e1> metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (<e2>MGSTs</e2>), and microsomal prostaglandin E synthase 1 (ref.","Substrate"
"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>glutathione</e1> metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and <e2>microsomal prostaglandin E synthase 1</e2> (ref.","Substrate"
"<e1>Phenelzine</e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (<e2>GABA-T</e2>), markedly increasing brain GABA levels.","Downregulator"
"<e1>Phenelzine</e1> causes an increase in brain ornithine that is prevented by prior <e2>monoamine oxidase</e2> inhibition.","Downregulator"
"<e1>Phenelzine</e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO</e2>), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.","Downregulator"
"<e1>Phenelzine</e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits <e2>GABA-transaminase</e2> (GABA-T), markedly increasing brain GABA levels.","Downregulator"
"To determine whether a metabolite formed by the action of <e2>MAO</e2> on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor <e1>tranylcypromine</e1> (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.","Downregulator"
"To determine whether a metabolite formed by the action of <e2>MAO</e2> on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (<e1>TCP</e1>) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.","Downregulator"
"<e1>Phenelzine</e1> causes an increase in brain ornithine that is prevented by prior <e2>monoamine oxidase</e2> inhibition.","Downregulator"
"Phenelzine (<e1>PLZ</e1>), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (<e2>GABA-T</e2>), markedly increasing brain GABA levels.","Downregulator"
"Phenelzine (<e1>PLZ</e1>), a nonselective irreversible inhibitor of <e2>monoamine oxidase</e2> (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.","Downregulator"
"Phenelzine (<e1>PLZ</e1>), a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO</e2>), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.","Downregulator"
"Phenelzine (<e1>PLZ</e1>), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits <e2>GABA-transaminase</e2> (GABA-T), markedly increasing brain GABA levels.","Downregulator"
"Phenelzine (<e1>PLZ</e1>), a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO</e2>), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.","Substrate"
"Phenelzine (<e1>PLZ</e1>), a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO</e2>), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.","Substrate"
"As further support, <e1>alpha-methyl-DL-aspartate</e1>, an inhibitor of <e2>argininosuccinate synthase</e2> (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.","Downregulator"
"As further support, <e1>alpha-methyl-DL-aspartate</e1>, an inhibitor of argininosuccinate synthase (<e2>AS</e2>), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.","Downregulator"
"Nitric oxide (<e1>NO</e1>) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by <e2>endothelial nitric oxide synthase</e2> (eNOS).","Substrate"
"Nitric oxide (<e1>NO</e1>) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS</e2>).","Substrate"
"<e1>Nitric oxide</e1> (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by <e2>endothelial nitric oxide synthase</e2> (eNOS).","Substrate"
"<e1>Nitric oxide</e1> (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS</e2>).","Substrate"
"Nitric oxide (NO) is an important vasorelaxant produced along with <e1>L-citrulline</e1> from L-arginine in a reaction catalyzed by <e2>endothelial nitric oxide synthase</e2> (eNOS).","Substrate"
"Nitric oxide (NO) is an important vasorelaxant produced along with <e1>L-citrulline</e1> from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS</e2>).","Substrate"
"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from <e1>L-arginine</e1> in a reaction catalyzed by <e2>endothelial nitric oxide synthase</e2> (eNOS).","Substrate"
"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from <e1>L-arginine</e1> in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS</e2>).","Substrate"
"It is more potent and selective than <e1>citalopram</e1> in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the <e2>histamine H1</e2> and muscarinic receptors.","Regulator"
"It is more potent and selective than <e1>citalopram</e1> in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and <e2>muscarinic receptors</e2>.","Regulator"
"Caution is necessary only when it is coadministered with drugs metabolised by <e2>CYP2D6</e2>, such as <e1>metoprolol</e1>, or administered to the elderly or patients with severe hepatic or renal impairment.","Substrate"
"<e1>AZD6140</e1> is a reversible oral <e2>P2Y(12)</e2> receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).","Antagonist"
"AZD6140 is a reversible oral <e2>P2Y(12)</e2> receptor antagonist that has been studied in ACS patients in comparison with <e1>clopidogrel</e1> (DISPERSE-2 study).","Antagonist"
"Inhibition of platelet aggregation by AZD6140, a reversible oral <e2>P2Y12</e2> receptor antagonist, compared with <e1>clopidogrel</e1> in patients with acute coronary syndromes.","Antagonist"
"Inhibition of platelet aggregation by <e1>AZD6140</e1>, a reversible oral <e2>P2Y12</e2> receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.","Antagonist"
"Compounds 1 and 2 potently displaced <e1>(3)H-NMS</e1> binding at m1, m3 and m4 receptors, but were less potent at the <e2>m2</e2> and m5 subtypes.","Regulator"
"Compounds 1 and 2 potently displaced <e1>(3)H-NMS</e1> binding at m1, m3 and m4 receptors, but were less potent at the m2 and <e2>m5</e2> subtypes.","Regulator"
"<e1>Oxybutynin</e1> (1) is a non-selective <e2>muscarinic receptor</e2> antagonist that is used clinically for the treatment of urinary incontinence.","Antagonist"
"Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not <e1>pilocarpine</e1> (0.3 mg/kg for 7 days po), recovered the <e2>AQP5</e2> protein level reduced by CTD and increased the AQP1 protein level above the control one.","Not"
"Administration of <e1>cevimeline hydrochloride</e1>, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the <e2>AQP5</e2> protein level reduced by CTD and increased the AQP1 protein level above the control one.","Not"
"Administration of <e1>cevimeline hydrochloride</e1>, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the <e2>AQP5</e2> protein level reduced by CTD and increased the AQP1 protein level above the control one.","Upregulator"
"Administration of <e1>cevimeline hydrochloride</e1>, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the <e2>AQP1</e2> protein level above the control one.","Upregulator"
"Administration of <e1>chloroquine</e1> (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the <e2>AQP5</e2> protein level reduced by CTD.","Upregulator"
"Degradation of submandibular gland <e2>AQP5</e2> by parasympathetic denervation of chorda tympani and its recovery by <e1>cevimeline</e1>, an M3 muscarinic receptor agonist.","Upregulator"
"Administration of <e1>cevimeline hydrochloride</e1>, an <e2>M3 muscarinic receptor</e2> agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.","Agonist"
"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by <e1>cevimeline</e1>, an <e2>M3 muscarinic receptor</e2> agonist.","Agonist"
"In both rodent and primate animal models, the binding of radiolabeled <e1>d-MPH</e1> to <e2>dopamine transporter</e2> was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.","Regulator"
"In both rodent and primate animal models, the binding of radiolabeled d-MPH to <e2>dopamine transporter</e2> was found to be selective, saturable, and reversible, whereas binding of <e1>l-MPH</e1> was diffuse and nonspecific.","Regulator"
"The importance of <e1>MPH</e1> chirality to central nervous system <e2>MPH receptor</e2> targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas l-MPH binding is nonspecific.","Regulator"
"<e1>threo-methylphenidate</e1> inhibits the <e2>dopamine transporter</e2> and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.","Downregulator"
"<e1>threo-methylphenidate</e1> inhibits the dopamine transporter and the <e2>norepinephrine transporter</e2>, resulting in elevations of these monoamines after impulse release.","Downregulator"
"threo-methylphenidate inhibits the <e2>dopamine transporter</e2> and the norepinephrine transporter, resulting in elevations of these <e1>monoamines</e1> after impulse release.","Substrate"
"threo-methylphenidate inhibits the dopamine transporter and the <e2>norepinephrine transporter</e2>, resulting in elevations of these <e1>monoamines</e1> after impulse release.","Substrate"
"Identification of <e1>N</e1>-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, <e2>adrenomedullin</e2>, and amylin receptor function.","Part_of"
"Identification of <e1>N</e1>-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and <e2>amylin receptor</e2> function.","Part_of"
"Identification of <e1>N</e1>-terminal receptor activity-modifying protein residues important for <e2>calcitonin gene-related peptide</e2>, adrenomedullin, and amylin receptor function.","Part_of"
"Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular <e2>stathmin</e2> levels and in the absence and presence of sublethal nitrosourea ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]; <e1>CCNU</e1>) concentrations.","Downregulator"
"Pharmacological and in silico investigations concerning the interactions of these compounds with the <e2>hERG</e2> channel revealed that compounds carrying a basic <e1>nitrogen</e1> in the side chain display a much higher affinity than those lacking such a group.","Regulator"
"Specifically, <e1>B2-O-CH(2)-CH(2)-N-piperidine</e1> and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards <e2>hERG</e2> channels than amiodarone.","Regulator"
"Specifically, B2-O-CH(2)-CH(2)-N-piperidine and <e1>B2-O-CH(2)-CH(2)-N-pyrrolidine</e1> revealed a higher affinity towards <e2>hERG</e2> channels than amiodarone.","Regulator"
"Interaction with the <e2>hERG</e2> channel and cytotoxicity of <e1>amiodarone</e1> and amiodarone analogues.","Regulator"
"Interaction with the <e2>hERG</e2> channel and cytotoxicity of <e1>amiodarone</e1> and amiodarone analogues.","Regulator"
"Interaction with the <e2>hERG</e2> channel and cytotoxicity of <e1>amiodarone</e1> and amiodarone analogues.","Regulator"
"CONCLUSIONS AND IMPLICATIONS: <e1>Amiodarone</e1> analogues with better <e2>hERG</e2> channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.","Downregulator"
"The principal aim of the study was to find <e1>amiodarone</e1> analogues that retained <e2>human ether-a-go-go-related protein (hERG) channel</e2> inhibition but with reduced cytotoxicity.","Downregulator"
"However, <e2>holo-alpha-lactalbumin</e2> was unable to bind <e1>fatty acids</e1> as measured by this technique.","Not"
"However, <e2>holo-alpha-lactalbumin</e2> was unable to bind <e1>fatty acids</e1> as measured by this technique.","Not"
"<e2>Apo-alpha-lactalbumin</e2>, obtained by treatment with EDTA, displays one binding site for <e1>fatty acids</e1>, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.","Regulator"
"<e2>Apo-alpha-lactalbumin</e2>, obtained by treatment with EDTA, displays one binding site for fatty acids, the association constants for <e1>oleic and palmitic acids</e1> being 1.9.10(6) and 4.2.10(5) M(-1), respectively.","Regulator"
"Interaction of <e2>human alpha-lactalbumin</e2> with <e1>fatty acids</e1>: determination of binding parameters.","Regulator"
"Interaction of <e2>human alpha-lactalbumin</e2> with <e1>fatty acids</e1>: determination of binding parameters.","Regulator"
"Oxytocin (OT) and <e1>vasopressin</e1> (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP <e2>V(1a)</e2> (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?","Regulator"
"Oxytocin (OT) and <e1>vasopressin</e1> (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), <e2>V(1b)</e2> (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?","Regulator"
"Oxytocin (OT) and <e1>vasopressin</e1> (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), <e2>V(2)</e2> (renal) receptors and a fifth putative AVP V(1c)?","Regulator"
"Oxytocin (OT) and <e1>vasopressin</e1> (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP <e2>V(1c)</e2>?","Regulator"
"Oxytocin (OT) and vasopressin (<e1>AVP</e1>) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP <e2>V(1a)</e2> (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?","Regulator"
"Oxytocin (OT) and vasopressin (<e1>AVP</e1>) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), <e2>V(1b)</e2> (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?","Regulator"
"Oxytocin (OT) and vasopressin (<e1>AVP</e1>) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), <e2>V(2)</e2> (renal) receptors and a fifth putative AVP V(1c)?","Regulator"
"Oxytocin (OT) and vasopressin (<e1>AVP</e1>) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP <e2>V(1c)</e2>?","Regulator"
"In addition to <e2>OT</e2> and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as <e1>carbetocin</e1> (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.","Agonist"
"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (<e1>desmopressin</e1>, <e2>V(2)</e2> agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.","Agonist"
"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), <e1>terlipressin</e1> (<e2>V(1a)</e2> agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.","Agonist"
"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (<e2>V(1a)</e2> agonist), <e1>felypressin</e1> (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.","Agonist"
"In addition to <e2>OT</e2> and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and <e1>atosiban</e1> (Tractocile OT antagonist) are also in clinical use.","Antagonist"
"In addition to <e2>OT</e2> and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (<e1>Tractocile</e1> OT antagonist) are also in clinical use.","Antagonist"
"While a number of orally active non-peptide <e2>V(2)</e2> antagonists (Vaptans); notably, <e1>Tolvaptan</e1>, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.","Antagonist"
"While a number of orally active non-peptide <e2>V(2)</e2> antagonists (Vaptans); notably, Tolvaptan, <e1>Lixivaptan</e1> and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.","Antagonist"
"While a number of orally active non-peptide <e2>V(2)</e2> antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and <e1>Satavaptan</e1>, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.","Antagonist"
"While a number of orally active non-peptide <e2>V(2)</e2> antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist <e1>Conivaptan</e1> (Vaprisol), has been approved by the US FDA for clinical use (by i.v.","Antagonist"
"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/<e2>V(1a)</e2>, antagonist <e1>Conivaptan</e1> (Vaprisol), has been approved by the US FDA for clinical use (by i.v.","Antagonist"
"While a number of orally active non-peptide <e2>V(2)</e2> antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (<e1>Vaprisol</e1>), has been approved by the US FDA for clinical use (by i.v.","Antagonist"
"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/<e2>V(1a)</e2>, antagonist Conivaptan (<e1>Vaprisol</e1>), has been approved by the US FDA for clinical use (by i.v.","Antagonist"
"<e1>Nicotinic acid</e1> and acipimox interfere with the biosynthesis of <e2>LDL</e2> and can also improve the clearance of VLDL/LDL.","Regulator"
"<e1>Nicotinic acid</e1> and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of <e2>VLDL</e2>/LDL.","Regulator"
"<e1>Nicotinic acid</e1> and acipimox interfere with the biosynthesis of <e2>LDL</e2> and can also improve the clearance of VLDL/LDL.","Regulator"
"<e1>Fibric acids</e1>, in particular, act by stimulating the catabolism of V<e2>LDL</e2> and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.","Regulator"
"Absorbable drugs (<e1>fibric acids</e1>, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce <e2>plasma very-low-density lipoproteins</e2> (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (<e1>fibric acids</e1>, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>VLDL</e2>) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (<e1>fibric acids</e1>, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-<e2>low-density lipoproteins</e2> (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (<e1>fibric acids</e1>, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (V<e2>LDL</e2>) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, <e1>nicotinic acid</e1>, probucol, HMG-CoA reductase inhibitors) reduce <e2>plasma very-low-density lipoproteins</e2> (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, <e1>nicotinic acid</e1>, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>VLDL</e2>) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, <e1>nicotinic acid</e1>, probucol, HMG-CoA reductase inhibitors) reduce plasma very-<e2>low-density lipoproteins</e2> (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, <e1>nicotinic acid</e1>, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (V<e2>LDL</e2>) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol</e1>, HMG-CoA reductase inhibitors) reduce <e2>plasma very-low-density lipoproteins</e2> (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol</e1>, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>VLDL</e2>) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol</e1>, HMG-CoA reductase inhibitors) reduce plasma very-<e2>low-density lipoproteins</e2> (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol</e1>, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (V<e2>LDL</e2>) and/or low-density lipoproteins (LDL) by a variety of mechanisms.","Downregulator"
"<e1>Fibric acids</e1>, in particular, act by stimulating the catabolism of <e2>VLDL</e2> and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.","Downregulator"
"accelerating reverse transport of <e1>cholesteryl esters</e1> from <e2>high-density lipoproteins</e2> to lower-density lipoproteins.","Substrate"
"accelerating reverse transport of <e1>cholesteryl esters</e1> from high-density lipoproteins to <e2>lower-density lipoproteins</e2>.","Substrate"
"It is indicated for use in combination with <e1>capecitabine</e1> for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress <e2>HER2</e2> (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.","Regulator"
"It is indicated for use in combination with <e1>capecitabine</e1> for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress <e2>HER2</e2> (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.","Regulator"
"It is indicated for use in combination with <e1>capecitabine</e1> for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress <e2>HER2</e2> (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.","Regulator"
"Search terms included <e1>lapatinib</e1>, GW572016, <e2>HER2</e2>, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.","Regulator"
"BACKGROUND: <e1>Lapatinib</e1>, the first dual inhibitor of epidermal growth factor receptor (<e2>EGFR</e2>) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.","Downregulator"
"BACKGROUND: <e1>Lapatinib</e1>, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (<e2>HER2</e2>) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.","Downregulator"
"<e1>Lapatinib</e1>: a dual inhibitor of human epidermal growth factor receptor <e2>tyrosine kinases</e2>.","Downregulator"
"<e1>Lapatinib</e1>: a dual inhibitor of <e2>human epidermal growth factor receptor</e2> tyrosine kinases.","Downregulator"
"<e1>Lapatinib</e1>: a dual inhibitor of human epidermal growth factor receptor <e2>tyrosine kinases</e2>.","Downregulator"
"BACKGROUND: <e1>Lapatinib</e1>, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (<e2>HER2</e2>) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.","Downregulator"
"<e1>Lapatinib</e1>: a dual inhibitor of human epidermal growth factor receptor <e2>tyrosine kinases</e2>.","Downregulator"
"<e1>Lapatinib</e1>: a dual inhibitor of human <e2>epidermal growth factor receptor</e2> tyrosine kinases.","Downregulator"
"BACKGROUND: <e1>Lapatinib</e1>, the first dual inhibitor of epidermal growth factor receptor (<e2>EGFR</e2>) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.","Downregulator"
"BACKGROUND: <e1>Lapatinib</e1>, the first dual inhibitor of epidermal growth factor receptor (EGFR) and <e2>human epidermal growth factor receptor 2</e2> (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.","Downregulator"
"<e1>Lapatinib</e1> is metabolized primarily by the <e2>cytochrome P450 3A4</e2> isozyme, with 1 metabolite remaining active against EGFR but not HER2.","Substrate"
"Phenelzine is a more potent <e2>monoamine oxidase</e2> inhibitor than is <e1>N2-acetylphenelzine</e1>.","Downregulator"
"Acetylation of <e1>phenelzine</e1> at the N2 position presumably interferes with the inhibition of the <e2>transaminase</e2> enzymes for gamma-aminobutyric acid and alanine.","Downregulator"
"Acetylation of phenelzine at the <e1>N2</e1> position presumably interferes with the inhibition of the <e2>transaminase</e2> enzymes for gamma-aminobutyric acid and alanine.","Downregulator"
"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the <e2>transaminase</e2> enzymes for <e1>gamma-aminobutyric acid</e1> and alanine.","Downregulator"
"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the <e2>transaminase</e2> enzymes for gamma-aminobutyric acid and <e1>alanine</e1>.","Downregulator"
"<e1>Phenelzine</e1> is a more potent <e2>monoamine oxidase</e2> inhibitor than is N2-acetylphenelzine.","Downregulator"
"<e1>Quinpirole</e1> and 7-OH-DPAT also increased the phosphorylation of <e2>extracellular signal-regulated kinase</e2> (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.","Upregulator"
"<e1>Quinpirole</e1> and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (<e2>ERK</e2>) within minutes, an effect blocked by pretreatment with SB-277011-A.","Upregulator"
"Quinpirole and <e1>7-OH-DPAT</e1> also increased the phosphorylation of <e2>extracellular signal-regulated kinase</e2> (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.","Upregulator"
"Quinpirole and <e1>7-OH-DPAT</e1> also increased the phosphorylation of extracellular signal-regulated kinase (<e2>ERK</e2>) within minutes, an effect blocked by pretreatment with SB-277011-A.","Upregulator"
"Quinpirole and 7-OH-DPAT also increased the phosphorylation of <e2>extracellular signal-regulated kinase</e2> (ERK) within minutes, an effect blocked by pretreatment with <e1>SB-277011-A</e1>.","Downregulator"
"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (<e2>ERK</e2>) within minutes, an effect blocked by pretreatment with <e1>SB-277011-A</e1>.","Downregulator"
"All neurotrophic effects were blocked by the unselective D2/<e2>D3 receptor</e2> antagonist sulpiride (5 microm) and by the selective D3 receptor antagonist <e1>SB-277011-A</e1> at a low dose (50 nm).","Antagonist"
"This study identified four clinically approved antihypertensive drugs (<e1>efonidipine</e1>, felodipine, isradipine, and nitrendipine) as potent <e2>T-channel</e2> blockers (IC(50) < 3 microM).","Downregulator"
"This study identified four clinically approved antihypertensive drugs (efonidipine, <e1>felodipine</e1>, isradipine, and nitrendipine) as potent <e2>T-channel</e2> blockers (IC(50) < 3 microM).","Downregulator"
"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, <e1>isradipine</e1>, and nitrendipine) as potent <e2>T-channel</e2> blockers (IC(50) < 3 microM).","Downregulator"
"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and <e1>nitrendipine</e1>) as potent <e2>T-channel</e2> blockers (IC(50) < 3 microM).","Downregulator"
"Triphosphate nucleotides (ATP, GTP, and <e1>UTP</e1>) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of <e2>purine receptors</e2>.","Not"
"<e1>Triphosphate nucleotides</e1> (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of <e2>purine receptors</e2>.","Not"
"Triphosphate nucleotides (<e1>ATP</e1>, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of <e2>purine receptors</e2>.","Not"
"Triphosphate nucleotides (ATP, <e1>GTP</e1>, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of <e2>purine receptors</e2>.","Not"
"Triphosphate nucleotides (ATP, GTP, and <e1>UTP</e1>) rapidly and reversibly inhibited <e2>Panx1</e2> currents via mechanism(s) independent of purine receptors.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: <e1>carbenoxolone</e1> > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > <e1>disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate</e1> (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (<e1>DIDS</e1>) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately <e1>disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate</e1> approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately <e1>5-nitro-2-(3-phenylpropylamino)benzoic acid</e1> > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > <e1>indanyloxyacetic acid 94</e1> >> probenecid >> flufenamic acid = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> <e1>probenecid</e1> >> flufenamic acid = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> <e1>flufenamic acid</e1> = niflumic acid.","Downregulator"
"We found compounds that inhibited <e2>Panx1</e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = <e1>niflumic acid</e1>.","Downregulator"
"<e1>Triphosphate nucleotides</e1> (ATP, GTP, and UTP) rapidly and reversibly inhibited <e2>Panx1</e2> currents via mechanism(s) independent of purine receptors.","Downregulator"
"Triphosphate nucleotides (<e1>ATP</e1>, GTP, and UTP) rapidly and reversibly inhibited <e2>Panx1</e2> currents via mechanism(s) independent of purine receptors.","Downregulator"
"Triphosphate nucleotides (ATP, <e1>GTP</e1>, and UTP) rapidly and reversibly inhibited <e2>Panx1</e2> currents via mechanism(s) independent of purine receptors.","Downregulator"
"When Panx1 was coexpressed with purinergic P2X(7) receptor (<e2>P2X(7)R</e2>), <e1>DIDS</e1> was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.","Antagonist"
"We investigated the effect of captopril, an ACE inhibitor, on <e2>MMP-2</e2> and MMP-9 in <e1>monocrotaline</e1>-induced right ventricular hypertrophy.","Upregulator"
"We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and <e2>MMP-9</e2> in <e1>monocrotaline</e1>-induced right ventricular hypertrophy.","Upregulator"
"We investigated the effect of captopril, an ACE inhibitor, on <e2>MMP-2</e2> and MMP-9 in <e1>monocrotaline</e1>-induced right ventricular hypertrophy.","Upregulator"
"We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and <e2>MMP-9</e2> in <e1>monocrotaline</e1>-induced right ventricular hypertrophy.","Upregulator"
"We investigated the effect of captopril, an ACE inhibitor, on <e2>MMP-2</e2> and MMP-9 in <e1>monocrotaline</e1>-induced right ventricular hypertrophy.","Upregulator"
"We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and <e2>MMP-9</e2> in <e1>monocrotaline</e1>-induced right ventricular hypertrophy.","Upregulator"
"We investigated the effect of <e1>captopril</e1>, an ACE inhibitor, on <e2>MMP-2</e2> and MMP-9 in monocrotaline-induced right ventricular hypertrophy.","Downregulator"
"We investigated the effect of <e1>captopril</e1>, an ACE inhibitor, on MMP-2 and <e2>MMP-9</e2> in monocrotaline-induced right ventricular hypertrophy.","Downregulator"
"We investigated the effect of <e1>captopril</e1>, an ACE inhibitor, on <e2>MMP-2</e2> and MMP-9 in monocrotaline-induced right ventricular hypertrophy.","Downregulator"
"We investigated the effect of <e1>captopril</e1>, an ACE inhibitor, on MMP-2 and <e2>MMP-9</e2> in monocrotaline-induced right ventricular hypertrophy.","Downregulator"
"We investigated the effect of <e1>captopril</e1>, an ACE inhibitor, on <e2>MMP-2</e2> and MMP-9 in monocrotaline-induced right ventricular hypertrophy.","Downregulator"
"We investigated the effect of <e1>captopril</e1>, an ACE inhibitor, on MMP-2 and <e2>MMP-9</e2> in monocrotaline-induced right ventricular hypertrophy.","Downregulator"
"We investigated the effect of <e1>captopril</e1>, an <e2>ACE</e2> inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.","Downregulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with <e1>chlorthalidone</e1>, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).","Regulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with chlorthalidone, <e1>trichloromethiazide</e1>, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).","Regulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with chlorthalidone, trichloromethiazide, and <e1>furosemide</e1> being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).","Regulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas <e1>indapamide</e1> is a much weaker one (K(I) of 2520 nM).","Regulator"
"<e1>Chlorthalidone</e1> bound within the <e2>CA II</e2> active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong hydrogen bonds with Asn67 and a water molecule.","Regulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with <e1>chlorthalidone</e1>, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).","Downregulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with chlorthalidone, <e1>trichloromethiazide</e1>, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).","Downregulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with chlorthalidone, trichloromethiazide, and <e1>furosemide</e1> being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).","Downregulator"
"Some of these structurally related compounds have a very different behavior against the widespread isozyme <e2>CA II</e2>, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas <e1>indapamide</e1> is a much weaker one (K(I) of 2520 nM).","Downregulator"
"<e1>Thiazide</e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.","Downregulator"
"<e1>Thiazide</e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.","Downregulator"
"<e1>Thiazide</e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as <e1>acetazolamide</e1>, methazolamide, and ethoxzolamide.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>) with a very different profile as compared to classical inhibitors, such as <e1>acetazolamide</e1>, methazolamide, and ethoxzolamide.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as <e1>acetazolamide</e1>, methazolamide, and ethoxzolamide.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>methazolamide</e1>, and ethoxzolamide.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>) with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>methazolamide</e1>, and ethoxzolamide.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>methazolamide</e1>, and ethoxzolamide.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>ethoxzolamide</e1>.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>ethoxzolamide</e1>.","Downregulator"
"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>ethoxzolamide</e1>.","Downregulator"
"These data indicate that <e1>sergliflozin etabonate</e1> could improve glycemic control without its use resulting in <e2>insulin</e2> secretion, hypoglycemia, and body weight gain, and may provide a unique approach to the treatment of diabetes.","Not"
"<e1>Sergliflozin etabonate</e1> increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of <e2>insulin</e2> secretion in normal rats.","Not"
"Chronic treatment with <e1>sergliflozin etabonate</e1> reduced the levels of <e2>glycated hemoglobin</e2> and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.","Downregulator"
"We discovered <e1>sergliflozin etabonate</e1>, a novel selective <e2>SGLT2</e2> inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.","Downregulator"
"We discovered <e1>sergliflozin etabonate</e1>, a novel selective <e2>SGLT2</e2> inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.","Downregulator"
"In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an <e2>alpha-glucosidase</e2> inhibitor (<e1>voglibose</e1>).","Downregulator"
"<e1>Sergliflozin etabonate</e1>, a selective <e2>SGLT2</e2> inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.","Downregulator"
"The low-affinity sodium <e1>glucose</e1> cotransporter (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.","Substrate"
"The low-affinity sodium <e1>glucose</e1> cotransporter (<e2>SGLT2</e2>) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.","Substrate"
"A <e2>PKC</e2> or MAP kinase inhibitor blocked the inhibitory effect of <e1>fenoldopam</e1> on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway.","Regulator"
"A PKC or <e2>MAP kinase</e2> inhibitor blocked the inhibitory effect of <e1>fenoldopam</e1> on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway.","Regulator"
"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with <e1>fenoldopam</e1>, a D1-like receptor agonist, inhibited the stimulatory effect of <e2>insulin</e2>.","Downregulator"
"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with <e1>fenoldopam</e1>, a D1-like receptor agonist, inhibited the stimulatory effect of <e2>insulin</e2>.","Downregulator"
"<e1>Fenoldopam</e1> also inhibited <e2>insulin receptor</e2> mRNA and protein expression, which was time dependent and concentration dependent.","Downregulator"
"A PKC or MAP kinase inhibitor blocked the inhibitory effect of <e1>fenoldopam</e1> on <e2>insulin receptor</e2> expression, indicating that PKC and MAP kinase were involved in the signaling pathway.","Downregulator"
"Although the <e2>D1-like receptor</e2>, by itself, had no effect on VSMC proliferation, stimulation with <e1>fenoldopam</e1>, a D1-like receptor agonist, inhibited the stimulatory effect of insulin.","Agonist"
"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by <e1>SCH23390</e1>, a <e2>D1-like receptor</e2> antagonist.","Antagonist"
"The progress of the enzymatic reaction of the hydrolysis of <e1>acetylthiocholine</e1> at pH 8 in the presence of <e2>AChE</e2> and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).","Substrate"
"atropine, <e2>AChE</e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, <e1>trimedoxime</e1>, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.","Upregulator"
"atropine, <e2>AChE</e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, <e1>obidoxime</e1> and HI-6) and diazepam are used for the treatment of OP poisoning in humans.","Upregulator"
"atropine, <e2>AChE</e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and <e1>HI-6</e1>) and diazepam are used for the treatment of OP poisoning in humans.","Upregulator"
"atropine, <e2>AChE</e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and <e1>diazepam</e1> are used for the treatment of OP poisoning in humans.","Upregulator"
"<e1>atropine</e1>, <e2>AChE</e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.","Upregulator"
"atropine, <e2>AChE</e2> reactivator such as one of the recommended <e1>pyridinium oximes</e1> (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.","Upregulator"
"atropine, <e2>AChE</e2> reactivator such as one of the recommended pyridinium oximes (<e1>pralidoxime</e1>, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.","Upregulator"
"The mechanism of <e1>OP</e1> poisoning involves inhibition of acetylcholinesterase (<e2>AChE</e2>) leading to inactivation of the enzyme which has an important role in neurotransmission.","Downregulator"
"The mechanism of <e1>OP</e1> poisoning involves inhibition of <e2>acetylcholinesterase</e2> (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.","Downregulator"
"The mechanism of <e1>OP</e1> poisoning involves inhibition of acetylcholinesterase (<e2>AChE</e2>) leading to inactivation of the enzyme which has an important role in neurotransmission.","Downregulator"
"The mechanism of <e1>OP</e1> poisoning involves inhibition of acetylcholinesterase (<e2>AChE</e2>) leading to inactivation of the enzyme which has an important role in neurotransmission.","Downregulator"
"(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine (<e1>(18)F-AV-45</e1>) is such as an agent currently in phase III clinical studies for PET of <e2>Abeta</e2> plaques in the brain.","Regulator"
"(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine (<e1>(18)F-AV-45</e1>) is such as an agent currently in phase III clinical studies for PET of <e2>Abeta</e2> plaques in the brain.","Regulator"
"<e1>(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine</e1> ((18)F-AV-45) is such as an agent currently in phase III clinical studies for PET of <e2>Abeta</e2> plaques in the brain.","Regulator"
"(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine (<e1>(18)F-AV-45</e1>) is such as an agent currently in phase III clinical studies for PET of <e2>Abeta</e2> plaques in the brain.","Regulator"
"(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine (<e1>(18)F-AV-45</e1>) is such as an agent currently in phase III clinical studies for PET of <e2>Abeta</e2> plaques in the brain.","Regulator"
"Preclinical properties of <e1>18F-AV-45</e1>: a PET agent for <e2>Abeta</e2> plaques in the brain.","Regulator"
"Oral <e1>palonosetron</e1> is likely to be a useful addition to oral formulations of other <e2>5-HT3 recepto</e2>r antagonists in preventing CINV in patients receiving MEC.","Antagonist"
"<e1>Palonosetron</e1> is a second-generation serotonin <e2>5-HT3 receptor</e2> antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.","Antagonist"
"<e1>Palonosetron</e1> is a second-generation <e2>serotonin 5-HT3 receptor</e2> antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.","Antagonist"
"Two pure GnRH antagonists have been developed, <e1>abarelix</e1> and degarelix, that are devoid of any agonist effect on the <e2>GnRH receptor</e2> and consequently do not result in testosterone flare.","Regulator"
"Two pure GnRH antagonists have been developed, abarelix and <e1>degarelix</e1>, that are devoid of any agonist effect on the <e2>GnRH receptor</e2> and consequently do not result in testosterone flare.","Regulator"
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as <e1>buserelin</e1>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor</e2>, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Upregulator"
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, <e1>goserelin</e1>, leuprorelin and triptorelin, stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor</e2>, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Upregulator"
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, <e1>leuprorelin</e1> and triptorelin, stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor</e2>, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Upregulator"
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin</e1>, stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor</e2>, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Upregulator"
"Luteinizing hormone-releasing hormone (<e2>LH</e2>RH) agonists, such as <e1>buserelin</e1>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Downregulator"
"Luteinizing hormone-releasing hormone (<e2>LH</e2>RH) agonists, such as buserelin, <e1>goserelin</e1>, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Downregulator"
"Luteinizing hormone-releasing hormone (<e2>LH</e2>RH) agonists, such as buserelin, goserelin, <e1>leuprorelin</e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Downregulator"
"Luteinizing hormone-releasing hormone (<e2>LH</e2>RH) agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin</e1>, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Downregulator"
"<e2>Luteinizing hormone-releasing hormone</e2> (LHRH) agonists, such as <e1>buserelin</e1>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"Luteinizing hormone-releasing hormone (<e2>LHRH</e2>) agonists, such as <e1>buserelin</e1>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"<e2>Luteinizing hormone-releasing hormone</e2> (LHRH) agonists, such as buserelin, <e1>goserelin</e1>, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"Luteinizing hormone-releasing hormone (<e2>LHRH</e2>) agonists, such as buserelin, <e1>goserelin</e1>, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"<e2>Luteinizing hormone-releasing hormone</e2> (LHRH) agonists, such as buserelin, goserelin, <e1>leuprorelin</e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"Luteinizing hormone-releasing hormone (<e2>LHRH</e2>) agonists, such as buserelin, goserelin, <e1>leuprorelin</e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"<e2>Luteinizing hormone-releasing hormone</e2> (LHRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin</e1>, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"Luteinizing hormone-releasing hormone (<e2>LHRH</e2>) agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin</e1>, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.","Agonist"
"Two pure <e2>GnRH</e2> antagonists have been developed, <e1>abarelix</e1> and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.","Antagonist"
"Two pure <e2>GnRH</e2> antagonists have been developed, abarelix and <e1>degarelix</e1>, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.","Antagonist"
"<e1>Abarelix</e1> was the first <e2>GnRH</e2> antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.","Antagonist"
"<e1>Fulvestrant</e1>, a pure <e2>estrogen receptor</e2> downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.","Downregulator"
"<e2>Alpha-2B adrenergic receptor</e2> mediated hemodynamic profile of <e1>etomidate</e1>.","Regulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to <e2>MAP2</e2> measured by the disassembly of chick brain MAP2:tubulin microtubules.","Regulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to <e2>MAP2</e2> measured by the disassembly of chick brain MAP2:tubulin microtubules.","Regulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to <e2>MAP2</e2> measured by the disassembly of chick brain MAP2:tubulin microtubules.","Regulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to <e2>MAP2</e2> measured by the disassembly of chick brain MAP2:tubulin microtubules.","Regulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to <e2>MAP2</e2> measured by the disassembly of chick brain MAP2:tubulin microtubules.","Regulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to MAP2 measured by the disassembly of <e2>chick brain MAP2</e2>:tubulin microtubules.","Upregulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to MAP2 measured by the disassembly of chick brain MAP2:<e2>tubulin</e2> microtubules.","Upregulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to MAP2 measured by the disassembly of <e2>chick brain MAP2</e2>:tubulin microtubules.","Downregulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to MAP2 measured by the disassembly of chick brain MAP2:<e2>tubulin</e2> microtubules.","Downregulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to <e2>MAP2</e2> measured by the disassembly of chick brain MAP2:tubulin microtubules.","Downregulator"
"Stoichiometry of <e1>estramustine phosphate</e1> binding to MAP2 measured by the disassembly of chick brain MAP2:<e2>tubulin</e2> microtubules.","Downregulator"
"<e1>Cabozantinib</e1> may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including <e2>MET</e2>, VEGFR2, and RET.","Regulator"
"<e1>Cabozantinib</e1> may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, <e2>VEGFR2</e2>, and RET.","Regulator"
"<e1>Cabozantinib</e1> may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and <e2>RET</e2>.","Regulator"
"PURPOSE: XL184 (<e1>cabozantinib</e1>) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (<e2>VEGFR2</e2>), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"PURPOSE: XL184 (<e1>cabozantinib</e1>) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and <e2>RET</e2>, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"PURPOSE: XL184 (<e1>cabozantinib</e1>) is a potent inhibitor of <e2>MET</e2>, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"PURPOSE: XL184 (<e1>cabozantinib</e1>) is a potent inhibitor of MET, <e2>vascular endothelial growth factor receptor 2</e2> (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"PURPOSE: <e1>XL184</e1> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (<e2>VEGFR2</e2>), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"PURPOSE: <e1>XL184</e1> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and <e2>RET</e2>, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"PURPOSE: <e1>XL184</e1> (cabozantinib) is a potent inhibitor of <e2>MET</e2>, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"PURPOSE: <e1>XL184</e1> (cabozantinib) is a potent inhibitor of MET, <e2>vascular endothelial growth factor receptor 2</e2> (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","Downregulator"
"Activity of <e1>XL184</e1> (Cabozantinib), an oral <e2>tyrosine kinase</e2> inhibitor, in patients with medullary thyroid cancer.","Downregulator"
"Activity of XL184 (<e1>Cabozantinib</e1>), an oral <e2>tyrosine kinase</e2> inhibitor, in patients with medullary thyroid cancer.","Downregulator"
"Whole-exome analysis of the <e2>Pik3ca</e2>(H1047R)-driven mammary tumors identified multiple mutations, including <e1>Trp</e1>53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.","Part_of"
"Whole-exome analysis of the Pik3ca(<e2>H1047R</e2>)-driven mammary tumors identified multiple mutations, including <e1>Trp</e1>53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.","Part_of"
"Further, we used this model to test the efficacy of <e1>GDC-0941</e1>, a <e2>PI3K</e2> inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.","Downregulator"
"Further, we used this model to test the efficacy of <e1>GDC-0941</e1>, a <e2>PI3K</e2> inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.","Downregulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including <e2>Fnta</e2>, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, <e2>Pon1</e2>, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, <e2>Pparg</e2>, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, <e2>Aldh1b1</e2>, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, <e2>Apoa4</e2>, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, <e2>Abcg5</e2>, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, <e2>Gpam</e2>, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, <e2>Acaca</e2>, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, <e2>Cd36</e2>, Fdft1, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, <e2>Fdft1</e2>, and Fasn, relative to those in HFD control mice.","Regulator"
"<e1>Quercetin</e1> supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and <e2>Fasn</e2>, relative to those in HFD control mice.","Regulator"
"By synthesizing and testing a series of alanine point-mutated <e2>cyclic peptides</e2>, we identified which <e1>amino acid</e1> was important for the inhibition of the phospholamban function.","Part_of"
"By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which <e1>amino acid</e1> was important for the inhibition of the <e2>phospholamban</e2> function.","Part_of"
"By synthesizing and testing a series of <e1>alanine</e1> point-mutated <e2>cyclic peptides</e2>, we identified which amino acid was important for the inhibition of the phospholamban function.","Part_of"
"By synthesizing and testing a series of <e1>alanine</e1> point-mutated <e2>cyclic peptides</e2>, we identified which amino acid was important for the inhibition of the phospholamban function.","Part_of"
"<e1>4-MA</e1>, a well known <e2>5 alpha-reductase</e2> inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM.","Downregulator"
"<e1>4-MA</e1>, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of <e2>3 beta-HSD</e2> with a Ki value of 56 nM.","Downregulator"
"<e1>Cyproterone acetate</e1>, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD</e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","Downregulator"
"Cyproterone acetate, a <e1>progestin</e1> used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD</e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","Downregulator"
"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as <e1>norgestrel</e1> and norethindrone that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD</e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","Downregulator"
"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and <e1>norethindrone</e1> that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD</e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","Downregulator"
"Inhibitory effect of synthetic <e1>progestins</e1>, 4-MA and cyanoketone on <e2>human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase</e2> activity.","Downregulator"
"Inhibitory effect of synthetic progestins, <e1>4-MA</e1> and cyanoketone on <e2>human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase</e2> activity.","Downregulator"
"Inhibitory effect of synthetic progestins, 4-MA and <e1>cyanoketone</e1> on <e2>human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase</e2> activity.","Downregulator"
"<e1>Trilostane</e1>, epostane and cyanoketone are potent inhibitors of <e2>3 beta-HSD</e2> with Ki values of approximately 50 nM.","Downregulator"
"Trilostane, <e1>epostane</e1> and cyanoketone are potent inhibitors of <e2>3 beta-HSD</e2> with Ki values of approximately 50 nM.","Downregulator"
"Trilostane, epostane and <e1>cyanoketone</e1> are potent inhibitors of <e2>3 beta-HSD</e2> with Ki values of approximately 50 nM.","Downregulator"
"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase</e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding <e1>3-keto-4-ene-steroids</e1> and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (<e2>3 beta-HSD</e2>) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding <e1>3-keto-4-ene-steroids</e1> and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase</e2> (3 beta-HSD) purified from human placenta transforms C-21 (<e1>pregnenolone</e1> and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (<e2>3 beta-HSD</e2>) purified from human placenta transforms C-21 (<e1>pregnenolone</e1> and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase</e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and <e1>17 alpha-hydroxy pregnenolone</e1>) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (<e2>3 beta-HSD</e2>) purified from human placenta transforms C-21 (pregnenolone and <e1>17 alpha-hydroxy pregnenolone</e1>) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase</e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (<e1>dehydroepiandrosterone</e1> and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (<e2>3 beta-HSD</e2>) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (<e1>dehydroepiandrosterone</e1> and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase</e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and <e1>androst-5-ene-3 beta, 17 beta-diol</e1>) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (<e2>3 beta-HSD</e2>) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and <e1>androst-5-ene-3 beta, 17 beta-diol</e1>) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.","Substrate"
"However, chronic treatment of cLH rats with <e1>MPEP</e1> did not reverse learned helplessness, indicating that the enhanced <e2>mGlu5 receptor</e2> function is not the only player in the behavioral phenotype of this genetic model of depression.","Upregulator"
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while <e1>MS-275</e1> or PEPA (<e2>AMPA receptor</e2> potentiator) failed to affect extinction acquisition in S1 mice.","Upregulator"
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or <e1>PEPA</e1> (<e2>AMPA receptor</e2> potentiator) failed to affect extinction acquisition in S1 mice.","Upregulator"
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of <e1>valproic acid</e1> (a GABAergic enhancer and <e2>HDAC</e2> inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.","Downregulator"
"Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or <e1>MS-275</e1> (<e2>histone deacetylase</e2> (HDAC) inhibitor), applied after extinction training.","Downregulator"
"Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or <e1>MS-275</e1> (histone deacetylase (<e2>HDAC</e2>) inhibitor), applied after extinction training.","Downregulator"
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or <e1>AMN082</e1> [<e2>metabotropic glutamate receptor 7</e2> (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.","Agonist"
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or <e1>AMN082</e1> [metabotropic glutamate receptor 7 (<e2>mGlu7</e2>) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.","Agonist"
"These findings suggest that oral consumption of <e1>nicotine</e1> enhances the efficacy of <e2>nicotinic acetylcholine receptors</e2>.","Upregulator"
"Electroencephalographic recordings during substance consumption showed reduced alpha activity and <e2>P300</e2> latencies in the <e1>nicotine</e1> group compared to the control group.","Downregulator"
"Our study determined whether there was a significant dose-dependent correlation between increasing <e1>Hg</e1> exposure from dental amalgams and <e2>GST-</e2> and GST- as biomarkers of kidney integrity.","Regulator"
"It was hypothesized that because <e1>Hg</e1> accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)- (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than <e2>GST-</e2> (suggestive of kidney damage at the level of the distal tubules).","Regulator"
"Our study determined whether there was a significant dose-dependent correlation between increasing <e1>Hg</e1> exposure from dental amalgams and <e2>GST-</e2> and GST- as biomarkers of kidney integrity.","Regulator"
"It was hypothesized that because <e1>Hg</e1> accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)- (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than <e2>GST-</e2> (suggestive of kidney damage at the level of the distal tubules).","Regulator"
"It was hypothesized that because <e1>Hg</e1> accumulates in the proximal tubules (PTs), <e2>glutathione-S-transferases (GST)-</e2> (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST- (suggestive of kidney damage at the level of the distal tubules).","Regulator"
"It was hypothesized that because <e1>Hg</e1> accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)- (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than <e2>GST-</e2> (suggestive of kidney damage at the level of the distal tubules).","Regulator"
"Furthermore, elevations in blood neutrophil count, serum <e2>monocyte chemoattractant protein-1</e2>, and other markers of inflammation corresponded to <e1>GDC-0152</e1> exposure and toxicity and thus may have utility as safety biomarkers.","Regulator"
"<e1>GDC-0152</e1> induces NF-B transcriptional activity leading to expression of several <e2>chemokines</e2> and cytokines, of which tumor necrosis factor alpha (TNF-) is the most important for single-agent tumor activity.","Regulator"
"<e1>GDC-0152</e1> induces NF-B transcriptional activity leading to expression of several chemokines and <e2>cytokines</e2>, of which tumor necrosis factor alpha (TNF-) is the most important for single-agent tumor activity.","Regulator"
"<e1>GDC-0152</e1> induces NF-B transcriptional activity leading to expression of several chemokines and cytokines, of which <e2>tumor necrosis factor alpha</e2> (TNF-) is the most important for single-agent tumor activity.","Regulator"
"Toxicity profile of small-molecule IAP antagonist <e1>GDC-0152</e1> is linked to <e2>TNF-</e2> pharmacology.","Regulator"
"Toxicity profile of small-molecule IAP antagonist <e1>GDC-0152</e1> is linked to <e2>TNF-</e2> pharmacology.","Regulator"
"<e1>GDC-0152</e1> induces <e2>NF-B</e2> transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-) is the most important for single-agent tumor activity.","Upregulator"
"<e1>GDC-0152</e1> is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing <e2>IAPs</e2>.","Antagonist"
"Toxicity profile of small-molecule <e2>IAP</e2> antagonist <e1>GDC-0152</e1> is linked to TNF- pharmacology.","Antagonist"
"<e2>Tub</e2> <e1>tyr</e1>osine phosphorylation (Tub-p-tyr) is modulated by nutritional status.","Part_of"
"<e2>Tub</e2> <e1>tyrosine</e1> phosphorylation (Tub-p-tyr) is modulated by nutritional status.","Part_of"
"<e2>Tub</e2> <e1>tyr</e1>osine phosphorylation (Tub-p-tyr) is modulated by nutritional status.","Part_of"
"Since <e2>PARP-1</e2> is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the PARP inhibitor <e1>PJ34</e1> on several properties of thyroid cancer cell lines was investigated.","Regulator"
"The PARP inhibitor <e1>PJ34</e1> modifies proliferation, <e2>NIS</e2> expression and epigenetic marks in thyroid cancer cell lines.","Regulator"
"Accordingly, in transfection experiments performed in TPC1 cells, treatment with <e1>PJ34</e1> increased <e2>NIS promoter</e2> activity without affecting PARP-1 binding to the promoter sequence.","Upregulator"
"The PARP inhibitor <e1>PJ34</e1> modifies proliferation, <e2>NIS</e2> expression and epigenetic marks in thyroid cancer cell lines.","Upregulator"
"We also investigated the epigenetic status of NIS promoter after <e1>PJ34</e1> treatment in TPC1 cell line: in addition to an increase of <e2>histone modification activation marks</e2> (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.","Upregulator"
"We also investigated the epigenetic status of NIS promoter after <e1>PJ34</e1> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (<e2>H3K9K14ac</e2>, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.","Upregulator"
"We also investigated the epigenetic status of NIS promoter after <e1>PJ34</e1> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, <e2>H3K4me3</e2>), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.","Upregulator"
"The <e2>PARP</e2> inhibitor <e1>PJ34</e1> modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.","Downregulator"
"The <e2>PARP</e2> inhibitor <e1>PJ34</e1> modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.","Downregulator"
"Both <e1>apo-lycopenoic acids</e1> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in <e2>NOX-4</e2> and COX-2 expressions caused by CSE.","Downregulator"
"Both <e1>apo-lycopenoic acids</e1> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and <e2>COX-2</e2> expressions caused by CSE.","Downregulator"
"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (<e2>BChE</e2>), which is capable of breaking down naturally occurring (-)-<e1>cocaine</e1> before the drug can influence the reward centers of the brain or affect other areas of the body.","Substrate"
"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme <e2>butyrylcholinesterase</e2> (BChE), which is capable of breaking down naturally occurring <e1>(-)-cocaine</e1> before the drug can influence the reward centers of the brain or affect other areas of the body.","Substrate"
"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (<e2>BChE</e2>), which is capable of breaking down naturally occurring <e1>(-)-cocaine</e1> before the drug can influence the reward centers of the brain or affect other areas of the body.","Substrate"
"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (<e2>BChE</e2>), which is capable of breaking down naturally occurring <e1>(-)-cocaine</e1> before the drug can influence the reward centers of the brain or affect other areas of the body.","Substrate"
"We examined in cats the 1) ulcerogenic effects of selective <e2>COX</e2>-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and <e1>cimetidine</e1> on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.","Downregulator"
"We examined in cats the 1) ulcerogenic effects of selective <e2>COX-1</e2> (<e1>SC-560</e1>, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.","Downregulator"
"We examined in cats the 1) ulcerogenic effects of selective <e2>COX-1</e2> (SC-560, <e1>ketorolac</e1>) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.","Downregulator"
"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and <e2>COX-2</e2> (<e1>celecoxib</e1>, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.","Downregulator"
"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and <e2>COX-2</e2> (celecoxib, <e1>meloxicam</e1>) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.","Downregulator"
"DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of <e2>D2</e2> and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or <e1>neurotensin</e1> receptors.","Upregulator"
"Reversal of inhibition by <e2>D2</e2> agonist quinpirole was produced by <e1>serotonin</e1> (50 M) and by neurotensin (5-10 nM).","Upregulator"
"Reversal of inhibition by <e2>D2</e2> agonist <e1>quinpirole</e1> was produced by serotonin (50 M) and by neurotensin (5-10 nM).","Agonist"
"Serotonin-induced or neurotensin-induced reversal was blocked by -ARK1 inhibitor, dynasore, or <e2>cPKC</e2> antagonist <e1>5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile</e1> (G6976).","Antagonist"
"Serotonin-induced or neurotensin-induced reversal was blocked by -ARK1 inhibitor, dynasore, or <e2>cPKC</e2> antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (<e1>G6976</e1>).","Antagonist"
"However, 4'G-RSV, but not <e1>3G-RSV</e1>, induced <e2>SIRT1</e2>-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.","Not"
"However, 4'G-RSV, but not <e1>3G-RSV</e1>, induced SIRT1-dependent <e2>histone H3</e2> deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.","Not"
"However, 4'G-RSV, but not <e1>3G-RSV</e1>, induced SIRT1-dependent histone H3 deacetylation and <e2>SOD2</e2> expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.","Not"
"However, <e1>4'G-RSV</e1>, but not 3G-RSV, induced SIRT1-dependent <e2>histone H3</e2> deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.","Regulator"
"However, <e1>4'G-RSV</e1>, but not 3G-RSV, induced <e2>SIRT1</e2>-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.","Upregulator"
"<e1>RSV</e1> targets and activates the <e2>NAD(+)-dependent protein deacetylase SIRT1</e2>; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).","Upregulator"
"<e1>RSV</e1> targets and activates the NAD(+)-dependent protein deacetylase <e2>SIRT1</e2>; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).","Upregulator"
"However, <e1>4'G-RSV</e1>, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and <e2>SOD2</e2> expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.","Upregulator"
"<e1>RSV</e1> targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing <e2>mitochondrial superoxide dismutase</e2> (SOD2).","Upregulator"
"<e1>RSV</e1> targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (<e2>SOD2</e2>).","Upregulator"
"Hydrophobic <e1>amino acids</e1> in the hinge region of the <e2>5A apolipoprotein</e2> mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.","Part_of"
"Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting <e1>cholesterol</e1> efflux by the <e2>ABCA1</e2> transporter.","Substrate"
"The bihelical <e2>apolipoprotein mimetic peptide 5A</e2> effluxes <e1>cholesterol</e1> from cells and reduces inflammation and atherosclerosis in animal models.","Substrate"
"Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting <e1>cholesterol</e1> efflux by the <e2>ABCA1</e2> transporter.","Substrate"
"Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting <e1>cholesterol</e1> efflux by the <e2>ABCA1</e2> transporter.","Substrate"
"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the <e2>GluK1</e2> (GluR5)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist <e1>(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid</e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.","Antagonist"
"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<e2>GluR5</e2>)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist <e1>(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid</e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.","Antagonist"
"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/<e2>-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor</e2> antagonist <e1>(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid</e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.","Antagonist"
"Efficacy of the <e2>GluK1</e2>/AMPA receptor antagonist <e1>LY293558</e1> against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.","Antagonist"
"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<e2>GluR5</e2>)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>LY293558</e1>) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.","Antagonist"
"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/<e2>-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor</e2> antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>LY293558</e1>) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.","Antagonist"
"Efficacy of the <e2>GluK1</e2>/AMPA receptor antagonist <e1>LY293558</e1> against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.","Antagonist"
"Efficacy of the GluK1/<e2>AMPA receptor</e2> antagonist <e1>LY293558</e1> against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.","Antagonist"
"In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but <e1>GM6001</e1>-insensitive <e2>metalloprotease</e2>, with the possible additional involvement of a thiol isomerase.","Not"
"In an effort to understand the shedding process of <e2>AChE</e2>, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an <e1>EDTA</e1>- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.","Regulator"
"In an effort to understand the shedding process of <e2>AChE</e2>, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and <e1>batimastat</e1>-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.","Regulator"
"In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and <e1>batimastat</e1>-sensitive, but GM6001-insensitive <e2>metalloprotease</e2>, with the possible additional involvement of a thiol isomerase.","Regulator"
"Cellular release of <e2>AChE</e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists <e1>carbachol</e1> or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.","Upregulator"
"Cellular release of <e2>AChE</e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or <e1>muscarine</e1>, with the effect of carbachol blocked by the mAChR antagonist atropine.","Upregulator"
"Cellular release of <e2>AChE</e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists <e1>carbachol</e1> or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.","Upregulator"
"Cellular release of <e2>AChE</e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist <e1>atropine</e1>.","Downregulator"
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the <e2>muscarinic acetylcholine receptor</e2> (mAChR) agonists <e1>carbachol</e1> or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.","Agonist"
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<e2>mAChR</e2>) agonists <e1>carbachol</e1> or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.","Agonist"
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the <e2>muscarinic acetylcholine receptor</e2> (mAChR) agonists carbachol or <e1>muscarine</e1>, with the effect of carbachol blocked by the mAChR antagonist atropine.","Agonist"
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<e2>mAChR</e2>) agonists carbachol or <e1>muscarine</e1>, with the effect of carbachol blocked by the mAChR antagonist atropine.","Agonist"
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<e2>mAChR</e2>) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist <e1>atropine</e1>.","Antagonist"
"Although <e1>acetylcholine</e1>sterase (<e2>AChE</e2>) is primarily a hydrolytic enzyme, metabolising the neurotransmitter acetylcholine in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.","Substrate"
"Characterisation of <e1>acetylcholine</e1>sterase release from neuronal cells.","Substrate"
"Nevertheless, low <e1>L-BMAA</e1> concentrations ( 0.1mM, 48 h) increased protein ubiquitination, <e2>20S proteasomal</e2> and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2 in SH-SY5Y cells.","Upregulator"
"<e1>L-BMAA</e1> induced ER stress and enhanced <e2>caspase 12</e2> cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.","Upregulator"
"Nevertheless, low <e1>L-BMAA</e1> concentrations ( 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of <e2>elf2</e2> in SH-SY5Y cells.","Upregulator"
"Nevertheless, low <e1>L-BMAA</e1> concentrations ( 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker <e2>CHOP</e2>, and enhanced phosphorylation of elf2 in SH-SY5Y cells.","Upregulator"
"<e1>L-BMAA</e1> induced ER stress and enhanced <e2>caspase 12</e2> cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.","Upregulator"
"It was reported previously that <e2>FVII</e2> gene (F7) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Regulator"
"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as <e1>mycophenolic acid</e1> and 6-mercaptopurine, up-regulated <e2>F7</e2> expression.","Upregulator"
"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and <e1>6-mercaptopurine</e1>, up-regulated <e2>F7</e2> expression.","Upregulator"
"<e1>Ribavirin</e1> unregulated <e2>ELL</e2> (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.","Upregulator"
"<e1>Ribavirin</e1> unregulated ELL (<e2>eleven-nineteen lysine-rich leukaemia) 3</e2> mRNA expression before F7 up-regulation.","Upregulator"
"<e1>Ribavirin</e1> unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before <e2>F7</e2> up-regulation.","Upregulator"
"We observed that <e1>ribavirin</e1> enhanced <e2>ELL3</e2> recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.","Upregulator"
"It was reported previously that FVII gene (<e2>F7</e2>) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Upregulator"
"<e1>Ribavirin</e1>-induced intracellular GTP depletion activates transcription elongation in <e2>coagulation factor VII</e2> gene expression.","Upregulator"
"It was reported previously that <e2>FVII</e2> gene (F7) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Upregulator"
"<e1>Ribavirin</e1> also enhanced recruitment of <e2>CDK9</e2> (cyclin-dependent kinase 9) and AFF4 to F7.","Upregulator"
"<e1>Ribavirin</e1> also enhanced recruitment of CDK9 (<e2>cyclin-dependent kinase 9</e2>) and AFF4 to F7.","Upregulator"
"<e1>Ribavirin</e1> also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and <e2>AFF4</e2> to F7.","Upregulator"
"<e1>Ribavirin</e1> unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before <e2>F7</e2> up-regulation.","Upregulator"
"These data suggest that <e1>ribavirin</e1>-induced intracellular GTP depletion recruits a super elongation complex containing <e2>P-TEFb</e2>, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.","Upregulator"
"These data suggest that <e1>ribavirin</e1>-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, <e2>AFF4</e2> and ELL3, to F7, and modulates FVII mRNA transcription elongation.","Upregulator"
"We observed that <e1>ribavirin</e1> enhanced <e2>ELL3</e2> recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.","Upregulator"
"It was reported previously that FVII gene (<e2>F7</e2>) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Upregulator"
"It was reported previously that <e2>FVII</e2> gene (F7) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Upregulator"
"It was reported previously that <e2>FVII</e2> gene (F7) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Upregulator"
"It was reported previously that FVII gene (<e2>F7</e2>) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Upregulator"
"It was reported previously that FVII gene (<e2>F7</e2>) expression was up-regulated by <e1>ribavirin</e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.","Upregulator"
"Neuropeptide Y Y1 receptor knockdown can modify <e2>glutathione peroxidase</e2> and c-AMP response element-binding protein in <e1>phenylpropanolamine</e1>-treated rats.","Regulator"
"Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and <e2>c-AMP response element-binding protein</e2> in <e1>phenylpropanolamine</e1>-treated rats.","Regulator"
"Using site-directed mutagenesis, we identified three serines (<e1>Ser</e1>833, Ser836, and Ser840) within the membrane proximal region of the <e2>GluK5</e2> C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.","Part_of"
"Using site-directed mutagenesis, we identified three serines (<e1>Ser</e1>833, Ser836, and Ser840) within the membrane proximal region of the <e2>GluK5</e2> C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.","Part_of"
"Protein kinase <e1>C</e1> (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/<e2>GluK5</e2>, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.","Part_of"
"Using site-directed mutagenesis, we identified three <e1>serines</e1> (Ser833, Ser836, and Ser840) within the membrane proximal region of the <e2>GluK5</e2> C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.","Part_of"
"Using site-directed mutagenesis, we identified three serines (<e1>Ser</e1>833, Ser836, and Ser840) within the membrane proximal region of the <e2>GluK5</e2> C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.","Part_of"
"Protein kinase C (<e2>PKC</e2>) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by <e1>phorbol 12-myristate,13-acetate</e1> potentiated GluK2/GluK5.","Upregulator"
"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of <e2>GluK2</e2>/GluK5, and conversely, direct activation of PKC by <e1>phorbol 12-myristate,13-acetate</e1> potentiated GluK2/GluK5.","Upregulator"
"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/<e2>GluK5</e2>, and conversely, direct activation of PKC by <e1>phorbol 12-myristate,13-acetate</e1> potentiated GluK2/GluK5.","Upregulator"
"The potentiation of heteromeric <e2>KARs</e2> by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator <e1>1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid</e1> (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.","Downregulator"
"The potentiation of heteromeric KARs by <e2>mGlu1</e2> activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator <e1>1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid</e1> (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.","Downregulator"
"The potentiation of heteromeric <e2>KARs</e2> by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (<e1>BAPTA</e1>), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.","Downregulator"
"The potentiation of heteromeric KARs by <e2>mGlu1</e2> activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (<e1>BAPTA</e1>), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.","Downregulator"
"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the <e2>phosphatase</e2> inhibitor <e1>okadaic acid</e1>, but unaffected by the tyrosine kinase inhibitor lavendustin A.","Downregulator"
"The potentiation of heteromeric <e2>KARs</e2> by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor <e1>okadaic acid</e1>, but unaffected by the tyrosine kinase inhibitor lavendustin A.","Downregulator"
"The potentiation of heteromeric KARs by <e2>mGlu1</e2> activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor <e1>okadaic acid</e1>, but unaffected by the tyrosine kinase inhibitor lavendustin A.","Downregulator"
"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the <e2>tyrosine kinase</e2> inhibitor <e1>lavendustin A</e1>.","Downregulator"
"The potentiation of heteromeric <e2>KARs</e2> by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor <e1>lavendustin A</e1>.","Downregulator"
"The potentiation of heteromeric KARs by <e2>mGlu1</e2> activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor <e1>lavendustin A</e1>.","Downregulator"
"However, recent evidence suggests that the action of <e1>FTY720</e1> involves <e2>S1PRs</e2> expressed by cells resident in the CNS, including neurons.","Regulator"
"<e1>Fingolimod</e1> (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different <e2>sphingosine-1-phosphate receptor</e2> (S1PR) subtypes.","Upregulator"
"<e1>Fingolimod</e1> (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (<e2>S1PR</e2>) subtypes.","Upregulator"
"Fingolimod (<e1>FTY720</e1>), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different <e2>sphingosine-1-phosphate receptor</e2> (S1PR) subtypes.","Upregulator"
"Fingolimod (<e1>FTY720</e1>), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (<e2>S1PR</e2>) subtypes.","Upregulator"
"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective <e2>type-1 S1PR</e2> (S1P1R) antagonist, <e1>W146</e1>, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.","Antagonist"
"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (<e2>S1P1R</e2>) antagonist, <e1>W146</e1>, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.","Antagonist"
"Pharmacokinetics and metabolism of [(14)C]<e1>anagliptin</e1>, a novel <e2>dipeptidyl peptidase-4</e2> inhibitor, in humans.","Downregulator"
"Pharmacokinetics and metabolism of <e1>[(14)C]anagliptin</e1>, a novel <e2>dipeptidyl peptidase-4</e2> inhibitor, in humans.","Downregulator"
"Renal clearance of unbound <e1>anagliptin</e1> and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of <e2>OAT1</e2>, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","Substrate"
"Renal clearance of unbound <e1>anagliptin</e1> and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, <e2>OAT3</e2>, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","Substrate"
"Renal clearance of unbound <e1>anagliptin</e1> and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, <e2>MDR1</e2> and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","Substrate"
"Renal clearance of unbound <e1>anagliptin</e1> and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and <e2>MRP2</e2>, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","Substrate"
"Antiretroviral <e2>protease</e2> inhibitors <e1>lopinavir</e1> (LPV) and ritonavir (RTV) are reported BSEP inhibitors.","Downregulator"
"Antiretroviral protease inhibitors <e1>lopinavir</e1> (LPV) and ritonavir (RTV) are reported <e2>BSEP</e2> inhibitors.","Downregulator"
"Antiretroviral <e2>protease</e2> inhibitors lopinavir (<e1>LPV</e1>) and ritonavir (RTV) are reported BSEP inhibitors.","Downregulator"
"Antiretroviral protease inhibitors lopinavir (<e1>LPV</e1>) and ritonavir (RTV) are reported <e2>BSEP</e2> inhibitors.","Downregulator"
"Antiretroviral <e2>protease</e2> inhibitors lopinavir (LPV) and <e1>ritonavir</e1> (RTV) are reported BSEP inhibitors.","Downregulator"
"Antiretroviral protease inhibitors lopinavir (LPV) and <e1>ritonavir</e1> (RTV) are reported <e2>BSEP</e2> inhibitors.","Downregulator"
"Antiretroviral <e2>protease</e2> inhibitors lopinavir (LPV) and ritonavir (<e1>RTV</e1>) are reported BSEP inhibitors.","Downregulator"
"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (<e1>RTV</e1>) are reported <e2>BSEP</e2> inhibitors.","Downregulator"
"<e1>GHRP-6</e1> is a <e2>growth hormone</e2> secretagogue that also enhances tissue viability in different organs.","Upregulator"
"The altered activities of key enzymes such as <e2>glucose-6-phosphatase</e2> and fructose-1,6-bisphosphatase of <e1>carbohydrate</e1> metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).","Substrate"
"The altered activities of key enzymes such as glucose-6-phosphatase and <e2>fructose-1,6-bisphosphatase</e2> of <e1>carbohydrate</e1> metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).","Substrate"
"In contrast, <e1>ibandronate</e1> did not affect <e2>FAS</e2> and DNMT1 expression in MC3T3-E1 non-neoplastic cells.","Not"
"In contrast, <e1>ibandronate</e1> did not affect FAS and <e2>DNMT1</e2> expression in MC3T3-E1 non-neoplastic cells.","Not"
"Further we found stimulation of <e2>FAS</e2>-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both <e1>geranylgeranyl-pyrophosphate</e1> and farnesylpyrophosphate.","Regulator"
"Further we found stimulation of <e2>FAS</e2>-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and <e1>farnesylpyrophosphate</e1>.","Regulator"
"Data suggest that <e1>bisphosphonates</e1> via modulation of the activity of small-<e2>GTPases</e2> induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.","Regulator"
"Data suggest that <e1>bisphosphonates</e1> via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-<e2>CpG</e2>-demethylation and stimulation of FAS-expression.","Regulator"
"<e1>Ibandronate</e1> increases the expression of the pro-apoptotic gene <e2>FAS</e2> by epigenetic mechanisms in tumor cells.","Upregulator"
"Data suggest that <e1>bisphosphonates</e1> via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of <e2>FAS</e2>-expression.","Upregulator"
"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of <e2>DNMT1</e2>, which was rescued by re-isoprenylation by both <e1>geranylgeranyl-pyrophosphate</e1> and farnesylpyrophosphate.","Upregulator"
"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of <e2>DNMT1</e2>, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and <e1>farnesylpyrophosphate</e1>.","Upregulator"
"<e1>TCDD</e1> acts through the aryl hydrocarbon receptor (AhR), which interacts with the androgen receptor (<e2>AR</e2>).","Not"
"<e1>TCDD</e1> acts through the aryl hydrocarbon receptor (AhR), which interacts with the androgen receptor (<e2>AR</e2>).","Regulator"
"<e1>TCDD</e1> acts through the aryl hydrocarbon receptor (AhR), which interacts with the androgen receptor (<e2>AR</e2>).","Regulator"
"<e1>TCDD</e1> acts through the <e2>aryl hydrocarbon receptor</e2> (AhR), which interacts with the androgen receptor (AR).","Regulator"
"<e1>TCDD</e1> acts through the aryl hydrocarbon receptor (<e2>AhR</e2>), which interacts with the androgen receptor (AR).","Regulator"
"<e1>TCDD</e1> acts through the aryl hydrocarbon receptor (<e2>AhR</e2>), which interacts with the androgen receptor (AR).","Regulator"
"<e1>TCDD</e1> acts through the aryl hydrocarbon receptor (AhR), which interacts with the androgen receptor (<e2>AR</e2>).","Upregulator"
"The AhR target gene <e2>CYP1A1</e2> mRNA expression was induced by <e1>TCDD</e1>, but was not affected by the AR CAG length.","Upregulator"
"Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several <e2>cytokines</e2> in mice and replacement of plasmid by <e1>polyglutamate</e1> reduced the elevation of all assayed cytokines.","Downregulator"
"We found that <e1>helenalin</e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (<e2>ATF4</e2>) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).","Not"
"We found that <e1>helenalin</e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (<e2>CHOP</e2>).","Not"
"We found that <e1>helenalin</e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as <e2>regulated in development and DNA damage responses (REDD) 1</e2>, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).","Upregulator"
"We found that <e1>helenalin</e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, <e2>activating transcription factor-4</e2> (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).","Upregulator"
"We found that <e1>helenalin</e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (<e2>ATF4</e2>) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).","Upregulator"
"We found that <e1>helenalin</e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the <e2>CCAAT enhancer-binding protein-homologous protein</e2> (CHOP).","Upregulator"
"We found that <e1>helenalin</e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (<e2>CHOP</e2>).","Upregulator"
"This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and <e1>platinum</e1> drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (<e2>rCtr1</e2>) as a membrane transporter of copper and platinum drugs.","Substrate"
"This study aimed to understand the role of <e1>copper</e1> transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (<e2>rCtr1</e2>) as a membrane transporter of copper and platinum drugs.","Substrate"
"Heterologous expression of <e2>rCtr1</e2> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, <e1>oxaliplatin</e1>, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.","Substrate"
"This study aimed to understand the role of <e1>copper</e1> transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (<e2>rCtr1</e2>) as a membrane transporter of copper and platinum drugs.","Substrate"
"This study aimed to understand the role of <e1>copper</e1> transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (<e2>rCtr1</e2>) as a membrane transporter of copper and platinum drugs.","Substrate"
"Heterologous expression of <e2>rCtr1</e2> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, <e1>oxaliplatin</e1>, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.","Substrate"
"Heterologous expression of <e2>rCtr1</e2> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, <e1>oxaliplatin</e1>, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.","Substrate"
"Heterologous expression of <e2>rCtr1</e2> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, <e1>cisplatin</e1> and carboplatin, in comparison to isogenic vector-transfected control cells.","Substrate"
"Heterologous expression of <e2>rCtr1</e2> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, <e1>cisplatin</e1> and carboplatin, in comparison to isogenic vector-transfected control cells.","Substrate"
"Heterologous expression of <e2>rCtr1</e2> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and <e1>carboplatin</e1>, in comparison to isogenic vector-transfected control cells.","Substrate"
"Heterologous expression of <e2>rCtr1</e2> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and <e1>carboplatin</e1>, in comparison to isogenic vector-transfected control cells.","Substrate"
"This study aimed to understand the role of <e1>copper</e1> transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (<e2>rCtr1</e2>) as a membrane transporter of copper and platinum drugs.","Substrate"
"This study aimed to understand the role of <e1>copper</e1> transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (<e2>rCtr1</e2>) as a membrane transporter of copper and platinum drugs.","Substrate"
"Contributions of <e2>rat Ctr1</e2> to the uptake and toxicity of <e1>copper</e1> and platinum anticancer drugs in dorsal root ganglion neurons.","Substrate"
"Contributions of <e2>rat Ctr1</e2> to the uptake and toxicity of copper and <e1>platinum</e1> anticancer drugs in dorsal root ganglion neurons.","Substrate"
"This study aimed to understand the role of <e1>copper</e1> transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (<e2>rCtr1</e2>) as a membrane transporter of copper and platinum drugs.","Substrate"
"In addition, <e1>glucosamine</e1> attenuated <e2>p21</e2> protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.","Regulator"
"Altogether, our results suggest that a high dose of <e1>glucosamine</e1> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, <e2>p53</e2> and HO-1 expression, and nuclear p21 accumulation.","Regulator"
"Altogether, our results suggest that a high dose of <e1>glucosamine</e1> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and <e2>HO-1</e2> expression, and nuclear p21 accumulation.","Regulator"
"In addition, <e1>glucosamine</e1> attenuated <e2>p21</e2> protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.","Upregulator"
"In addition, <e1>glucosamine</e1> attenuated <e2>p21</e2> protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.","Upregulator"
"<e1>Glucosamine</e1> at 50mM was demonstrated to elevate both the mRNA and protein expression of <e2>p53</e2> and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.","Upregulator"
"<e1>Glucosamine</e1> at 50mM was demonstrated to elevate both the mRNA and protein expression of p53 and <e2>heme oxygenase-1</e2> (HO-1), but also caused a reduction in p21 protein expression.","Upregulator"
"In addition, <e1>glucosamine</e1> attenuated <e2>p21</e2> protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.","Downregulator"
"<e1>Glucosamine</e1> at 50mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in <e2>p21</e2> protein expression.","Downregulator"
"Examination of phosphorylation in retinoblastoma (<e2>Rb</e2>) protein, we found an inhibitory effect by <e1>glucosamine</e1> at 20 and 50mM.","Downregulator"
"Examination of phosphorylation in <e2>retinoblastoma (Rb) protein</e2>, we found an inhibitory effect by <e1>glucosamine</e1> at 20 and 50mM.","Downregulator"
"Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a <e1>benzyloxyl</e1> substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased <e2>MT(1)</e2> potency.","Not"
"The pharmacological potencies of a series of substituted N-[3-(<e1>3-methoxyphenyl</e1>)propyl] amides towards human melatonin <e2>MT(1)</e2> and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.","Not"
"Structure-activity relationship analysis of highly potent subtype-selective ligands (<e2>MT(2)</e2> EC(50) 10-90 pM) revealed that a <e1>benzyloxyl</e1> substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased MT(1) potency.","Regulator"
"The pharmacological potencies of a series of substituted N-[3-(<e1>3-methoxyphenyl</e1>)propyl] amides towards human melatonin MT(1) and <e2>MT(2)</e2> receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.","Regulator"
"The two subtypes of mammalian G protein-coupled <e1>melatonin</e1> receptors are primarily responsible for mediating the actions of melatonin.","Regulator"
"Characterization of substituted <e1>phenylpropylamides</e1> as highly selective agonists at the <e2>melatonin MT2 receptor</e2>.","Agonist"
"In sum, identification of <e2>PIM-1</e2> as an ER target gene adds a novel potential mechanism by which <e1>estrogens</e1> can contribute to breast cancer cell proliferation and carcinogenesis.","Regulator"
"In sum, identification of PIM-1 as an <e2>ER</e2> target gene adds a novel potential mechanism by which <e1>estrogens</e1> can contribute to breast cancer cell proliferation and carcinogenesis.","Regulator"
"We show that the expression of PIM-1 is induced in response to <e1>estradiol</e1> in MCF-7 cells and that the induction is mediated by <e2>ER</e2>-regulated enhancers located distally upstream from the gene.","Upregulator"
"We show that the expression of <e2>PIM-1</e2> is induced in response to <e1>estradiol</e1> in MCF-7 cells and that the induction is mediated by ER-regulated enhancers located distally upstream from the gene.","Upregulator"
"In contrast, <e1>flunisolide</e1> was only metabolized via CYP3A4, with no significant turnover by <e2>CYP3A5</e2> or CYP3A7.","Not"
"In contrast, <e1>flunisolide</e1> was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or <e2>CYP3A7</e2>.","Not"
"In this work, the metabolism of four frequently prescribed inhaled GCs, <e1>triamcinolone acetonide</e1>, flunisolide, budesonide, and fluticasone propionate, by the <e2>CYP3A</e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.","Substrate"
"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, <e1>flunisolide</e1>, budesonide, and fluticasone propionate, by the <e2>CYP3A</e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.","Substrate"
"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, <e1>budesonide</e1>, and fluticasone propionate, by the <e2>CYP3A</e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.","Substrate"
"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and <e1>fluticasone propionate</e1>, by the <e2>CYP3A</e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.","Substrate"
"<e2>CYP3A5</e2>, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize <e1>triamcinolone acetonide</e1>, budesonide, and fluticasone propionate.","Substrate"
"<e2>CYP3A5</e2>, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, <e1>budesonide</e1>, and fluticasone propionate.","Substrate"
"<e2>CYP3A5</e2>, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and <e1>fluticasone propionate</e1>.","Substrate"
"In contrast, <e1>flunisolide</e1> was only metabolized via <e2>CYP3A4</e2>, with no significant turnover by CYP3A5 or CYP3A7.","Substrate"
"Distinct roles of <e1>methamphetamine</e1> in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of <e2>ERK</e2> and CREB activation in hippocampus and prefrontal cortex.","Upregulator"
"Distinct roles of <e1>methamphetamine</e1> in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and <e2>CREB</e2> activation in hippocampus and prefrontal cortex.","Upregulator"
"Activation of both <e2>ERK</e2> and CREB in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in <e1>METH</e1>-treated mouse groups.","Upregulator"
"Activation of both ERK and <e2>CREB</e2> in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in <e1>METH</e1>-treated mouse groups.","Upregulator"
"Activation of both <e2>ERK</e2> and CREB in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in <e1>METH</e1>-treated mouse groups.","Upregulator"
"Activation of both ERK and <e2>CREB</e2> in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in <e1>METH</e1>-treated mouse groups.","Upregulator"
"A reporter construct driven by 4 kb of the <e2>chicken ras-dva</e2> 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by <e1>corticosterone</e1>.","Upregulator"
"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative <e2>pituitary-specific transcription factor-1 (Pit-1) binding sites</e2> and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by <e1>corticosterone</e1>.","Upregulator"
"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential <e2>glucocorticoid receptor (GR) binding sites</e2>, was highly activated in embryonic pituitary cells and up-regulated by <e1>corticosterone</e1>.","Upregulator"
"However, mutating putative <e2>GR binding sites</e2> did not substantially reduce induction of ras-dva promoter activity by <e1>corticosterone</e1>, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.","Upregulator"
"However, mutating putative GR binding sites did not substantially reduce induction of <e2>ras-dva promoter</e2> activity by <e1>corticosterone</e1>, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.","Upregulator"
"To investigate the role of <e2>mGluR8</e2> in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist <e1>(S)-3,4-dicarboxyphenylglycine</e1> (DCPG).","Agonist"
"To investigate the role of <e2>mGluR8</e2> in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (<e1>DCPG</e1>).","Agonist"
"To investigate the role of <e2>mGluR8</e2> in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, <e1>AZ12216052</e1> (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).","Modulator"
"<e1>UCCB01-125</e1>, a dimeric inhibitor of <e2>PSD-95</e2>, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the NMDA receptor antagonist MK-801.","Downregulator"
"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the <e2>NMDAR</e2> antagonist, <e1>MK-801</e1>, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.","Antagonist"
"UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the <e2>NMDA receptor</e2> antagonist <e1>MK-801</e1>.","Antagonist"
"Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction <e1>amino acid</e1> sequence of the <e2>translocator protein TSPO</e2>.","Part_of"
"A domain in the <e1>carboxy</e1>-terminus of <e2>TSPO</e2> was identified and characterized as the cholesterol recognition/interaction amino acid consensus (CRAC).","Part_of"
"Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction <e1>amino acid</e1> sequence of the translocator protein <e2>TSPO</e2>.","Part_of"
"Control of hyper<e1>cholesterol</e1>emia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein <e2>TSPO</e2>.","Regulator"
"The <e2>translocator protein (18-kDa) TSPO</e2> is an ubiquitous high affinity <e1>cholesterol</e1>-binding protein reported to be present in the endothelial and smooth muscle cells of the blood vessels; its expression dramatically increased in macrophages found in atherosclerotic plaques.","Regulator"
"The treatment also prevented the high <e1>cholesterol</e1> diet-induced increase in serum <e2>creatine kinase</e2>, total and isoforms, markers of neurological, cardiac and muscular damage.","Upregulator"
"GIP potentiates <e1>glucose</e1>-stimulated <e2>insulin</e2> secretion and induces energy accumulation into adipose tissue, resulting in obesity.","Upregulator"
"We concluded that in overweight and obese women with PCOS <e1>Orlistat</e1> administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and <e2>insulin</e2> sensitivity, and increased serum AMH levels.","Regulator"
"Diet, physical exercise and <e1>Orlistat</e1> administration increase serum Anti-Mllerian Hormone (<e2>AMH</e2>) levels in women with polycystic ovary syndrome (PCOS).","Upregulator"
"Diet, physical exercise and <e1>Orlistat</e1> administration increase serum <e2>Anti-Mllerian Hormone</e2> (AMH) levels in women with polycystic ovary syndrome (PCOS).","Upregulator"
"Diet, physical exercise and <e1>Orlistat</e1> administration increase serum Anti-Mllerian Hormone (<e2>AMH</e2>) levels in women with polycystic ovary syndrome (PCOS).","Upregulator"
"Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of <e2>organic anion transporter</e2> (Oat)1 and Oat3 in rat kidney in response to <e1>1,25(OH)(2)D(3)</e1> treatment.","Regulator"
"Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter <e2>(Oat)1</e2> and Oat3 in rat kidney in response to <e1>1,25(OH)(2)D(3)</e1> treatment.","Regulator"
"Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter (Oat)1 and <e2>Oat3</e2> in rat kidney in response to <e1>1,25(OH)(2)D(3)</e1> treatment.","Regulator"
"Inhibitory effect of <e1>1,25-dihydroxyvitamin D</e1> on excretion of JBP485 via <e2>organic anion transporters</e2> in rats.","Regulator"
"Moreover, <e1>1,25(OH)(2)D(3)</e1> decreased expression of <e2>Oat1</e2> and Oat3 in rat kidney.","Downregulator"
"Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter (Oat)1 and <e2>Oat3</e2> in rat kidney in response to <e1>1,25(OH)(2)D(3)</e1> treatment.","Downregulator"
"The mechanism of interaction between JBP485 and <e1>1,25(OH)(2)D(3)</e1> could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of <e2>Oats</e2> in rat kidney.","Downregulator"
"These results indicate that neonatal <e1>diazinon</e1> exposure impaired the hippocampus-dependent novel object recognition ability, accompanied by a modulation in the expressions of the <e2>NMDA receptor</e2> and neurotrophin in young adult and adult mice.","Regulator"
"<e1>ISO</e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of ISO on <e2>MAPK</e2> signaling pathways remain unknown.","Regulator"
"Furthermore, <e1>U0126</e1> (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of <e2>cytochrome c</e2> to the cytosol fraction, and the levels of cleaved caspase-3.","Regulator"
"Furthermore, <e1>U0126</e1> (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved <e2>caspase-3</e2>.","Regulator"
"<e2>MAPK</e2> signaling pathways regulate mitochondrial-mediated apoptosis induced by <e1>isoorientin</e1> in human hepatoblastoma cancer cells.","Regulator"
"<e1>ISO</e1> significantly inhibited the levels of ERK1/2 kinase and increased the expression of <e2>JNK</e2> and p38 kinases.","Upregulator"
"<e1>ISO</e1> significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and <e2>p38</e2> kinases.","Upregulator"
"The present study investigated the effects of <e1>ISO</e1> on this pathway, and the roles of MAPK <e2>kinases</e2> on mitochondrial-mediated apoptosis in HepG2 cells.","Upregulator"
"<e1>ISO</e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of ISO on <e2>MAPK</e2> signaling pathways remain unknown.","Upregulator"
"<e1>ISO</e1> significantly inhibited the levels of ERK1/2 kinase and increased the expression of <e2>JNK</e2> and p38 kinases.","Upregulator"
"<e1>ISO</e1> significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and <e2>p38</e2> kinases.","Upregulator"
"The present study investigated the effects of <e1>ISO</e1> on this pathway, and the roles of MAPK <e2>kinases</e2> on mitochondrial-mediated apoptosis in HepG2 cells.","Upregulator"
"Furthermore, <e1>U0126</e1> (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the <e2>Bax</e2>/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.","Upregulator"
"Furthermore, <e1>U0126</e1> (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/<e2>Bcl-2</e2> ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.","Upregulator"
"Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the <e1>ISO</e1>-induced the <e2>Bax</e2>/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.","Upregulator"
"Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the <e1>ISO</e1>-induced the Bax/<e2>Bcl-2</e2> ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.","Upregulator"
"<e1>ISO</e1> significantly inhibited the levels of ERK1/2 kinase and increased the expression of <e2>JNK</e2> and p38 kinases.","Upregulator"
"<e1>ISO</e1> significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and <e2>p38</e2> kinases.","Upregulator"
"<e1>ISO</e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of <e2>PI3K</e2>/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.","Downregulator"
"<e1>ISO</e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/<e2>Akt</e2> signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.","Downregulator"
"While <e1>SP600125</e1> (a <e2>JNK</e2> inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.","Downregulator"
"While SP600125 (a JNK inhibitor) and <e1>SB203580</e1> (a <e2>p38</e2> inhibitor) markedly prevented the expression of these proteins induced by ISO.","Downregulator"
"<e1>NAC</e1> also suppressed the p-<e2>JNK</e2> and p-p38, but failed to reverse the effects of ISO.","Downregulator"
"<e1>NAC</e1> also suppressed the p-JNK and <e2>p-p38</e2>, but failed to reverse the effects of ISO.","Downregulator"
"Treatment with <e1>IMG</e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>thrombin</e2> and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Upregulator"
"Treatment with <e1>IMG</e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>FXa</e2>, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Downregulator"
"Treatment with IMG and <e1>hyperoside</e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>thrombin</e2> and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Downregulator"
"Treatment with IMG and <e1>hyperoside</e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>FXa</e2>, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Downregulator"
"In addition, treatment with <e1>IMG</e1> and hyperoside resulted in inhibition of TNF--induced production of <e2>PAI-1</e2>, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.","Downregulator"
"In addition, treatment with IMG and <e1>hyperoside</e1> resulted in inhibition of TNF--induced production of <e2>PAI-1</e2>, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.","Downregulator"
"In addition, treatment with <e1>IMG</e1> and hyperoside resulted in inhibition of TNF--induced production of <e2>PAI-1</e2>, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.","Downregulator"
"In addition, treatment with <e1>IMG</e1> and hyperoside resulted in inhibition of TNF--induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to <e2>t-PA</e2> ratio.","Downregulator"
"Treatment with <e1>IMG</e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>thrombin</e2> and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Downregulator"
"Treatment with <e1>IMG</e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>FXa</e2>, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Downregulator"
"Treatment with IMG and <e1>hyperoside</e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>thrombin</e2> and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Downregulator"
"Treatment with IMG and <e1>hyperoside</e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>FXa</e2>, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.","Downregulator"
"In addition, treatment with <e1>IMG</e1> and hyperoside resulted in inhibition of <e2>TNF-</e2>-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.","Downregulator"
"In addition, treatment with IMG and <e1>hyperoside</e1> resulted in inhibition of <e2>TNF-</e2>-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.","Downregulator"
"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4</e1>) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and <e2>human leukotriene A(4) hydrolase</e2> (LTA(4)H-h) was found.","Downregulator"
"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4</e1>) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (<e2>LTA(4)H-h</e2>) was found.","Downregulator"
"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4</e1>) for <e2>human nonpancreatic secretory phospholipase A(2)</e2> (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.","Downregulator"
"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4</e1>) for human nonpancreatic secretory phospholipase A(2) (<e2>hnps-PLA(2)</e2>) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.","Downregulator"
"Optimization of <e1>5-hydroxytryptamines</e1> as dual function inhibitors targeting <e2>phospholipase A2</e2> and leukotriene A4 hydrolase.","Downregulator"
"Optimization of <e1>5-hydroxytryptamines</e1> as dual function inhibitors targeting phospholipase A2 and <e2>leukotriene A4 hydrolase</e2>.","Downregulator"
"Dual function inhibitors targeting phospholipase A(2) (<e2>PLA(2)</e2>) and leukotriene A(4) hydrolase (LTA(4)H) may balance the <e1>arachidonic acid</e1> (AA) metabolic network and be used as new anti-inflammatory drugs.","Substrate"
"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and <e2>leukotriene A(4) hydrolase</e2> (LTA(4)H) may balance the <e1>arachidonic acid</e1> (AA) metabolic network and be used as new anti-inflammatory drugs.","Substrate"
"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (<e2>LTA(4)H</e2>) may balance the <e1>arachidonic acid</e1> (AA) metabolic network and be used as new anti-inflammatory drugs.","Substrate"
"Dual function inhibitors targeting <e2>phospholipase A(2)</e2> (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the <e1>arachidonic acid</e1> (AA) metabolic network and be used as new anti-inflammatory drugs.","Substrate"
"Here, we show that <e2>rTRPV1</e2>, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward <e1>apomorphine</e1> treatment.","Not"
"Here, we show that rTRPV1, <e2>rTRPV2</e2>, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward <e1>apomorphine</e1> treatment.","Not"
"Here, we show that rTRPV1, rTRPV2, <e2>rTRPV3</e2>, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward <e1>apomorphine</e1> treatment.","Not"
"Here, we show that rTRPV1, rTRPV2, rTRPV3, and <e2>mTRPV4</e2>, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward <e1>apomorphine</e1> treatment.","Not"
"Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as <e2>hTRPM8</e2>, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward <e1>apomorphine</e1> treatment.","Not"
"Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and <e2>rTRPM3</e2>, which are expressed in dorsal root ganglion neurons, are insensitive toward <e1>apomorphine</e1> treatment.","Not"
"On the contrary, <e2>human TRPA1</e2> could be concentration-dependently modulated by <e1>apomorphine</e1>.","Regulator"
"<e1>Apomorphine</e1> is a bimodal modulator of <e2>TRPA1</e2> channels.","Regulator"
"On the contrary, human <e2>TRPA1</e2> could be concentration-dependently modulated by <e1>apomorphine</e1>.","Regulator"
"On the contrary, <e2>human TRPA1</e2> could be concentration-dependently modulated by <e1>apomorphine</e1>.","Regulator"
"On the contrary, human <e2>TRPA1</e2> could be concentration-dependently modulated by <e1>apomorphine</e1>.","Upregulator"
"On the contrary, human <e2>TRPA1</e2> could be concentration-dependently modulated by <e1>apomorphine</e1>.","Upregulator"
"On the contrary, human <e2>TRPA1</e2> could be concentration-dependently modulated by <e1>apomorphine</e1>.","Upregulator"
"On the contrary, human <e2>TRPA1</e2> could be concentration-dependently modulated by <e1>apomorphine</e1>.","Downregulator"
"Dietary <e1>carbohydrates</e1> increase SCD-1 gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and <e2>SREBP-1c</e2> -independent pathways.","Not"
"Dietary <e1>carbohydrates</e1> increase SCD-1 gene expression in liver by <e2>sterol response element binding protein (SREBP)-1c</e2>-dependent and SREBP-1c -independent pathways.","Regulator"
"Dietary <e1>carbohydrates</e1> increase <e2>SCD-1</e2> gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.","Upregulator"
"Previous report demonstrated that <e1>thyroid hormone</e1> (TH) negatively regulates <e2>mouse SCD-1 gene promoter</e2> before SREBP-1c was revealed.","Downregulator"
"<e2>Human stearoyl-CoA desaturase 1</e2> (SCD-1) gene expression is negatively regulated by <e1>thyroid hormone</e1> without direct binding of thyroid hormone receptor to the gene promoter.","Downregulator"
"Human stearoyl-CoA desaturase 1 (<e2>SCD-1</e2>) gene expression is negatively regulated by <e1>thyroid hormone</e1> without direct binding of thyroid hormone receptor to the gene promoter.","Downregulator"
"Conversely, activation of AMPK by <e1>metformin</e1> stimulated JNK1-<e2>Bcl-2</e2> signaling and disrupted the Beclin1-Bcl-2 complex.","Regulator"
"Conversely, activation of AMPK by <e1>metformin</e1> stimulated JNK1-Bcl-2 signaling and disrupted the <e2>Beclin1</e2>-Bcl-2 complex.","Regulator"
"We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between <e2>Beclin1</e2> and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high <e1>glucose</e1>-treated H9c2 cardiac myoblast cells.","Regulator"
"We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and <e2>Bcl-2</e2>, a switch between autophagy and apoptosis, in diabetic mice and high <e1>glucose</e1>-treated H9c2 cardiac myoblast cells.","Regulator"
"Conversely, activation of AMPK by <e1>metformin</e1> stimulated <e2>JNK1</e2>-Bcl-2 signaling and disrupted the Beclin1-Bcl-2 complex.","Upregulator"
"Conversely, activation of AMPK by <e1>metformin</e1> stimulated JNK1-<e2>Bcl-2</e2> signaling and disrupted the Beclin1-Bcl-2 complex.","Upregulator"
"Exposure of H9c2 cells to high <e1>glucose</e1> reduced AMPK activity, inhibited <e2>Jun NH2-terminal kinase 1</e2> (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.","Downregulator"
"Exposure of H9c2 cells to high <e1>glucose</e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (<e2>JNK1</e2>)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.","Downregulator"
"Exposure of H9c2 cells to high <e1>glucose</e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-<e2>B-cell lymphoma 2</e2> (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.","Downregulator"
"We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and <e2>Bcl-2</e2>, a switch between autophagy and apoptosis, in diabetic mice and high <e1>glucose</e1>-treated H9c2 cardiac myoblast cells.","Downregulator"
"We hypothesized that <e2>AMPK</e2>-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high <e1>glucose</e1>-treated H9c2 cardiac myoblast cells.","Downregulator"
"Metformin-mediated downregulation of p38 <e2>mitogen-activated protein kinase</e2>-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to <e1>paclitaxel</e1>.","Upregulator"
"Metformin-mediated downregulation of <e2>p38</e2> mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to <e1>paclitaxel</e1>.","Upregulator"
"In this current study, <e1>paclitaxel</e1> was found to increase phosphorylation of mitogen-activated protein kinase (<e2>MAPK</e2>) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.","Upregulator"
"Metformin-mediated downregulation of <e2>p38</e2> mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to <e1>paclitaxel</e1>.","Upregulator"
"In this current study, <e1>paclitaxel</e1> was found to increase phosphorylation of mitogen-activated protein kinase (<e2>MAPK</e2>) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.","Upregulator"
"In this current study, <e1>paclitaxel</e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of <e2>ERCC1</e2> in H1650 and H1703 cells.","Upregulator"
"In this current study, <e1>paclitaxel</e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of <e2>ERCC1</e2> in H1650 and H1703 cells.","Upregulator"
"In this current study, <e1>paclitaxel</e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of <e2>ERCC1</e2> in H1650 and H1703 cells.","Upregulator"
"<e1>Metformin</e1>-mediated downregulation of <e2>p38</e2> mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.","Downregulator"
"<e1>Metformin</e1>-mediated downregulation of p38 <e2>mitogen-activated protein kinase</e2>-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.","Downregulator"
"Furthermore, <e1>metformin</e1> was able to not only decrease the paclitaxel-induced p38 MAPK-mediated <e2>ERCC1</e2> expression, but also augment the cytotoxic effect induced by paclitaxel.","Downregulator"
"Furthermore, <e1>metformin</e1> was able to not only decrease the paclitaxel-induced p38 MAPK-mediated <e2>ERCC1</e2> expression, but also augment the cytotoxic effect induced by paclitaxel.","Downregulator"
"In this current study, <e1>paclitaxel</e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of <e2>ERCC1</e2> in H1650 and H1703 cells.","Downregulator"
"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of <e2>p38</e2> activity by either a p38 MAPK inhibitor <e1>SB202190</e1> or p38 knockdown with specific small interfering RNA (siRNA).","Downregulator"
"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of <e2>p38</e2> activity by either a p38 MAPK inhibitor <e1>SB202190</e1> or p38 knockdown with specific small interfering RNA (siRNA).","Downregulator"
"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 <e2>MAPK</e2> inhibitor <e1>SB202190</e1> or p38 knockdown with specific small interfering RNA (siRNA).","Downregulator"
"Furthermore, <e1>metformin</e1> was able to not only decrease the paclitaxel-induced <e2>p38</e2> MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.","Downregulator"
"Furthermore, <e1>metformin</e1> was able to not only decrease the paclitaxel-induced p38 <e2>MAPK</e2>-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.","Downregulator"
"Furthermore, <e1>metformin</e1> was able to not only decrease the paclitaxel-induced <e2>p38</e2> MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.","Downregulator"
"Furthermore, <e1>metformin</e1> was able to not only decrease the paclitaxel-induced p38 <e2>MAPK</e2>-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward <e2>CES1</e2> than CES2, a carboxylesterase with little lipase activity.","Not"
"<e2>Carboxylesterase-2</e2> is a highly sensitive target of the antiobesity agent <e1>orlistat</e1> with profound implications in the activation of anticancer prodrugs.","Regulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward CES1 than <e2>CES2</e2>, a carboxylesterase with little lipase activity.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward CES1 than <e2>CES2</e2>, a carboxylesterase with little lipase activity.","Downregulator"
"<e1>Orlistat</e1> has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal <e2>lipases</e2>.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward CES1 than CES2, a <e2>carboxylesterase</e2> with little lipase activity.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits <e2>CESs</e2> with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward <e2>CES1</e2> than CES2, a carboxylesterase with little lipase activity.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward CES1 than <e2>CES2</e2>, a carboxylesterase with little lipase activity.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward CES1 than CES2, a <e2>carboxylesterase</e2> with little lipase activity.","Downregulator"
"This study was designed to test the hypothesis that <e1>orlistat</e1> inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little <e2>lipase</e2> activity.","Downregulator"
"Exchange of domains between the two isoforms indicates that the C1b domain and the <e1>N</e1>-terminus of the <e2>C1a domain</e2> are important for directing selective regulation of AC7 by the G(13) pathway.","Part_of"
"On stimulation by G(s), the activities of <e2>ACs</e2> can be further selectively modulated by other pathways to ensure precise control of intracellular <e1>cAMP</e1> responses to specific stimuli.","Substrate"
"Regulation of multiple <e2>adenylyl cyclases</e2> (AC) provides unique inputs to mediate the synthesis of <e1>cAMP</e1>, a ubiquitous second messenger that controls many aspects of cellular function.","Substrate"
"Regulation of multiple adenylyl cyclases (<e2>AC</e2>) provides unique inputs to mediate the synthesis of <e1>cAMP</e1>, a ubiquitous second messenger that controls many aspects of cellular function.","Substrate"
"<e1>E235</e1>-mediated induction of senescence was not dependent on <e2>p21</e2> or p53; however, p21 conferred protection against the growth inhibitory effects of E235.","Not"
"<e1>E235</e1>-mediated induction of senescence was not dependent on p21 or <e2>p53</e2>; however, p21 conferred protection against the growth inhibitory effects of E235.","Not"
"E235 also activated DNA damage response signaling, resulting in increased levels of <e1>Ser</e1>15-<e2>phosphorylated p53</e2>, -H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.","Part_of"
"<e1>E235</e1>-mediated induction of senescence was not dependent on <e2>p21</e2> or p53; however, p21 conferred protection against the growth inhibitory effects of E235.","Regulator"
"We identified one compound, <e1>E235</e1> (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of <e2>ATF4</e2> in transformed cells.","Upregulator"
"We identified one compound, E235 <e1>(N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)</e1>, that activated the ISR and dose-dependently increased levels of <e2>ATF4</e2> in transformed cells.","Upregulator"
"<e1>E235</e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-<e2>phosphorylated p53</e2>, -H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.","Upregulator"
"<e1>E235</e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, <e2>-H2AX</e2>, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.","Upregulator"
"<e1>E235</e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, -H2AX, and <e2>phosphorylated checkpoint kinase 2</e2> (Chk2), although E235 does not appear to cause physical DNA damage.","Upregulator"
"<e1>E235</e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, -H2AX, and phosphorylated checkpoint kinase 2 (<e2>Chk2</e2>), although E235 does not appear to cause physical DNA damage.","Upregulator"
"We aim to ""tilt"" the stability of the <e2>H1</e2> loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the <e1>amino acid</e1> sequence of the H1, H2, and proximal residues.","Part_of"
"We aim to ""tilt"" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the <e1>amino acid</e1> sequence of the H1, <e2>H2</e2>, and proximal residues.","Part_of"
"Cell culture studies demonstrated that <e1>PKAA</e1> is capable of delivering anti-TNF (tumor necrosis factor)- siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of <e2>TNF-</e2>.","Downregulator"
"<e1>PKAA</e1>/anti-TNF- siRNA nanocomplexes significantly reduced the <e2>ALT</e2> (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.","Downregulator"
"<e1>PKAA</e1>/anti-TNF- siRNA nanocomplexes significantly reduced the ALT (<e2>alanine transaminase</e2>) and the hepatic cellular damages in APAP-intoxicated mice.","Downregulator"
"Moreover, wogonin repressed <e1>anisomycin</e1>-induced phosphorylation of <e2>p38</e2>, cav-1 and vascular permeability.","Upregulator"
"Moreover, wogonin repressed <e1>anisomycin</e1>-induced phosphorylation of p38, <e2>cav-1</e2> and vascular permeability.","Upregulator"
"The mechanism revealed that wogonin inhibited <e1>H2O2</e1>-induced phosphorylation of caveolin-1 (<e2>cav-1</e2>) associating with the suppression of stabilization of VE-cadherin and -catenin.","Upregulator"
"Wogonin inhibits <e1>H2O2</e1>-induced vascular permeability through suppressing the phosphorylation of <e2>caveolin-1</e2>.","Upregulator"
"Wogonin inhibits <e1>H2O2</e1>-induced vascular permeability through suppressing the phosphorylation of <e2>caveolin-1</e2>.","Upregulator"
"The mechanism revealed that wogonin inhibited <e1>H2O2</e1>-induced phosphorylation of caveolin-1 (<e2>cav-1</e2>) associating with the suppression of stabilization of VE-cadherin and -catenin.","Upregulator"
"We found that wogonin can suppress the <e1>H2O2</e1>-stimulated <e2>actin</e2> remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.","Upregulator"
"We found that wogonin can suppress the <e1>H2O2</e1>-stimulated actin remodeling and <e2>albumin</e2> uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.","Upregulator"
"We found that <e1>wogonin</e1> can suppress the H2O2-stimulated <e2>actin</e2> remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.","Downregulator"
"We found that <e1>wogonin</e1> can suppress the H2O2-stimulated actin remodeling and <e2>albumin</e2> uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.","Downregulator"
"The mechanism revealed that <e1>wogonin</e1> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of <e2>VE-cadherin</e2> and -catenin.","Downregulator"
"The mechanism revealed that <e1>wogonin</e1> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and <e2>-catenin</e2>.","Downregulator"
"Moreover, <e1>wogonin</e1> repressed anisomycin-induced phosphorylation of <e2>p38</e2>, cav-1 and vascular permeability.","Downregulator"
"The mechanism revealed that <e1>wogonin</e1> inhibited H2O2-induced phosphorylation of caveolin-1 (<e2>cav-1</e2>) associating with the suppression of stabilization of VE-cadherin and -catenin.","Downregulator"
"The mechanism revealed that <e1>wogonin</e1> inhibited H2O2-induced phosphorylation of caveolin-1 (<e2>cav-1</e2>) associating with the suppression of stabilization of VE-cadherin and -catenin.","Downregulator"
"<e1>Wogonin</e1> inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of <e2>caveolin-1</e2>.","Downregulator"
"The mechanism revealed that <e1>wogonin</e1> inhibited H2O2-induced phosphorylation of <e2>caveolin-1</e2> (cav-1) associating with the suppression of stabilization of VE-cadherin and -catenin.","Downregulator"
"The mechanism revealed that <e1>wogonin</e1> inhibited H2O2-induced phosphorylation of caveolin-1 (<e2>cav-1</e2>) associating with the suppression of stabilization of VE-cadherin and -catenin.","Downregulator"
"In an attempt to further improve overall profiles of the <e1>oxadiazine</e1> series of GSMs, in particular the <e2>hERG</e2> activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.","Regulator"
"The discovery of fused <e1>oxadiazepines</e1> as <e2>gamma secretase</e2> modulators for treatment of Alzheimer's disease.","Regulator"
"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the <e2>hERG</e2> activity, conformational modifications of the core structure resulted in the identification of fused <e1>oxadiazepines</e1> such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.","Downregulator"
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors <e2>survivin</e2>, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA</e1>.","Downregulator"
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, <e2>Bcl-2</e2>, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA</e1>.","Downregulator"
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and <e2>X-linked inhibitor of apoptosis protein</e2>, These effects could be completely blocked by <e1>BZA</e1>.","Downregulator"
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of <e2>MAPK</e2>, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA</e1>.","Downregulator"
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, <e2>Akt</e2>, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA</e1>.","Downregulator"
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and <e2>p70S6K</e2> and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA</e1>.","Downregulator"
"The reduction of BiFC signal mediated by <e1>nutlin-3</e1> was correlated with an increase in <e2>Puma</e2> transactivation, PARP cleavage, and cell death.","Upregulator"
"The reduction of BiFC signal mediated by <e1>nutlin-3</e1> was correlated with an increase in Puma transactivation, <e2>PARP</e2> cleavage, and cell death.","Upregulator"
"We used <e1>nutlin-3</e1>, a well-known disruptor of <e2>p53</e2>-Mdm2 interaction, to validate the specificity of the assay.","Downregulator"
"We used <e1>nutlin-3</e1>, a well-known disruptor of p53-<e2>Mdm2</e2> interaction, to validate the specificity of the assay.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced <e2>pAkt</e2> level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced pAkt level and its downstream effectors: <e2>pCREB</e2>, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, <e2>pGSK-3</e2>, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, <e2>Bcl-2</e2> and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and <e2>neurotrophins</e2> GDNF, BDNF suggesting repressed PI3K/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins <e2>GDNF</e2>, BDNF suggesting repressed PI3K/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, <e2>BDNF</e2> suggesting repressed PI3K/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed <e2>PI3K</e2>/Akt signaling.","Downregulator"
"<e1>Sal</e1> toxicity coincided with reduced p<e2>Akt</e2> level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.","Downregulator"
"This was confirmed on adding <e1>LY294002</e1> the <e2>PI3K</e2> inhibitor which abolished the protection.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial <e2>glutathione peroxidase</e2>, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, <e2>glutathione reductase</e2>, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and <e2>NADH-dehydrogenases</e2>, cytochrome-C-oxidase and adenosine triphosphate.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, <e2>cytochrome-C-oxidase</e2> and adenosine triphosphate.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial <e2>glutathione peroxidase</e2>, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, <e2>glutathione reductase</e2>, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and <e2>NADH-dehydrogenases</e2>, cytochrome-C-oxidase and adenosine triphosphate.","Downregulator"
"<e1>Isoproterenol</e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, <e2>cytochrome-C-oxidase</e2> and adenosine triphosphate.","Downregulator"
"Increased urinary excretion of <e2>albumin</e2>, hemopexin, transferrin and VDBP correlates with chronic sensitization to <e1>gentamicin</e1> nephrotoxicity in rats.","Upregulator"
"Increased urinary excretion of albumin, <e2>hemopexin</e2>, transferrin and VDBP correlates with chronic sensitization to <e1>gentamicin</e1> nephrotoxicity in rats.","Upregulator"
"Increased urinary excretion of albumin, hemopexin, <e2>transferrin</e2> and VDBP correlates with chronic sensitization to <e1>gentamicin</e1> nephrotoxicity in rats.","Upregulator"
"Increased urinary excretion of albumin, hemopexin, transferrin and <e2>VDBP</e2> correlates with chronic sensitization to <e1>gentamicin</e1> nephrotoxicity in rats.","Upregulator"
"Design and synthesis of novel <e1>2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one</e1> derivatives as <e2>telomerase</e2> inhibitors.","Downregulator"
"<e1>DPEP</e1> induced dose-dependent reduction of the protein levels of <e2>inducible nitric oxide synthase</e2> (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).","Downregulator"
"<e1>DPEP</e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (<e2>iNOS</e2>) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).","Downregulator"
"<e1>DPEP</e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and <e2>cyclooxygenase-2</e2> (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).","Downregulator"
"<e1>DPEP</e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (<e2>COX-2</e2>) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).","Downregulator"
"Additionally, <e1>DPEP</e1> suppressed the production of inflammatory <e2>cytokines</e2>, including tumor necrosis factor- (TNF-), interleukin (IL)-1, and IL-6.","Downregulator"
"Additionally, <e1>DPEP</e1> suppressed the production of inflammatory cytokines, including <e2>tumor necrosis factor-</e2> (TNF-), interleukin (IL)-1, and IL-6.","Downregulator"
"Additionally, <e1>DPEP</e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor- (<e2>TNF-</e2>), interleukin (IL)-1, and IL-6.","Downregulator"
"Additionally, <e1>DPEP</e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor- (TNF-), <e2>interleukin (IL)-1</e2>, and IL-6.","Downregulator"
"Additionally, <e1>DPEP</e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor- (TNF-), interleukin (IL)-1, and <e2>IL-6</e2>.","Downregulator"
"<e1>DPEP</e1> inhibited LPS-induced phosphorylation of <e2>ERK</e2>, JNK, and p38.","Downregulator"
"<e1>DPEP</e1> inhibited LPS-induced phosphorylation of ERK, <e2>JNK</e2>, and p38.","Downregulator"
"<e1>DPEP</e1> inhibited LPS-induced phosphorylation of ERK, JNK, and <e2>p38</e2>.","Downregulator"
"Furthermore, <e1>DPEP</e1> inhibited the LPS-induced phosphorylation of inhibitor B (IB)- and NF-B <e2>p50</e2>.","Downregulator"
"Furthermore, <e1>DPEP</e1> inhibited the LPS-induced phosphorylation of <e2>inhibitor B (IB)-</e2> and NF-B p50.","Downregulator"
"We investigated the mechanism by which <e1>DPEP</e1> inhibits NO and PGE(2) by examining the level of nuclear factor-B (<e2>NF-B</e2>) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.","Downregulator"
"We investigated the mechanism by which <e1>DPEP</e1> inhibits NO and PGE(2) by examining the level of nuclear factor-B (<e2>NF-B</e2>) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.","Downregulator"
"We investigated the mechanism by which <e1>DPEP</e1> inhibits NO and PGE(2) by examining the level of nuclear factor-B (NF-B) activation within the mitogen-activated protein kinase (<e2>MAPK</e2>) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.","Downregulator"
"During base excision repair of this mispair, <e2>DNA polymerase (pol) </e2> is confronted with gap filling opposite <e1>8-oxoG</e1>.","Regulator"
"To determine how <e2>pol </e2> discriminates between <e1>anti- and syn-8-oxoG</e1>, we introduced a point mutation (R283K) to alter insertion specificity.","Regulator"
"To determine how pol  discriminates between anti- and syn-<e1>8-oxoG</e1>, we introduced a point mutation (<e2>R283K</e2>) to alter insertion specificity.","Regulator"
"To determine how <e2>pol </e2> discriminates between anti- and syn-<e1>8-oxoG</e1>, we introduced a point mutation (R283K) to alter insertion specificity.","Regulator"
"<e2>DNA polymerase minor groove</e2> interactions modulate mutagenic bypass of a templating <e1>8-oxoguanine</e1> lesion.","Regulator"
"In contrast to wild-type <e2>pol </e2>, the ternary complex of the R283K mutant with an incoming <e1>dATP</e1>-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.","Regulator"
"In contrast to wild-type pol , the ternary complex of the <e2>R283K</e2> mutant with an incoming <e1>dATP</e1>-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.","Regulator"
"To determine how pol  discriminates between anti- and syn-<e1>8-oxoG</e1>, we introduced a point mutation (<e2>R283K</e2>) to alter insertion specificity.","Regulator"
"To determine how pol  discriminates between anti- and syn-<e1>8-oxoG</e1>, we introduced a point mutation (<e2>R283K</e2>) to alter insertion specificity.","Regulator"
"These results demonstrate that the incoming <e1>nucleotide</e1> is unable to induce a syn-8-oxoG conformation without <e2>minor groove</e2> DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.","Regulator"
"These results demonstrate that the incoming <e1>nucleotide</e1> is unable to induce a syn-8-oxoG conformation without minor groove <e2>DNA polymerase</e2> interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.","Regulator"
"These results demonstrate that the incoming nucleotide is unable to induce a <e1>syn-8-oxoG</e1> conformation without <e2>minor groove</e2> DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.","Regulator"
"These results demonstrate that the incoming nucleotide is unable to induce a <e1>syn-8-oxoG</e1> conformation without minor groove <e2>DNA polymerase</e2> interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.","Regulator"
"This leads to decreased expression of <e1>glutamate</e1> aspartate transporter, which in turn reduces glutamate transport.","Substrate"
"<e1>Tetrahydropyrroloquinolinone</e1> type dual inhibitors of <e2>aromatase</e2>/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.","Downregulator"
"<e1>Tetrahydropyrroloquinolinone</e1> type dual inhibitors of aromatase/<e2>aldosterone synthase</e2> as a novel strategy for breast cancer patients with elevated cardiovascular risks.","Downregulator"
"Furthermore, <e1>MDZ</e1> caused mechanism-based inactivation of <e2>cytochrome P450 3A</e2>-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.","Downregulator"
"Furthermore, MDZ caused mechanism-based inactivation of <e2>cytochrome P450 3A</e2>-dependent <e1>TRZ</e1> 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.","Substrate"
"We previously found that the <e1>ganglioside</e1>-enriched microdomains (ganglioside clusters) in presynaptic neuronal membranes play a key role in the initiation of the <e2>A</e2> assembly process.","Regulator"
"We previously found that the <e1>ganglioside</e1>-enriched microdomains (ganglioside clusters) in presynaptic neuronal membranes play a key role in the initiation of the <e2>A</e2> assembly process.","Regulator"
"Although <e1>tamoxifen</e1> (TAM), a selective <e2>estrogen receptor</e2> modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.","Regulator"
"Although tamoxifen (<e1>TAM</e1>), a selective <e2>estrogen receptor</e2> modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.","Regulator"
"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as <e2>Snail</e2> and N-cadherin increased, whereas E-cadherin decreased in the <e1>TAM</e1>-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.","Upregulator"
"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and <e2>N-cadherin</e2> increased, whereas E-cadherin decreased in the <e1>TAM</e1>-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.","Upregulator"
"<e1>Tamoxifen</e1> represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating <e2>c-Myc</e2> in endometrial carcinoma cell lines.","Upregulator"
"In this report, we explored the role of microRNAs (miRNAs) in <e1>TAM</e1>-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found miR-200 is involved in this process via the regulation of <e2>c-Myc</e2>.","Upregulator"
"In this report, we explored the role of microRNAs (miRNAs) in <e1>TAM</e1>-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found <e2>miR-200</e2> is involved in this process via the regulation of c-Myc.","Downregulator"
"<e1>Tamoxifen</e1> represses <e2>miR-200</e2> microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.","Downregulator"
"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas <e2>E-cadherin</e2> decreased in the <e1>TAM</e1>-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.","Downregulator"
"In this report, we explored the role of microRNAs (miRNAs) in <e1>TAM</e1>-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found <e2>miR-200</e2> is involved in this process via the regulation of c-Myc.","Downregulator"
"In this report, we explored the role of microRNAs (miRNAs) in <e1>TAM</e1>-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found <e2>miR-200</e2> is involved in this process via the regulation of c-Myc.","Downregulator"
"The pro-hypertrophic co-activator <e2>p300</e2> protein but not p300 mRNA was up-regulated in the mdx heart, and <e1>resveratrol</e1> administration down-regulated the p300 protein level.","Not"
"We found that SIRT1 induced p300 down-regulation via the <e2>ubiquitin</e2>-proteasome pathway by deacetylation of <e1>lysine</e1> residues for ubiquitination.","Part_of"
"We found that SIRT1 induced p300 down-regulation via the ubiquitin-<e2>proteasome</e2> pathway by deacetylation of <e1>lysine</e1> residues for ubiquitination.","Part_of"
"<e1>Resveratrol</e1> improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of <e2>p300</e2> protein.","Regulator"
"<e1>Resveratrol</e1> improves cardiomyopathy in dystrophin-deficient mice through <e2>SIRT1</e2> protein-mediated modulation of p300 protein.","Regulator"
"Here, we show that oral administration of <e1>resveratrol</e1>, which leads to activation of an <e2>NAD(+)-dependent protein deacetylase SIRT1</e2>, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.","Upregulator"
"The pro-hypertrophic co-activator <e2>p300</e2> protein but not p300 mRNA was up-regulated in the mdx heart, and <e1>resveratrol</e1> administration down-regulated the p300 protein level.","Downregulator"
"The pro-hypertrophic co-activator <e2>p300</e2> protein but not p300 mRNA was up-regulated in the mdx heart, and <e1>resveratrol</e1> administration down-regulated the p300 protein level.","Downregulator"
"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (<e1>CA-Xaa-NHOH</e1>) acted as both a good antioxidant and <e2>tyrosinase</e2> inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.","Downregulator"
"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and <e2>tyrosinase</e2> inhibitor, in particular when <e1>caffeic acid</e1> was conjugated with proline or amino acids having aromatic ring like phenylalanine.","Downregulator"
"In addition, derivatives of caffeic acid and <e1>sinapic acid</e1> efficiently inhibited <e2>tyrosinase</e2> activity and reduced melanin content in melanocytes Mel-Ab cell.","Downregulator"
"Synthesis and dual biological effects of <e1>hydroxycinnamoyl phenylalanyl</e1>/prolyl hydroxamic acid derivatives as <e2>tyrosinase</e2> inhibitor and antioxidant.","Downregulator"
"Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl/<e1>prolyl hydroxamic acid</e1> derivatives as <e2>tyrosinase</e2> inhibitor and antioxidant.","Downregulator"
"We previously reported that <e1>caffeoyl-amino acidyl-hydroxamic acid</e1> (CA-Xaa-NHOH) acted as both a good antioxidant and <e2>tyrosinase</e2> inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.","Downregulator"
"<e1>Ruxolitinib</e1> is a small-molecule inhibitorof <e2>JAK1</e2> and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.","Downregulator"
"<e1>Ruxolitinib</e1> is a small-molecule inhibitorof JAK1 and <e2>JAK2</e2> and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.","Downregulator"
"<e1>AMP</e1>K is a cellular energy sensor conserved across eukaryotes that in C. elegans prolongs life span and mimics dietary restriction.","Regulator"
"<e1>AMP</e1>K is a cellular energy sensor conserved across eukaryotes that in C. elegans prolongs life span and mimics dietary restriction.","Regulator"
"Ex vivo samples of human oral mucosa were exposed to <e1>Pb</e1> or BaP, and immunohistochemical staining was performed to evaluate active <e2>caspase-3</e2>, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).","Upregulator"
"Ex vivo samples of human oral mucosa were exposed to Pb or <e1>BaP</e1>, and immunohistochemical staining was performed to evaluate active <e2>caspase-3</e2>, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).","Upregulator"
"<e1>TAA</e1> increased the number and area of <e2>glutathione S-transferase placental form</e2> (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.","Upregulator"
"<e1>TAA</e1> increased the number and area of glutathione S-transferase placental form (<e2>GST-P</e2>)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.","Upregulator"
"<e1>TAA</e1> also increased the numbers of ED2(+), <e2>cyclooxygenase-2</e2>(+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.","Downregulator"
"<e1>TAA</e1> also increased the numbers of ED2(+), cyclooxygenase-2(+), and <e2>heme oxygenase-1</e2>(+) liver cells, as well as the number of CD3(+) lymphocytes.","Downregulator"
"<e1>TAA</e1> also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of <e2>CD3</e2>(+) lymphocytes.","Downregulator"
"With the exception of three residues, the specific <e1>amino acids</e1> that form the putative binding pocket for ICA in <e2>ERG</e2> are conserved in EAG.","Part_of"
"With the exception of three residues, the specific <e1>amino acids</e1> that form the putative binding pocket for ICA in ERG are conserved in <e2>EAG</e2>.","Part_of"
"<e1>ICA-105574</e1> interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Regulator"
"<e1>ICA-105574</e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Regulator"
"<e1>ICA-105574</e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG <e2>potassium channels</e2>.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Regulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Upregulator"
"<e1>ICA-105574</e1> interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Upregulator"
"<e1>ICA-105574</e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Upregulator"
"<e1>ICA-105574</e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG <e2>potassium channels</e2>.","Upregulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Downregulator"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Agonist"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG</e2> and ERG potassium channels.","Agonist"
"<e1>ICA</e1>-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG</e2> potassium channels.","Agonist"
"Methylation of <e2>histone H3</e2> on <e1>lysine</e1> 4 by the lysine methyltransferase SET1 protein is needed for normal clock gene expression.","Part_of"
"PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10mg/kg) that was significantly reduced by the <e2>serotonin 5-HT1a receptor</e2> antagonist <e1>WAY-100135</e1>.","Antagonist"
"However the <e2>7 receptor</e2> antagonist <e1>methyllycaconitine</e1> was unable to reverse these anxiety-like effects seen with PNU-282987.","Antagonist"
"<e2>Carnitine palmitoyltransferase 2</e2> and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of <e1>acylcarnitines</e1>.","Substrate"
"Carnitine palmitoyltransferase 2 and <e2>carnitine/acylcarnitine translocase</e2> are involved in the mitochondrial synthesis and export of <e1>acylcarnitines</e1>.","Substrate"
"<e2>Carnitine palmitoyltransferase 2</e2> and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of <e1>acylcarnitines</e1>.","Substrate"
"Carnitine palmitoyltransferase 2 and <e2>carnitine/acylcarnitine translocase</e2> are involved in the mitochondrial synthesis and export of <e1>acylcarnitines</e1>.","Substrate"
"We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (<e2>CPT2</e2>)-, carnitine/<e1>acylcarnitine</e1> translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.","Substrate"
"We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/<e1>acylcarnitine</e1> translocase (<e2>CACT</e2>)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.","Substrate"
"As a result of this study, <e1>microgrewiapine A</e1> (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit <e2>nicotinic receptor</e2> antagonistic activity for both the h34 and h42 receptor subtypes.","Antagonist"
"Cell-mapping studies in wild-type mice revealed that <e2>Pitx3</e2> is primarily expressed in the ventral SN, a region particularly susceptible to <e1>MPTP</e1> and other dopaminergic neurotoxins.","Not"
"IKK phosphorylates <e2>BAD</e2> at <e1>serine</e1>-26 (Ser26) and primes it for inactivation.","Part_of"
"IKK phosphorylates <e2>BAD</e2> at serine-26 (<e1>Ser</e1>26) and primes it for inactivation.","Part_of"
"IKK phosphorylates <e2>BAD</e2> at serine-26 (<e1>Ser</e1>26) and primes it for inactivation.","Part_of"
"<e1>Almorexant</e1> effects on <e2>CYP3A4</e2> activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.","Regulator"
"PURPOSE: To characterise further the previously observed <e2>cytochrome P450 3A4</e2> (CYP3A4) interaction of the dual orexin receptor antagonist <e1>almorexant</e1>.","Regulator"
"PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (<e2>CYP3A4</e2>) interaction of the dual orexin receptor antagonist <e1>almorexant</e1>.","Regulator"
"PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual <e2>orexin receptor</e2> antagonist <e1>almorexant</e1>.","Antagonist"
"Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of <e2>CYP1A2</e2>, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: <e1>caffeine</e1>, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.","Regulator"
"Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, <e2>CYP2C9</e2>, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, <e1>chlorzoxazone</e1>, tolbutamide, metoprolol and midazolam, respectively.","Regulator"
"Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, <e2>CYP2E1</e2>, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, <e1>tolbutamide</e1>, metoprolol and midazolam, respectively.","Regulator"
"Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, <e2>CYP2D6</e2> and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, <e1>metoprolol</e1> and midazolam, respectively.","Regulator"
"Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and <e2>CYP3A4</e2>, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and <e1>midazolam</e1>, respectively.","Regulator"
"N-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (<e1>Arg</e1>(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).","Part_of"
"N-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<e1>Lys</e1>(290)).","Part_of"
"<e1>N</e1>-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).","Part_of"
"N-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (<e1>Arg</e1>(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).","Part_of"
"N-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<e1>Lys</e1>(290)).","Part_of"
"<e1>N</e1>-terminal sequencing indicated that <e2>pro-BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).","Part_of"
"N-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (<e1>Arg</e1>(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).","Part_of"
"N-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<e1>Gln</e1>(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).","Part_of"
"<e1>N</e1>-terminal sequencing indicated that pro-<e2>BMP-2</e2> was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).","Part_of"
"Evidence also outlines a role for <e2>oxytocin</e2> in the prosocial effects of <e1>3,4-methylenedioxymethamphetamine</e1> (MDMA, Ecstasy) in both rodents and humans.","Regulator"
"Evidence also outlines a role for <e2>oxytocin</e2> in the prosocial effects of 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>, Ecstasy) in both rodents and humans.","Regulator"
"Evidence also outlines a role for <e2>oxytocin</e2> in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, <e1>Ecstasy</e1>) in both rodents and humans.","Regulator"
"Evidence also outlines a role for <e2>oxytocin</e2> in the prosocial effects of 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>, Ecstasy) in both rodents and humans.","Regulator"
"There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) <e2>5-HT2C</e2> receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (<e1>DOI</e1>).","Regulator"
"Invitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the <e1>DOI</e1>-elicited-HTR also reduced the efficacy of DOI to activate mouse 5-HT2C receptor-mediated <e2>PLC</e2> signaling in HEK cells.","Regulator"
"There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) <e2>5-HT2C</e2> receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (<e1>DOI</e1>).","Regulator"
"Invitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the <e1>DOI</e1>-elicited-HTR also reduced the efficacy of DOI to activate <e2>mouse 5-HT2C</e2> receptor-mediated PLC signaling in HEK cells.","Upregulator"
"Commercially-available <e2>5-HT2C</e2> agonists (<e1>CP 809101</e1>, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Agonist"
"Commercially-available <e2>5-HT2C</e2> agonists (CP 809101, <e1>Ro 60-0175</e1>, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Agonist"
"Commercially-available <e2>5-HT2C</e2> agonists (CP 809101, Ro 60-0175, <e1>WAY 161503</e1>, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Agonist"
"Commercially-available <e2>5-HT2C</e2> agonists (CP 809101, Ro 60-0175, WAY 161503, <e1>mCPP</e1>, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Agonist"
"Commercially-available <e2>5-HT2C</e2> agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and <e1>1-methylpsilocin</e1>), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Agonist"
"Commercially-available <e2>5-HT2C</e2> agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel<e1>4-phenyl-2-N,N-dimethyl-aminotetralin</e1> (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Agonist"
"Commercially-available <e2>5-HT2C</e2> agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (<e1>PAT</e1>)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Agonist"
"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with <e2>5-HT2A</e2>/2B antagonist activity), and antagonists selective for 5-HT2A (<e1>M100907</e1>), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Antagonist"
"Commercially-available <e2>5-HT2C</e2> agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (<e1>SB-242084</e1>), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Antagonist"
"This investigation tested the hypothesis that <e2>CYP2B6</e2> is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor <e1>ticlopidine</e1>, given orally for 4 days.","Downregulator"
"<e1>Methadone</e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>CYP3A4</e2>, but clinical disposition is often attributed to CYP3A4.","Substrate"
"<e1>Methadone</e1> N-demethylation in vitro is catalyzed by hepatic <e2>cytochrome P4502B6</e2> (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.","Substrate"
"<e1>Methadone</e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>CYP2B6</e2>) and CYP3A4, but clinical disposition is often attributed to CYP3A4.","Substrate"
"<e1>Methadone</e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>CYP3A4</e2>, but clinical disposition is often attributed to CYP3A4.","Substrate"
"Methadone <e1>N</e1>-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>CYP3A4</e2>, but clinical disposition is often attributed to CYP3A4.","Substrate"
"Methadone <e1>N</e1>-demethylation in vitro is catalyzed by hepatic <e2>cytochrome P4502B6</e2> (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.","Substrate"
"Methadone <e1>N</e1>-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>CYP2B6</e2>) and CYP3A4, but clinical disposition is often attributed to CYP3A4.","Substrate"
"Methadone <e1>N</e1>-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>CYP3A4</e2>, but clinical disposition is often attributed to CYP3A4.","Substrate"
"This investigation tested the hypothesis that <e2>CYP2B6</e2> is a prominent CYP isoform responsible for clinical <e1>methadone</e1> N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.","Substrate"
"This investigation tested the hypothesis that <e2>CYP2B6</e2> is a prominent CYP isoform responsible for clinical <e1>methadone</e1> N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.","Substrate"
"This investigation tested the hypothesis that <e2>CYP</e2>2B6 is a prominent CYP isoform responsible for clinical <e1>methadone</e1> N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.","Substrate"
"Methadone <e1>N</e1>-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>CYP2B6</e2>) and CYP3A4, but clinical disposition is often attributed to CYP3A4.","Substrate"
"Methadone <e1>N</e1>-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>CYP</e2>2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.","Substrate"
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>quinpirole</e1>, triggered an increase in the expression of <e2>GDNF</e2> that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.","Upregulator"
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>quinpirole</e1>, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of <e2>zinc-finger protein 268</e2> (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.","Upregulator"
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>quinpirole</e1>, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (<e2>Zif268</e2>), a DNA-binding transcription factor encoded by an immediate-early gene.","Upregulator"
"Moreover, the D2R inhibitor <e1>raclopride</e1> blocked the increase of both <e2>GDNF</e2> and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.","Downregulator"
"Moreover, the D2R inhibitor <e1>raclopride</e1> blocked the increase of both GDNF and <e2>Zif268</e2> expression following potassium-evoked dopamine release in SH-SY5Y cells.","Downregulator"
"Moreover, the <e2>D2R</e2> inhibitor <e1>raclopride</e1> blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.","Downregulator"
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the <e2>dopamine D2 receptor</e2> (D2R) agonist, <e1>quinpirole</e1>, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.","Agonist"
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (<e2>D2R</e2>) agonist, <e1>quinpirole</e1>, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.","Agonist"
"In this paper a series of new <e1>1,3,4-thiadiazole</e1> derivatives has been designed, synthesized and evaluated as the <e2>acetyl- and butyrylcholinesterase</e2> inhibitors.","Downregulator"
"Synthesis and biological evaluation of <e1>1,3,4-thiadiazole</e1> analogues as novel <e2>AChE</e2> and BuChE inhibitors.","Downregulator"
"Synthesis and biological evaluation of <e1>1,3,4-thiadiazole</e1> analogues as novel AChE and <e2>BuChE</e2> inhibitors.","Downregulator"
"<e1>LY294002</e1>, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate <e2>JNK</e2>.","Not"
"<e1>LY294002</e1>, a specific PI3K/AKT inhibitor, selectively activated the <e2>p38</e2> MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","Upregulator"
"<e1>LY294002</e1>, a specific PI3K/AKT inhibitor, selectively activated the p38 <e2>MAPK</e2> kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","Upregulator"
"<e1>LY294002</e1>, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK <e2>kinase</e2> pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","Upregulator"
"<e1>LY294002</e1>, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced <e2>c-Jun</e2> phosphorylation, but did not activate JNK.","Upregulator"
"<e1>LY294002</e1>, a specific <e2>PI3K</e2>/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","Downregulator"
"<e1>LY294002</e1>, a specific PI3K/<e2>AKT</e2> inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","Downregulator"
"The pharmacological inhibitors <e1>SB203580</e1> (<e2>p38</e2> inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.","Downregulator"
"The pharmacological inhibitors SB203580 (p38 inhibitor) and <e1>SP600125</e1> (a <e2>JNK</e2> inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.","Downregulator"
"Autophagy takes place in mutated <e2>p53</e2> neuroblastoma cells in response to hypoxia mimetic <e1>CoCl(2)</e1>.","Regulator"
"Today, we used <e1>cobalt chloride</e1>, a hypoxia mimetic that inhibits proteasomal <e2>HIF-1</e2> degradation and generates reactive oxygen species (ROS).","Upregulator"
"We focused on <e1>CoCl2</e1>-induced cell death in a DNA-binding mutated <e2>p53</e2> neuroblastoma cell line (SKNBE(2c)).","Downregulator"
"The myosin-18A isoform, additionally, has an <e1>N</e1>-terminal <e2>PDZ domain</e2>.","Part_of"
"Both <e2>myosin-18A</e2> isoforms bound <e1>N-methylanthraniloyl-nucleotides</e1>, but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.","Regulator"
"<e2>Actin</e2> binding was unchanged by presence of <e1>nucleotide</e1>.","Regulator"
"R<e1>N</e1>Ai-mediated knockdown of a new splice form of <e2>supervillin</e2> (isoform 4) or both isoforms 1 and 4 increases the amount of p53 and cell death, whereas p53 levels decrease after overexpression of either supervillin isoform.","Part_of"
"Cellular responses to DNA damage induced by <e1>etoposide</e1> or doxorubicin include down-regulation of endogenous supervillin coincident with increases in <e2>p53</e2>.","Upregulator"
"Cellular responses to DNA damage induced by etoposide or <e1>doxorubicin</e1> include down-regulation of endogenous supervillin coincident with increases in <e2>p53</e2>.","Upregulator"
"Cellular responses to DNA damage induced by <e1>etoposide</e1> or doxorubicin include down-regulation of endogenous <e2>supervillin</e2> coincident with increases in p53.","Downregulator"
"Cellular responses to DNA damage induced by etoposide or <e1>doxorubicin</e1> include down-regulation of endogenous <e2>supervillin</e2> coincident with increases in p53.","Downregulator"
"Novel <e1>acylethanolamide</e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (<e2>POMC</e2>) and/or decreased neuropeptide Y (NPY).","Upregulator"
"Novel <e1>acylethanolamide</e1> derivatives that modulate body weight through enhancement of hypothalamic <e2>pro-opiomelanocortin</e2> (POMC) and/or decreased neuropeptide Y (NPY).","Upregulator"
"Novel <e1>acylethanolamide</e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased <e2>neuropeptide Y</e2> (NPY).","Downregulator"
"Novel <e1>acylethanolamide</e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (<e2>NPY</e2>).","Downregulator"
"We apply DFTB in a QM/MM framework to perform vibrational analysis of buried <e1>aspartic acids</e1> in <e2>bacteriorhodopsin</e2> and channelrhodopsin-2.","Part_of"
"We apply DFTB in a QM/MM framework to perform vibrational analysis of buried <e1>aspartic acids</e1> in bacteriorhodopsin and <e2>channelrhodopsin-2</e2>.","Part_of"
"Despite the importance of <e2>UDP-glucuronosyltransferase (UGT) 1A1</e2>*28 in <e1>irinotecan</e1> pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited.","Regulator"
"Refining the <e2>UGT1A</e2> haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with <e1>5-fluorouracil</e1>/irinotecan-based regimens.","Regulator"
"Refining the <e2>UGT1A</e2> haplotype associated with <e1>irinotecan</e1>-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.","Regulator"
"Refining the <e2>UGT1A</e2> haplotype associated with <e1>irinotecan</e1>-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.","Regulator"
"Androgen action is exerted through the <e1>androgen</e1> receptor.","Regulator"
"<e1>Androgen</e1> action is exerted through the <e2>androgen receptor</e2>.","Regulator"
"Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and <e1>dexamethasone</e1>-<e2>GC receptor</e2> complex was bound to JunD, which forms heterodimers with FosB.","Regulator"
"Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and <e1>dexamethasone</e1>-GC receptor complex was bound to <e2>JunD</e2>, which forms heterodimers with FosB.","Regulator"
"Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting <e2>FosB</e2> expression or Smad1 phosphorylation, and <e1>dexamethasone</e1>-GC receptor complex was bound to JunD, which forms heterodimers with FosB.","Regulator"
"<e1>Dexamethasone</e1> suppressed <e2>IL-11</e2> gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with FosB.","Downregulator"
"Number and area of preneoplastic foci positive for <e2>glutathione S-transferase placental form</e2> (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with <e1>HEP</e1> or HCB alone.","Upregulator"
"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GST-P</e2>) were consistently higher in these groups than the sum of individual values in the groups treated with <e1>HEP</e1> or HCB alone.","Upregulator"
"Number and area of preneoplastic foci positive for <e2>glutathione S-transferase placental form</e2> (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or <e1>HCB</e1> alone.","Upregulator"
"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GST-P</e2>) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or <e1>HCB</e1> alone.","Upregulator"
"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GST-P</e2>) were consistently higher in these groups than the sum of individual values in the groups treated with <e1>HEP</e1> or HCB alone.","Upregulator"
"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GST-P</e2>) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or <e1>HCB</e1> alone.","Upregulator"
"Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of <e1>DON</e1> to induce histological changes in the intestine and to activate the <e2>MAPK</e2> ERK 1/2, p38 and JNK.","Upregulator"
"The food contaminant <e1>deoxynivalenol</e1> activates the <e2>mitogen activated protein kinases</e2> in the intestine: interest of ex vivo models as an alternative to in vivo experiments.","Upregulator"
"Moreover, <e1>Paeoniflorin</e1> promoted the nuclear translocation of <e2>nuclear factor erythroid 2 related factor-2</e2> (Nrf-2).","Regulator"
"Moreover, <e1>Paeoniflorin</e1> promoted the nuclear translocation of nuclear factor erythroid 2 related factor-2 (<e2>Nrf-2</e2>).","Regulator"
"<e1>Paeoniflorin</e1> protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the <e2>NF-E2-related factor 2</e2>/heme oxygenase-1 pathway.","Upregulator"
"<e1>Paeoniflorin</e1> protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/<e2>heme oxygenase-1</e2> pathway.","Upregulator"
"Treatment of these cells with <e1>Paeoniflorin</e1> significantly induced <e2>HO-1</e2> expression.","Upregulator"
"The <e1>Paeoniflorin</e1>-induced HO-1 expression was abrogated by <e2>Nrf2</e2> siRNA.","Upregulator"
"Treatment of these cells with <e1>Paeoniflorin</e1> significantly induced <e2>HO-1</e2> expression.","Upregulator"
"In particular, we showed that <e1>Paeoniflorin</e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and <e2>superoxide dismutase</e2> (SOD) in EA.hy926 cells.","Upregulator"
"In particular, we showed that <e1>Paeoniflorin</e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (<e2>SOD</e2>) in EA.hy926 cells.","Upregulator"
"Treatment of these cells with <e1>Paeoniflorin</e1> significantly induced <e2>HO-1</e2> expression.","Upregulator"
"Treatment of these cells with <e1>Paeoniflorin</e1> significantly induced <e2>HO-1</e2> expression.","Upregulator"
"In particular, we showed that <e1>Paeoniflorin</e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and <e2>lactate dehydrogenase</e2> (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.","Downregulator"
"In particular, we showed that <e1>Paeoniflorin</e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (<e2>LDH</e2>) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.","Downregulator"
"Furthermore, inhibition of <e2>HO-1</e2> with <e1>zinc protoporphyrin IX</e1> (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.","Downregulator"
"Furthermore, inhibition of <e2>HO-1</e2> with zinc protoporphyrin IX (<e1>ZNPP</e1>) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.","Downregulator"
"<e1>Palonosetron</e1>, a second-generation <e2>5-HT3</e2> receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.","Antagonist"
"<e1>Aprepitant</e1>, the first and only agent clinically available in the <e2>NK1 receptor</e2> antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.","Antagonist"
"<e1>Rolapitant</e1> and netupitant are other <e2>NK1 receptor</e2> antagonists that are currently in phase III clinical trials.","Antagonist"
"Rolapitant and <e1>netupitant</e1> are other <e2>NK1 receptor</e2> antagonists that are currently in phase III clinical trials.","Antagonist"
"As part of a comprehensive study of the physiochemical and biological properties of <e1>phytosteryl phenolates</e1>, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, -carotene-linoleate model system and low-density lipoprotein cholesterol (<e2>LDL</e2>-C) oxidation assay.","Downregulator"
"Aqueous <e1>ethanol</e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting <e2>15-LOX</e2> (IC(50), 55 g/ml), with moderate COX-1 (IC(50), 66 g/ml) and COX-2 (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","Downregulator"
"Aqueous <e1>ethanol</e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 g/ml), with moderate <e2>COX-1</e2> (IC(50), 66 g/ml) and COX-2 (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","Downregulator"
"Aqueous <e1>ethanol</e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 g/ml), with moderate COX-1 (IC(50), 66 g/ml) and <e2>COX-2</e2> (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","Downregulator"
"Aqueous <e1>ethanol</e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 g/ml), with moderate <e2>COX</e2>-1 (IC(50), 66 g/ml) and COX-2 (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","Downregulator"
"Aqueous <e1>ethanol</e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-<e2>LOX</e2> (IC(50), 55 g/ml), with moderate COX-1 (IC(50), 66 g/ml) and COX-2 (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","Downregulator"
"We searched for inhibitors of <e2>HDC</e2> from the <e1>ethyl acetate</e1> extract of the petal of Filipendula ulmaria, also called meadowsweet.","Downregulator"
"<e2>Histidine decarboxylase</e2> (HDC) catalyses the formation of hist<e1>amine</e1>, a bioactive amine.","Substrate"
"Histidine decarboxylase (<e2>HDC</e2>) catalyses the formation of hist<e1>amine</e1>, a bioactive amine.","Substrate"
"<e2>Histidine decarboxylase</e2> (HDC) catalyses the formation of <e1>histamine</e1>, a bioactive amine.","Substrate"
"Histidine decarboxylase (<e2>HDC</e2>) catalyses the formation of <e1>histamine</e1>, a bioactive amine.","Substrate"
"High throughput screening led to the identification of a novel series of <e1>quinolone</e1> 7 nicotinic acetylcholine receptor (<e2>nAChR</e2>) agonists.","Agonist"
"Discovery of a novel series of <e1>quinolone</e1> <e2>7 nicotinic acetylcholine receptor</e2> agonists.","Agonist"
"Discovery of a novel series of <e1>quinolone</e1> <e2>7 nicotinic acetylcholine receptor</e2> agonists.","Agonist"
"SAR and lead optimization studies for <e2>Rock</e2> inhibitors based on <e1>amino acid</e1>-derived quinazolines are described.","Downregulator"
"This is distinct from Rock inhibitors based on non-<e1>amino acid</e1> derived quinazolinones, where high selectivity against <e2>PKA</e2> could be obtained.","Downregulator"
"Studies demonstrated that these amino acid derived <e1>quinazolinones</e1> were mainly pan-<e2>Rock</e2> (I & II) inhibitors.","Downregulator"
"This is distinct from Rock inhibitors based on non-amino acid derived <e1>quinazolinones</e1>, where high selectivity against <e2>PKA</e2> could be obtained.","Downregulator"
"SAR and lead optimization studies for <e2>Rock</e2> inhibitors based on <e1>amino acid</e1>-derived quinazolines are described.","Downregulator"
"Amino acid derived <e1>quinazolines</e1> as <e2>Rock</e2>/PKA inhibitors.","Downregulator"
"<e1>Amino acid</e1> derived quinazolines as <e2>Rock</e2>/PKA inhibitors.","Downregulator"
"<e1>Amino acid</e1> derived quinazolines as Rock/<e2>PKA</e2> inhibitors.","Downregulator"
"Amino acid derived <e1>quinazolines</e1> as <e2>Rock</e2>/PKA inhibitors.","Downregulator"
"Amino acid derived <e1>quinazolines</e1> as Rock/<e2>PKA</e2> inhibitors.","Downregulator"
"The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the <e2>IIA subdomain</e2> and that upon binding, it acetylates <e1>lysine</e1> 199.","Part_of"
"The <e2>acetylated albumin</e2> had twofold weaker binding affinity for <e1>diflunisal</e1> as demonstrated by fluorescence quenching.","Regulator"
"The <e2>acetylated albumin</e2> had twofold weaker binding affinity for <e1>diflunisal</e1> as demonstrated by fluorescence quenching.","Regulator"
"About 99% of a dose of <e1>diflunisal</e1> is unavailable for reaction with the target enzyme, because diflunisal strongly binds to <e2>human serum albumin</e2> (HSA).","Regulator"
"About 99% of a dose of <e1>diflunisal</e1> is unavailable for reaction with the target enzyme, because diflunisal strongly binds to human serum albumin (<e2>HSA</e2>).","Regulator"
"Human serum <e2>albumin</e2>-based design of a <e1>diflunisal</e1> prodrug.","Regulator"
"The crystal structure of <e2>HSA</e2> complexed with <e1>fatty acid</e1> and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.","Regulator"
"The crystal structure of <e2>HSA</e2> complexed with fatty acid and <e1>acetyldiflunisal</e1> revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.","Regulator"
"The crystal structure of HSA complexed with fatty acid and <e1>acetyldiflunisal</e1> revealed that acetyldiflunisal binds to the <e2>IIA subdomain</e2> and that upon binding, it acetylates lysine 199.","Regulator"
"The <e2>cyclooxygenase-2</e2> inhibitor, <e1>diflunisal</e1>, is used in the clinic for its anti-inflammatory activity.","Downregulator"
"Although there was no change in the levels of <e2>insulin receptor</e2> (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Not"
"Although there was no change in the levels of insulin receptor (<e2>IR</e2>), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Not"
"Although there was no change in the levels of insulin receptor (IR), <e2>Akt</e2> (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Not"
"Although there was no change in the levels of insulin receptor (IR), Akt (<e2>protein kinase B</e2>) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Not"
"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and <e2>glucose transporter-4</e2> (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Not"
"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (<e2>GLUT4</e2>) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Not"
"Although there was no change in the levels of insulin receptor (IR), <e2>Akt</e2> (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Downregulator"
"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (<e2>GLUT4</e2>) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Downregulator"
"Although there was no change in the levels of insulin receptor (<e2>IR</e2>), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Downregulator"
"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (<e2>GLUT4</e2>) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Downregulator"
"Although there was no change in the levels of insulin receptor (IR), <e2>Akt</e2> (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA</e1> significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.","Downregulator"
"The obtained results showed that <e1>Cd</e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, <e2>lactate dehydrogenase</e2>, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","Downregulator"
"The obtained results showed that <e1>Cd</e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, <e2>acid phosphatase</e2>, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","Downregulator"
"The obtained results showed that <e1>Cd</e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, <e2>alkaline phosphatase</e2> and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","Downregulator"
"The obtained results showed that <e1>Cd</e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and <e2>testicular steroidogenic enzymes</e2>: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","Downregulator"
"The obtained results showed that <e1>Cd</e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: <e2>3-hydroxysteroid dehydrogenase</e2> (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","Downregulator"
"The obtained results showed that <e1>Cd</e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (<e2>HSD</e2>), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","Downregulator"
"The obtained results showed that <e1>Cd</e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), <e2>17-HSD</e2> activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (<e2>GST</e2>)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (<e2>superoxide dismutase</e2> (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (<e2>SOD</e2>), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), <e2>catalase</e2> (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (<e2>CAT</e2>), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), <e2>glutathione peroxidase</e2> (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (<e2>GSH-Px</e2>), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), <e2>glutathione reductase</e2> (GR), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (<e2>GR</e2>), glutathione (GSH), and glutathione-S-transferase (GST)).","Downregulator"
"Acute intoxication with <e1>Cd</e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and <e2>glutathione-S-transferase</e2> (GST)).","Downregulator"
"The <e2>tyrosine hydroxylase</e2> inhibitor -methyltyrosine (300M, 24h) completely abolished <e1>MeHg</e1>-induced DA release.","Upregulator"
"The <e2>tyrosine hydroxylase</e2> inhibitor <e1>-methyltyrosine</e1> (300M, 24h) completely abolished MeHg-induced DA release.","Downregulator"
"The solubility-driven structural modification of (pyridin-3-yl) <e1>benzoxazinyl-oxazolidinone</e1>s is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low <e2>hERG</e2> inhibition.","Downregulator"
"Activity of ponatinib against clinically-relevant <e1>AC220</e1>-resistant <e2>kinase domain</e2> mutants of FLT3-ITD.","Not"
"Activity of ponatinib against clinically-relevant <e1>AC220</e1>-resistant kinase domain mutants of <e2>FLT3</e2>-ITD.","Not"
"The switch control inhibitor <e1>DCC-2036</e1> was similarly inactive against <e2>FLT3</e2> AL mutations.","Not"
"Substitution of the <e2>FLT3</e2> ""gatekeeper"" <e1>phenylalanine</e1> with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.","Part_of"
"Substitution of the <e2>FLT3</e2> ""gatekeeper"" phenylalanine with <e1>leucine</e1> (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.","Part_of"
"Activity of <e1>ponatinib</e1> against clinically-relevant AC220-resistant <e2>kinase domain</e2> mutants of FLT3-ITD.","Regulator"
"Activity of <e1>ponatinib</e1> against clinically-relevant AC220-resistant kinase domain mutants of <e2>FLT3</e2>-ITD.","Regulator"
"<e1>Ponatinib</e1> has demonstrated early clinical efficacy in chemotherapy-resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in <e2>FLT3</e2>.","Regulator"
"Activity of ponatinib against clinically-relevant <e1>AC220</e1>-resistant kinase domain mutants of <e2>FLT3</e2>-ITD.","Downregulator"
"Secondary point mutations in the Fms-like tyrosine kinase 3 (<e2>FLT3</e2>) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (<e1>quizartinib</e1>) and sorafenib.","Downregulator"
"Secondary point mutations in the Fms-like tyrosine kinase 3 (<e2>FLT3</e2>) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and <e1>sorafenib</e1>.","Downregulator"
"<e1>Ponatinib</e1> (AP24534) is a <e2>multikinase</e2> inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.","Downregulator"
"Ponatinib (<e1>AP24534</e1>) is a <e2>multikinase</e2> inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.","Downregulator"
"Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in <e2>p53</e2> levels could be detected in MCF-7 cells after <e1>BSC</e1> 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","Not"
"However, the involvement of the <e2>caspase</e2>-dependent pathway in the process of cell death induced by either <e1>BSC</e1> 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor z-VAD-fmk.","Regulator"
"<e1>Bisacylimidoselenocarbamates</e1> Cause G2/M Arrest Associated with the Modulation of <e2>CDK1</e2> and Chk2 in Human Breast Cancer MCF-7 Cells.","Regulator"
"<e1>Bisacylimidoselenocarbamates</e1> Cause G2/M Arrest Associated with the Modulation of CDK1 and <e2>Chk2</e2> in Human Breast Cancer MCF-7 Cells.","Regulator"
"Moreover, since reduced levels of <e2>p21CIP1</e2> and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after <e1>BSC</e1> 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","Downregulator"
"Moreover, since reduced levels of p21CIP1 and <e2>Chk2</e2> proteins but no change in p53 levels could be detected in MCF-7 cells after <e1>BSC</e1> 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","Downregulator"
"However, the involvement of the <e2>caspase</e2>-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor <e1>z-VAD-fmk</e1>.","Downregulator"
"These compounds were evaluated for their acetylcholinesterase (<e2>AChE</e2>) inhibitory activity and <e1>5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile</e1> was found to be the most potent against AChE with IC50 4.16 mol/L.","Downregulator"
"A one-pot domino synthesis and discovery of highly functionalized <e1>dihydrobenzo[b]thiophenes</e1> as <e2>AChE</e2> inhibitors.","Downregulator"
"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including <e1>paclitaxel</e1>, doxorubicin, actinomycin-D, and rapamycin, which are also <e2>P-gp</e2> substrates.","Substrate"
"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, <e1>doxorubicin</e1>, actinomycin-D, and rapamycin, which are also <e2>P-gp</e2> substrates.","Substrate"
"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, <e1>actinomycin-D</e1>, and rapamycin, which are also <e2>P-gp</e2> substrates.","Substrate"
"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and <e1>rapamycin</e1>, which are also <e2>P-gp</e2> substrates.","Substrate"
"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<e1>MMC</e1> rats showed higher <e2>quinone reductase</e2> and depleted xanthine oxidase activities.","Upregulator"
"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<e1>MMC</e1> rats showed higher quinone reductase and depleted <e2>xanthine oxidase</e2> activities.","Downregulator"
"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (<e2>CCBL</e2>) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<e1>MMC</e1> rats showed higher quinone reductase and depleted xanthine oxidase activities.","Substrate"
"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (<e2>JNK</e2>) inhibitor (<e1>SP600125</e1>, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.","Downregulator"
"N-acetylcysteine (NAC, 33 mM) and the <e2>c-jun N-terminal kinase</e2> (JNK) inhibitor (<e1>SP600125</e1>, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.","Downregulator"
"The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a <e2>BK 1</e2> site that includes <e1>Thr</e1>169.","Part_of"
"The endogenous steroid <e1>lithocholic acid</e1> (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a <e2>BK 1</e2> site that includes Thr169.","Regulator"
"The endogenous steroid lithocholic acid (<e1>LCA</e1>) dilates cerebral arteries via BK channel activation, which requires recognition by a <e2>BK 1</e2> site that includes Thr169.","Regulator"
"<e1>HENA</e1> failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets 1-containing BK channels via the <e2>BK 1</e2> steroid-sensing site.","Regulator"
"Cerebrovascular Dilation via Selective Targeting of the <e1>Cholane</e1> Steroid-Recognition Site in the <e2>BK Channel 1-Subunit</e2> by a Novel Nonsteroidal Agent.","Regulator"
"Cerebrovascular Dilation via Selective Targeting of the Cholane <e1>Steroid</e1>-Recognition Site in the <e2>BK Channel 1-Subunit</e2> by a Novel Nonsteroidal Agent.","Regulator"
"Finally, carotid artery-infusion of <e1>HENA</e1> (45 M) dilated the pial cerebral arterioles via selective <e2>BK-channel</e2> targeting.","Regulator"
"The endogenous <e1>steroid</e1> lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a <e2>BK 1</e2> site that includes Thr169.","Regulator"
"The endogenous steroid <e1>lithocholic acid</e1> (LCA) dilates cerebral arteries via <e2>BK channel</e2> activation, which requires recognition by a BK 1 site that includes Thr169.","Regulator"
"The endogenous steroid lithocholic acid (<e1>LCA</e1>) dilates cerebral arteries via <e2>BK channel</e2> activation, which requires recognition by a BK 1 site that includes Thr169.","Regulator"
"<e1>HENA</e1> failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets 1-containing BK channels via the <e2>BK 1</e2> steroid-sensing site.","Regulator"
"The endogenous <e1>steroid</e1> lithocholic acid (LCA) dilates cerebral arteries via <e2>BK channel</e2> activation, which requires recognition by a BK 1 site that includes Thr169.","Regulator"
"<e1>HENA</e1> activated the <e2>BK (cbv1 + 1) channels</e2> cloned from rat cerebral artery myocytes with a potency (EC50 = 53 M) similar to and an efficacy (2.5 potentiation) significantly greater than that of LCA.","Upregulator"
"HENA activated the <e2>BK (cbv1 + 1) channels</e2> cloned from rat cerebral artery myocytes with a potency (EC50 = 53 M) similar to and an efficacy (2.5 potentiation) significantly greater than that of <e1>LCA</e1>.","Upregulator"
"<e1>HENA</e1> failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets <e2>1-containing BK channels</e2> via the BK 1 steroid-sensing site.","Upregulator"
"RATIONALE: <e2>Histamine H3 receptor</e2> antagonists, such as <e1>ABT-288</e1>, have been shown to possess cognitive-enhancing and wakefulness-promoting effects.","Antagonist"
"Assessment of the abuse liability of <e1>ABT-288</e1>, a novel <e2>histamine H3 receptor</e2> antagonist.","Antagonist"
"Assessment of the abuse liability of <e1>ABT-288</e1>, a novel histamine <e2>H3</e2> receptor antagonist.","Antagonist"
"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1</e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), <e1>pitavastatin</e1> (84%-98%) and lopinavir (64%-89%).","Substrate"
"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1</e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and <e1>lopinavir</e1> (64%-89%).","Substrate"
"Uptake of <e1>estrone-3-sulfate</e1> (5nM) by <e2>OATP1B1</e2> was reduced by 82%-95%.","Substrate"
"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1</e2> uptake in human hepatocytes for <e1>olmesartan</e1> (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).","Substrate"
"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1</e2> uptake in human hepatocytes for olmesartan (42%-62%), <e1>valsartan</e1> (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).","Substrate"
"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1</e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), <e1>rosuvastatin</e1> (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).","Substrate"
"The docking data indicated that <e1>l-glutamine</e1> bind to the <e2>GLP-1 receptor</e2>.","Regulator"
"Plasma <e1>glucose</e1>, active <e2>GLP-1</e2> (7-36) amide concentration and insulin levels were measured after glucose loading.","Regulator"
"Plasma <e1>glucose</e1>, active GLP-1 (7-36) amide concentration and <e2>insulin</e2> levels were measured after glucose loading.","Regulator"
"<e1>l-glutamine</e1> decreased plasma glucose, increased plasma and pancreatic <e2>insulin</e2>, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.","Upregulator"
"Oral <e1>l-glutamine</e1> increases active <e2>GLP-1</e2> (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.","Upregulator"
"The objective of the present investigation was to evaluate <e1>l-glutamine</e1> increases <e2>glucagon like peptide-1</e2> (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.","Upregulator"
"Oral <e1>l-glutamine</e1> increases active <e2>GLP-1</e2> (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.","Upregulator"
"Oral <e1>l-glutamine</e1> increases active <e2>GLP-1</e2> (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.","Upregulator"
"While these behaviors can be modulated by corticotropin releasing factor (<e2>CRF</e2>) and catecholamine signaling, the mechanism(s) by which these signals modify CeA <e1>glutamate</e1>rgic neurotransmission remains unclear.","Not"
"In the present study, <e1>hinokitiol</e1> (1 and 2M) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including <e2>thrombin</e2>, arachidonic acid, and ADP.","Not"
"<e1>Hinokitiol</e1> did not influence the binding of a fluorescent triflavin probe to the <e2>IIb3 integrin</e2> on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.","Not"
"In the present study, <e1>hinokitiol</e1> (1 and 2M) inhibited the <e2>collagen</e2>-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of <e2>phospholipase C (PLC)2</e2>, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of phospholipase C (PLC)2, <e2>protein kinase C</e2> (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (<e2>PKC</e2>), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), <e2>mitogen-activated protein kinases</e2> (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (<e2>MAPKs</e2>), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and <e2>Akt</e2> in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in <e2>collagen</e2>-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"<e1>Hinokitiol</e1> inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (<e2>PKC</e2>), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.","Downregulator"
"In conclusion, <e1>hinokitiol</e1> may inhibit platelet activation by inhibiting the <e2>PLC2</e2>-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.","Downregulator"
"In conclusion, <e1>hinokitiol</e1> may inhibit platelet activation by inhibiting the PLC2-<e2>PKC</e2> cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.","Downregulator"
"In conclusion, <e1>hinokitiol</e1> may inhibit platelet activation by inhibiting the PLC2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of <e2>MAPKs</e2> and Akt.","Downregulator"
"In conclusion, <e1>hinokitiol</e1> may inhibit platelet activation by inhibiting the PLC2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and <e2>Akt</e2>.","Downregulator"
"Novel <e1>5-(benzyloxy)pyridin-2(1H)-one</e1> derivatives as potent <e2>c-Met</e2> inhibitors.","Downregulator"
"Of the new compounds, Dmt(1)-(R)-Pro(2)-<e1>Trp</e1>(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward <e2>MOR</e2>, in the picomolar range (Ki() = 3.72 pM).","Regulator"
"Of the new compounds, Dmt(1)-(R)-Pro(2)-Trp(3)-<e1>(2-furyl)Map</e1>(4) (analogue 12) displayed the highest affinity toward <e2>MOR</e2>, in the picomolar range (Ki() = 3.72 pM).","Regulator"
"Of the new compounds, <e1>Dmt</e1>(1)-(R)-Pro(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward <e2>MOR</e2>, in the picomolar range (Ki() = 3.72 pM).","Regulator"
"Of the new compounds, Dmt(1)-<e1>(R)-Pro</e1>(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward <e2>MOR</e2>, in the picomolar range (Ki() = 3.72 pM).","Regulator"
"Design, Synthesis, and Pharmacological Characterization of Novel <e1>Endomorphin-1</e1> Analogues as Extremely Potent <e2>-Opioid</e2> Agonists.","Agonist"
"We report that two common variants of <e2>high-temperature requirement A1</e2> (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for <e1>Ala</e1>34 and Gly36 to less frequently used codons.","Part_of"
"We report that two common variants of high-temperature requirement A1 (<e2>HTRA1</e2>) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for <e1>Ala</e1>34 and Gly36 to less frequently used codons.","Part_of"
"We report that two common variants of high-temperature requirement A1 (<e2>HTRA1</e2>) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for <e1>Ala</e1>34 and Gly36 to less frequently used codons.","Part_of"
"We report that two common variants of <e2>high-temperature requirement A1</e2> (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and <e1>Gly</e1>36 to less frequently used codons.","Part_of"
"We report that two common variants of high-temperature requirement A1 (<e2>HTRA1</e2>) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and <e1>Gly</e1>36 to less frequently used codons.","Part_of"
"We report that two common variants of high-temperature requirement A1 (<e2>HTRA1</e2>) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and <e1>Gly</e1>36 to less frequently used codons.","Part_of"
"In search of a basis for the impressive potency of an endoprotease that cleaves S<e1>N</e1>AP-25, botulinum neurotoxin type A (<e2>BoNT/A</e2>), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons.","Part_of"
"<e1>Tetrodotoxin</e1>-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1pM BoNT/A despite cleaving <20% of the <e2>SNAP-25</e2>.","Regulator"
"Wild-type mice were more sensitive to <e1>DEX</e1>-dependent decreases in <e2>insulin</e2> sensitivity than GR(dim/dim) mice.","Regulator"
"Interestingly, insulin treatment of XBPKD cells reduced <e1>tyrosine</e1> phosphorylation of <e2>IRS-1</e2> (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.","Part_of"
"Interestingly, insulin treatment of XBPKD cells reduced tyrosine phosphorylation of <e2>IRS-1</e2> (pY(896)), and phosphorylation of Akt, while enhancing <e1>serine</e1> phosphorylation (pS(307)) of IRS-1.","Part_of"
"Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; <e1>tetrahydrocannabinol</e1> was included as the classical non-endogenous <e2>cannabinoid receptor</e2> ligand.","Regulator"
"Toxicological profiles of selected synthetic <e1>cannabinoids</e1> showing high binding affinities to the <e2>cannabinoid receptor subtype CB1</e2>.","Regulator"
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and <e2>TNF</e2> levels) was seen in LPS-stimulated human PBMCs, except with <e1>JWH-210</e1> and JWH-122 which caused a decrease of TNF and IL-12/23p40.","Downregulator"
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, <e2>IL-12</e2>/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with <e1>JWH-210</e1> and JWH-122 which caused a decrease of TNF and IL-12/23p40.","Downregulator"
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/<e2>23p40</e2> and TNF levels) was seen in LPS-stimulated human PBMCs, except with <e1>JWH-210</e1> and JWH-122 which caused a decrease of TNF and IL-12/23p40.","Downregulator"
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and <e2>TNF</e2> levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>JWH-122</e1> which caused a decrease of TNF and IL-12/23p40.","Downregulator"
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, <e2>IL-12</e2>/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>JWH-122</e1> which caused a decrease of TNF and IL-12/23p40.","Downregulator"
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/<e2>23p40</e2> and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>JWH-122</e1> which caused a decrease of TNF and IL-12/23p40.","Downregulator"
"<e1>Curcuminoids</e1> Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and <e2>Oxidized LDL</e2> in Obese Individuals.","Not"
"<e1>Curcuminoids</e1> Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to <e2>Heat Shock Protein 27</e2> and Oxidized LDL in Obese Individuals.","Not"
"GTLE pretreatment completely reversed the damaging effects of <e1>AlCl3</e1> on AA and <e2>superoxide dismutase</e2> activity, markedly corrected COX and AChE activities, and moderately improved TGC.","Downregulator"
"<e1>AlCl3</e1> markedly reduced AA performance and activities of cytochrome c oxidase (<e2>COX</e2>) and acetylcholinesterase (AChE) in all regions.","Downregulator"
"<e1>AlCl3</e1> markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (<e2>AChE</e2>) in all regions.","Downregulator"
"<e1>AlCl3</e1> markedly reduced AA performance and activities of <e2>cytochrome c oxidase</e2> (COX) and acetylcholinesterase (AChE) in all regions.","Downregulator"
"<e1>AlCl3</e1> markedly reduced AA performance and activities of cytochrome c oxidase (<e2>COX</e2>) and acetylcholinesterase (AChE) in all regions.","Downregulator"
"<e1>AlCl3</e1> markedly reduced AA performance and activities of cytochrome c oxidase (COX) and <e2>acetylcholinesterase</e2> (AChE) in all regions.","Downregulator"
"<e1>AlCl3</e1> markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (<e2>AChE</e2>) in all regions.","Downregulator"
"Furthermore, the <e1>(22R)-spirosolanol glycoside</e1> (11) selectively induced apoptosis in A549 cells without affecting the <e2>caspase-3</e2> activity level.","Not"
"The present study aimed to determine the protective effects and the underlying mechanisms of <e1>curcumin</e1> on <e2>ovalbumin</e2> (OVA)-induced allergic inflammation in a mouse model of allergic asthma.","Regulator"
"Our study demonstrated that <e1>curcumin</e1> inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased <e2>IL-10</e2> level in bronchoalveolar lavage fluid.","Upregulator"
"The present study aimed to determine the protective effects and the underlying mechanisms of <e1>curcumin</e1> on ovalbumin (<e2>OVA</e2>)-induced allergic inflammation in a mouse model of allergic asthma.","Downregulator"
"The present study aimed to determine the protective effects and the underlying mechanisms of <e1>curcumin</e1> on <e2>ovalbumin</e2> (OVA)-induced allergic inflammation in a mouse model of allergic asthma.","Downregulator"
"The present study aimed to determine the protective effects and the underlying mechanisms of <e1>curcumin</e1> on ovalbumin (<e2>OVA</e2>)-induced allergic inflammation in a mouse model of allergic asthma.","Downregulator"
"Our study demonstrated that <e1>curcumin</e1> inhibited OVA-induced increases in eosinophil count; <e2>interleukin (IL)-17A</e2> level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.","Downregulator"
"Here, we report the first crystal structure of <e2>KIF4</e2> complexed with the non-hydrolyzable <e1>ATP</e1> analog, AMPPNP (adenylyl imidodiphosphate), at 1.7 resolution.","Regulator"
"Here, we report the first crystal structure of <e2>KIF4</e2> complexed with the non-hydrolyzable ATP analog, <e1>AMPPNP</e1> (adenylyl imidodiphosphate), at 1.7 resolution.","Regulator"
"Here, we report the first crystal structure of <e2>KIF4</e2> complexed with the non-hydrolyzable ATP analog, AMPPNP (<e1>adenylyl imidodiphosphate</e1>), at 1.7 resolution.","Regulator"
"By combining our structure with previously solved <e2>KIF1A</e2> structures complexed with two <e1>ATP</e1> analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.","Regulator"
"Structural Basis for the <e1>ATP</e1>-Induced Isomerization of <e2>Kinesin</e2>.","Regulator"
"Previous studies have revealed that the <e1>ATP</e1> binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of <e2>ATPase</e2> activity to guarantee the processive movement of dimeric KIFs.","Regulator"
"Kinesin superfamily proteins (<e2>KIFs</e2>) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of <e1>ATP</e1>.","Regulator"
"Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that <e1>N</e1>-terminal <e2>PTHrP</e2> peptides might be considered a promising bone anabolic therapy.","Part_of"
"<e1>C</e1>urrent perspectives on parathyroid hormone (<e2>PTH</e2>) and PTH-related protein (PTHrP) as bone anabolic therapies.","Part_of"
"Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that <e1>N</e1>-terminal <e2>PTHrP</e2> peptides might be considered a promising bone anabolic therapy.","Part_of"
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a <e1>Gd</e1>-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to <e2>proton pumps</e2> in the stomach and colon.","Regulator"
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (<e1>DOTA</e1>), with pantoprazole, which is a widely used proton pump inhibitor that binds to <e2>proton pumps</e2> in the stomach and colon.","Regulator"
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with <e1>pantoprazole</e1>, which is a widely used proton pump inhibitor that binds to <e2>proton pumps</e2> in the stomach and colon.","Regulator"
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a <e1>Gd</e1>-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used <e2>proton pump</e2> inhibitor that binds to proton pumps in the stomach and colon.","Downregulator"
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (<e1>DOTA</e1>), with pantoprazole, which is a widely used <e2>proton pump</e2> inhibitor that binds to proton pumps in the stomach and colon.","Downregulator"
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with <e1>pantoprazole</e1>, which is a widely used <e2>proton pump</e2> inhibitor that binds to proton pumps in the stomach and colon.","Downregulator"
"Synthesis of a <e1>DOTA</e1> (Gd(3+))-conjugate of <e2>proton-pump</e2> inhibitor pantoprazole for gastric wall imaging studies.","Downregulator"
"Synthesis of a DOTA (<e1>Gd(3+)</e1>)-conjugate of <e2>proton-pump</e2> inhibitor pantoprazole for gastric wall imaging studies.","Downregulator"
"Synthesis of a DOTA (Gd(3+))-conjugate of <e2>proton-pump</e2> inhibitor <e1>pantoprazole</e1> for gastric wall imaging studies.","Downregulator"
"Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible <e2>AChE</e2> inhibitor <e1>donepezil</e1> (100nM).","Downregulator"
"<e2>CYP3A5</e2> carrier status had no influence on midazolam oral clearance or its inhibition by <e1>ketoconazole</e1>.","Downregulator"
"We then evaluated the interactions with the <e2>CYP3A</e2> inhibitor <e1>ketoconazole</e1> (400mg q.d.)","Downregulator"
"A Nanogram Dose of the <e2>CYP3A</e2> Probe Substrate <e1>Midazolam</e1> to Evaluate Drug Interactions.","Substrate"
"We administered four escalating single doses of oral <e1>midazolam</e1> (0.0001-3mg) to 12 healthy participants, stratified according to <e2>CYP3A5</e2> carrier status, to assess pharmacokinetics linearity.","Substrate"
"CYP3A4 and CYP3A5 metabolized <e1>BDP</e1> via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; <e2>CYP3A7</e2> did not metabolize BDP.","Not"
"This hypothesis was explored by evaluating the contributions of <e2>CYP3A4</e2>, 3A5, 3A7, and esterase enzymes in the metabolism of <e1>BDP</e1> in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.","Substrate"
"CYP3A4 and <e2>CYP3A5</e2> metabolized <e1>BDP</e1> via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.","Substrate"
"It is possible that variations in <e2>cytochrome P450 3A</e2> enzyme-mediated metabolism of <e1>BDP</e1> may contribute to this phenomenon.","Substrate"
"This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and <e2>esterase</e2> enzymes in the metabolism of <e1>BDP</e1> in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.","Substrate"
"This hypothesis was explored by evaluating the contributions of <e2>CYP3A4</e2>, 3A5, 3A7, and esterase enzymes in the metabolism of <e1>BDP</e1> in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.","Substrate"
"CYP3A4 and <e2>CYP3A5</e2> metabolized <e1>BDP</e1> via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.","Substrate"
"Metabolism of <e1>Beclomethasone Dipropionate</e1> by <e2>Cytochrome P450 3A</e2> Enzymes.","Substrate"
"Effect of the Potent Antiviral <e1>1-Cinnamoyl-3,11-Dihydroxymeliacarpin</e1> on <e2>Cytokine</e2> Production by Murine Macrophages Stimulated with HSV-2.","Regulator"
"The antiherpetic action of <e1>CDM</e1> was measured by plaque reduction assay, and the immunomodulatory effect was determined by measuring the <e2>cytokine</e2> production using a bioassay and ELISA method.","Regulator"
"In macrophages, levels of <e2>TNF-</e2>, IFN-, NO, IL-6 and IL-10 were increased by <e1>CDM</e1> used alone or in combination with HSV-2.","Upregulator"
"In macrophages, levels of TNF-, <e2>IFN-</e2>, NO, IL-6 and IL-10 were increased by <e1>CDM</e1> used alone or in combination with HSV-2.","Upregulator"
"In macrophages, levels of TNF-, IFN-, NO, <e2>IL-6</e2> and IL-10 were increased by <e1>CDM</e1> used alone or in combination with HSV-2.","Upregulator"
"In macrophages, levels of TNF-, IFN-, NO, IL-6 and <e2>IL-10</e2> were increased by <e1>CDM</e1> used alone or in combination with HSV-2.","Upregulator"
"In macrophages, levels of <e2>TNF-</e2>, IFN-, NO, IL-6 and IL-10 were increased by <e1>CDM</e1> used alone or in combination with HSV-2.","Upregulator"
"In macrophages, levels of TNF-, <e2>IFN-</e2>, NO, IL-6 and IL-10 were increased by <e1>CDM</e1> used alone or in combination with HSV-2.","Upregulator"
"The antiherpetic action of <e1>CDM</e1> was measured by plaque reduction assay, and the immunomodulatory effect was determined by measuring the <e2>cytokine</e2> production using a bioassay and ELISA method.","Upregulator"
"Intestinal and hepatic first-pass extraction of the <e2>11-HSD1</e2> inhibitor <e1>AMG 221</e1> in rats with chronic vascular catheters.","Downregulator"
"Intestinal and hepatic first-pass extraction of the <e2>11-HSD1</e2> inhibitor <e1>AMG 221</e1> in rats with chronic vascular catheters.","Downregulator"
"In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to <e1>elisidepsin</e1>, whereas the presence of <e2>KRAS</e2> activating mutations was associated with resistance.","Not"
"In addition, high <e2>ErbB3</e2> and Muc1 expression was correlated with sensitivity to <e1>elisidepsin</e1>, whereas the presence of KRAS activating mutations was associated with resistance.","Regulator"
"In addition, high ErbB3 and <e2>Muc1</e2> expression was correlated with sensitivity to <e1>elisidepsin</e1>, whereas the presence of KRAS activating mutations was associated with resistance.","Regulator"
"In DU-PM cells with acquired resistance to <e1>elisidepsin</e1>, ErbB3 expression was decreased, while <e2>Bcl2</e2> was increased.","Upregulator"
"In addition, high <e2>ErbB3</e2> and Muc1 expression was correlated with sensitivity to <e1>elisidepsin</e1>, whereas the presence of KRAS activating mutations was associated with resistance.","Downregulator"
"Administration of <e1>bicuculline</e1>, a <e2>GABAA</e2> inhibitor, isolated a single response to -agatoxin, which was characterized by a reduction in network activity.","Downregulator"
"Administration of <e1>bicuculline</e1>, a GABAA inhibitor, isolated a single response to <e2>-agatoxin</e2>, which was characterized by a reduction in network activity.","Downregulator"
"Compounds 8b and 10c selectively inhibited HDAC6 at the nanomolar level, whereas the other <e1>hydroxamates</e1> effected an increase in <e2>acetyl--tubulin</e2> levels in human acute myeloid leukemia U937 cells.","Upregulator"
"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the <e1>tert-butylcarbamate</e1> group at the CAP moiety as <e2>histone deacetylase</e2> (HDAC) inhibitors.","Downregulator"
"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the <e1>tert-butylcarbamate</e1> group at the CAP moiety as histone deacetylase (<e2>HDAC</e2>) inhibitors.","Downregulator"
"Herein we report novel <e1>pyrrole</e1>- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase</e2> (HDAC) inhibitors.","Downregulator"
"Herein we report novel <e1>pyrrole</e1>- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC</e2>) inhibitors.","Downregulator"
"Herein we report novel pyrrole- and <e1>benzene</e1>-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase</e2> (HDAC) inhibitors.","Downregulator"
"Herein we report novel pyrrole- and <e1>benzene</e1>-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC</e2>) inhibitors.","Downregulator"
"Herein we report novel pyrrole- and benzene-based <e1>hydroxamates</e1> (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase</e2> (HDAC) inhibitors.","Downregulator"
"Herein we report novel pyrrole- and benzene-based <e1>hydroxamates</e1> (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC</e2>) inhibitors.","Downregulator"
"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and <e1>2'-aminoanilides</e1> (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase</e2> (HDAC) inhibitors.","Downregulator"
"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and <e1>2'-aminoanilides</e1> (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC</e2>) inhibitors.","Downregulator"
"<e1>tert-Butylcarbamate</e1>-Containing <e2>Histone Deacetylase</e2> Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.","Downregulator"
"As a potent synthetic <e2>APN</e2> inhibitor (IC50=850nM, versus <e1>bestatin</e1> of 8.1M), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.","Downregulator"
"<e1>LB-4b</e1> is the first synthetic <e2>APN</e2> inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.","Downregulator"
"As a potent synthetic <e2>APN</e2> inhibitor (IC50=850nM, versus <e1>bestatin</e1> of 8.1M), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.","Downregulator"
"<e1>LB-4b</e1> is the first synthetic <e2>APN</e2> inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.","Downregulator"
"Discovery of a synthetic <e2>Aminopeptidase N</e2> inhibitor <e1>LB-4b</e1> as a potential anticancer agent.","Downregulator"
"Both types of granules contain <e2>catechol oxidase</e2> that catalyzes oxidative cross-linking of <e1>L-DOPA</e1>.","Substrate"
"Under <e1>NaCl</e1> and sorbitol stresses, <e2>catalase</e2> (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.","Upregulator"
"Under <e1>NaCl</e1> and sorbitol stresses, catalase (<e2>CAT</e2>) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.","Upregulator"
"Under NaCl and <e1>sorbitol</e1> stresses, <e2>catalase</e2> (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.","Upregulator"
"Under NaCl and <e1>sorbitol</e1> stresses, catalase (<e2>CAT</e2>) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.","Upregulator"
"Immunofluorescence staining and western blotting demonstrated that <e1>cilostazol</e1> treatment reduced GFAP and <e2>VEGF</e2> expression in the retinas of OLETF rats.","Downregulator"
"Immunofluorescence staining and western blotting demonstrated that <e1>cilostazol</e1> treatment reduced <e2>GFAP</e2> and VEGF expression in the retinas of OLETF rats.","Downregulator"
"Other dams received 1.8ng/kg/day of a mixture of <e2>aryl hydrocarbon receptor</e2> (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and <e1>PC-dibenzofurans</e1>) without or with 0.5M (0.5MAhR).","Agonist"
"Other dams received 1.8ng/kg/day of a mixture of <e2>aryl hydrocarbon receptor</e2> (AhR) agonists (<e1>non-ortho PCB</e1>s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).","Agonist"
"Other dams received 1.8ng/kg/day of a mixture of <e2>aryl hydrocarbon receptor</e2> (AhR) agonists (non-ortho PCBs, <e1>PC-dibenzodioxins</e1> and PC-dibenzofurans) without or with 0.5M (0.5MAhR).","Agonist"
"Phlebotomy and dietary <e1>iron</e1> restriction reduces <e2>serum transaminase</e2> in NAFLD/NASH patients.","Regulator"
"We report the discovery of a novel series of ATP-competitive <e2>Janus kinase 3</e2> (JAK3) inhibitors based on the <e1>5H-pyrrolo[2,3-b]pyrazine</e1> scaffold.","Downregulator"
"Discovery of a series of novel <e1>5H-pyrrolo[2,3-b]pyrazine</e1>-2-phenyl ethers, as potent <e2>JAK3</e2> kinase inhibitors.","Downregulator"
"Discovery of a series of novel <e1>5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers</e1>, as potent <e2>JAK3</e2> kinase inhibitors.","Downregulator"
"Discovery of a series of novel <e1>5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers</e1>, as potent JAK3 <e2>kinase</e2> inhibitors.","Downregulator"
"<e1>ATO</e1> inhibited the phosphorylation and activation of AKT and STAT3 through <e2>Notch</e2> signaling blockade.","Downregulator"
"<e1>ATO</e1> inhibited the phosphorylation and activation of AKT and <e2>STAT3</e2> through Notch signaling blockade.","Downregulator"
"<e1>ATO</e1> inhibited the phosphorylation and activation of <e2>AKT</e2> and STAT3 through Notch signaling blockade.","Downregulator"
"<e1>ATO</e1> inhibited the phosphorylation and activation of AKT and STAT3 through <e2>Notch</e2> signaling blockade.","Downregulator"
"<e1>Arsenic trioxide</e1> depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of <e2>Notch</e2> pathway.","Downregulator"
"Genomic variation in the <e2>MAP3K5</e2> gene is associated with -thalassemia disease severity and <e1>hydroxyurea</e1> treatment efficacy.","Regulator"
"Finally, epididymal mRNA abundance of <e2>GLUT4</e2> was significantly increased by <e1>fisetin</e1> supplementation, compared to levels in the control and HF groups.","Upregulator"
"Finally, epididymal mRNA abundance of <e2>GLUT4</e2> was significantly increased by <e1>fisetin</e1> supplementation, compared to levels in the control and HF groups.","Upregulator"
"The high fat diet significantly increased hepatic mRNA expressions of <e2>PPAR</e2>, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>fisetin</e1>.","Downregulator"
"The high fat diet significantly increased hepatic mRNA expressions of PPAR, <e2>SREBP1C</e2> and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>fisetin</e1>.","Downregulator"
"The high fat diet significantly increased hepatic mRNA expressions of PPAR, SREBP1C and <e2>SCD-1</e2> genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>fisetin</e1>.","Downregulator"
"In addition, <e1>fisetin</e1> supplementation significantly reduced hepatic mRNA abundance of <e2>FAS</e2>, ATPCL and G6Pase compared to the control group.","Downregulator"
"In addition, <e1>fisetin</e1> supplementation significantly reduced hepatic mRNA abundance of FAS, <e2>ATPCL</e2> and G6Pase compared to the control group.","Downregulator"
"In addition, <e1>fisetin</e1> supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and <e2>G6Pase</e2> compared to the control group.","Downregulator"
"While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (<e1>VU0467903</e1>), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent <e2>mAChR</e2> selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.","Regulator"
"While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, <e1>ML326</e1> (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent <e2>mAChR</e2> selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.","Regulator"
"While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar <e2>M5</e2> PAM, ML326 (<e1>VU0467903</e1>), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.","Modulator"
"While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar <e2>M5</e2> PAM, ML326 (<e1>VU0467903</e1>), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.","Modulator"
"This Letter describes the further chemical optimization of the <e2>M5</e2> PAM MLPCN probes <e1>ML129</e1> and ML172.","Modulator"
"This Letter describes the further chemical optimization of the <e2>M5</e2> PAM MLPCN probes ML129 and <e1>ML172</e1>.","Modulator"
"Discovery of <e1>ML326</e1>: The first sub-micromolar, selective <e2>M5</e2> PAM.","Modulator"
"An HTS campaign identified several weak <e2>M5</e2> PAMs (M5 EC50 >10M) with a structurally related <e1>isatin</e1> core that possessed a southern phenethyl ether linkage.","Modulator"
"An HTS campaign identified several weak <e2>M5</e2> PAMs (M5 EC50 >10M) with a structurally related isatin core that possessed a southern <e1>phenethyl ether</e1> linkage.","Modulator"
"An HTS campaign identified several weak <e2>M5</e2> PAMs (M5 EC50 >10M) with a structurally related isatin core that possessed a southern <e1>phenethyl ether</e1> linkage.","Modulator"
"This Letter describes the further chemical optimization of the <e2>M5</e2> PAM MLPCN probes <e1>ML129</e1> and ML172.","Modulator"
"This Letter describes the further chemical optimization of the <e2>M5</e2> PAM MLPCN probes ML129 and <e1>ML172</e1>.","Modulator"
"Discovery of <e1>ML326</e1>: The first sub-micromolar, selective <e2>M5</e2> PAM.","Modulator"
"Discovery of <e1>ML326</e1>: The first sub-micromolar, selective <e2>M5</e2> PAM.","Modulator"
"Meanwhile, the alterations of cyclin A and B1, <e2>p-CDK1</e2> and p-cdc25c levels were also observed in response to <e1>DICO</e1> treatment.","Regulator"
"Meanwhile, the alterations of cyclin A and B1, p-CDK1 and <e2>p-cdc25c</e2> levels were also observed in response to <e1>DICO</e1> treatment.","Regulator"
"Western blot assay demonstrated that <e1>DICO</e1> decreased Bcl-2 level and induced <e2>Bax</e2> translocation to cause cytochrome c release.","Upregulator"
"Western blot assay demonstrated that <e1>DICO</e1> decreased Bcl-2 level and induced Bax translocation to cause <e2>cytochrome c</e2> release.","Upregulator"
"Western blot assay demonstrated that <e1>DICO</e1> decreased <e2>Bcl-2</e2> level and induced Bax translocation to cause cytochrome c release.","Downregulator"
"<e1>Quercetin</e1> and rutin also increased <e2>alkaline phosphatase</e2> activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).","Upregulator"
"Quercetin and <e1>rutin</e1> also increased <e2>alkaline phosphatase</e2> activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).","Upregulator"
"Further, both the <e1>flavonoids</e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like <e2>osteopontin</e2>, osterix, RunX2, osteoprotegerin and osteocalcin.","Upregulator"
"Further, both the <e1>flavonoids</e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, <e2>osterix</e2>, RunX2, osteoprotegerin and osteocalcin.","Upregulator"
"Further, both the <e1>flavonoids</e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, <e2>RunX2</e2>, osteoprotegerin and osteocalcin.","Upregulator"
"Further, both the <e1>flavonoids</e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, <e2>osteoprotegerin</e2> and osteocalcin.","Upregulator"
"Further, both the <e1>flavonoids</e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and <e2>osteocalcin</e2>.","Upregulator"
"<e1>S</e1>-nitrosation of <e2>glutathione transferase P1-1</e2> is controlled by the conformation of a dynamic active-site helix.","Part_of"
"C47 of G<e1>S</e1>TP1-1 is S-nitrosated in two steps, with the chemical step limited by a pre-equilibrium between the open and closed conformations of helix 2 at the active site.","Part_of"
"C47 of G<e1>S</e1>TP1-1 is S-nitrosated in two steps, with the chemical step limited by a pre-equilibrium between the open and closed conformations of helix 2 at the active site.","Part_of"
"LPO was increased while as GSH, <e2>CAT</e2> and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of <e1>NAC</e1> restored these liver markers to normal levels (p<0.001).","Upregulator"
"LPO was increased while as GSH, CAT and <e2>GPx</e2> decreased by the administration of CCl4 and TAA (p<0.001); co-administration of <e1>NAC</e1> restored these liver markers to normal levels (p<0.001).","Upregulator"
"Serum markers of liver damage (<e2>AST</e2>, ALT, ALP and Bilirubin) were increased by <e1>CCl4</e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).","Upregulator"
"Serum markers of liver damage (AST, <e2>ALT</e2>, ALP and Bilirubin) were increased by <e1>CCl4</e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).","Upregulator"
"Serum markers of liver damage (AST, ALT, <e2>ALP</e2> and Bilirubin) were increased by <e1>CCl4</e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).","Upregulator"
"Serum markers of liver damage (<e2>AST</e2>, ALT, ALP and Bilirubin) were increased by CCl4 and <e1>TAA</e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).","Upregulator"
"Serum markers of liver damage (AST, <e2>ALT</e2>, ALP and Bilirubin) were increased by CCl4 and <e1>TAA</e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).","Upregulator"
"Serum markers of liver damage (AST, ALT, <e2>ALP</e2> and Bilirubin) were increased by CCl4 and <e1>TAA</e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).","Upregulator"
"Serum markers of liver damage (<e2>AST</e2>, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>NAC</e1> reversed such changes (p<0.001).","Downregulator"
"Serum markers of liver damage (AST, <e2>ALT</e2>, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>NAC</e1> reversed such changes (p<0.001).","Downregulator"
"Serum markers of liver damage (AST, ALT, <e2>ALP</e2> and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>NAC</e1> reversed such changes (p<0.001).","Downregulator"
"<e2>Cytochrome P450 2E1</e2> (CYP 450 2E1), activity was determined as hydroxylation of <e1>aniline</e1> in liver microsomes.","Substrate"
"Cytochrome P450 2E1 (<e2>CYP 450 2E1</e2>), activity was determined as hydroxylation of <e1>aniline</e1> in liver microsomes.","Substrate"
"<e1>Oxysterol</e1>-dependent <e2>NOX1</e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.","Upregulator"
"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial <e2>NOX1</e2> down-regulation and was ineffective in interleukin synthesis induced by dietary <e1>oxysterol</e1>s.","Upregulator"
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory <e2>interleukins</e2>, IL-6 and IL-8, caused by a mixture of <e1>oxysterols</e1> representative of a high cholesterol diet.","Upregulator"
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, <e2>IL-6</e2> and IL-8, caused by a mixture of <e1>oxysterols</e1> representative of a high cholesterol diet.","Upregulator"
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and <e2>IL-8</e2>, caused by a mixture of <e1>oxysterols</e1> representative of a high cholesterol diet.","Upregulator"
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory <e2>interleukins</e2>, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high <e1>cholesterol</e1> diet.","Upregulator"
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, <e2>IL-6</e2> and IL-8, caused by a mixture of oxysterols representative of a high <e1>cholesterol</e1> diet.","Upregulator"
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and <e2>IL-8</e2>, caused by a mixture of oxysterols representative of a high <e1>cholesterol</e1> diet.","Upregulator"
"<e1>Oxysterol</e1>-dependent NOX1 activation, as well as <e2>interleukin</e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.","Upregulator"
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory <e2>interleukin</e2>s, IL-6 and IL-8, caused by a mixture of <e1>oxysterols</e1> representative of a high cholesterol diet.","Upregulator"
"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial <e2>NOX1</e2> down-regulation and was ineffective in interleukin synthesis induced by dietary <e1>oxysterols</e1>.","Upregulator"
"Oxysterol-dependent NOX1 activation, as well as <e2>interleukin</e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular <e1>phenolic acids</e1> and flavonoids.","Downregulator"
"Oxysterol-dependent NOX1 activation, as well as <e2>interleukin</e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and <e1>flavonoids</e1>.","Downregulator"
"Oxysterol-dependent <e2>NOX1</e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular <e1>phenolic acids</e1> and flavonoids.","Downregulator"
"Oxysterol-dependent <e2>NOX1</e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and <e1>flavonoids</e1>.","Downregulator"
"Induction of <e2>NOX1</e2> was markedly while not fully inhibited by CaCo-2 cell pre-incubation with <e1>phenolic</e1> extracts obtained from well-selected wines from typical grape varieties grown in Sardinia.","Downregulator"
"In virtual bone marrow transplant (BMT) patients, 500 pg/ml of <e2>IL-6</e2> resulted in increase in <e1>cyclosporine</e1> AUC that was in good agreement with the observed data (45% versus 39%).","Regulator"
"In the African-American cohort, after excluding Y186C carriers, homozygous carriers of <e2>C29R</e2> showed 27% higher DPD activity as compared with noncarriers (609152 and 480152 pmol <e1>5-FU</e1> min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038/clpt.2013.69.","Regulator"
"The responses to <e1>5-FU</e1>, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (<e2>DPD</e2>, encoded by the DPYD gene).","Regulator"
"The responses to <e1>5-FU</e1>, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme <e2>dihydropyrimidine dehydrogenase</e2> (DPD, encoded by the DPYD gene).","Regulator"
"The responses to <e1>5-FU</e1>, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (<e2>DPD</e2>, encoded by the DPYD gene).","Regulator"
"The responses to <e1>5-FU</e1>, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the <e2>DPYD</e2> gene).","Regulator"
"The responses to <e1>5-FU</e1>, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the <e2>DPYD</e2> gene).","Regulator"
"The DPYD-<e2>Y186C</e2> variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (27935 vs. 514168 pmol <e1>5-FU</e1> min(-1) mg(-1); P = 0.00029).","Regulator"
"The responses to <e1>5-FU</e1>, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (<e2>DPD</e2>, encoded by the DPYD gene).","Regulator"
"In contrast, activation of Nrf2 by <e1>sulforaphane</e1> and tert-butylhydroquinone depend upon Keap1-C151 and not <e2>p62</e2> (the canonical mechanism).","Not"
"In contrast, activation of Nrf2 by sulforaphane and <e1>tert-butylhydroquinone</e1> depend upon Keap1-C151 and not <e2>p62</e2> (the canonical mechanism).","Not"
"<e1>Arsenic</e1> inhibits autophagic flux activating the Nrf2-Keap1 pathway in a <e2>p62</e2>-dependent manner.","Regulator"
"Thus, <e1>arsenic</e1> activates Nrf2 through a non-canonical mechanism (<e2>p62</e2>-dependent), leading to a chronic, sustained activation of Nrf2.","Regulator"
"In contrast, activation of Nrf2 by <e1>sulforaphane</e1> and tert-butylhydroquinone depend upon <e2>Keap1</e2>-C151 and not p62 (the canonical mechanism).","Regulator"
"In contrast, activation of Nrf2 by sulforaphane and <e1>tert-butylhydroquinone</e1> depend upon <e2>Keap1</e2>-C151 and not p62 (the canonical mechanism).","Regulator"
"<e1>Arsenic</e1> inhibits autophagic flux activating the <e2>Nrf2</e2>-Keap1 pathway in a p62-dependent manner.","Upregulator"
"<e1>Arsenic</e1> inhibits autophagic flux activating the Nrf2-<e2>Keap1</e2> pathway in a p62-dependent manner.","Upregulator"
"Here, we report a novel mechanism of <e2>Nrf2</e2> activation by <e1>arsenic</e1> that is distinct from that of chemopreventive compounds.","Upregulator"
"Here, we report a novel mechanism of <e2>Nrf2</e2> activation by <e1>arsenic</e1> that is distinct from that of chemopreventive compounds.","Upregulator"
"Here, we report a novel mechanism of <e2>Nrf2</e2> activation by <e1>arsenic</e1> that is distinct from that of chemopreventive compounds.","Upregulator"
"Here, we report a novel mechanism of <e2>Nrf2</e2> activation by <e1>arsenic</e1> that is distinct from that of chemopreventive compounds.","Upregulator"
"In contrast, activation of <e2>Nrf2</e2> by <e1>sulforaphane</e1> and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).","Upregulator"
"In contrast, activation of <e2>Nrf2</e2> by sulforaphane and <e1>tert-butylhydroquinone</e1> depend upon Keap1-C151 and not p62 (the canonical mechanism).","Upregulator"
"<e1>Arsenic</e1> inhibits autophagic flux activating the Nrf2-Keap1 pathway in a <e2>p62</e2>-dependent manner.","Downregulator"
"<e1>Arsenic</e1> inhibits autophagic flux activating the Nrf2-<e2>Keap1</e2> pathway in a p62-dependent manner.","Downregulator"
"<e1>Arsenic</e1> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and <e2>LC3</e2>.","Downregulator"
"Ovarian <e2>AR</e2> was not influenced by either treatment, and oviduct AR was reduced after <e1>ethanol</e1>-melatonin combination.","Not"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (<e2>AR</e2>, ER- and ER-, PRA, PRB and MT1R, respectively).","Not"
"<e1>Ethanol</e1> and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of <e2>sex steroid receptors</e2> in female reproductive tissues.","Regulator"
"Ethanol and <e1>melatonin</e1> exert opposite effects on E2 and P4, and they differentially regulate the expression of <e2>sex steroid receptors</e2> in female reproductive tissues.","Regulator"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (AR, ER- and ER-, PRA, PRB and <e2>MT1R</e2>, respectively).","Upregulator"
"Ovarian <e2>AR</e2> was not influenced by either treatment, and oviduct AR was reduced after <e1>ethanol</e1>-melatonin combination.","Downregulator"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (<e2>AR</e2>, ER- and ER-, PRA, PRB and MT1R, respectively).","Downregulator"
"Oviduct <e2>ER-</e2>, ER- and uterine ER- were down-regulated by either <e1>ethanol</e1> or melatonin.","Downregulator"
"Oviduct ER-, <e2>ER-</e2> and uterine ER- were down-regulated by either <e1>ethanol</e1> or melatonin.","Downregulator"
"Oviduct ER-, <e2>ER-</e2> and uterine ER- were down-regulated by either <e1>ethanol</e1> or melatonin.","Downregulator"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (AR, <e2>ER-</e2> and ER-, PRA, PRB and MT1R, respectively).","Downregulator"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (AR, ER- and <e2>ER-</e2>, PRA, PRB and MT1R, respectively).","Downregulator"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (AR, ER- and <e2>ER-</e2>, PRA, PRB and MT1R, respectively).","Downregulator"
"Conversely, ovarian <e2>PRA</e2> and PRB were positively regulated by <e1>ethanol</e1> and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.","Downregulator"
"Conversely, ovarian <e2>PRA</e2> and PRB were positively regulated by <e1>ethanol</e1> and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.","Modulator"
"Conversely, ovarian PRA and <e2>PRB</e2> were positively regulated by <e1>ethanol</e1> and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.","Modulator"
"Conversely, ovarian <e2>PRA</e2> and PRB were positively regulated by <e1>ethanol</e1> and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.","Modulator"
"Conversely, ovarian PRA and <e2>PRB</e2> were positively regulated by <e1>ethanol</e1> and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.","Modulator"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (AR, ER- and ER-, <e2>PRA</e2>, PRB and MT1R, respectively).","Modulator"
"After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and <e1>melatonin</e1> receptor subunits (AR, ER- and ER-, PRA, <e2>PRB</e2> and MT1R, respectively).","Modulator"
"Intraplantar or intrathecal administered Ph1 reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with <e1>SB366791</e1>, a specific <e2>TRPV1</e2> antagonist.","Antagonist"
"While <e1>imatinib</e1> was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of <e2>p53</e2>, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.","Not"
"While imatinib was unable to block <e1>cisplatin</e1>-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of <e2>TAp63</e2> and upregulation of Bax, thereby abrogating oocyte cell death.","Upregulator"
"We found that, before apoptosis, <e1>cisplatin</e1> induces c-Abl and <e2>TAp73</e2> expression in the oocyte.","Upregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against <e1>cisplatin</e1>.","Upregulator"
"Recently, the c-Abl <e2>kinase</e2> inhibitor <e1>imatinib</e1> mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Upregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against <e1>cisplatin</e1>.","Upregulator"
"Recently, the c-Abl <e2>kinase</e2> inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against <e1>cisplatin</e1>.","Upregulator"
"We found that, before apoptosis, <e1>cisplatin</e1> induces c-Abl and <e2>TAp73</e2> expression in the oocyte.","Upregulator"
"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin</e1> activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced <e2>BAX</e2> expression.","Upregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against <e1>cisplatin</e1>.","Upregulator"
"We found that, before apoptosis, <e1>cisplatin</e1> induces c-Abl and <e2>TAp73</e2> expression in the oocyte.","Upregulator"
"While imatinib was unable to block <e1>cisplatin</e1>-induced DNA damage and damage response, such as the upregulation of <e2>p53</e2>, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.","Upregulator"
"While <e1>imatinib</e1> was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of <e2>TAp63</e2> and upregulation of Bax, thereby abrogating oocyte cell death.","Upregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against <e1>cisplatin</e1>.","Upregulator"
"We found that, before apoptosis, <e1>cisplatin</e1> induces c-Abl and <e2>TAp73</e2> expression in the oocyte.","Upregulator"
"While imatinib was unable to block <e1>cisplatin</e1>-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of <e2>Bax</e2>, thereby abrogating oocyte cell death.","Upregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against <e1>cisplatin</e1>.","Upregulator"
"We found that, before apoptosis, <e1>cisplatin</e1> induces c-Abl and <e2>TAp73</e2> expression in the oocyte.","Upregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against <e1>cisplatin</e1>.","Upregulator"
"We found that, before apoptosis, <e1>cisplatin</e1> induces c-Abl and <e2>TAp73</e2> expression in the oocyte.","Upregulator"
"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin</e1> activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced <e2>BAX</e2> expression.","Upregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor <e1>imatinib</e1> mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"While <e1>imatinib</e1> was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/<e2>TAp73</e2> and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.","Downregulator"
"While <e1>imatinib</e1> was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of <e2>Bax</e2>, thereby abrogating oocyte cell death.","Downregulator"
"While imatinib was unable to block <e1>cisplatin</e1>-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of <e2>TAp63</e2> and upregulation of Bax, thereby abrogating oocyte cell death.","Downregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor <e1>imatinib mesylate</e1> (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"Recently, the c-Abl <e2>kinase</e2> inhibitor <e1>imatinib mesylate</e1> (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor <e1>imatinib</e1> mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"Recently, the c-Abl <e2>kinase</e2> inhibitor <e1>imatinib</e1> mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor <e1>imatinib</e1> mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"While <e1>imatinib</e1> was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/<e2>TAp73</e2> and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.","Downregulator"
"Our findings indicate that <e1>imatinib</e1> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-<e2>BAX</e2>-mediated apoptosis.","Downregulator"
"Recently, the <e2>c-Abl</e2> kinase inhibitor <e1>imatinib</e1> mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"Recently, the c-Abl <e2>kinase</e2> inhibitor <e1>imatinib</e1> mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.","Downregulator"
"Among the possible transporters involved in the uptake of <e1>Cd(2+)</e1> and Mn(2+), the expression of <e2>ZIP8</e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Among the possible transporters involved in the uptake of <e1>Cd(2+)</e1> and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by <e2>Slc39a8</e2>, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Among the possible transporters involved in the uptake of <e1>Cd(2+)</e1> and Mn(2+), the expression of <e2>ZIP8</e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Among the possible transporters involved in the uptake of <e1>Cd(2+)</e1> and Mn(2+), the expression of ZIP8 (<e2>Zrt-, Irt-related protein 8</e2>), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Among the possible transporters involved in the uptake of Cd(2+) and <e1>Mn(2+)</e1>, the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by <e2>Slc39a8</e2>, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Among the possible transporters involved in the uptake of Cd(2+) and <e1>Mn(2+)</e1>, the expression of <e2>ZIP8</e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Among the possible transporters involved in the uptake of Cd(2+) and <e1>Mn(2+)</e1>, the expression of ZIP8 (<e2>Zrt-, Irt-related protein 8</e2>), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Among the possible transporters involved in the uptake of Cd(2+) and <e1>Mn(2+)</e1>, the expression of <e2>ZIP8</e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Substrate"
"Optimization of a <e1>1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione</e1> series of <e2>HIV capsid</e2> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety.","Downregulator"
"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of <e1>1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione</e1> inhibitors of HIV capsid (<e2>CA</e2>) assembly are described.","Downregulator"
"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of <e2>HIV capsid</e2> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-<e1>phenyl</e1> moiety.","Downregulator"
"Optimization of a <e1>1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione</e1> series of <e2>HIV capsid</e2> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety.","Downregulator"
"<e1>Arsenic</e1> upregulates the expression of <e2>angiotensin II Type I receptor</e2> in mouse aortic endothelial cells.","Upregulator"
"Taken together, our results indicate that <e1>arsenic</e1> indeed upregulates the <e2>AT1R</e2> expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.","Upregulator"
"Taken together, our results indicate that <e1>arsenic</e1> indeed upregulates the <e2>AT1R</e2> expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.","Upregulator"
"To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (<e2>AT1R</e2>) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following <e1>sodium arsenite</e1> (SA) treatment.","Upregulator"
"To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, <e2>AT1AR</e2> and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following <e1>sodium arsenite</e1> (SA) treatment.","Upregulator"
"To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and <e2>AT1BR</e2>, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following <e1>sodium arsenite</e1> (SA) treatment.","Upregulator"
"Finally, SA-induced <e2>AT1R</e2> expression was found to be prevented both by NAC and specific JNK inhibitor, <e1>SP6001325</e1>, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.","Downregulator"
"Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific <e2>JNK</e2> inhibitor, <e1>SP6001325</e1>, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.","Downregulator"
"The expressions of <e2>HSP70</e2> and HO-1 were significantly (P<0.05) increased in the <e1>NaAsO2</e1> group and reduced in the combined treatment group.","Upregulator"
"The expressions of HSP70 and <e2>HO-1</e2> were significantly (P<0.05) increased in the <e1>NaAsO2</e1> group and reduced in the combined treatment group.","Upregulator"
"The mRNA levels of <e2>SOD1</e2>, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined <e1>Na2SeO3</e1>+NaAsO2 treatment group.","Upregulator"
"The mRNA levels of SOD1, <e2>CAT</e2>, GPx and Txnrd1 were increased significantly (P<0.05) in the combined <e1>Na2SeO3</e1>+NaAsO2 treatment group.","Upregulator"
"The mRNA levels of SOD1, CAT, <e2>GPx</e2> and Txnrd1 were increased significantly (P<0.05) in the combined <e1>Na2SeO3</e1>+NaAsO2 treatment group.","Upregulator"
"The mRNA levels of <e2>SOD1</e2>, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2</e1> treatment group.","Downregulator"
"The mRNA levels of SOD1, <e2>CAT</e2>, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2</e1> treatment group.","Downregulator"
"The mRNA levels of SOD1, CAT, <e2>GPx</e2> and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2</e1> treatment group.","Downregulator"
"The mRNA levels of SOD1, CAT, GPx and <e2>Txnrd1</e2> were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2</e1> treatment group.","Downregulator"
"The mRNA levels of SOD1, CAT, GPx and <e2>Txnrd1</e2> were increased significantly (P<0.05) in the combined <e1>Na2SeO3</e1>+NaAsO2 treatment group.","Downregulator"
"From the 10 isolated compounds, <e1>methyl-3,5-di-O-caffeoylquinate</e1> showed the most potent inhibition, with IC50 values of 0.30 and 0.67M for rAR and <e2>rhAR</e2>, respectively.","Downregulator"
"From the 10 isolated compounds, <e1>methyl-3,5-di-O-caffeoylquinate</e1> showed the most potent inhibition, with IC50 values of 0.30 and 0.67M for <e2>rAR</e2> and rhAR, respectively.","Downregulator"
"From the 10 isolated compounds, <e1>methyl-3,5-di-O-caffeoylquinate</e1> showed the most potent inhibition, with IC50 values of 0.30 and 0.67M for rAR and <e2>rhAR</e2>, respectively.","Downregulator"
"This preference is partial because <e2>UGT2B10</e2> did not conjugate the <e1>tertiary cyclic amine</e1> in trifluoperazine.","Not"
"<e2>UGT2B10</e2> was inactive in the glucuronidation of <e1>desipramine</e1>, nortriptyline, carbamazepine and afloqualone.","Not"
"<e2>UGT2B10</e2> was inactive in the glucuronidation of desipramine, <e1>nortriptyline</e1>, carbamazepine and afloqualone.","Not"
"<e2>UGT2B10</e2> was inactive in the glucuronidation of desipramine, nortriptyline, <e1>carbamazepine</e1> and afloqualone.","Not"
"<e2>UGT2B10</e2> was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine and <e1>afloqualone</e1>.","Not"
"This group of drugs contains <e1>secondary or primary amines</e1>, and these results suggest that <e2>UGT2B10</e2> preferably conjugates tertiary amines.","Not"
"This preference is partial because <e2>UGT2B10</e2> did not conjugate the tertiary cyclic amine in <e1>trifluoperazine</e1>.","Not"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of <e1>amitriptyline</e1>, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>amitriptyline</e1>, imipramine, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>amitriptyline</e1>, imipramine, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, <e1>imipramine</e1>, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine</e1>, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine</e1>, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and <e2>UGT1A3</e2>, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine</e1>, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, <e1>diphenhydramine</e1>, tamoxifen, ketoconazole and midazolam.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine</e1> are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine</e1> are significantly higher than the corresponding values of UGT1A4 and <e2>UGT1A3</e2>, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine</e1> are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Regulator"
"This group of drugs contains secondary or primary amines, and these results suggest that <e2>UGT2B10</e2> preferably conjugates <e1>tertiary amines</e1>.","Regulator"
"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>tertiary amines</e1> with higher affinities and clearance values than those of <e2>UGT1A4</e2> and UGT1A3.","Regulator"
"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>tertiary amines</e1> with higher affinities and clearance values than those of UGT1A4 and <e2>UGT1A3</e2>.","Regulator"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of <e1>amitriptyline</e1>, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, <e1>imipramine</e1>, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, <e1>ketotifen</e1>, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, <e1>pizotifen</e1>, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, <e1>olanzapine</e1>, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, <e1>diphenhydramine</e1>, tamoxifen, ketoconazole and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, <e1>tamoxifen</e1>, ketoconazole and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, <e1>ketoconazole</e1> and midazolam.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and <e1>midazolam</e1>.","Substrate"
"This group of drugs contains secondary or primary amines, and these results suggest that <e2>UGT2B10</e2> preferably conjugates <e1>tertiary amines</e1>.","Substrate"
"Recent observations revealed that <e2>human UDP-glucuronosyltransferase (UGT) 2B10</e2> catalyzes N-glucuronidation of <e1>amine</e1>-containing compounds.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of <e1>amitriptyline</e1>, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>amitriptyline</e1>, imipramine, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>amitriptyline</e1>, imipramine, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, <e1>imipramine</e1>, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine</e1>, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine</e1>, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and <e2>UGT1A3</e2>, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine</e1>, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"Using recombinant <e2>UGT2B10</e2>, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, <e1>diphenhydramine</e1>, tamoxifen, ketoconazole and midazolam.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine</e1> are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine</e1> are significantly higher than the corresponding values of UGT1A4 and <e2>UGT1A3</e2>, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine</e1> are significantly higher than the corresponding values of <e2>UGT1A4</e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.","Substrate"
"This group of drugs contains secondary or primary amines, and these results suggest that <e2>UGT2B10</e2> preferably conjugates <e1>tertiary amines</e1>.","Substrate"
"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>tertiary amines</e1> with higher affinities and clearance values than those of <e2>UGT1A4</e2> and UGT1A3.","Substrate"
"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>tertiary amines</e1> with higher affinities and clearance values than those of UGT1A4 and <e2>UGT1A3</e2>.","Substrate"
"Molecular docking studies suggested that SB has a good affinity towards <e1>vinblastine</e1>-binding site on <e2>-tubulin</e2> subunit.","Regulator"
"<e1>SB225002</e1> (SB) is an <e2>IL-8</e2> receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.","Downregulator"
"<e1>SB225002</e1> (SB) is an <e2>IL-8 receptor B</e2> (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.","Antagonist"
"<e1>SB225002</e1> (SB) is an IL-8 receptor B (<e2>IL-8RB</e2>) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.","Antagonist"
"Of note, <e1>SB265610</e1> which is a close structural analogue of SB225002 with a potent <e2>IL-8RB</e2> antagonistic activity did not exhibit a similar antimitotic activity.","Antagonist"
"<e1>SB225002</e1> (SB) is an IL-8 receptor B (<e2>IL-8RB</e2>) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.","Antagonist"
"Furthermore, expression of a multivalent but not a monovalent GAG containing <e2>syndecan-1</e2> proteoglycan recapitulates the elongation phenotype observed with the bivalent <e1>xylosides</e1>.","Regulator"
"In support of this observation, elongation can be reversed by the <e2>tyrosine kinase</e2> inhibitor <e1>SU5402</e1>, mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, <e2>Akt1</e2>, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Not"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, <e2>Akt2</e2>, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Not"
"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt <e1>Ser</e1>473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, <e2>phospho-Rb</e2> Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Part_of"
"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, <e2>phospho-Akt</e2> <e1>Ser</e1>473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Part_of"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor <e2>p27Kip</e2>.","Upregulator"
"<e1>Caffeic Acid Phenethyl Ester</e1> Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of <e2>Akt</e2> Signaling.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of <e2>Akt</e2>, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, <e2>Akt1</e2>, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, <e2>Akt2</e2>, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, <e2>Akt3</e2>, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, <e2>phospho-Akt</e2> Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, <e2>phospho-Akt</e2> Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, <e2>GSK3</e2>, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, <e2>FOXO1</e2>, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, <e2>FOXO3a</e2>, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, <e2>phospho-FOXO1</e2> Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, <e2>phospho-FoxO3a</e2> Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, <e2>NF-B</e2>, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, <e2>phospho-NF-B</e2> Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, <e2>Rb</e2>, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, <e2>phospho-Rb</e2> Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, <e2>Skp2</e2>, and cyclin D1, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Treatment with <e1>CAPE</e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and <e2>cyclin D1</e2>, but increased cell cycle inhibitor p27Kip.","Downregulator"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both <e2>Nrf2</e2> and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Not"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both Nrf2 and <e2>ATF4</e2> as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Regulator"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both <e2>Nrf2</e2> and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Upregulator"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both Nrf2 and <e2>ATF4</e2> as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Upregulator"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both <e2>Nrf2</e2> and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Upregulator"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both Nrf2 and <e2>ATF4</e2> as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Upregulator"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both <e2>Nrf2</e2> and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Upregulator"
"Here we show that <e1>fisetin</e1> rapidly increases the levels of both Nrf2 and <e2>ATF4</e2> as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.","Upregulator"
"<e1>Amino acid</e1> sequences of cynomolgus <e2>FMO1-5</e2>, respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with human FMO1-5.","Part_of"
"<e2>Cynomolgus FMO1</e2>, FMO2, FMO3, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, <e2>FMO2</e2>, FMO3, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, FMO3, and <e2>FMO5</e2> metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Cynomolgus <e2>FMO1</e2>, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized <e1>methimazole</e1> and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized <e1>methimazole</e1> and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized <e1>methimazole</e1> and trimethylamine, respectively.","Substrate"
"Cynomolgus <e2>FMO1</e2>, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and <e1>trimethylamine</e1>, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and <e1>trimethylamine</e1>, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and <e1>trimethylamine</e1>, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Rates of benzydamine <e1>N</e1>-oxygenation (catalyzed by <e2>FMO3</e2>) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Rates of benzydamine <e1>N</e1>-oxygenation (catalyzed by <e2>FMO3</e2>) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.","Substrate"
"<e2>Cynomolgus FMO6</e2> metabolized <e1>benzydamine</e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.","Substrate"
"Cynomolgus <e2>FMO1</e2>, FMO2, FMO3, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, <e2>FMO2</e2>, FMO3, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, <e2>FMO3</e2>, and FMO5 metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Cynomolgus FMO1, FMO2, FMO3, and <e2>FMO5</e2> metabolized <e1>benzydamine</e1>, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.","Substrate"
"Activation of AMPK using AICAR resulted in <e2>STIM1</e2> phosphorylation on <e1>serine</e1> residues and prevented PAR-1-induced Ca2+ entry.","Part_of"
"The <e1>Ca2+</e1> sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through TRPC and <e2>Orai channels</e2>.","Regulator"
"Store-operated <e1>Ca2+</e1> Entry (SOCE) Induced by Protease-activated Receptor-1 mediates <e2>STIM1</e2> Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.","Regulator"
"The <e1>Ca2+</e1> sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through <e2>TRPC</e2> and Orai channels.","Regulator"
"Interestingly, <e1>SB203580</e1>, a selective inhibitor of p38 MAPK, blocked <e2>STIM1</e2> phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.","Regulator"
"Activation of <e2>AMPK</e2> using <e1>AICAR</e1> resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.","Upregulator"
"Activation of AMPK using <e1>AICAR</e1> resulted in <e2>STIM1</e2> phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.","Upregulator"
"Activation of AMPK using <e1>AICAR</e1> resulted in STIM1 phosphorylation on serine residues and prevented <e2>PAR-1</e2>-induced Ca2+ entry.","Downregulator"
"Activation of AMPK using <e1>AICAR</e1> resulted in STIM1 phosphorylation on serine residues and prevented <e2>PAR-1</e2>-induced Ca2+ entry.","Downregulator"
"Interestingly, <e1>SB203580</e1>, a selective inhibitor of <e2>p38</e2> MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.","Downregulator"
"Interestingly, <e1>SB203580</e1>, a selective inhibitor of p38 <e2>MAPK</e2>, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.","Downregulator"
"Interestingly, <e1>SB203580</e1>, a selective inhibitor of p38 MAPK, blocked <e2>STIM1</e2> phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.","Downregulator"
"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the <e1>cholesterol</e1> side-chain cleavage enzyme, <e2>P450scc</e2>, and its two electron-transfer partners, ferredoxin reductase and ferredoxin.","Substrate"
"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the <e1>cholesterol</e1> side-chain cleavage enzyme, <e2>P450scc</e2>, and its two electron-transfer partners, ferredoxin reductase and ferredoxin.","Substrate"
"New series of <e1>pyrrolidine mercaptosulfide</e1>, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine <e2>matrix metalloproteinase</e2> inhibitors (MMPIs) were designed, synthesized, and evaluated.","Downregulator"
"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates</e1>), these newly reported compounds are capable of modulating activities of several <e2>MMPs</e2> in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).","Downregulator"
"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates</e1>), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including <e2>MMP-2</e2> (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).","Downregulator"
"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates</e1>), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), <e2>MMP-13</e2> (~2 to 50 nM), and MMP-14 (~4 to 60 nM).","Downregulator"
"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates</e1>), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and <e2>MMP-14</e2> (~4 to 60 nM).","Downregulator"
"New series of pyrrolidine mercaptosulfide, <e1>2-mercaptocyclopentane arylsulfonamide</e1>, and 3-mercapto-4-arylsulfonamido pyrrolidine <e2>matrix metalloproteinase</e2> inhibitors (MMPIs) were designed, synthesized, and evaluated.","Downregulator"
"New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and <e1>3-mercapto-4-arylsulfonamido pyrrolidine</e1> <e2>matrix metalloproteinase</e2> inhibitors (MMPIs) were designed, synthesized, and evaluated.","Downregulator"
"<e2>Matrix Metalloproteinase</e2> Inhibitors Based on the <e1>3-Mercaptopyrrolidine</e1> Core.","Downregulator"
"An X-ray crystal structure of cytochrome P450 <e2>2B4</e2> in complex with the drug <e1>paroxetine</e1> was solved at 2.14  resolution.","Regulator"
"An X-ray crystal structure of <e2>cytochrome P450 2B4</e2> in complex with the drug <e1>paroxetine</e1> was solved at 2.14  resolution.","Regulator"
"A Structural Snapshot of <e2>Cytochrome P450 2B4</e2> in Complex with <e1>Paroxetine</e1> Provides Insights into Ligand Binding and Clusters of Conformational States.","Regulator"
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA</e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as <e2>interleukin-1</e2> (IL-1), and apoptosis (Bax and caspase 3 expression).","Downregulator"
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA</e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1 (<e2>IL-1</e2>), and apoptosis (Bax and caspase 3 expression).","Downregulator"
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA</e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1 (IL-1), and apoptosis (<e2>Bax</e2> and caspase 3 expression).","Downregulator"
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA</e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1 (IL-1), and apoptosis (Bax and <e2>caspase 3</e2> expression).","Downregulator"
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA</e1> significantly decreased <e2>nuclear factor (NF)-kB</e2> translocation, pro-inflammatory cytokine production such as interleukin-1 (IL-1), and apoptosis (Bax and caspase 3 expression).","Downregulator"
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA</e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory <e2>cytokine</e2> production such as interleukin-1 (IL-1), and apoptosis (Bax and caspase 3 expression).","Downregulator"
"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon <e2>myrosinase</e2> hydrolysis release the corresponding <e1>isothiocyanates</e1>.","Substrate"
"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in <e1>glucosinolates</e1>, which upon <e2>myrosinase</e2> hydrolysis release the corresponding isothiocyanates.","Substrate"
"In the presence of <e1>H2O2</e1>, calycopterin inhibited decrease in GSH level and <e2>SOD</e2> activity.","Regulator"
"Involvement of p-<e2>CREB</e2> and phase II detoxifying enzyme system in neuroprotection mediated by the flavonoid <e1>calycopterin</e1> isolated from Dracocephalum kotschyi.","Regulator"
"Moreover, <e1>calycopterin</e1>, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and <e2>Nrf2</e2>, which play an important role in antioxidant capacity of the cell.","Regulator"
"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>H2O2</e1>-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (<e2>CREB</e2>) phosphorylation.","Regulator"
"Moreover, calycopterin, in presence of <e1>H2O2</e1> inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and <e2>Nrf2</e2>, which play an important role in antioxidant capacity of the cell.","Regulator"
"Involvement of <e2>p-CREB</e2> and phase II detoxifying enzyme system in neuroprotection mediated by the flavonoid <e1>calycopterin</e1> isolated from Dracocephalum kotschyi.","Regulator"
"Involvement of p-CREB and <e2>phase II detoxifying enzyme</e2> system in neuroprotection mediated by the flavonoid <e1>calycopterin</e1> isolated from Dracocephalum kotschyi.","Regulator"
"In the presence of H2O2, <e1>calycopterin</e1> inhibited decrease in GSH level and <e2>SOD</e2> activity.","Upregulator"
"There was also an increase in <e2>-GCS</e2> and HO-1 levels in <e1>calycopterin</e1> pretreated cells.","Upregulator"
"There was also an increase in -GCS and <e2>HO-1</e2> levels in <e1>calycopterin</e1> pretreated cells.","Upregulator"
"Involvement of p-<e2>CREB</e2> and phase II detoxifying enzyme system in neuroprotection mediated by the flavonoid <e1>calycopterin</e1> isolated from Dracocephalum kotschyi.","Upregulator"
"Moreover, <e1>calycopterin</e1>, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and <e2>Nrf2</e2>, which play an important role in antioxidant capacity of the cell.","Upregulator"
"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>H2O2</e1>-induced disruption of <e2>phase II detoxifying enzyme</e2> system and cAMP response element binding protein (CREB) phosphorylation.","Downregulator"
"In H2O2-treated cells, <e1>calycopterin</e1> also suppressed <e2>cytochrome C</e2> release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.","Downregulator"
"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>H2O2</e1>-induced disruption of phase II detoxifying enzyme system and <e2>cAMP response element binding protein</e2> (CREB) phosphorylation.","Downregulator"
"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>H2O2</e1>-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (<e2>CREB</e2>) phosphorylation.","Downregulator"
"I3S increased expression of RORt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as <e1>2,3,7,8-tetrachlorodibenzo-p-dioxin</e1> (TCDD), a prototypical <e2>AhR</e2> ligand.","Regulator"
"I3S increased expression of RORt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>), a prototypical <e2>AhR</e2> ligand.","Regulator"
"In the present study, using in vitro Th17 differentiation model, we examined effects of <e2>AhR</e2> activation by indoxyl 3-sulfate (<e1>I3S</e1>), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.","Regulator"
"I3S increased expression of RORt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>), a prototypical <e2>AhR</e2> ligand.","Regulator"
"Activation of <e2>STAT3</e2>, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and <e1>TCDD</e1>.","Upregulator"
"Activation of STAT3, which is phosphorylated by the <e2>IL-6</e2> signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and <e1>TCDD</e1>.","Upregulator"
"Phosphorylation of <e2>c-Src</e2>, which was shown to be activated by AhR ligands, was also increased by <e1>I3S</e1> and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Upregulator"
"Phosphorylation of <e2>c-Src</e2>, which was shown to be activated by AhR ligands, was also increased by I3S and <e1>TCDD</e1>, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Upregulator"
"<e1>Indoxyl 3-sulfate</e1> stimulates Th17 differentiation enhancing phosphorylation of <e2>c-Src</e2> and STAT3 to worsen experimental autoimmune encephalomyelitis.","Upregulator"
"<e1>Indoxyl 3-sulfate</e1> stimulates Th17 differentiation enhancing phosphorylation of c-Src and <e2>STAT3</e2> to worsen experimental autoimmune encephalomyelitis.","Upregulator"
"Phosphorylation of <e2>c-Src</e2>, which was shown to be activated by AhR ligands, was also increased by <e1>I3S</e1> and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Upregulator"
"Activation of <e2>STAT3</e2>, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by <e1>I3S</e1> and TCDD.","Upregulator"
"Phosphorylation of <e2>c-Src</e2>, which was shown to be activated by AhR ligands, was also increased by I3S and <e1>TCDD</e1>, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Upregulator"
"Activation of <e2>STAT3</e2>, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and <e1>TCDD</e1>.","Upregulator"
"In the present study, using in vitro Th17 differentiation model, we examined effects of <e2>AhR</e2> activation by <e1>indoxyl 3-sulfate</e1> (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.","Upregulator"
"In the present study, using in vitro Th17 differentiation model, we examined effects of <e2>AhR</e2> activation by indoxyl 3-sulfate (<e1>I3S</e1>), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.","Upregulator"
"Activation of <e2>STAT3</e2>, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by <e1>I3S</e1> and TCDD.","Upregulator"
"Activation of STAT3, which is phosphorylated by the <e2>IL-6</e2> signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by <e1>I3S</e1> and TCDD.","Upregulator"
"Finally, we found that <e1>I3S</e1> worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of <e2>IL-17</e2>-producing cells in draining lymph nodes.","Upregulator"
"<e1>I3S</e1> increased expression of <e2>RORt</e2>, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.","Upregulator"
"Phosphorylation of <e2>c-Src</e2>, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by <e1>4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine</e1> (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Downregulator"
"Phosphorylation of <e2>c-Src</e2>, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by <e1>4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine</e1> (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Downregulator"
"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by <e1>4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine</e1> (PP2) inhibited phosphorylation of both c-Src and <e2>STAT3</e2>, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.","Downregulator"
"This inhibition was mediated by a <e1>TCDD</e1>-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (<e2>IGFBP-4</e2>).","Not"
"<e1>TCDD</e1> treatment of the cells largely prevented the activation of <e2>eukaryotic translation initiation factor 4E-binding protein 1</e2>, a regulator of translation initiation and substrate of the mammalian target of rapamycin (mTOR).","Not"
"The observations suggest that in 5L cells the <e2>Igfbp-4</e2> gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of IGFBP-4 by <e1>TCDD</e1>.","Regulator"
"The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing <e2>dioxin responsive element(s)</e2> leading to the induction of IGFBP-4 by <e1>TCDD</e1>.","Regulator"
"<e1>TCDD</e1> treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the <e2>mammalian target of rapamycin</e2> (mTOR).","Regulator"
"<e1>TCDD</e1> treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of rapamycin (<e2>mTOR</e2>).","Regulator"
"By ""working upwards"" from mTOR, we observed that <e1>TCDD</e1> inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of <e2>insulin receptor substrate 1</e2>.","Regulator"
"This inhibition was mediated by a <e1>TCDD</e1>-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (<e2>IGFBP-4</e2>).","Regulator"
"<e1>TCDD</e1> induces the expression of <e2>insulin-like growth factor binding protein 4</e2> in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.","Upregulator"
"<e1>TCDD</e1> induces the expression of <e2>insulin-like growth factor binding protein 4</e2> in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.","Upregulator"
"This inhibition was mediated by a <e1>TCDD</e1>-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (<e2>IGFBP-4</e2>).","Upregulator"
"This inhibition was mediated by a <e1>TCDD</e1>-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (<e2>IGFBP-4</e2>).","Upregulator"
"By ""working upwards"" from mTOR, we observed that <e1>TCDD</e1> inhibited endogenous and IGF-I-induced <e2>AKT</e2> and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.","Downregulator"
"By ""working upwards"" from mTOR, we observed that <e1>TCDD</e1> inhibited endogenous and IGF-I-induced AKT and <e2>ERK</e2> activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.","Downregulator"
"This inhibition was mediated by a <e1>TCDD</e1>-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (<e2>IGFBP-4</e2>).","Downregulator"
"By ""working upwards"" from mTOR, we observed that <e1>TCDD</e1> inhibited endogenous and <e2>IGF-I</e2>-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.","Downregulator"
"<e1>Pimozide</e1> and thioridazine had no effect on the estradiol binding properties of the MCF-7 <e2>ER</e2>, nor did pimozide interfere with the induction of progesterone receptors by estradiol.","Not"
"Pimozide and <e1>thioridazine</e1> had no effect on the estradiol binding properties of the MCF-7 <e2>ER</e2>, nor did pimozide interfere with the induction of progesterone receptors by estradiol.","Not"
"Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did <e1>pimozide</e1> interfere with the induction of <e2>progesterone receptors</e2> by estradiol.","Not"
"Similar concentrations of these compounds blocked <e1>estradiol</e1>-induced growth of MCF-7 cells, but estrogen receptor (<e2>ER</e2>) interactions do not seem to be involved.","Regulator"
"Furthermore, <e1>pimozide</e1> also inhibited incorporation of [3H]thymidine into MCF-7 cells stimulated by <e2>polypeptide hormone</e2>s in serum-free medium.","Regulator"
"We conclude that pimozide and <e1>thioridazine</e1> may be useful in the control of estradiol- and <e2>polypeptide hormone</e2>-induced growth of ER-positive and ER-negative human breast tumors.","Regulator"
"Pimozide and thioridazine had no effect on the <e1>estradiol</e1> binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of <e2>progesterone receptors</e2> by estradiol.","Regulator"
"Although numerous mechanisms of action of <e1>pimozide</e1> and thioridazine have been identified, both drugs are <e2>calmodulin</e2> antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.","Downregulator"
"Inhibition of MCF-7 cell growth by the selective <e2>calmodulin</e2> antagonists <e1>W-13</e1> and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.","Antagonist"
"Inhibition of MCF-7 cell growth by the selective <e2>calmodulin</e2> antagonists W-13 and <e1>W-12</e1> is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.","Antagonist"
"Although numerous mechanisms of action of <e1>pimozide</e1> and thioridazine have been identified, both drugs are <e2>calmodulin</e2> antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.","Antagonist"
"Although numerous mechanisms of action of pimozide and <e1>thioridazine</e1> have been identified, both drugs are <e2>calmodulin</e2> antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.","Antagonist"
"), <e2>MAO-B</e2> by <e1>(-)deprenyl</e1> (1 mg/kg i.p.","Downregulator"
"), both <e2>MAO-A</e2> and MAO-B by <e1>nialamide</e1> (75 mg/kg i.p.)","Downregulator"
"), both MAO-A and <e2>MAO-B</e2> by <e1>nialamide</e1> (75 mg/kg i.p.)","Downregulator"
"or peripheral neuronal <e2>MAO</e2> by <e1>debrisoquin</e1> (40 mg/kg i.p.).","Downregulator"
"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of <e2>monoamine oxidase type A</e2> (MAO-A) by <e1>clorgyline</e1> (4 mg/kg i.p.","Downregulator"
"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (<e2>MAO-A</e2>) by <e1>clorgyline</e1> (4 mg/kg i.p.","Downregulator"
"Levels of homovanillic acid (<e1>HVA</e1>), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (<e2>MAO-A</e2>) by clorgyline (4 mg/kg i.p.","Substrate"
"The results suggest that most of the HVA in plasma is derived from deamination of <e1>DA</e1> by <e2>MAO-A</e2> in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.","Substrate"
"<e1>Loperamide</e1> modifies but does not block the <e2>corticotropin-releasing hormone</e2>-induced ACTH response in patients with Addison's disease.","Not"
"<e1>Loperamide</e1> modifies but does not block the corticotropin-releasing hormone-induced <e2>ACTH</e2> response in patients with Addison's disease.","Not"
"The effect of <e1>loperamide</e1> - a peripheral opiate agonist - on plasma ACTH response to Corticotropin-releasing Hormone (<e2>CRH</e2>) has been investigated in 6 patients with Addison's disease.","Regulator"
"The effect of <e1>loperamide</e1> - a peripheral opiate agonist - on plasma <e2>ACTH</e2> response to Corticotropin-releasing Hormone (CRH) has been investigated in 6 patients with Addison's disease.","Upregulator"
"The effect of <e1>loperamide</e1> - a peripheral opiate agonist - on plasma <e2>ACTH</e2> response to Corticotropin-releasing Hormone (CRH) has been investigated in 6 patients with Addison's disease.","Downregulator"
"Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the <e2>acetylcholinesterase</e2> inhibitor <e1>neostigmine</e1>.","Downregulator"
"These data suggested that <e1>ambenonium</e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of <e2>acetylcholinesterase</e2> and concomitant antagonism by blockade of muscarinic receptors.","Downregulator"
"These data suggested that <e1>ambenonium</e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of <e2>muscarinic receptors</e2>.","Downregulator"
"<e1>Ambenonium</e1> is known to be an inhibitor of <e2>acetylcholinesterase</e2>, and recent data have shown this drug to antagonize muscarinic receptors as well.","Downregulator"
"Ambenonium is known to be an inhibitor of <e1>acetylcholine</e1>sterase, and recent data have shown this drug to antagonize muscarinic receptors as well.","Agonist"
"These data suggested that <e1>ambenonium</e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of <e2>muscarinic receptors</e2>.","Antagonist"
"<e1>Ambenonium</e1> is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize <e2>muscarinic receptors</e2> as well.","Antagonist"
"However, <e1>betaxolol</e1> produces less systemic beta 2- and possibly <e2>beta 1-adrenergic receptor</e2> blockade than either timolol or levobunolol.","Downregulator"
"However, betaxolol produces less systemic beta 2- and possibly <e2>beta 1-adrenergic receptor</e2> blockade than either <e1>timolol</e1> or levobunolol.","Downregulator"
"However, betaxolol produces less systemic beta 2- and possibly <e2>beta 1-adrenergic receptor</e2> blockade than either timolol or <e1>levobunolol</e1>.","Downregulator"
"<e2>Phenol oxidase</e2> inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site <e1>copper</e1> of the enzyme in the catalysis.","Part_of"
"<e2>Phenol oxidase</e2> inhibitors such as <e1>phenylthiourea</e1>, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.","Downregulator"
"<e2>Phenol oxidase</e2> inhibitors such as phenylthiourea, <e1>potassium cyanide</e1>, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.","Downregulator"
"<e2>Phenol oxidase</e2> inhibitors such as phenylthiourea, potassium cyanide, and <e1>sodium azide</e1> inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.","Downregulator"
"<e1>Mimosine</e1>, a well-known competitive inhibitor of <e2>tyrosinase</e2>, competitively inhibited the new reaction also.","Downregulator"
"Present studies demonstrate that <e2>mushroom tyrosinase</e2> will also catalyze <e1>quinone methide</e1> production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.","Substrate"
"Present studies demonstrate that <e2>mushroom tyrosinase</e2> will also catalyze quinone methide production with the same active site copper if a suitable substrate such as <e1>3,4-dihydroxymandelic acid</e1> is provided.","Substrate"
"<e2>Tyrosinase</e2> usually catalyzes the conversion of <e1>monophenols</e1> to o-diphenols and oxidation of diphenols to the corresponding quinones.","Substrate"
"<e2>Tyrosinase</e2> usually catalyzes the conversion of monophenols to o-<e1>diphenols</e1> and oxidation of diphenols to the corresponding quinones.","Substrate"
"<e2>Tyrosinase</e2> catalyzes an unusual oxidative decarboxylation of <e1>3,4-dihydroxymandelate</e1>.","Substrate"
"<e1>Chloride</e1> functions as a result of its binding to <e2>[Glu1]Pg</e2>, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-t-PA. EACA stimulates the activation in Cl-(-)containing solutions, with a Ka of approximately 4.0 mM, primarily by reversal of the Cl-(-)inhibitory effect.","Regulator"
"Chloride functions as a result of its binding to <e2>[Glu1]Pg</e2>, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-t-PA. EACA stimulates the activation in <e1>Cl-</e1>(-)containing solutions, with a Ka of approximately 4.0 mM, primarily by reversal of the Cl-(-)inhibitory effect.","Regulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA</e2>) is inhibited by <e1>Cl-</e1>, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).","Regulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA</e2>) is inhibited by <e1>Cl-</e1>, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).","Regulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA</e2>) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid</e1> (EACA), as well as fibrin(ogen).","Upregulator"
"The activation of <e2>human [Glu1]plasminogen</e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid</e1> (EACA), as well as fibrin(ogen).","Upregulator"
"The activation of human [Glu1]plasminogen [<e2>( Glu1]Pg</e2>) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid</e1> (EACA), as well as fibrin(ogen).","Upregulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>tissue plasminogen activator</e2> (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid</e1> (EACA), as well as fibrin(ogen).","Upregulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA</e2>) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA</e1>), as well as fibrin(ogen).","Upregulator"
"The activation of <e2>human [Glu1]plasminogen</e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA</e1>), as well as fibrin(ogen).","Upregulator"
"The activation of human [Glu1]plasminogen [<e2>( Glu1]Pg</e2>) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA</e1>), as well as fibrin(ogen).","Upregulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>tissue plasminogen activator</e2> (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA</e1>), as well as fibrin(ogen).","Upregulator"
"Chloride functions as a result of its binding to <e2>[Glu1]Pg</e2>, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-t-PA. EACA stimulates the activation in <e1>Cl-</e1>(-)containing solutions, with a Ka of approximately 4.0 mM, primarily by reversal of the Cl-(-)inhibitory effect.","Downregulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA</e2>) is inhibited by <e1>Cl-</e1>, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).","Downregulator"
"The activation of <e2>human [Glu1]plasminogen</e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by <e1>Cl-</e1>, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).","Downregulator"
"The activation of human [Glu1]plasminogen [<e2>( Glu1]Pg</e2>) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by <e1>Cl-</e1>, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).","Downregulator"
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>tissue plasminogen activator</e2> (t-PA) is inhibited by <e1>Cl-</e1>, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).","Downregulator"
"To explore the relationship between catecholamine transport and ion permeation through the <e1>NE</e1> transporter, we established a human norepinephrine transporter (<e2>hNET</e2>) cell line suitable for biochemical analysis and patch-clamp recording.","Upregulator"
"Sodium-dependent <e1>norepinephrine</e1>-induced currents in <e2>norepinephrine-transporter</e2>-transfected HEK-293 cells blocked by cocaine and antidepressants.","Upregulator"
"Whole-cell voltage-clamp of <e2>hNET</e2>-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and <e1>cocaine</e1> that are absent in parental cells.","Downregulator"
"Sodium-dependent norepinephrine-induced currents in <e2>norepinephrine-transporter</e2>-transfected HEK-293 cells blocked by <e1>cocaine</e1> and antidepressants.","Downregulator"
"To explain our observations, we propose that h<e1>NE</e1>Ts function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to NE transport.","Substrate"
"The <e1>C</e1>-terminal half of <e2>TSG-6</e2> contains a so-called CUB domain, characteristic for developmentally regulated proteins.","Part_of"
"<e2>TSG-6</e2> is a secreted 35-kDa glycoprotein, inducible by T<e1>N</e1>F and IL-1.","Part_of"
"The protein that binds TSG-6 was purified from human serum and identified as <e2>inter-alpha-inhibitor</e2> (I alpha I) by <e1>N</e1>-terminal microsequencing.","Part_of"
"The protein that binds TSG-6 was purified from human serum and identified as inter-alpha-inhibitor (<e2>I alpha I</e2>) by <e1>N</e1>-terminal microsequencing.","Part_of"
"BACKGROUND: The active metabolite of the anti-inflammatory drug <e1>nabumetone</e1> has been characterized as a selective inhibitor of the inducible <e2>prostaglandin H synthase</e2> (PGHS).","Downregulator"
"BACKGROUND: The active metabolite of the anti-inflammatory drug <e1>nabumetone</e1> has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (<e2>PGHS</e2>).","Downregulator"
"The daily administration of low-dose <e1>aspirin</e1> (40 mg), a selective inhibitor of platelet <e2>PGHS-1</e2>, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.","Downregulator"
"CONCLUSIONS: <e1>Nabumetone</e1> does dose-dependently inhibit the <e2>cyclooxygenase</e2> activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.","Downregulator"
"CONCLUSIONS: <e1>Nabumetone</e1> does dose-dependently inhibit the cyclooxygenase activity of platelet <e2>PGHS-1</e2> of healthy subjects both in vivo and ex vivo.","Downregulator"
"Moreover, the production of <e1>TXB2</e1> during whole blood clotting was assessed as an index of the <e2>cyclooxygenase</e2> activity of platelet PGHS-1 ex vivo.","Substrate"
"METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [<e1>TXB2</e1>]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive <e2>PGHS-1</e2> pathway.","Substrate"
"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet <e2>PGHS-1</e2>, caused a cumulative inhibition of urinary <e1>11-dehydro-TXB2</e1> and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.","Substrate"
"METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [<e1>TXB2</e1>]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive <e2>PGHS-1</e2> pathway.","Substrate"
"<e1>Emedastine</e1> (0.1%) failed to significantly attenuate either serotonin or platelet-activating-factor induced vascular permeability changes indicating high selectivity for the <e2>histamine H1 receptor</e2>.","Regulator"
"Preclinical efficacy of <e1>emedastine</e1>, a potent, selective <e2>histamine H1</e2> antagonist for topical ocular use.","Antagonist"
"(2) Exposure histories vary in secondary 11q23 leukemia, as the only <e2>topoisomerase II</e2> inhibitor was <e1>dactinomycin</e1> in one case, and, in another case, no topoisomerase II inhibitor was administered.","Downregulator"
"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, <e1>aspirin</e1> treatment of <e2>PGHS-2</e2> causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.","Regulator"
"<e1>Indomethacin</e1>, piroxicam, and sulindac sulfide were found to preferentially inhibit <e2>PGHS-1</e2>.","Downregulator"
"Indomethacin, <e1>piroxicam</e1>, and sulindac sulfide were found to preferentially inhibit <e2>PGHS-1</e2>.","Downregulator"
"Indomethacin, piroxicam, and <e1>sulindac sulfide</e1> were found to preferentially inhibit <e2>PGHS-1</e2>.","Downregulator"
"<e1>6-Methoxy-2-naphthylacetic acid</e1>, the active metabolite of Relafen, inhibits murine <e2>PGHS-2</e2> preferentially.","Downregulator"
"6-Methoxy-2-naphthylacetic acid, the active metabolite of <e1>Relafen</e1>, inhibits murine <e2>PGHS-2</e2> preferentially.","Downregulator"
"<e1>Aspirin</e1> irreversibly inhibits <e2>PGHS-1</e2>, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.","Downregulator"
"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of <e2>PGHS-2</e2> causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (<e1>15-HETE</e1>) instead of PGH2.","Substrate"
"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of <e2>PGHS-2</e2> causes this enzyme to form <e1>15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid</e1> (15-HETE) instead of PGH2.","Substrate"
"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and <e1>phenylpropanolamine</e1> seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly <e2>alpha 1-adrenoceptors</e2>.","Upregulator"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst <e1>sumatriptan</e1>, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Not"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, <e1>renzapride</e1> and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Not"
"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C</e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, <e1>renzapride</e1> and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Not"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and <e1>8-hydroxy-2-(di-n-propylamino) tetralin</e1> (8-OH-DPAT) were very weak or inactive.","Not"
"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C</e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and <e1>8-hydroxy-2-(di-n-propylamino) tetralin</e1> (8-OH-DPAT) were very weak or inactive.","Not"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (<e1>8-OH-DPAT</e1>) were very weak or inactive.","Not"
"We conclude that despite small differences concerning the enantiomeric selectivity and affinity of <e1>rauwolscine</e1> and yohimbine, the close pharmacological identity of <e2>5-HT receptors</e2> in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.","Regulator"
"We conclude that despite small differences concerning the enantiomeric selectivity and affinity of <e1>rauwolscine</e1> and yohimbine, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned <e2>5-HT2B</e2> receptor is maintained.","Regulator"
"We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and <e1>yohimbine</e1>, the close pharmacological identity of <e2>5-HT receptors</e2> in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.","Regulator"
"We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and <e1>yohimbine</e1>, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned <e2>5-HT2B</e2> receptor is maintained.","Regulator"
"<e1>SB 200646</e1>, which demonstrates some selectivity for <e2>5-HT receptors</e2> in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of 5-HT2B function both in vitro and in vivo.","Regulator"
"<e1>SB 200646</e1>, which demonstrates some selectivity for 5-HT receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of <e2>5-HT2B</e2> function both in vitro and in vivo.","Regulator"
"Under these conditions, blockade of <e2>monoamine oxidase</e2> with <e1>pargyline</e1> (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.","Downregulator"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), <e1>Ru 24969</e1>, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C</e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), <e1>Ru 24969</e1>, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, <e1>MK 212</e1> and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C</e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, <e1>MK 212</e1> and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and <e1>SCH 23390</e1> were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C</e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and <e1>SCH 23390</e1> were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including <e1>1-m-chlorophenylpiperazine</e1> (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C</e2> receptors including <e1>1-m-chlorophenylpiperazine</e1> (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either <e2>5-HT2A</e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (<e1>m-CPP</e1>), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C</e2> receptors including 1-m-chlorophenylpiperazine (<e1>m-CPP</e1>), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.","Agonist"
"Only strains of P. aeruginosa producing large amounts of <e2>beta-lactamase</e2> may be resistant to both <e1>ceftazidime</e1> and cefepime.","Not"
"Only strains of P. aeruginosa producing large amounts of <e2>beta-lactamase</e2> may be resistant to both ceftazidime and <e1>cefepime</e1>.","Not"
"Actinomycin D caused <e2>alpha-AR</e2> mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of <e1>H-7</e1> to decrease basal alpha-AR mRNA level.","Regulator"
"Neither ryanodine nor <e1>EGTA</e1> inhibited down-regulation of <e2>alpha-AR</e2> mRNA by NE.","Upregulator"
"Neither <e1>ryanodine</e1> nor EGTA inhibited down-regulation of <e2>alpha-AR</e2> mRNA by NE.","Upregulator"
"The mechanism by which norepinephrine (<e1>NE</e1>) down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR</e2>) mRNA was studied in rabbit aortic smooth muscle cells.","Downregulator"
"<e1>Actinomycin D</e1> caused <e2>alpha-AR</e2> mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.","Downregulator"
"<e1>Actinomycin D</e1> caused <e2>alpha-AR</e2> mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.","Downregulator"
"The mechanism by which norepinephrine (<e1>NE</e1>) down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR</e2>) mRNA was studied in rabbit aortic smooth muscle cells.","Downregulator"
"NE, <e1>phorbol esters</e1>, and bradykinin each decreased <e2>alpha-AR</e2> mRNA levels by 70-80%.","Downregulator"
"The mechanism by which norepinephrine (<e1>NE</e1>) down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR</e2>) mRNA was studied in rabbit aortic smooth muscle cells.","Downregulator"
"NE, <e1>phorbol esters</e1>, and bradykinin each decreased <e2>alpha-AR</e2> mRNA levels by 70-80%.","Downregulator"
"The mechanism by which norepinephrine (<e1>NE</e1>) down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR</e2>) mRNA was studied in rabbit aortic smooth muscle cells.","Downregulator"
"Phorbol esters and <e1>norepinephrine</e1> destabilize <e2>alpha 1B-adrenergic receptor</e2> mRNA in vascular smooth muscle cells.","Downregulator"
"NE, <e1>phorbol esters</e1>, and bradykinin each decreased <e2>alpha-AR</e2> mRNA levels by 70-80%.","Downregulator"
"Phorbol esters and <e1>norepinephrine</e1> destabilize <e2>alpha 1B-adrenergic receptor</e2> mRNA in vascular smooth muscle cells.","Downregulator"
"The mechanism by which <e1>norepinephrine</e1> (NE) down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR</e2>) mRNA was studied in rabbit aortic smooth muscle cells.","Downregulator"
"The mechanism by which norepinephrine (<e1>NE</e1>) down-regulates <e2>alpha 1B-adrenergic receptor</e2> (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.","Downregulator"
"The mechanism by which norepinephrine (<e1>NE</e1>) down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR</e2>) mRNA was studied in rabbit aortic smooth muscle cells.","Downregulator"
"The <e2>protein phosphatase</e2> inhibitor <e1>okadaic acid</e1> prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.","Downregulator"
"The <e2>protein kinase C</e2> inhibitor <e1>(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride</e1> (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.","Downregulator"
"The <e2>protein kinase C</e2> inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (<e1>H-7</e1>) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.","Downregulator"
"Degenerate oligonucleotides corresponding to conserved <e1>amino acids</e1> from transmembrane domains III, V, and VI of known receptors [<e2>5-HT1A</e2>, 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.","Part_of"
"Degenerate oligonucleotides corresponding to conserved <e1>amino acids</e1> from transmembrane domains III, V, and VI of known receptors [5-HT1A, <e2>5-HT1C</e2>, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.","Part_of"
"Degenerate oligonucleotides corresponding to conserved <e1>amino acids</e1> from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and <e2>5-HT2</e2>; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.","Part_of"
"Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% <e1>amino acid</e1> identity with the known <e2>rat 5-HT1A</e2>, rat 5-HT1B, rat 5-HT1D, and human 5-HT1E receptors, respectively.","Part_of"
"Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% <e1>amino acid</e1> identity with the known rat 5-HT1A, <e2>rat 5-HT1B</e2>, rat 5-HT1D, and human 5-HT1E receptors, respectively.","Part_of"
"Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% <e1>amino acid</e1> identity with the known rat 5-HT1A, rat 5-HT1B, <e2>rat 5-HT1D</e2>, and human 5-HT1E receptors, respectively.","Part_of"
"Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% <e1>amino acid</e1> identity with the known rat 5-HT1A, rat 5-HT1B, rat 5-HT1D, and <e2>human 5-HT1E</e2> receptors, respectively.","Part_of"
"HeLa cells transfected with the MR77 gene exhibited inhibition of <e2>adenylate cyclase</e2> in response to <e1>serotonin</e1>.","Downregulator"
"The specific binding is displaced by the selective <e2>5-HT1D</e2> agonist <e1>sumatriptan</e1> but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.","Agonist"
"), a cholinesterase inhibitor that potentiates the effects of <e1>acetylcholine</e1> at the <e2>muscarinic cholinergic receptor</e2>, terminated VT in four of four patients, an effect that was reversed by atropine.","Regulator"
"The antiarrhythmic effects of exogenous <e1>adenosine</e1> and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial <e2>chemoreceptors</e2>, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.","Upregulator"
"), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the <e2>muscarinic cholinergic receptor</e2>, terminated VT in four of four patients, an effect that was reversed by <e1>atropine</e1>.","Downregulator"
"VT recurred with the addition of <e1>aminophylline</e1>, a competitive <e2>adenosine A1-receptor</e2> antagonist.","Antagonist"
"However, amantadine induction of <e2>Fos</e2> in the striatum was unaffected by the dopamine D2 receptor antagonist, <e1>sulpiride</e1>.","Not"
"These results suggest that <e1>amantadine</e1> induction of Fos in the rat striatum is related to dopamine D1 and <e2>NMDA receptors</e2>.","Regulator"
"The distribution pattern of <e2>Fos</e2> induced by <e1>amantadine</e1> was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.","Upregulator"
"The distribution pattern of <e2>Fos</e2> induced by <e1>amantadine</e1> was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.","Upregulator"
"The distribution pattern of <e2>Fos</e2> induced by <e1>amantadine</e1> was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.","Upregulator"
"<e1>Amantadine</e1> induces <e2>c-fos</e2> in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.","Upregulator"
"<e1>Amantadine</e1> (1-aminoadamantane) induced <e2>Fos</e2> expression in the central, dorsal-medial and ventral-medial part of the striatum.","Upregulator"
"Amantadine (<e1>1-aminoadamantane</e1>) induced <e2>Fos</e2> expression in the central, dorsal-medial and ventral-medial part of the striatum.","Upregulator"
"The distribution pattern of <e2>Fos</e2> induced by <e1>amantadine</e1> was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.","Upregulator"
"Pretreatment with the dopamine D1 receptor antagonist, <e1>SCH23390</e1>, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of <e2>Fos</e2> in the striatum.","Downregulator"
"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, <e1>MK-801</e1>, blocked amantadine induction of <e2>Fos</e2> in the striatum.","Downregulator"
"However, amantadine induction of Fos in the striatum was unaffected by the <e2>dopamine D2 receptor</e2> antagonist, <e1>sulpiride</e1>.","Antagonist"
"Pretreatment with the <e2>dopamine D1 receptor</e2> antagonist, <e1>SCH23390</e1>, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.","Antagonist"
"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the <e2>NMDA receptor</e2> antagonist, <e1>MK-801</e1>, blocked amantadine induction of Fos in the striatum.","Antagonist"
"bolus); finally, 8 rabbits received <e1>aurintrycarboxilic acid</e1> (ATA), an inhibitor of platelet <e2>glycoprotein Ib</e2>/von Willebrand factor interaction (10 mg/kg i.v.","Downregulator"
"bolus); finally, 8 rabbits received <e1>aurintrycarboxilic acid</e1> (ATA), an inhibitor of platelet glycoprotein Ib/<e2>von Willebrand factor</e2> interaction (10 mg/kg i.v.","Downregulator"
"bolus); finally, 8 rabbits received aurintrycarboxilic acid (<e1>ATA</e1>), an inhibitor of platelet <e2>glycoprotein Ib</e2>/von Willebrand factor interaction (10 mg/kg i.v.","Downregulator"
"bolus); finally, 8 rabbits received aurintrycarboxilic acid (<e1>ATA</e1>), an inhibitor of platelet glycoprotein Ib/<e2>von Willebrand factor</e2> interaction (10 mg/kg i.v.","Downregulator"
"These events are stimulated by NE and by guanethidine, an <e2>hNET</e2> substrate, and they are blocked by <e1>cocaine</e1> and the antidepressant desipramine.","Downregulator"
"These events are stimulated by NE and by guanethidine, an <e2>hNET</e2> substrate, and they are blocked by cocaine and the antidepressant <e1>desipramine</e1>.","Downregulator"
"Voltage-clamp data combined with <e1>NE</e1> uptake data from these same cells indicate that <e2>hNETs</e2> have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).","Substrate"
"Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (<e1>NE</e1>)+, Na+, and Cl-], human NE (<e2>hNET</e2>) in the gamma-aminobutyric acid transporter gene family.","Substrate"
"These events are stimulated by NE and by <e1>guanethidine</e1>, an <e2>hNET</e2> substrate, and they are blocked by cocaine and the antidepressant desipramine.","Substrate"
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with <e1>aldosterone</e1> and intracerebroventricularly with the mineralocorticoid receptor (<e2>MR</e2>) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.","Regulator"
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with <e1>aldosterone</e1> and intracerebroventricularly with the mineralocorticoid receptor (<e2>MR</e2>) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.","Regulator"
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the <e2>mineralocorticoid receptor</e2> (MR) antagonist <e1>RU28318</e1>; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.","Antagonist"
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (<e2>MR</e2>) antagonist <e1>RU28318</e1>; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.","Antagonist"
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (<e2>MR</e2>) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist <e1>potassium canrenoate</e1>; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.","Antagonist"
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (<e2>MR</e2>) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist <e1>potassium canrenoate</e1>; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.","Antagonist"
"When <e2>MAO-B</e2> was also inhibited, 10 nmol/l <e1>amezinium</e1> caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs.","Undefined"
"Previous studies have resulted in the classification of <e1>amezinium</e1> as a selective inhibitor of neuronal monoamine oxidase (<e2>MAO</e2>), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.","Downregulator"
"In addition, another drug that is both a substrate of uptake1 and a <e2>MAO</e2> inhibitor, <e1>debrisoquine</e1>, was investigated in the study.","Downregulator"
"<e1>Amezinium</e1> is much less potent as a <e2>MAO</e2> inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.","Downregulator"
"When MAO-B was also inhibited, 10 nmol/l <e1>amezinium</e1> caused 84% inhibition of the deamination of noradrenaline by <e2>MAO-A</e2> in the lungs.","Downregulator"
"Previous studies have resulted in the classification of <e1>amezinium</e1> as a selective inhibitor of neuronal <e2>monoamine oxidase</e2> (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.","Downregulator"
"Previous studies have resulted in the classification of <e1>amezinium</e1> as a selective inhibitor of neuronal monoamine oxidase (<e2>MAO</e2>), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.","Downregulator"
"Previous studies have resulted in the classification of <e1>amezinium</e1> as a selective inhibitor of neuronal monoamine oxidase (<e2>MAO</e2>), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.","Downregulator"
"In addition, another drug that is both a substrate of uptake1 and a <e2>MAO</e2> inhibitor, <e1>debrisoquine</e1>, was investigated in the study.","Downregulator"
"<e1>Amezinium</e1> and debrisoquine are substrates of uptake1 and potent inhibitors of <e2>monoamine oxidase</e2> in perfused lungs of rats.","Downregulator"
"Amezinium and <e1>debrisoquine</e1> are substrates of uptake1 and potent inhibitors of <e2>monoamine oxidase</e2> in perfused lungs of rats.","Downregulator"
"When MAO-B was also inhibited, 10 nmol/l <e1>amezinium</e1> caused 84% inhibition of the deamination of noradrenaline by <e2>MAO-A</e2> in the lungs.","Downregulator"
"Previous studies have resulted in the classification of <e1>amezinium</e1> as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by <e2>uptake1</e2>, than in tissue homogenates.","Substrate"
"Amezinium and <e1>debrisoquine</e1> are substrates of <e2>uptake1</e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats.","Substrate"
"<e1>Amezinium</e1> is much less potent as a MAO inhibitor in cells with the <e2>uptake2 transporter</e2>, such as the myocardial cells of the heart.","Substrate"
"Amezinium and <e1>debrisoquine</e1> are substrates of <e2>uptake1</e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats.","Substrate"
"<e1>Amezinium</e1> and debrisoquine are substrates of <e2>uptake1</e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats.","Substrate"
"Amezinium and <e1>debrisoquine</e1> are substrates of <e2>uptake1</e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats.","Substrate"
"Role of <e2>tachykinin and bradykinin receptors</e2> and mast cells in gaseous <e1>formaldehyde</e1>-induced airway microvascular leakage in rats.","Regulator"
"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin <e2>NK1 receptor</e2> antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous <e1>formaldehyde</e1>.","Regulator"
"We have investigated the effects of <e1>CP-99,994</e1> [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a <e2>tachykinin NK1 receptor</e2> antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.","Antagonist"
"We have investigated the effects of CP-99,994 <e1>[(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]</e1>, a <e2>tachykinin NK1 receptor</e2> antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.","Antagonist"
"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, <e1>HOE 140</e1> (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a <e2>bradykinin B2 receptor</e2> antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.","Antagonist"
"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 <e1>(D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)</e1>, a <e2>bradykinin B2 receptor</e2> antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.","Antagonist"
"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and <e1>ketotifen</e1> (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a <e2>histamine H1 receptor</e2> antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.","Antagonist"
"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen <e1>(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)</e1>, a <e2>histamine H1 receptor</e2> antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.","Antagonist"
"To identify the molecular determinants for dofetilide block, we first engineered chimeras between <e2>HERG</e2> and BEAG and then used site-directed mutagenesis to localize single <e1>amino acid</e1> residues responsible for block.","Part_of"
"To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and <e2>BEAG</e2> and then used site-directed mutagenesis to localize single <e1>amino acid</e1> residues responsible for block.","Part_of"
"Thus, the <e1>serine</e1> in position <e2>HERG</e2> 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.","Part_of"
"Molecular determinants of <e1>dofetilide</e1> block of <e2>HERG</e2> K+ channels.","Regulator"
"By contrast, the closely related bovine ether-a-go-go channel (<e2>BEAG</e2>) is 100-fold less sensitive to <e1>dofetilide</e1>.","Regulator"
"Moreover, the reverse mutation BEAG <e2>T432S</e2> increased the affinity of BEAG K+ channels for <e1>dofetilide</e1>, whereas C-type inactivation could not be recovered.","Regulator"
"By contrast, the closely related bovine ether-a-go-go channel (<e2>BEAG</e2>) is 100-fold less sensitive to <e1>dofetilide</e1>.","Regulator"
"Molecular determinants of <e1>dofetilide</e1> block of HERG <e2>K+ channels</e2>.","Regulator"
"Molecular determinants of <e1>dofetilide</e1> block of <e2>HERG</e2> K+ channels.","Regulator"
"By contrast, the closely related <e2>bovine ether-a-go-go channel</e2> (BEAG) is 100-fold less sensitive to <e1>dofetilide</e1>.","Regulator"
"By contrast, the closely related bovine ether-a-go-go channel (<e2>BEAG</e2>) is 100-fold less sensitive to <e1>dofetilide</e1>.","Regulator"
"<e2>HERG</e2>/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, <e1>E4031</e1>, and MK-499, at submicromolar concentrations.","Downregulator"
"HERG/<e2>IKr</e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, <e1>E4031</e1>, and MK-499, at submicromolar concentrations.","Downregulator"
"<e2>HERG</e2>/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and <e1>MK-499</e1>, at submicromolar concentrations.","Downregulator"
"HERG/<e2>IKr</e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and <e1>MK-499</e1>, at submicromolar concentrations.","Downregulator"
"Molecular determinants of <e1>dofetilide</e1> block of <e2>HERG</e2> K+ channels.","Downregulator"
"Molecular determinants of <e1>dofetilide</e1> block of HERG <e2>K+ channels</e2>.","Downregulator"
"<e2>HERG</e2>/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic <e1>methanesulfonanilide</e1> drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.","Downregulator"
"HERG/<e2>IKr</e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic <e1>methanesulfonanilide</e1> drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.","Downregulator"
"Molecular determinants of <e1>dofetilide</e1> block of <e2>HERG</e2> K+ channels.","Downregulator"
"HERG/<e2>IKr</e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as <e1>dofetilide</e1>, E4031, and MK-499, at submicromolar concentrations.","Downregulator"
"Treatment using a combination of <e1>testosterone</e1> and the <e2>aromatase</e2> inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than testosterone alone.","Regulator"
"Treatment using a combination of testosterone and the <e2>aromatase</e2> inhibitor <e1>testolactone</e1> may have significantly better effects on sexual function and also seizure frequency than testosterone alone.","Downregulator"
"For example, it is clear that the closed conformation of the regulatory <e1>N</e1>-terminal domain in Ca2+-bound cardiac troponin C (<e2>cTnC</e2>) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.","Part_of"
"Identification of binding sites for bepridil and trifluoperazine on cardiac troponin <e1>C</e1>.
The solution structure of cardiac troponin C (<e2>cTnC</e2>) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J.","Part_of"
"For example, it is clear that the closed conformation of the regulatory <e1>N</e1>-terminal domain in Ca2+-bound <e2>cardiac troponin C</e2> (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.","Part_of"
"For example, it is clear that the closed conformation of the regulatory <e1>N</e1>-terminal domain in Ca2+-bound cardiac troponin C (<e2>cTnC</e2>) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.","Part_of"
"Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [<e1>methyl-13C</e1>]Met-labeled <e2>cTnC</e2> indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.","Regulator"
"Identification of binding sites for <e1>bepridil</e1> and trifluoperazine on cardiac troponin C.
The solution structure of cardiac troponin C (<e2>cTnC</e2>) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J.","Regulator"
"Identification of binding sites for bepridil and <e1>trifluoperazine</e1> on cardiac troponin C.
The solution structure of cardiac troponin C (<e2>cTnC</e2>) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J.","Regulator"
"Identification of binding sites for <e1>bepridil</e1> and trifluoperazine on <e2>cardiac troponin C</e2>.
The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J.","Regulator"
"Identification of binding sites for bepridil and <e1>trifluoperazine</e1> on <e2>cardiac troponin C</e2>.
The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J.","Regulator"
"For example, it is clear that the closed conformation of the regulatory N-terminal domain in <e1>Ca2+</e1>-bound <e2>cardiac troponin C</e2> (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.","Regulator"
"For example, it is clear that the closed conformation of the regulatory N-terminal domain in <e1>Ca2+</e1>-bound cardiac troponin C (<e2>cTnC</e2>) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.","Regulator"
"Identification of binding sites for bepridil and <e1>trifluoperazine</e1> on cardiac troponin C.
The solution structure of cardiac troponin C (<e2>cTnC</e2>) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J.","Regulator"
"Identification of binding sites for <e1>bepridil</e1> and trifluoperazine on cardiac troponin C.
The solution structure of cardiac troponin C (<e2>cTnC</e2>) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J.","Regulator"
"For example, it is clear that the closed conformation of the regulatory N-terminal domain in <e1>Ca2+</e1>-bound cardiac troponin C (<e2>cTnC</e2>) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.","Regulator"
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II</e2> inhibitors, etoposide and mitoxantrone, and the alkylating agent, <e1>cyclophosphamide</e1>.","Regulator"
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II</e2> inhibitors, etoposide and mitoxantrone, and the alkylating agent, <e1>cyclophosphamide</e1>.","Regulator"
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II</e2> inhibitors, <e1>etoposide</e1> and mitoxantrone, and the alkylating agent, cyclophosphamide.","Downregulator"
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II</e2> inhibitors, etoposide and <e1>mitoxantrone</e1>, and the alkylating agent, cyclophosphamide.","Downregulator"
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II</e2> inhibitors, <e1>etoposide</e1> and mitoxantrone, and the alkylating agent, cyclophosphamide.","Downregulator"
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II</e2> inhibitors, etoposide and <e1>mitoxantrone</e1>, and the alkylating agent, cyclophosphamide.","Downregulator"
"Unlike the nonselective <e2>MAO</e2> inhibitors, <e1>selegiline</e1> does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.","Downregulator"
"A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible <e2>MAO-A</e2> inhibitor, <e1>moclobemide</e1>.","Downregulator"
"<e1>Selegiline</e1> (deprenyl), a selective, irreversible inhibitor of <e2>monoamine oxidase type B</e2> (MAO-B) is widely used in the treatment of Parkinson's disease.","Downregulator"
"<e1>Selegiline</e1> (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (<e2>MAO-B</e2>) is widely used in the treatment of Parkinson's disease.","Downregulator"
"Unlike the nonselective <e2>MAO</e2> inhibitors, <e1>selegiline</e1> does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.","Downregulator"
"Selegiline (<e1>deprenyl</e1>), a selective, irreversible inhibitor of <e2>monoamine oxidase type B</e2> (MAO-B) is widely used in the treatment of Parkinson's disease.","Downregulator"
"Selegiline (<e1>deprenyl</e1>), a selective, irreversible inhibitor of monoamine oxidase type B (<e2>MAO-B</e2>) is widely used in the treatment of Parkinson's disease.","Downregulator"
"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit <e1>cAMP</e1>-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of <e2>CFTR</e2> Cl- channels as well as basolateral membrane K+ channels.","Regulator"
"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit <e1>cAMP</e1>-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR <e2>Cl- channels</e2> as well as basolateral membrane K+ channels.","Regulator"
"<e1>Ibuprofen</e1> inhibits <e2>cystic fibrosis transmembrane conductance regulator</e2>-mediated Cl- secretion.","Downregulator"
"<e1>Ibuprofen</e1> (300 microM) reduced <e2>CFTR</e2> Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).","Downregulator"
"To determine whether this inhibition of ICl was due to the inhibition of <e2>CFTR</e2>, the effects of ibuprofen and <e1>salicylic acid</e1> on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated.","Downregulator"
"To determine whether this inhibition of ICl was due to the inhibition of <e2>CFTR</e2>, the effects of <e1>ibuprofen</e1> and salicylic acid on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated.","Downregulator"
"To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of <e1>ibuprofen</e1> and salicylic acid on CFTR <e2>Cl- channels</e2> in excised, inside-out patches from L-cells were evaluated.","Downregulator"
"Based on these results, we conclude that the NSAIDs <e1>ibuprofen</e1> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane <e2>K+ channels</e2>.","Downregulator"
"To determine whether this inhibition of ICl was due to the inhibition of <e2>CFTR</e2>, the effects of ibuprofen and <e1>salicylic acid</e1> on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated.","Downregulator"
"To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and <e1>salicylic acid</e1> on CFTR <e2>Cl- channels</e2> in excised, inside-out patches from L-cells were evaluated.","Downregulator"
"Based on these results, we conclude that the NSAIDs ibuprofen and <e1>salicylic acid</e1> inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane <e2>K+ channels</e2>.","Downregulator"
"These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective <e2>5-HT2A</e2>/5-HT2C antagonist <e1>ritanserin</e1>.","Antagonist"
"These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/<e2>5-HT2C</e2> antagonist <e1>ritanserin</e1>.","Antagonist"
"These data indicate that mixed <e2>5-HT1</e2>/5-HT2 receptor antagonists such as <e1>pizotifen</e1> and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.","Antagonist"
"These data indicate that mixed 5-HT1/<e2>5-HT2</e2> receptor antagonists such as <e1>pizotifen</e1> and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.","Antagonist"
"These data indicate that mixed <e2>5-HT1</e2>/5-HT2 receptor antagonists such as pizotifen and <e1>methysergide</e1>, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.","Antagonist"
"These data indicate that mixed 5-HT1/<e2>5-HT2</e2> receptor antagonists such as pizotifen and <e1>methysergide</e1>, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.","Antagonist"
"The cardiovascular effects of three different <e2>acetylcholinesterase</e2> inhibitors: <e1>physostigmine</e1>, tacrine and rivastigmine injected by intravenous (i.v.)","Downregulator"
"Pressor and bradycardic effects of <e1>tacrine</e1> and other <e2>acetylcholinesterase</e2> inhibitors in the rat.","Downregulator"
"The cardiovascular effects of three different <e2>acetylcholinesterase</e2> inhibitors: physostigmine, tacrine and <e1>rivastigmine</e1> injected by intravenous (i.v.)","Downregulator"
"The <e2>alpha1-adrenoceptor</e2> antagonist <e1>prazosin</e1> or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.","Antagonist"
"The alpha1-adrenoceptor antagonist prazosin or the <e2>vasopressin V1 receptor</e2> antagonist, <e1>[beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin</e1> partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.","Antagonist"
"administration of the non-selective <e2>muscarinic receptor</e2> antagonist <e1>atropine</e1> (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).","Antagonist"
"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the <e2>muscarinic M1 receptor</e2> antagonist <e1>pirenzepine</e1> (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).","Antagonist"
"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the <e2>muscarinic M2 receptor</e2> antagonist <e1>methoctramine</e1> (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).","Antagonist"
"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the <e2>muscarinic M3 receptor</e2> antagonist <e1>para-fluoro-hexahydro-sila-difenidol</e1> (ID50 = 31.19 microg).","Antagonist"
"<e1>Cocaine</e1> block of <e2>human cardiac (hH1)</e2> and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.","Downregulator"
"<e1>Cocaine</e1> block of human cardiac (hH1) and <e2>rat skeletal (mu1) muscle sodium channels</e2> was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.","Downregulator"
"<e1>Cocaine</e1> block of <e2>hH1 channels</e2> was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.","Downregulator"
"<e1>Cocaine</e1> block of hH1 channels was greater than block of <e2>mu1 channels</e2> at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.","Downregulator"
"<e1>Cocaine</e1> block of <e2>hH1 channels</e2> was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.","Downregulator"
"Cocaine block of <e2>hH1 channels</e2> was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to <e1>cocaine</e1> block.","Downregulator"
"State-dependent <e1>cocaine</e1> block of <e2>sodium channel</e2> isoforms, chimeras, and channels coexpressed with the beta1 subunit.","Downregulator"
